Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific A2M CPAMD5, FWP007, S863-7 ENSG00000175899 Alpha-2-macroglobulin 12 9067664-9116229 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA002265, CAB017621 Supported Expressed in all Expressed in all lung: 1921.7 AARS2 AARSL, bA444E17.1, KIAA1270 ENSG00000124608 Alanyl-tRNA synthetase 2, mitochondrial 6 44299654-44313326 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA035636, HPA061396 Approved Validated Mitochondria Expressed in all Mixed parathyroid gland: 11.1 ABCB1 ABC20, CD243, CLCS, GP170, MDR1, P-gp, PGY1 ENSG00000085563 ATP-binding cassette, sub-family B (MDR/TAP), member 1 7 87503633-87713323 Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB001716, HPA002199 Approved Approved Nucleoplasm
Focal adhesion sites
Cytosol Renal cancer:2.95e-4 (favourable), Pancreatic cancer:3.33e-4 (favourable) Tissue enhanced Tissue enhanced adrenal gland: 138.6;small intestine: 83.9 kidney: 37.0 ABCC1 GS-X, MRP, MRP1 ENSG00000103222 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 16 15949577-16143074 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA002380 Uncertain Supported Plasma membrane Renal cancer:1.55e-6 (unfavourable), Liver cancer:5.42e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 18.1 ABCC2 CMOAT, cMRP, DJS, MRP2 ENSG00000023839 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 10 99782732-99852192 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA004860, CAB037271 Approved Renal cancer:1.93e-5 (unfavourable) Tissue enhanced Group enriched 10 duodenum: 44.7;gallbladder: 42.8;kidney: 20.8;liver: 67.6;small intestine: 50.5 breast: 4.3 ABCC3 cMOAT2, EST90757, MLP2, MOAT-D, MRP3 ENSG00000108846 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 17 50634777-50692252 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB037136, HPA048483 Approved Approved Plasma membrane Renal cancer:4.68e-6 (unfavourable), Pancreatic cancer:9.57e-4 (unfavourable) Mixed Mixed adrenal gland: 20.8 ABCC5 EST277145, MOAT-C, MRP5, SMRP ENSG00000114770 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 3 183919934-184018015 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA044067, HPA052295 Uncertain Supported Nucleus
Plasma membrane
Cell Junctions Liver cancer:6.78e-8 (unfavourable), Prostate cancer:3.40e-4 (unfavourable) Expressed in all Expressed in all stomach: 72.0 ABCC6 ARA, EST349056, MLP1, MRP6, PXE, URG7 ENSG00000091262 ATP-binding cassette, sub-family C (CFTR/MRP), member 6 16 16148928-16223522 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA038105 Supported Plasma membrane Liver cancer:3.82e-4 (favourable) Tissue enhanced Tissue enhanced kidney: 15.2;liver: 19.1 duodenum: 11.6 ABCG2 ABCP, BCRP, CD338, EST157481, MXR ENSG00000118777 ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group) 4 88090264-88231322 Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB037299, HPA054719 Supported Validated Nucleus
Plasma membrane Mixed Tissue enhanced small intestine: 116.1 seminal vesicle: 55.4 ABI1 ABI-1, E3B1, SSH3BP1 ENSG00000136754 Abl-interactor 1 10 26746593-26861087 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB008375, HPA029973, HPA068407 Approved Supported Plasma membrane
Cell Junctions Expressed in all Expressed in all cerebral cortex: 87.6 ABL1 ABL, c-ABL, JTK7, p150 ENSG00000097007 ABL proto-oncogene 1, non-receptor tyrosine kinase 9 130713946-130887675 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB002686, HPA027251, HPA027280, HPA028409 Supported Validated Nucleoplasm
Nuclear bodies Expressed in all Expressed in all parathyroid gland: 82.2 ABL2 ABLL, ARG ENSG00000143322 ABL proto-oncogene 2, non-receptor tyrosine kinase 1 179099327-179229684 Cancer-related genes, Enzymes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA001866, CAB017106 Uncertain Supported Nucleoplasm Renal cancer:1.78e-7 (unfavourable), Cervical cancer:3.50e-4 (unfavourable), Urothelial cancer:8.40e-4 (unfavourable) Expressed in all Mixed gallbladder: 20.3 ACAP1 CENTB1, KIAA0050 ENSG00000072818 ArfGAP with coiled-coil, ankyrin repeat and PH domains 1 17 7336529-7351478 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA062130 Approved Vesicles Renal cancer:1.65e-10 (unfavourable), Endometrial cancer:2.97e-5 (favourable), Head and neck cancer:4.17e-5 (favourable), Cervical cancer:3.66e-4 (favourable) Expressed in all Tissue enhanced lymph node: 95.5 spleen: 71.2 ACKR3 CMKOR1, CXCR7, GPR159, RDC1 ENSG00000144476 Atypical chemokine receptor 3 2 236567787-236582358 Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA032003, HPA049718 Approved Supported Vesicles
Plasma membrane Renal cancer:1.76e-6 (unfavourable), Stomach cancer:2.01e-4 (unfavourable), Urothelial cancer:2.93e-4 (unfavourable), Cervical cancer:4.64e-4 (unfavourable) Expressed in all Expressed in all placenta: 175.2 ACLY ACL, ATPCL, CLATP ENSG00000131473 ATP citrate lyase 17 41866908-41930542 Cancer-related genes, Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB007783, HPA022434, HPA022953, HPA022959, HPA028758 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Cervical cancer:1.79e-4 (unfavourable), Liver cancer:3.66e-4 (unfavourable) Expressed in all Expressed in all prostate: 95.8 ACO1 IREB1, IREBP, IRP1 ENSG00000122729 Aconitase 1, soluble 9 32384603-32454769 Cancer-related genes, Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019371, HPA024157 Supported Supported Mitochondria
Cytosol Renal cancer:5.73e-5 (favourable) Expressed in all Expressed in all adipose tissue: 104.8 ACPP ACP-3, ACP3, PAP ENSG00000014257 Acid phosphatase, prostate 3 132317367-132368298 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000071, HPA004335, HPA063916 Supported Tissue enriched Tissue enriched 153 prostate: 6368.2 esophagus: 41.6 ACSL3 ACS3, FACL3, PRO2194 ENSG00000123983 Acyl-CoA synthetase long-chain family member 3 2 222860934-222944639 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011315, HPA071021 Uncertain Approved Nucleoli
Lipid droplets Liver cancer:2.75e-4 (unfavourable), Lung cancer:8.78e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 670.1 ACSL6 ACS2, FACL6, KIAA0837, LACS2, LACS5 ENSG00000164398 Acyl-CoA synthetase long-chain family member 6 5 131949973-132012243 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040470 Uncertain Group enriched Group enriched 6 bone marrow: 18.0;cerebral cortex: 62.1;parathyroid gland: 22.1;seminal vesicle: 28.7;testis: 51.2 adrenal gland: 6.5 ACVR1 ACVR1A, ACVRLK2, ALK2, SKR1 ENSG00000115170 Activin A receptor, type I 2 157736444-157875862 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007505 Approved Urothelial cancer:5.17e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 73.9 ACVR1B ActRIB, ACVRLK4, ALK4, SKR2 ENSG00000135503 Activin A receptor, type IB 12 51951667-51997078 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB026126, HPA063761 Approved Validated Cytosol Expressed in all Expressed in all parathyroid gland: 53.7 ACVR2A ACTRII, ACVR2 ENSG00000121989 Activin A receptor, type IIA 2 147844517-147930826 Cancer-related genes, Enzymes, Predicted membrane proteins Evidence at protein level HPA046997 Approved Approved Cytosol Renal cancer:1.62e-4 (favourable) Expressed in all Mixed skin: 22.5 ACVR2B ActR-IIB ENSG00000114739 Activin A receptor, type IIB 3 38453851-38493142 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA007398, CAB025115 Approved Approved Nucleus
Nuclear bodies
Cytosol Expressed in all Mixed parathyroid gland: 6.3 ADAM10 CD156c, HsT18717, kuz, MADM ENSG00000137845 ADAM metallopeptidase domain 10 15 58588807-58749978 Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB001709, HPA050670 Approved Supported Vesicles
Plasma membrane Lung cancer:8.46e-5 (unfavourable), Pancreatic cancer:1.90e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 47.8 ADAM9 CORD9, KIAA0021, MCMP, MDC9, Mltng ENSG00000168615 ADAM metallopeptidase domain 9 8 38996869-39105144 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA004000 Approved Endoplasmic reticulum
Vesicles Liver cancer:7.21e-6 (unfavourable), Pancreatic cancer:2.52e-5 (unfavourable), Breast cancer:1.14e-4 (unfavourable), Cervical cancer:2.25e-4 (unfavourable), Renal cancer:3.99e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 116.7 ADAMTS1 C3-C5, KIAA1346, METH1 ENSG00000154734 ADAM metallopeptidase with thrombospondin type 1 motif, 1 21 26835747-26845409 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB016394, HPA031498, HPA031499 Uncertain Validated Cytosol Head and neck cancer:5.13e-4 (unfavourable) Expressed in all Tissue enhanced ovary: 410.9 adipose tissue: 276.6 ADAMTS14 ENSG00000138316 ADAM metallopeptidase with thrombospondin type 1 motif, 14 10 70672803-70762441 Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA034605 Uncertain Cytosol Mixed Tissue enhanced gallbladder: 10.9;placenta: 11.0 urinary bladder: 4.5 ADAMTS18 ADAMTS21 ENSG00000140873 ADAM metallopeptidase with thrombospondin type 1 motif, 18 16 77247813-77435114 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA044326 Uncertain Mixed Tissue enriched 16 placenta: 28.9 cervix, uterine: 1.8 ADAMTS20 GON-1 ENSG00000173157 ADAM metallopeptidase with thrombospondin type 1 motif, 20 12 43353866-43551921 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA027608, HPA027609 Uncertain Not detected Not detected placenta: 0.8 ADAMTS3 ADAMTS-4, KIAA0366 ENSG00000156140 ADAM metallopeptidase with thrombospondin type 1 motif, 3 4 72280969-72568799 Cancer-related genes, Enzymes, Predicted secreted proteins Evidence at protein level HPA021368, HPA021369 Uncertain Approved Intermediate filaments Mixed Tissue enhanced parathyroid gland: 7.9 testis: 3.7 ADAMTS4 ADAMTS-2, ADMP-1, KIAA0688 ENSG00000158859 ADAM metallopeptidase with thrombospondin type 1 motif, 4 1 161184308-161199056 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB025876, HPA051296, HPA068374 Uncertain Approved Nuclear speckles Renal cancer:7.27e-7 (unfavourable), Lung cancer:5.00e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 62.7 appendix: 23.4 ADAMTS5 ADAMTS11, ADMP-2 ENSG00000154736 ADAM metallopeptidase with thrombospondin type 1 motif, 5 21 26917912-26966513 Cancer-related genes, Enzymes, Predicted secreted proteins Evidence at protein level HPA005661, CAB025996, HPA030906, HPA030908 Approved Supported Nucleoplasm Renal cancer:2.46e-4 (unfavourable), Thyroid cancer:8.54e-4 (unfavourable) Mixed Tissue enhanced placenta: 42.0 ovary: 24.2 ADAMTS6 ADAM-TS6 ENSG00000049192 ADAM metallopeptidase with thrombospondin type 1 motif, 6 5 65148736-65481920 Cancer-related genes, Enzymes, Predicted secreted proteins Evidence at protein level HPA043441 Supported Mixed Tissue enhanced placenta: 2.7 gallbladder: 2.3 ADAMTS8 ADAM-TS8, FLJ41712, METH2 ENSG00000134917 ADAM metallopeptidase with thrombospondin type 1 motif, 8 11 130404925-130428993 Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at transcript level HPA066349 Approved Endometrial cancer:1.38e-4 (favourable) Tissue enhanced Tissue enhanced appendix: 11.2;lung: 15.6 seminal vesicle: 5.5 ADAMTS9 KIAA1312 ENSG00000163638 ADAM metallopeptidase with thrombospondin type 1 motif, 9 3 64515654-64688000 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA028567, HPA028577, HPA028601 Approved Supported Endoplasmic reticulum
Vesicles Expressed in all Tissue enhanced placenta: 45.0 adipose tissue: 31.9 ADCY1 AC1 ENSG00000164742 Adenylate cyclase 1 (brain) 7 45574140-45723116 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB018364, HPA068274 Uncertain Approved Mitochondria Mixed Tissue enhanced cerebral cortex: 35.1 cervix, uterine: 8.2 ADGRB1 BAI1 ENSG00000181790 Adhesion G protein-coupled receptor B1 8 142449430-142545009 Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level Tissue enhanced Tissue enriched 9 cerebral cortex: 22.0 spleen: 2.3 ADM AM ENSG00000148926 Adrenomedullin 11 10304680-10307397 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB016075 Approved Renal cancer:6.33e-4 (unfavourable), Liver cancer:7.56e-4 (unfavourable) Expressed in all Expressed in all placenta: 157.8 ADNP ADNP1, KIAA0784 ENSG00000101126 Activity-dependent neuroprotector homeobox 20 50888919-50931240 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA006371 Supported Approved Nucleoplasm Liver cancer:1.65e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 80.3 ADORA2A ADORA2, RDC8 ENSG00000128271 Adenosine A2a receptor 22 24417879-24442360 Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Not detected Tissue enhanced bone marrow: 9.6 lymph node: 7.7 ADRA1B ENSG00000170214 Adrenoceptor alpha 1B 5 159916783-159972544 Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA074416 Supported Plasma membrane Renal cancer:1.40e-6 (unfavourable), Thyroid cancer:3.19e-5 (favourable), Endometrial cancer:6.00e-5 (unfavourable), Ovarian cancer:2.67e-4 (favourable), Glioma:6.07e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 14.8;spleen: 17.3 ovary: 4.8 AFF1 AF-4, AF4, MLLT2, PBM1 ENSG00000172493 AF4/FMR2 family, member 1 4 86935002-87141054 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA069947 Approved Nucleoplasm
Mitochondria Expressed in all Expressed in all thyroid gland: 91.1 AFF3 LAF4, MLLT2-like ENSG00000144218 AF4/FMR2 family, member 3 2 99545419-100142739 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA044512, HPA053379 Approved Supported Nucleoplasm
Cytosol Renal cancer:5.64e-4 (unfavourable) Tissue enhanced Mixed prostate: 27.1 AFF4 AF5Q31, MCEF ENSG00000072364 AF4/FMR2 family, member 4 5 132875379-132963634 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA023690, HPA029634 Approved Supported Nucleus
Nucleoli fibrillar center Thyroid cancer:6.44e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 73.0 AFP FETA, HPAFP ENSG00000081051 Alpha-fetoprotein 4 73431138-73456174 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA010607, HPA023600, CAB024283, CAB025339 Approved Validated Cytosol Group enriched Tissue enhanced liver: 1.9 breast: 0.4 AGER RAGE ENSG00000204305 Advanced glycosylation end product-specific receptor 6 32180968-32184324 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB011682, HPA064436 Approved Approved Nucleoli fibrillar center
Plasma membrane
Cell Junctions Renal cancer:9.01e-7 (unfavourable), Urothelial cancer:2.74e-6 (favourable), Pancreatic cancer:3.41e-4 (favourable) Expressed in all Tissue enriched 181 lung: 891.2 thyroid gland: 4.9 AHNAK2 C14orf78 ENSG00000185567 AHNAK nucleoprotein 2 14 104937244-104978357 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA000878, HPA002940, HPA004145, HPA020111 Supported Validated Plasma membrane
Cytosol Pancreatic cancer:4.05e-6 (unfavourable), Urothelial cancer:2.23e-5 (unfavourable), Lung cancer:2.79e-5 (unfavourable) Mixed Tissue enriched 8 skin: 346.3 smooth muscle: 45.9 AHR bHLHe76 ENSG00000106546 Aryl hydrocarbon receptor 7 17298622-17346152 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB005072, HPA029722, HPA029723 Supported Validated Nucleoplasm
Cytosol Expressed in all Mixed urinary bladder: 57.6 AHSG A2HS, FETUA, HSGA ENSG00000145192 Alpha-2-HS-glycoprotein 3 186612923-186621318 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA001524, HPA001525, CAB026209 Supported Supported Golgi apparatus Tissue enriched Tissue enriched 1899 liver: 2819.2 testis: 1.4 AJUBA JUB, MGC15563 ENSG00000129474 Ajuba LIM protein 14 22971174-22982642 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA006171 Approved Approved Nucleus
Golgi apparatus Pancreatic cancer:5.67e-4 (unfavourable) Expressed in all Tissue enhanced skin: 73.9 placenta: 27.9 AK9 AKD1, AKD2, C6orf199, C6orf224, dJ70A9.1, FLJ25791, FLJ42177, MGC26954 ENSG00000155085 Adenylate kinase 9 6 109492856-109691217 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA030804, HPA030805, HPA031779, HPA031781, HPA036324, HPA036711 Approved Validated Nucleoplasm
Nuclear membrane Mixed Tissue enhanced testis: 31.1 parathyroid gland: 16.8 AKAP12 AKAP250, SSeCKS ENSG00000131016 A kinase (PRKA) anchor protein 12 6 151239999-151358557 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006344, CAB026379, HPA056230 Supported Supported Plasma membrane
Cytosol Lung cancer:6.34e-5 (unfavourable), Endometrial cancer:7.08e-4 (unfavourable) Expressed in all Expressed in all testis: 183.8 AKAP9 AKAP350, AKAP450, CG-NAP, HYPERION, KIAA0803, LQT11, MU-RMS-40.16A, PPP1R45, PRKA9, YOTIAO ENSG00000127914 A kinase (PRKA) anchor protein 9 7 91940867-92110673 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008548, CAB012909, HPA026109 Supported Validated Golgi apparatus
Vesicles
Centrosome Renal cancer:2.10e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 37.2 AKR1B1 ALDR1, AR ENSG00000085662 Aldo-keto reductase family 1, member B1 (aldose reductase) 7 134442350-134459284 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA026425, CAB027391, CAB047353, HPA052751 Supported Supported Nucleus
Cytosol Stomach cancer:2.44e-5 (unfavourable), Urothelial cancer:7.00e-4 (unfavourable) Expressed in all Tissue enriched 6 adrenal gland: 2498.2 seminal vesicle: 444.1 AKT1 AKT, PKB, PRKBA, RAC ENSG00000142208 V-akt murine thymoma viral oncogene homolog 1 14 104769349-104795751 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA002891, CAB003765 Supported Supported Nucleus
Microtubules Renal cancer:2.12e-4 (favourable), Ovarian cancer:4.83e-4 (favourable) Expressed in all Expressed in all lung: 104.6 AKT2 ENSG00000105221 V-akt murine thymoma viral oncogene homolog 2 19 40230317-40285536 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB004204, HPA064521 Uncertain Supported Nucleus
Vesicles
Cytosol Endometrial cancer:1.05e-6 (unfavourable), Prostate cancer:4.74e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 169.5 AKT3 PKBG, PRKBG, RAC-gamma ENSG00000117020 V-akt murine thymoma viral oncogene homolog 3 1 243488233-243851079 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB013090, HPA026441 Approved Supported Cytosol Urothelial cancer:9.27e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 51.7 ALB ENSG00000163631 Albumin 4 73397114-73421412 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB006262, HPA031024, HPA031025 Supported Validated Endoplasmic reticulum
Golgi apparatus Stomach cancer:7.87e-4 (unfavourable) Tissue enriched Tissue enriched 221 liver: 105632.0 kidney: 478.5 ALCAM CD166, MEMD ENSG00000170017 Activated leukocyte cell adhesion molecule 3 105366909-105576900 Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002148, HPA010926 Approved Renal cancer:3.15e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 462.8 lung: 111.3 ALDH2 ENSG00000111275 Aldehyde dehydrogenase 2 family (mitochondrial) 12 111766887-111817529 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA051065 Approved Liver cancer:3.95e-7 (favourable), Renal cancer:5.24e-6 (favourable), Endometrial cancer:2.63e-4 (favourable), Urothelial cancer:7.71e-4 (unfavourable) Expressed in all Expressed in all liver: 440.7 ALDOA ENSG00000149925 Aldolase A, fructose-bisphosphate 16 30053090-30070457 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA004177, CAB006252 Supported Supported Cytosol Liver cancer:5.79e-5 (unfavourable), Lung cancer:7.32e-5 (unfavourable) Expressed in all Tissue enriched 7 skeletal muscle: 9379.1 esophagus: 1434.9 ALDOB ENSG00000136872 Aldolase B, fructose-bisphosphate 9 101420578-101435823 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA002198, CAB020827 Supported Tissue enriched Group enriched 23 duodenum: 3808.7;kidney: 6531.8;liver: 5081.5;small intestine: 5731.3 gallbladder: 232.6 ALDOC ENSG00000109107 Aldolase C, fructose-bisphosphate 17 28573115-28577264 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003282, CAB020828, HPA067442 Supported Supported Approved Nucleus
Nucleoli fibrillar center
Vesicles
Cytosol Renal cancer:1.29e-7 (unfavourable), Head and neck cancer:9.80e-4 (unfavourable) Tissue enriched Tissue enriched 7 cerebral cortex: 768.7 heart muscle: 110.6 ALK CD246 ENSG00000171094 Anaplastic lymphoma receptor tyrosine kinase 2 29192774-29921566 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010694 Approved Supported Plasma membrane Group enriched Tissue enhanced cerebral cortex: 3.5;testis: 2.3 adrenal gland: 0.9 ALKBH6 MGC15677 ENSG00000239382 AlkB homolog 6 19 36009120-36014239 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA073835, HPA074340 Supported Nucleoplasm
Focal adhesion sites Expressed in all Mixed cerebral cortex: 7.5 ALPK2 HAK ENSG00000198796 Alpha-kinase 2 18 58481247-58628957 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA027377, HPA027976, HPA028084, HPA029801 Uncertain Approved Cytosol Renal cancer:8.20e-5 (unfavourable) Tissue enriched Tissue enhanced heart muscle: 28.3;skeletal muscle: 14.1 lymph node: 6.9 ALPL HOPS, TNSALP ENSG00000162551 Alkaline phosphatase, liver/bone/kidney 1 21509372-21578412 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007105, HPA008765, CAB020829 Approved Approved Cytosol Melanoma:7.08e-4 (unfavourable) Expressed in all Tissue enhanced lung: 78.9 kidney: 47.0 ALPP ENSG00000163283 Alkaline phosphatase, placental 2 232378534-232382889 Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB026327, HPA038764, HPA038765, HPA051699 Supported Approved Plasma membrane Pancreatic cancer:4.33e-4 (unfavourable) Tissue enhanced Group enriched 14 cervix, uterine: 25.2;placenta: 45.5 fallopian tube: 2.5 AMER1 FAM123B, FLJ39827, RP11-403E24.2, WTX ENSG00000184675 APC membrane recruitment protein 1 X 64185117-64205744 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA065214, HPA065265 Approved Supported Nuclear bodies
Vesicles
Plasma membrane Expressed in all Mixed ovary: 7.7 AMPH ENSG00000078053 Amphiphysin 7 38383704-38631567 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB008559, HPA019828, HPA019829 Supported Supported Plasma membrane
Cytosol Pancreatic cancer:9.96e-4 (favourable) Tissue enhanced Tissue enriched 9 cerebral cortex: 84.0 cervix, uterine: 8.9 ANAPC1 APC1, MCPR, TSG24 ENSG00000153107 Anaphase promoting complex subunit 1 2 111766271-111884690 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036329, HPA036330, HPA042998 Approved Approved Vesicles Endometrial cancer:1.34e-4 (unfavourable) Expressed in all Expressed in all testis: 20.3 ANG RAA1, RNASE5 ENSG00000214274 Angiogenin, ribonuclease, RNase A family, 5 14 20684177-20698971 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Liver cancer:7.83e-5 (favourable), Endometrial cancer:6.85e-4 (favourable) Tissue enriched Tissue enriched 27 liver: 1557.7 prostate: 58.5 ANGPT1 Ang1, KIAA0003 ENSG00000154188 Angiopoietin 1 8 107249482-107498055 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB017815, HPA018793, HPA018816 Approved Renal cancer:4.40e-4 (favourable) Mixed Tissue enhanced seminal vesicle: 45.9 lung: 32.5 ANGPT2 Ang2 ENSG00000091879 Angiopoietin 2 8 6499651-6563409 Cancer-related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB011437, CAB017626 Approved Renal cancer:1.52e-7 (unfavourable), Liver cancer:6.36e-5 (unfavourable), Cervical cancer:7.99e-5 (unfavourable), Stomach cancer:3.87e-4 (unfavourable), Melanoma:4.48e-4 (unfavourable) Expressed in all Mixed placenta: 19.5 ANK3 ENSG00000151150 Ankyrin 3, node of Ranvier (ankyrin G) 10 60026298-60733490 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013249, CAB015179, HPA038455, HPA055643 Approved Approved Plasma membrane Renal cancer:8.88e-16 (favourable) Mixed Expressed in all parathyroid gland: 284.5 ANKRD12 FLJ20053, GAC-1, KIAA0874 ENSG00000101745 Ankyrin repeat domain 12 18 9136228-9285985 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA040705 Approved Supported Nucleoplasm
Cytosol Melanoma:6.71e-4 (unfavourable) Expressed in all Expressed in all testis: 54.2 ANXA1 ANX1, LPC1 ENSG00000135046 Annexin A1 9 73151757-73170393 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level HPA011271, HPA011272, CAB013023, CAB035987, CAB058693 Supported Validated Nucleoplasm
Plasma membrane
Cytosol Urothelial cancer:6.19e-6 (unfavourable), Thyroid cancer:4.57e-5 (favourable), Endometrial cancer:5.71e-5 (favourable) Expressed in all Tissue enriched 6 esophagus: 7577.8 tonsil: 1266.5 ANXA11 ANX11 ENSG00000122359 Annexin A11 10 80150889-80205572 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level CAB004851, HPA027545 Supported Supported Nucleoplasm
Cytosol Renal cancer:6.69e-8 (favourable) Expressed in all Expressed in all esophagus: 203.9 ANXA2 ANX2, ANX2L4, CAL1H, LIP2, LPC2D ENSG00000182718 Annexin A2 15 60347134-60402883 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level CAB004311 Approved Renal cancer:2.11e-6 (unfavourable), Pancreatic cancer:8.47e-6 (unfavourable), Liver cancer:2.54e-5 (unfavourable), Urothelial cancer:6.59e-5 (unfavourable), Endometrial cancer:6.88e-5 (favourable), Lung cancer:7.51e-4 (unfavourable) Expressed in all Expressed in all esophagus: 1494.3 ANXA4 ANX4 ENSG00000196975 Annexin A4 2 69644425-69827100 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB005076, HPA007393, CAB017560 Approved Approved Cytosol Ovarian cancer:2.38e-4 (unfavourable), Renal cancer:6.05e-4 (unfavourable), Breast cancer:8.55e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 884.9 ANXA7 ANX7 ENSG00000138279 Annexin A7 10 73375101-73414076 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB004312, HPA064290 Approved Approved Nucleoplasm
Cytosol Renal cancer:1.98e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 464.4 AOC3 HPAO, VAP-1, VAP1 ENSG00000131471 Amine oxidase, copper containing 3 17 42851184-42858130 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA000980, CAB025797 Supported Approved Golgi apparatus
Cytosol Renal cancer:1.79e-5 (unfavourable), Colorectal cancer:3.68e-4 (unfavourable), Urothelial cancer:6.98e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 449.0 smooth muscle: 203.0 AP2B1 ADTB2, CLAPB1 ENSG00000006125 Adaptor-related protein complex 2, beta 1 subunit 17 35578046-35726409 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB017631, HPA056733 Approved Supported Vesicles Renal cancer:2.62e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 260.8 APAF1 APAF-1, CED4 ENSG00000120868 Apoptotic peptidase activating factor 1 12 98645141-98735433 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA031373, CAB069399 Approved Approved Nucleoplasm
Golgi apparatus
Cytosol Colorectal cancer:5.90e-4 (favourable) Expressed in all Mixed bone marrow: 21.7 APC DP2, DP2.5, DP3, PPP1R46 ENSG00000134982 Adenomatous polyposis coli 5 112707498-112846239 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA013349, CAB025994 Approved Expressed in all Tissue enhanced cerebral cortex: 60.3 parathyroid gland: 19.5 APEX1 APE, APE-1, APEN, APEX, APX, HAP1, REF-1, REF1 ENSG00000100823 APEX nuclease (multifunctional DNA repair enzyme) 1 14 20455191-20457772 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA000956, HPA002564, CAB004294, CAB047307 Supported Validated Nucleus Liver cancer:7.82e-5 (unfavourable) Expressed in all Expressed in all ovary: 176.0 APOA1 ENSG00000118137 Apolipoprotein A-I 11 116835751-116837950 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB016778, HPA046715 Supported Approved Vesicles
Cytosol Renal cancer:1.67e-8 (unfavourable), Liver cancer:5.05e-4 (favourable) Tissue enriched Tissue enhanced liver: 8446.1;small intestine: 4222.2 duodenum: 1654.8 APOA2 ENSG00000158874 Apolipoprotein A-II 1 161222292-161223631 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB025885 Supported Tissue enriched Tissue enriched 1053 liver: 18141.3 bone marrow: 17.2 APOC1 ENSG00000130208 Apolipoprotein C-I 19 44914247-44919349 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA051518 Supported Liver cancer:1.15e-7 (favourable) Tissue enriched Tissue enriched 6 liver: 7217.4 adrenal gland: 1118.5 APOC3 ENSG00000110245 Apolipoprotein C-III 11 116829706-116833072 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Renal cancer:6.87e-5 (unfavourable), Liver cancer:3.77e-4 (favourable) Tissue enriched Tissue enriched 7 liver: 8606.5 small intestine: 1203.1 APOD ENSG00000189058 Apolipoprotein D 3 195568702-195584205 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA040520 Supported Thyroid cancer:4.12e-4 (unfavourable), Breast cancer:5.51e-4 (favourable), Stomach cancer:6.02e-4 (unfavourable) Expressed in all Tissue enriched 7 breast: 4546.8 adipose tissue: 668.0 APOE AD2 ENSG00000130203 Apolipoprotein E 19 44905754-44909393 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB008363, HPA065539, HPA068768, CAB069921 Supported Approved Vesicles Expressed in all Expressed in all adrenal gland: 1810.4 APOL2 APOL-II ENSG00000128335 Apolipoprotein L, 2 22 36226203-36239954 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001078 Uncertain Approved Nucleoplasm
Nuclear bodies
Cytosol Renal cancer:1.22e-7 (unfavourable), Urothelial cancer:5.06e-6 (favourable) Expressed in all Expressed in all gallbladder: 65.0 APPBP2 Hs.84084, KIAA0228, PAT1 ENSG00000062725 Amyloid beta precursor protein (cytoplasmic tail) binding protein 2 17 60443149-60526219 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA050874 Supported Cytosol Liver cancer:3.65e-4 (unfavourable) Expressed in all Expressed in all testis: 44.5 AR AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1 ENSG00000169083 Androgen receptor X 67544032-67730619 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000001, HPA065701, CAB065764 Supported Approved Mitochondria Renal cancer:1.03e-8 (favourable), Liver cancer:8.77e-4 (favourable) Mixed Mixed fallopian tube: 42.6 AREG AREGB, SDGF ENSG00000109321 Amphiregulin 4 74445134-74455009 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA008720, CAB023519 Approved Approved Mitochondria Lung cancer:1.05e-5 (unfavourable), Head and neck cancer:2.61e-5 (unfavourable), Pancreatic cancer:8.32e-5 (unfavourable) Expressed in all Tissue enhanced placenta: 461.0 gallbladder: 120.0 ARG2 ENSG00000081181 Arginase 2 14 67619798-67651720 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA000663, CAB009435 Supported Supported Mitochondria Expressed in all Tissue enhanced parathyroid gland: 96.3;prostate: 165.6;thyroid gland: 157.3 kidney: 63.5 ARHGAP26 GRAF, KIAA0621, OPHN1L, OPHN1L1 ENSG00000145819 Rho GTPase activating protein 26 5 142770384-143229011 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035106, HPA035107 Approved Approved Cytosol Urothelial cancer:2.88e-6 (favourable), Endometrial cancer:5.93e-6 (favourable), Cervical cancer:1.36e-4 (favourable), Breast cancer:2.05e-4 (favourable), Colorectal cancer:6.95e-4 (favourable) Expressed in all Mixed cerebral cortex: 30.9 ARHGAP32 GC-GAP, GRIT, KIAA0712, MGC1892, RICS ENSG00000134909 Rho GTPase activating protein 32 11 128965060-129279324 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA038382, HPA038389, HPA061505 Approved Approved Nucleoplasm
Nucleoli fibrillar center
Golgi apparatus Pancreatic cancer:6.64e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 44.2 ARHGAP35 GRF-1, GRLF1, KIAA1722, P190A, p190ARhoGAP, p190RhoGAP ENSG00000160007 Rho GTPase activating protein 35 19 46918676-47005077 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB037311, HPA055184, HPA056470 Approved Supported Nuclear bodies
Aggresome Renal cancer:5.55e-8 (favourable) Expressed in all Expressed in all testis: 96.5 ARHGEF12 KIAA0382, LARG ENSG00000196914 Rho guanine nucleotide exchange factor (GEF) 12 11 120336914-120489936 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA018911, CAB025581 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:5.43e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 143.2 ARHGEF6 alpha-PIX, alphaPIX, Cool-2, Cool2, KIAA0006, MRX46 ENSG00000129675 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 X 136665547-136782088 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA003578 Approved Approved Cytosol Expressed in all Mixed placenta: 62.7 ARID1A B120, BAF250, BAF250a, C10rf4, C1orf4, P270, SMARCF1 ENSG00000117713 AT rich interactive domain 1A (SWI-like) 1 26696033-26782104 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA005456, CAB016334 Supported Validated Nucleoplasm Liver cancer:4.18e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 40.4 ARID1B 6A3-5, BAF250b, DAN15, ELD/OSA1, KIAA1235, p250R ENSG00000049618 AT rich interactive domain 1B (SWI1-like) 6 156777374-157210779 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA016511, HPA075291 Approved Supported Nucleoplasm Breast cancer:1.04e-4 (unfavourable), Ovarian cancer:4.16e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 75.6 ARID2 BAF200, DKFZp686G052, FLJ30619, KIAA1557 ENSG00000189079 AT rich interactive domain 2 (ARID, RFX-like) 12 45729665-45908040 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA063044 Supported Nucleoplasm
Plasma membrane Head and neck cancer:5.75e-4 (favourable) Expressed in all Expressed in all testis: 47.3 ARID5B FLJ21150, MRF2 ENSG00000150347 AT rich interactive domain 5B (MRF1-like) 10 61901300-62096944 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA015037 Uncertain Approved Plasma membrane
Cytosol Expressed in all Expressed in all gallbladder: 62.1 ARNT bHLHe2, HIF-1beta ENSG00000143437 Aryl hydrocarbon receptor nuclear translocator 1 150809705-150876768 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA001759, CAB004318 Supported Supported Nucleus
Nuclear bodies Expressed in all Expressed in all ovary: 46.6 ASPH BAH, CASQ2BP1, HAAH, JCTN ENSG00000198363 Aspartate beta-hydroxylase 8 61500556-61714640 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA055161, HPA059303 Uncertain Supported Endoplasmic reticulum Renal cancer:1.57e-5 (unfavourable), Cervical cancer:8.07e-5 (unfavourable), Pancreatic cancer:1.75e-4 (unfavourable), Lung cancer:3.61e-4 (unfavourable), Thyroid cancer:4.24e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 394.0 ASPM ASP, Calmbp1, FLJ10517, FLJ10549, MCPH5 ENSG00000066279 Abnormal spindle microtubule assembly 1 197084128-197146694 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017816 Approved Approved Plasma membrane
Cytosol Liver cancer:1.25e-4 (unfavourable), Endometrial cancer:1.97e-4 (unfavourable), Pancreatic cancer:2.40e-4 (unfavourable), Lung cancer:2.41e-4 (unfavourable) Mixed Tissue enhanced bone marrow: 11.0 lymph node: 9.6 ASPSCR1 ASPL, ASPS, UBXD9, UBXN9 ENSG00000169696 Alveolar soft part sarcoma chromosome region, candidate 1 17 81976807-82017406 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA026749 Approved Supported Nucleoplasm
Vesicles
Plasma membrane Renal cancer:1.26e-4 (unfavourable), Pancreatic cancer:2.67e-4 (favourable), Head and neck cancer:8.55e-4 (favourable) Expressed in all Expressed in all testis: 21.3 ASXL1 KIAA0978 ENSG00000171456 Additional sex combs like transcriptional regulator 1 20 32358344-32439319 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA064156 Approved Nucleus
Nucleoli Endometrial cancer:2.86e-4 (unfavourable), Head and neck cancer:9.16e-4 (favourable) Expressed in all Expressed in all testis: 68.2 ASXL2 ASXH2, FLJ10898, KIAA1685 ENSG00000143970 Additional sex combs like transcriptional regulator 2 2 25733753-25878516 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA034646, HPA058040 Validated Nucleoplasm Expressed in all Expressed in all parathyroid gland: 26.1 ATF1 TREB36 ENSG00000123268 Activating transcription factor 1 12 50763710-50821122 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB016222, HPA055069, HPA055406 Supported Validated Nucleoplasm Liver cancer:1.53e-5 (unfavourable) Expressed in all Expressed in all thyroid gland: 39.5 ATG13 KIAA0652 ENSG00000175224 Autophagy related 13 11 46617527-46674818 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA039350 Approved Nucleoplasm
Plasma membrane
Cytosol Liver cancer:8.59e-5 (unfavourable) Expressed in all Expressed in all testis: 111.4 ATIC AICARFT, IMPCHASE, PURH ENSG00000138363 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase 2 215311817-215349773 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013462, HPA021012 Supported Validated Plasma membrane
Cytosol Liver cancer:1.99e-7 (unfavourable), Renal cancer:8.77e-4 (unfavourable) Expressed in all Expressed in all placenta,rectum: 44.5 ATM ATA, ATC, ATD, ATDC, TEL1, TELO1 ENSG00000149311 ATM serine/threonine kinase 11 108222484-108369102 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000102, HPA067142 Supported Supported Nucleoplasm Expressed in all Expressed in all lymph node: 41.6 ATOH1 bHLHa14, HATH1, MATH-1, Math1 ENSG00000172238 Atonal bHLH transcription factor 1 4 93828753-93830964 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at transcript level Colorectal cancer:3.26e-5 (favourable) Tissue enhanced Group enriched 9 colon: 18.0;duodenum: 11.4;rectum: 20.1;small intestine: 22.8 appendix: 2.0 ATP1A1 ENSG00000163399 ATPase, Na+/K+ transporting, alpha 1 polypeptide 1 116372668-116410261 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB018702, CAB069993 Supported Renal cancer:8.98e-8 (favourable), Liver cancer:1.42e-4 (unfavourable), Urothelial cancer:4.01e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 2441.5 ATP2B3 CFAP39, CLA2, PMCA3, SCAX1 ENSG00000067842 ATPase, Ca++ transporting, plasma membrane 3 X 153517676-153582939 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA001583 Supported Uncertain Golgi apparatus
Plasma membrane Not detected Group enriched 8 adrenal gland: 12.2;cerebral cortex: 19.1 fallopian tube: 2.0 ATP5B ATPSB ENSG00000110955 ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide 12 56638175-56646068 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001520, HPA001528, CAB017527 Supported Validated Mitochondria Renal cancer:1.43e-9 (favourable), Breast cancer:7.17e-6 (unfavourable) Expressed in all Expressed in all heart muscle: 1257.9 ATP7B WND ENSG00000123191 ATPase, Cu++ transporting, beta polypeptide 13 51930436-52012125 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA009137, HPA013187 Supported Supported Golgi apparatus Endometrial cancer:5.01e-4 (unfavourable) Mixed Mixed testis: 14.0 ATR FRP1, MEC1, SCKL, SCKL1 ENSG00000175054 ATR serine/threonine kinase 3 142449235-142578826 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054320 Supported Nucleoplasm
Golgi apparatus Pancreatic cancer:1.23e-5 (unfavourable), Liver cancer:8.39e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 15.2 ATRX JMS, MRX52, RAD54, XH2, XNP ENSG00000085224 Alpha thalassemia/mental retardation syndrome X-linked X 77504878-77786269 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA001906, CAB009372, HPA064684, CAB068176 Supported Supported Nuclear bodies Expressed in all Expressed in all parathyroid gland: 53.5 AURKA AIK, ARK1, AurA, BTAK, PPP1R47, STK15, STK6, STK7 ENSG00000087586 Aurora kinase A 20 56369389-56392337 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB001454, HPA002636 Approved Approved Nucleus
Centrosome
Cytosol Renal cancer:1.47e-8 (unfavourable), Endometrial cancer:9.40e-5 (unfavourable), Liver cancer:1.49e-4 (unfavourable), Pancreatic cancer:6.13e-4 (unfavourable) Expressed in all Tissue enhanced testis: 53.3 lymph node: 24.3 AURKB Aik2, AIM-1, ARK2, AurB, IPL1, PPP1R48, STK12, STK5 ENSG00000178999 Aurora kinase B 17 8204733-8210600 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB005862, HPA037708 Supported Supported Nucleoplasm
Midbody Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.24e-4 (unfavourable) Expressed in all Tissue enhanced lymph node: 45.0;tonsil: 35.2 bone marrow: 28.2 AXIN1 PPP1R49 ENSG00000103126 Axin 1 16 287440-352673 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB012987 Approved Supported Nucleoli
Vesicles Liver cancer:3.38e-5 (unfavourable) Expressed in all Expressed in all spleen: 15.8 AXIN2 DKFZp781B0869, MGC126582 ENSG00000168646 Axin 2 17 65528563-65561647 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB012283, CAB017783 Approved Uncertain Nucleus
Plasma membrane
Cytosol Pancreatic cancer:6.58e-4 (favourable) Expressed in all Mixed endometrium: 31.0 AZGP1 ZA2G, ZAG ENSG00000160862 Alpha-2-glycoprotein 1, zinc-binding 7 99966720-99976157 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA012582, CAB016087, CAB032276 Supported Renal cancer:1.53e-4 (favourable), Liver cancer:2.90e-4 (favourable) Group enriched Tissue enhanced breast: 1188.3;liver: 1270.8;prostate: 1556.6;salivary gland: 1431.4 kidney: 292.6 B2M ENSG00000166710 Beta-2-microglobulin 15 44711477-44718877 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB002572, HPA006361 Supported Validated Golgi apparatus
Plasma membrane
Cytosol Expressed in all Expressed in all lymph node: 5182.5 BAD BBC2, BCL2L8 ENSG00000002330 BCL2-associated agonist of cell death 11 64269830-64284704 Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB004205, HPA028185, HPA062105 Approved Validated Mitochondria Expressed in all Expressed in all cerebral cortex: 49.1 BAG1 ENSG00000107262 BCL2-associated athanogene 9 33247820-33264761 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB002486, HPA018121 Supported Supported Nucleoplasm Renal cancer:2.22e-16 (favourable) Expressed in all Expressed in all parathyroid gland: 171.9 BAP1 hucep-6, KIAA0272, UCHL2 ENSG00000163930 BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase) 3 52401013-52410350 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB004322, HPA028814, HPA028815, HPA055560 Approved Validated Nucleoplasm
Cytosol Renal cancer:3.29e-7 (favourable) Expressed in all Expressed in all testis: 118.1 BARD1 ENSG00000138376 BRCA1 associated RING domain 1 2 214725646-214809711 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB034106, HPA035354, HPA044864 Supported Supported Nuclear speckles Expressed in all Mixed testis: 11.0 BAX BCL2L4 ENSG00000087088 BCL2-associated X protein 19 48954815-48961798 Cancer-related genes, Predicted intracellular proteins, Transporters Evidence at protein level CAB004206, HPA027878 Approved Liver cancer:1.63e-5 (unfavourable) Expressed in all Expressed in all appendix: 83.2 BCL10 c-E10, CARMEN, CIPER, CLAP, mE10 ENSG00000142867 B-cell CLL/lymphoma 10 1 85266248-85277090 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB001944, HPA017925 Approved Approved Nucleoplasm Liver cancer:7.21e-7 (unfavourable), Colorectal cancer:2.51e-4 (favourable) Expressed in all Expressed in all gallbladder: 30.5 BCL11A BCL11A-L, BCL11A-S, BCL11A-XL, CTIP1, EVI9, HBFQTL5, ZNF856 ENSG00000119866 B-cell CLL/lymphoma 11A (zinc finger protein) 2 60451167-60553567 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB014891, HPA029003 Approved Validated Nucleoplasm
Nuclear bodies Mixed Tissue enhanced skin: 41.0 tonsil: 31.8 BCL11B CTIP-2, CTIP2, hRIT1-alpha, ZNF856B ENSG00000127152 B-cell CLL/lymphoma 11B (zinc finger protein) 14 99169287-99271524 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA049117 Supported Supported Approved Nucleus
Nucleoli fibrillar center Urothelial cancer:7.48e-4 (favourable) Mixed Tissue enhanced lymph node: 12.4;skin: 18.8 tonsil: 7.7 BCL2 Bcl-2, PPP1R50 ENSG00000171791 B-cell CLL/lymphoma 2 18 63123346-63320128 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000003, HPA055295 Supported Supported Nucleoplasm
Nuclear membrane Renal cancer:1.29e-8 (favourable), Cervical cancer:5.13e-5 (favourable), Thyroid cancer:2.47e-4 (unfavourable) Expressed in all Tissue enhanced thyroid gland: 69.2 parathyroid gland: 34.6 BCL2A1 ACC-1, ACC-2, ACC1, ACC2, BCL2L5, BFL1, GRS, HBPA1 ENSG00000140379 BCL2-related protein A1 15 79960889-79971446 Cancer-related genes, Predicted intracellular proteins Evidence at protein level Renal cancer:2.77e-5 (unfavourable) Expressed in all Tissue enhanced appendix: 117.8;bone marrow: 277.7 lymph node: 62.9 BCL2L1 Bcl-X, bcl-xL, bcl-xS, BCL2L, BCLX, PPP1R52 ENSG00000171552 BCL2-like 1 20 31664452-31723989 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters Evidence at protein level HPA035734, CAB072801 Approved Approved Mitochondria Renal cancer:8.89e-5 (favourable), Pancreatic cancer:5.87e-4 (unfavourable), Endometrial cancer:9.10e-4 (unfavourable), Melanoma:9.57e-4 (favourable) Expressed in all Expressed in all gallbladder: 100.9 BCL2L2 BCL-W, KIAA0271, PPP1R51 ENSG00000129473 BCL2-like 2 14 23298790-23311759 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB040539 Approved Renal cancer:1.99e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 89.1 BCL2L2-PABPN1 ENSG00000258643 BCL2L2-PABPN1 readthrough 14 23306835-23325369 Cancer-related genes, Predicted intracellular proteins, Transporters Evidence at protein level HPA000637 Approved Approved Mixed Mixed seminal vesicle: 28.8 BCL3 BCL4, D19S37 ENSG00000069399 B-cell CLL/lymphoma 3 19 44747705-44760044 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002051, HPA047514 Approved Supported Nucleoplasm
Vesicles
Midbody Renal cancer:3.13e-14 (unfavourable), Melanoma:3.74e-4 (favourable), Glioma:5.58e-4 (unfavourable), Breast cancer:9.67e-4 (favourable) Expressed in all Expressed in all appendix: 30.9 BCL6 BCL5, BCL6A, LAZ3, ZBTB27, ZNF51 ENSG00000113916 B-cell CLL/lymphoma 6 3 187721377-187745727 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000307, HPA004899, HPA050645 Supported Validated Nucleoplasm
Golgi apparatus Renal cancer:1.27e-9 (unfavourable) Expressed in all Expressed in all adipose tissue: 112.8 BCL7A BCL7 ENSG00000110987 B-cell CLL/lymphoma 7A 12 122019422-122062044 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA019762 Approved Approved Nucleoplasm
Vesicles Renal cancer:1.54e-6 (favourable), Liver cancer:2.04e-4 (unfavourable), Colorectal cancer:6.81e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 13.8 BCL9 ENSG00000116128 B-cell CLL/lymphoma 9 1 147541412-147626216 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA020274 Approved Approved Nucleoplasm
Nuclear bodies Liver cancer:6.74e-4 (unfavourable) Expressed in all Mixed fallopian tube: 26.3 BCLAF1 BTF, KIAA0164 ENSG00000029363 BCL2-associated transcription factor 1 6 136256863-136289851 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006484, HPA006669, HPA027770 Supported Validated Nuclear speckles Breast cancer:1.64e-4 (unfavourable), Colorectal cancer:3.44e-4 (favourable) Expressed in all Expressed in all bone marrow: 91.1 BCOR FLJ20285, KIAA1575 ENSG00000183337 BCL6 corepressor X 40049815-40177329 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA056308, HPA066234 Validated Nucleus Liver cancer:1.30e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 33.3 BCR ALL, BCR1, CML, D22S11, D22S662, PHL ENSG00000186716 Breakpoint cluster region 22 23179704-23318037 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB010421, CAB018545, HPA038337 Approved Approved Nucleoplasm
Cytosol Renal cancer:9.15e-10 (favourable) Expressed in all Expressed in all cerebral cortex: 48.5 BDNF ENSG00000176697 Brain-derived neurotrophic factor 11 27654893-27722058 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009564, HPA031440, HPA056104 Supported Supported Nuclear speckles
Mitochondria Mixed Tissue enhanced cerebral cortex: 12.0 epididymis: 5.8 BHMT2 ENSG00000132840 Betaine--homocysteine S-methyltransferase 2 5 79069717-79089466 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA044573 Supported Group enriched Group enriched 6 kidney: 360.3;liver: 238.4 epididymis: 46.4 BIRC2 API1, c-IAP1, cIAP1, hiap-2, MIHB, RNF48 ENSG00000110330 Baculoviral IAP repeat containing 2 11 102347211-102378670 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA005513, CAB020661 Supported Supported Nucleus
Nucleoli fibrillar center
Cytosol Expressed in all Expressed in all testis: 45.6 BIRC3 API2, c-IAP2, cIAP2, hiap-1, MALT2, MIHC, RNF49 ENSG00000023445 Baculoviral IAP repeat containing 3 11 102317450-102339403 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002317 Supported Approved Supported Nucleoplasm
Cytosol Renal cancer:6.66e-6 (unfavourable), Pancreatic cancer:3.03e-4 (unfavourable), Breast cancer:3.60e-4 (favourable), Colorectal cancer:9.35e-4 (favourable) Expressed in all Tissue enhanced lymph node: 139.7 appendix: 121.3 BIRC5 API4, EPR-1, survivin ENSG00000089685 Baculoviral IAP repeat containing 5 17 78214186-78225636 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA002830, CAB004270 Supported Validated Cytokinetic bridge Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.28e-6 (unfavourable), Lung cancer:4.49e-4 (unfavourable) Expressed in all Tissue enhanced testis: 26.7 bone marrow: 22.7 BIRC6 BRUCE ENSG00000115760 Baculoviral IAP repeat containing 6 2 32357028-32618899 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA074409, HPA074738 Supported Golgi apparatus
Vesicles Expressed in all Mixed parathyroid gland: 30.8 BLK MGC10442 ENSG00000136573 BLK proto-oncogene, Src family tyrosine kinase 8 11494001-11564604 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB005093 Approved Mixed Group enriched 10 appendix: 22.9;lymph node: 61.9;spleen: 41.3;tonsil: 54.0 urinary bladder: 4.5 BLM BS, RECQ2, RECQL3 ENSG00000197299 Bloom syndrome, RecQ helicase-like 15 90717327-90816165 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA005689 Approved Supported Nucleus
Cytosol Mixed Mixed lymph node: 3.8 BLMH BH ENSG00000108578 Bleomycin hydrolase 17 30248195-30292056 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA039548, HPA064307 Supported Supported Nucleoplasm
Nuclear bodies
Cytosol Expressed in all Expressed in all skin: 140.2 BMI1 PCGF4, RNF51 ENSG00000168283 BMI1 proto-oncogene, polycomb ring finger 10 22321211-22331484 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB011120, HPA030471, HPA030472 Supported Approved Nucleus
Nucleoli
Nuclear bodies
Cytosol Liver cancer:2.60e-8 (unfavourable) Expressed in all Expressed in all parathyroid gland: 84.7 BMP2 BMP2A ENSG00000125845 Bone morphogenetic protein 2 20 6767664-6780280 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA058610 Supported Vesicles Expressed in all Mixed thyroid gland: 31.1 BMP4 BMP2B ENSG00000125378 Bone morphogenetic protein 4 14 53949736-53958761 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB006863, HPA066235 Approved Expressed in all Mixed placenta: 63.6 BMPR1A ACVRLK3, ALK3, CD292 ENSG00000107779 Bone morphogenetic protein receptor, type IA 10 86756650-86932838 Cancer-related genes, CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB019398 Approved Approved Cytosol Liver cancer:8.93e-4 (unfavourable), Glioma:9.38e-4 (favourable) Expressed in all Mixed thyroid gland: 33.8 BNIP3 Nip3 ENSG00000176171 BCL2/adenovirus E1B 19kDa interacting protein 3 10 131966455-131982013 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA003015, CAB011676 Supported Uncertain Cytosol Renal cancer:4.55e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 84.4 BNIP3L BNIP3a, Nix ENSG00000104765 BCL2/adenovirus E1B 19kDa interacting protein 3-like 8 26382898-26505636 Cancer-related genes, Predicted membrane proteins, Transporters Evidence at protein level HPA015652, CAB025371 Supported Approved Nuclear speckles
Mitochondria Renal cancer:5.92e-5 (unfavourable), Thyroid cancer:3.95e-4 (unfavourable) Expressed in all Expressed in all placenta: 150.7 BRAF BRAF1 ENSG00000157764 B-Raf proto-oncogene, serine/threonine kinase 7 140719327-140924764 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA001328, CAB004552, HPA071048 Approved Approved Vesicles
Cytosol Expressed in all Expressed in all testis: 41.6 BRCA1 BRCC1, FANCS, PPP1R53, RNF53 ENSG00000012048 Breast cancer 1, early onset 17 43044295-43170245 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB001946, HPA034966 Approved Expressed in all Mixed testis: 23.9 BRCA2 BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, XRCC11 ENSG00000139618 Breast cancer 2, early onset 13 32315474-32400266 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA026815 Uncertain Approved Nucleoplasm
Cytosol Mixed Tissue enhanced testis: 5.1 bone marrow: 4.1 BRD3 KIAA0043, ORFX, RING3L ENSG00000169925 Bromodomain containing 3 9 134030305-134068535 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA051830 Approved Approved Nuclear bodies Renal cancer:2.71e-7 (favourable) Expressed in all Expressed in all cerebral cortex: 21.4 BRD4 CAP, HUNK1, HUNKI, MCAP ENSG00000141867 Bromodomain containing 4 19 15235519-15332545 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA015055, HPA061646, CAB068177, CAB068178 Supported Validated Nucleoplasm Expressed in all Expressed in all placenta: 41.6 BRE BRCC4, BRCC45 ENSG00000158019 Brain and reproductive organ-expressed (TNFRSF1A modulator) 2 27889941-28338901 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA017926 Approved Supported Cytosol Liver cancer:6.33e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 190.4 BRIP1 BACH1, FANCJ, OF ENSG00000136492 BRCA1 interacting protein C-terminal helicase 1 17 61681266-61863521 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA005474 Approved Supported Nucleus
Nuclear membrane Colorectal cancer:3.45e-5 (favourable), Head and neck cancer:3.62e-4 (favourable) Mixed Tissue enhanced testis: 14.4 bone marrow: 5.0 BRMS1 DKFZP564A063 ENSG00000174744 Breast cancer metastasis suppressor 1 11 66337333-66345125 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB010824, HPA019637 Approved Approved Centrosome Liver cancer:6.74e-4 (unfavourable) Expressed in all Expressed in all skin: 36.3 BTG1 ENSG00000133639 B-cell translocation gene 1, anti-proliferative 12 92140278-92145897 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA005972 Approved Nucleoplasm
Cytosol Renal cancer:1.95e-7 (unfavourable), Breast cancer:4.36e-5 (favourable) Expressed in all Expressed in all bone marrow: 261.6 BTG2 MGC126063, MGC126064, PC3, TIS21 ENSG00000159388 BTG family, member 2 1 203305491-203309602 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA002355 Uncertain Approved Nucleoplasm
Vesicles Breast cancer:8.53e-4 (favourable) Expressed in all Expressed in all ovary: 662.9 BUB1B Bub1A, BUBR1, MAD3L, SSK1 ENSG00000156970 BUB1 mitotic checkpoint serine/threonine kinase B 15 40161023-40221136 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA008419 Supported Cytosol Liver cancer:7.43e-6 (unfavourable), Pancreatic cancer:1.79e-4 (unfavourable), Lung cancer:3.56e-4 (unfavourable) Expressed in all Tissue enhanced testis: 40.2 lymph node: 15.1 C15orf65 FLJ27352 ENSG00000261652 Chromosome 15 open reading frame 65 15 55408548-55418764 Cancer-related genes, Predicted intracellular proteins Evidence at transcript level HPA067189 Approved Approved Nucleus
Cytosol Endometrial cancer:3.18e-7 (favourable) Expressed in all Mixed testis: 16.8 C18orf8 HsT2591, MIC-1, MIC1 ENSG00000141452 Chromosome 18 open reading frame 8 18 23503470-23531807 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA043589 Uncertain Uncertain Nucleus Liver cancer:3.94e-4 (unfavourable) Expressed in all Expressed in all testis: 33.0 C1QBP gC1Q-R, gC1qR, HABP1, p32, SF2p32 ENSG00000108561 Complement component 1, q subcomponent binding protein 17 5432777-5448830 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level HPA026483 Supported Approved Plasma membrane
Mitochondria Expressed in all Expressed in all rectum: 159.4 C2orf44 FLJ21945 ENSG00000163026 Chromosome 2 open reading frame 44 2 24029340-24049575 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA041054 Approved Approved Nucleoli
Cytosol Liver cancer:5.14e-8 (unfavourable), Endometrial cancer:6.53e-4 (unfavourable) Expressed in all Mixed testis: 9.2 C3orf70 ENSG00000187068 Chromosome 3 open reading frame 70 3 185078050-185153014 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA041861 Uncertain Approved Cytosol Renal cancer:6.40e-6 (unfavourable) Tissue enhanced Tissue enhanced smooth muscle: 25.7 cerebral cortex: 19.2 C6 ENSG00000039537 Complement component 6 5 41142234-41261438 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters Evidence at protein level HPA043823, CAB069427 Supported Renal cancer:4.31e-4 (favourable) Group enriched Group enriched 7 fallopian tube: 72.6;liver: 357.7 heart muscle: 30.6 C7 ENSG00000112936 Complement component 7 5 40909252-40982939 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA001465 Approved Liver cancer:5.89e-4 (favourable) Expressed in all Tissue enhanced adrenal gland: 1120.3 placenta: 710.8 CA8 CALS, CARP ENSG00000178538 Carbonic anhydrase VIII 8 60187347-60281412 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA024748, CAB025545, CAB047309 Supported Pancreatic cancer:5.79e-5 (favourable) Mixed Tissue enriched 6 parathyroid gland: 103.6 epididymis: 17.1 CACNA1D CACH3, CACN4, CACNL1A2, Cav1.3, CCHL1A2 ENSG00000157388 Calcium channel, voltage-dependent, L type, alpha 1D subunit 3 53494656-53813733 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA020215 Uncertain Approved Nuclear membrane Renal cancer:8.34e-8 (favourable) Mixed Mixed fallopian tube: 13.7 CAD ENSG00000084774 Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase 2 27217390-27243943 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB007781, HPA057266, HPA069341 Supported Supported Nucleoplasm Liver cancer:1.72e-11 (unfavourable), Renal cancer:1.82e-4 (unfavourable) Expressed in all Expressed in all skin: 22.0 CALCA CALC1 ENSG00000110680 Calcitonin-related polypeptide alpha 11 14966668-14972354 Cancer-related genes, Plasma proteins, Predicted secreted proteins, Transporters Evidence at protein level Endometrial cancer:4.49e-5 (unfavourable) Tissue enriched Group enriched 77 parathyroid gland: 832.9;thyroid gland: 181.9 kidney: 6.6 CALM1 CALML2, CAMI, DD132, PHKD ENSG00000198668 Calmodulin 1 (phosphorylase kinase, delta) 14 90396502-90408261 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins, Transporters Evidence at protein level CAB018558, HPA044999 Supported Approved Vesicles Urothelial cancer:2.38e-5 (unfavourable), Pancreatic cancer:5.62e-4 (favourable), Renal cancer:6.49e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 1329.9 CALM2 CAMII, PHKD ENSG00000143933 Calmodulin 2 (phosphorylase kinase, delta) 2 47160082-47176601 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins, Transporters Evidence at protein level CAB007790, HPA044999 Approved Thyroid cancer:1.94e-5 (favourable), Liver cancer:8.35e-5 (unfavourable), Endometrial cancer:4.84e-4 (unfavourable), Breast cancer:5.05e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 1537.9 CALM3 PHKD ENSG00000160014 Calmodulin 3 (phosphorylase kinase, delta) 19 46601074-46610793 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins, Transporters Evidence at protein level HPA044999 Approved Lung cancer:2.07e-4 (unfavourable), Thyroid cancer:9.10e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 1317.4 CALR cC1qR, CRT, FLJ26680, RO, SSA ENSG00000179218 Calreticulin 19 12938578-12944489 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB001513, HPA002242, CAB019952 Supported Renal cancer:1.11e-16 (unfavourable), Ovarian cancer:1.10e-4 (favourable) Expressed in all Expressed in all thyroid gland: 1647.1 CAMTA1 KIAA0833 ENSG00000171735 Calmodulin binding transcription activator 1 1 6785324-7769706 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA036342, HPA036343 Approved Supported Nucleoli
Cytosol Ovarian cancer:4.10e-4 (favourable), Liver cancer:5.25e-4 (unfavourable) Expressed in all Expressed in all epididymis: 98.1 CANT1 SCAN-1, SHAPY ENSG00000171302 Calcium activated nucleotidase 1 17 78991717-79009867 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019627, HPA019639, HPA022818 Supported Liver cancer:1.41e-4 (unfavourable), Lung cancer:2.90e-4 (unfavourable), Renal cancer:6.21e-4 (unfavourable) Expressed in all Expressed in all prostate: 110.0 CANX CNX, IP90, P90 ENSG00000127022 Calnexin 5 179678628-179730925 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB004738, HPA009433, HPA009696 Supported Validated Endoplasmic reticulum Colorectal cancer:1.38e-4 (favourable), Thyroid cancer:3.17e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 871.4 CAP2 ENSG00000112186 CAP, adenylate cyclase-associated protein, 2 (yeast) 6 17393216-17557792 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA050530, HPA054147 Supported Approved Nucleoplasm
Plasma membrane
Cytosol Expressed in all Tissue enhanced cerebral cortex: 125.5;skeletal muscle: 220.9 heart muscle: 69.1 CAPN6 CalpM, CANPX, CAPNX ENSG00000077274 Calpain 6 X 111245103-111270523 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA040383 Uncertain Cytosol Tissue enhanced Tissue enhanced epididymis: 251.6;placenta: 116.3;seminal vesicle: 99.3 endometrium: 36.9 CARD11 BIMP3, CARMA1 ENSG00000198286 Caspase recruitment domain family, member 11 7 2906141-3043945 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA052984 Approved Renal cancer:6.68e-8 (unfavourable), Urothelial cancer:1.10e-4 (favourable) Expressed in all Tissue enhanced lymph node: 55.1;spleen: 41.0 appendix: 29.3 CARM1 PRMT4 ENSG00000142453 Coactivator-associated arginine methyltransferase 1 19 10871513-10923070 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB032961, HPA043561, HPA048073 Supported Validated Nucleoplasm Renal cancer:7.88e-6 (unfavourable), Urothelial cancer:8.37e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 37.1 CARS CARS1 ENSG00000110619 Cysteinyl-tRNA synthetase 11 3000922-3057613 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA002383, HPA002384, CAB075734, CAB075735, CAB075736, CAB075737 Supported Validated Cytosol Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.16e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 28.2 CASC3 BTZ, MLN51 ENSG00000108349 Cancer susceptibility candidate 3 17 40140318-40172183 Cancer-related genes, Predicted intracellular proteins, Transporters Evidence at protein level HPA024592, HPA050262 Approved Approved Nuclear membrane Expressed in all Expressed in all testis: 94.9 CASC5 AF15Q14, CT29, D40, hKNL-1, hSpc105, KNL1, PPP1R55, Spc7 ENSG00000137812 Cancer susceptibility candidate 5 15 40594020-40664342 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA026624, HPA049647 Supported Validated Nucleoplasm
Nuclear bodies Lung cancer:2.11e-4 (unfavourable) Mixed Tissue enriched 7 testis: 31.6 lymph node: 4.5 CASP1 ICE, IL1BC ENSG00000137752 Caspase 1, apoptosis-related cysteine peptidase 11 105025443-105035250 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB002685, HPA003056 Approved Supported Nucleoplasm
Cytosol Renal cancer:3.11e-4 (unfavourable) Expressed in all Mixed small intestine: 142.8 CASP10 MCH4 ENSG00000003400 Caspase 10, apoptosis-related cysteine peptidase 2 201182881-201229406 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB003780, HPA017059 Approved Uncertain Golgi apparatus
Vesicles Renal cancer:6.05e-7 (unfavourable), Liver cancer:8.54e-4 (unfavourable) Expressed in all Mixed spleen: 24.6 CASP2 ICH1, MGC2181, NEDD2, PPP1R57 ENSG00000106144 Caspase 2, apoptosis-related cysteine peptidase 7 143288215-143307696 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB012175, HPA050678 Approved Approved Nucleoplasm Renal cancer:5.01e-6 (unfavourable), Liver cancer:2.34e-4 (unfavourable), Ovarian cancer:2.89e-4 (favourable), Cervical cancer:7.38e-4 (favourable) Expressed in all Expressed in all lymph node: 25.3 CASP3 apopain, CPP32, CPP32B, Yama ENSG00000164305 Caspase 3, apoptosis-related cysteine peptidase 4 184627696-184649509 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000091, HPA002643, CAB008381 Approved Supported Nucleoplasm
Mitochondria Renal cancer:2.30e-5 (unfavourable), Endometrial cancer:2.24e-4 (favourable) Expressed in all Expressed in all duodenum: 55.9 CASP4 ICE(rel)II, ICH-2, TX ENSG00000196954 Caspase 4, apoptosis-related cysteine peptidase 11 104942866-104969436 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA027588, CAB037167 Approved Approved Plasma membrane
Cytosol Renal cancer:3.27e-11 (unfavourable) Expressed in all Expressed in all placenta: 71.5 CASP5 ICE(rel)III ENSG00000137757 Caspase 5, apoptosis-related cysteine peptidase 11 104994235-105023168 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA040937 Uncertain Group enriched Group enriched 6 appendix: 20.7;colon: 16.2;duodenum: 10.4;rectum: 14.7;small intestine: 19.3 smooth muscle: 2.6 CASP6 MCH2 ENSG00000138794 Caspase 6, apoptosis-related cysteine peptidase 4 109688622-109703583 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB003775, HPA011337, HPA024303 Supported Supported Nucleus
Cytosol Colorectal cancer:2.64e-5 (favourable), Urothelial cancer:9.93e-4 (favourable) Expressed in all Expressed in all small intestine: 47.1 CASP7 CMH-1, ICE-LAP3, MCH3 ENSG00000165806 Caspase 7, apoptosis-related cysteine peptidase 10 113679162-113730907 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB025563 Approved Breast cancer:2.11e-4 (favourable), Renal cancer:5.90e-4 (unfavourable) Expressed in all Expressed in all small intestine: 75.9 CASP8 Casp-8, FLICE, MACH, MCH5 ENSG00000064012 Caspase 8, apoptosis-related cysteine peptidase 2 201233443-201287711 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA001302, CAB002047, HPA005688, HPA006191 Approved Validated Nucleoplasm
Cytosol Renal cancer:1.27e-6 (unfavourable), Ovarian cancer:1.25e-4 (favourable), Liver cancer:3.02e-4 (unfavourable) Expressed in all Expressed in all spleen: 45.6 CASP9 APAF-3, ICE-LAP6, MCH6, PPP1R56 ENSG00000132906 Caspase 9, apoptosis-related cysteine peptidase 1 15490832-15526534 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA001473, CAB004348, HPA046488 Approved Approved Mitochondria Urothelial cancer:1.67e-5 (favourable), Breast cancer:5.91e-4 (favourable) Expressed in all Expressed in all adrenal gland: 37.3 CAST ENSG00000153113 Calpastatin 5 96525267-96779595 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009491, HPA036881, HPA036882 Approved Validated Endoplasmic reticulum
Cytosol Stomach cancer:1.20e-5 (unfavourable), Pancreatic cancer:9.27e-5 (unfavourable), Urothelial cancer:4.98e-4 (unfavourable) Expressed in all Expressed in all esophagus: 403.4 CAT ENSG00000121691 Catalase 11 34438925-34472062 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB001515, HPA051282, HPA055838 Supported Supported Vesicles
Cytosol Renal cancer:1.96e-8 (favourable), Liver cancer:9.67e-4 (favourable) Expressed in all Expressed in all liver: 624.4 CAV1 CAV ENSG00000105974 Caveolin 1, caveolae protein, 22kDa 7 116524785-116561184 Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB003791, HPA049326 Supported Supported Golgi apparatus Lung cancer:7.17e-5 (unfavourable), Renal cancer:1.29e-4 (unfavourable) Expressed in all Tissue enhanced lung: 860.5 adipose tissue: 638.7 CBFA2T3 MTG16, MTGR2, ZMYND4 ENSG00000129993 Core-binding factor, runt domain, alpha subunit 2; translocated to, 3 16 88874858-88977204 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA059931, HPA062423, HPA065890 Approved Validated Nucleoplasm Head and neck cancer:3.95e-4 (favourable) Mixed Tissue enhanced spleen: 19.1 lymph node: 10.6 CBFB PEBP2B ENSG00000067955 Core-binding factor, beta subunit 16 67029116-67101058 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA038852 Uncertain Approved Nucleus
Cytosol Renal cancer:2.89e-8 (unfavourable), Liver cancer:2.83e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 95.6 CBL c-Cbl, CBL2, RNF55 ENSG00000110395 Cbl proto-oncogene, E3 ubiquitin protein ligase 11 119206276-119308149 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB004350, HPA027956 Supported Supported Cytosol Expressed in all Mixed testis: 33.1 CBLB Cbl-b, RNF56 ENSG00000114423 Cbl proto-oncogene B, E3 ubiquitin protein ligase 3 105655461-105869552 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA018327, HPA019880 Approved Supported Nucleoplasm
Cytosol Expressed in all Expressed in all lymph node: 28.4 CBLC CBL-3, CBL-SL, RNF57 ENSG00000142273 Cbl proto-oncogene C, E3 ubiquitin protein ligase 19 44777869-44800634 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB008087, HPA035266 Approved Approved Nucleoplasm Renal cancer:3.11e-6 (favourable) Mixed Tissue enhanced duodenum: 53.9;skin: 42.0;small intestine: 44.9 colon: 21.8 CCAR1 CARP-1, CARP1, FLJ10590 ENSG00000060339 Cell division cycle and apoptosis regulator 1 10 68721012-68792377 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA007856, HPA048513 Supported Supported Nucleoplasm
Golgi apparatus Liver cancer:1.41e-5 (unfavourable), Ovarian cancer:4.05e-5 (favourable), Renal cancer:1.37e-4 (unfavourable) Expressed in all Expressed in all lymph node: 35.2 CCDC120 JM11 ENSG00000147144 Coiled-coil domain containing 120 X 49053572-49069857 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA000561 Approved Uncertain Mitochondria Expressed in all Mixed skin: 17.9 CCDC6 D10S170, H4, PTC, TPC, TST1 ENSG00000108091 Coiled-coil domain containing 6 10 59788763-59906656 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA019049, HPA019051 Supported Supported Cytosol Liver cancer:1.11e-4 (unfavourable), Pancreatic cancer:3.95e-4 (unfavourable), Head and neck cancer:5.48e-4 (favourable) Expressed in all Expressed in all smooth muscle: 43.8 CCKBR ENSG00000110148 Cholecystokinin B receptor 11 6259736-6272127 Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Tissue enriched Group enriched 14 cerebral cortex: 13.7;pancreas: 5.4;stomach: 16.1 prostate: 0.8 CCL11 eotaxin, MGC22554, SCYA11 ENSG00000172156 Chemokine (C-C motif) ligand 11 17 34285668-34288334 Cancer-related genes, Predicted secreted proteins Evidence at protein level Head and neck cancer:1.99e-4 (favourable), Colorectal cancer:8.70e-4 (favourable) Mixed Tissue enhanced appendix: 40.5;small intestine: 38.0 duodenum: 31.7 CCL13 CKb10, MCP-4, MGC17134, NCC-1, SCYA13, SCYL1 ENSG00000181374 Chemokine (C-C motif) ligand 13 17 34356452-34358610 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Mixed Mixed lung: 31.6 CCL14 CKb1, HCC-1, HCC-3, MCIF, NCC-2, SCYA14, SCYL2 ENSG00000276409 Chemokine (C-C motif) ligand 14 17 35983291-35987004 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB004423, HPA030268 Uncertain Mixed Tissue enhanced spleen: 276.2 adipose tissue: 123.1 CCL16 CKb12, HCC-4, LCC-1, LEC, LMC, Mtn-1, NCC-4, SCYA16, SCYL4 ENSG00000275152 Chemokine (C-C motif) ligand 16 17 35976493-35981496 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Tissue enriched Tissue enriched 73 liver: 60.7 spleen: 0.8 CCL18 AMAC-1, CKb7, DC-CK1, DCCK1, MIP-4, PARC, SCYA18 ENSG00000275385 Chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) 17 36064280-36072032 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Expressed in all Tissue enhanced adipose tissue: 20.6;lung: 13.1;tonsil: 10.9 lymph node: 6.3 CCL19 CKb11, ELC, exodus-3, MIP-3b, SCYA19 ENSG00000172724 Chemokine (C-C motif) ligand 19 9 34689567-34691277 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA067758 Supported Renal cancer:8.63e-7 (unfavourable), Cervical cancer:9.91e-6 (favourable), Breast cancer:2.88e-5 (favourable) Expressed in all Group enriched 5 adipose tissue: 171.7;appendix: 807.5;lymph node: 715.5;tonsil: 578.1 urinary bladder: 110.3 CCL2 GDCF-2, HC11, MCAF, MCP-1, MCP1, MGC9434, SCYA2, SMC-CF ENSG00000108691 Chemokine (C-C motif) ligand 2 17 34255218-34257203 Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB013676, HPA019163 Approved Approved Golgi apparatus
Vesicles Renal cancer:4.51e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 412.4 CCL21 6Ckine, CKb9, ECL, exodus-2, SCYA21, SLC, TCA4 ENSG00000137077 Chemokine (C-C motif) ligand 21 9 34709005-34710124 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB005067, HPA051210 Supported Mixed Tissue enhanced lymph node: 3206.9 tonsil: 984.2 CCL23 Ckb-8, CKb8, MIP-3, MPIF-1, SCYA23 ENSG00000274736 Chemokine (C-C motif) ligand 23 17 36013056-36017968 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA042015 Uncertain Mixed Tissue enhanced smooth muscle: 15.2 lung: 11.2 CCL3 G0S19-1, LD78ALPHA, MIP-1-alpha, SCYA3 ENSG00000277632 Chemokine (C-C motif) ligand 3 17 36088256-36090169 Cancer-related genes, Predicted secreted proteins Evidence at protein level Expressed in all Tissue enhanced bone marrow: 50.3 cerebral cortex: 12.4 CCL4 Act-2, AT744.1, LAG1, MIP-1-beta, SCYA4 ENSG00000275302 Chemokine (C-C motif) ligand 4 17 36103590-36105621 Cancer-related genes, Predicted secreted proteins Evidence at protein level CAB007805 Approved Endometrial cancer:1.97e-5 (favourable), Renal cancer:1.68e-4 (unfavourable), Colorectal cancer:3.54e-4 (favourable), Melanoma:3.97e-4 (favourable) Expressed in all Tissue enhanced spleen: 25.2 lymph node: 17.9 CCL5 D17S136E, MGC17164, RANTES, SCYA5, SISd, TCP228 ENSG00000271503 Chemokine (C-C motif) ligand 5 17 35871491-35880793 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Renal cancer:3.61e-7 (unfavourable), Endometrial cancer:1.34e-5 (favourable), Melanoma:2.42e-4 (favourable) Expressed in all Tissue enhanced spleen: 81.8 lymph node: 69.9 CCL7 FIC, MARC, MCP-3, MCP3, NC28, SCYA6, SCYA7 ENSG00000108688 Chemokine (C-C motif) ligand 7 17 34270221-34272242 Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Mixed Group enriched 8 appendix: 3.6;bone marrow: 15.3 gallbladder,rectum: 1.1 CCL8 HC14, MCP-2, SCYA8 ENSG00000108700 Chemokine (C-C motif) ligand 8 17 34319036-34321402 Cancer-related genes, Predicted secreted proteins Evidence at protein level Renal cancer:1.05e-7 (unfavourable) Mixed Mixed adipose tissue: 13.0 CCNA1 CT146 ENSG00000133101 Cyclin A1 13 36431520-36442882 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA060646 Approved Nucleoplasm
Nuclear bodies Head and neck cancer:1.70e-4 (unfavourable) Tissue enhanced Tissue enhanced parathyroid gland: 58.7;testis: 143.7 fallopian tube: 27.6 CCNA2 CCN1, CCNA ENSG00000145386 Cyclin A2 4 121816444-121823933 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB000114, HPA020626 Approved Validated Nucleoplasm
Cytosol Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:4.43e-6 (unfavourable), Liver cancer:9.17e-5 (unfavourable), Lung cancer:4.27e-4 (unfavourable), Endometrial cancer:8.78e-4 (unfavourable) Expressed in all Mixed lymph node: 29.6 CCNB1 CCNB ENSG00000134057 Cyclin B1 5 69167010-69178245 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level CAB000115, CAB003804, HPA030741, HPA061448 Supported Validated Cytosol Renal cancer:1.11e-16 (unfavourable), Liver cancer:1.54e-7 (unfavourable), Lung cancer:3.38e-4 (unfavourable) Expressed in all Mixed lymph node: 66.3 CCNB1IP1 C14orf18, HEI10 ENSG00000100814 Cyclin B1 interacting protein 1, E3 ubiquitin protein ligase 14 20311368-20333312 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Renal cancer:5.18e-6 (favourable) Expressed in all Expressed in all ovary: 120.3 CCNB2 HsT17299 ENSG00000157456 Cyclin B2 15 59105078-59125045 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level HPA008873, CAB009575 Supported Validated Golgi apparatus
Cytosol Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:1.74e-5 (unfavourable), Melanoma:3.21e-5 (unfavourable), Liver cancer:2.83e-4 (unfavourable), Lung cancer:4.63e-4 (unfavourable) Expressed in all Tissue enhanced testis: 122.0 bone marrow: 44.8 CCND1 BCL1, D11S287E, PRAD1, U21B31 ENSG00000110092 Cyclin D1 11 69641087-69654474 Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB000024, HPA027802 Uncertain Supported Nucleoplasm Pancreatic cancer:1.96e-4 (unfavourable), Head and neck cancer:5.51e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 335.1 skin: 140.9 CCND2 ENSG00000118971 Cyclin D2 12 4273772-4305350 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA049138, HPA054196 Approved Supported Nucleoplasm Thyroid cancer:9.76e-5 (favourable), Pancreatic cancer:2.52e-4 (favourable) Expressed in all Mixed epididymis: 55.1 CCND3 ENSG00000112576 Cyclin D3 6 41934933-42050357 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB000116, HPA055107 Approved Supported Plasma membrane
Focal adhesion sites
Cytosol Thyroid cancer:8.08e-6 (favourable) Expressed in all Expressed in all lymph node: 161.4 CCNE1 CCNE ENSG00000105173 Cyclin E1 19 29811898-29824308 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB000308, CAB016682, HPA018169 Approved Validated Nucleoplasm Endometrial cancer:6.35e-6 (unfavourable), Liver cancer:3.89e-5 (unfavourable), Ovarian cancer:2.97e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 44.3 testis: 22.4 CCNE2 CYCE2 ENSG00000175305 Cyclin E2 8 94879770-94896678 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB007825, CAB019374 Approved Head and neck cancer:5.87e-4 (favourable), Lung cancer:8.77e-4 (unfavourable) Mixed Mixed testis: 27.0 CCNG1 CCNG ENSG00000113328 Cyclin G1 5 163437569-163446151 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000350 Supported Supported Nucleoplasm Colorectal cancer:7.00e-4 (favourable) Expressed in all Expressed in all duodenum: 141.4 CCNG2 ENSG00000138764 Cyclin G2 4 77157151-77433388 Cancer-related genes, Predicted intracellular proteins Evidence at transcript level HPA034684 Approved Approved Nucleoplasm
Cytosol Renal cancer:2.47e-5 (favourable), Pancreatic cancer:8.57e-4 (unfavourable) Expressed in all Expressed in all esophagus: 151.2 CCNH CycH, p34, p37 ENSG00000134480 Cyclin H 5 87391494-87413019 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB019416, HPA044138 Approved Supported Nucleoplasm Renal cancer:3.92e-5 (unfavourable), Ovarian cancer:4.35e-4 (unfavourable) Expressed in all Expressed in all testis: 88.5 CCR10 GPR2 ENSG00000184451 Chemokine (C-C motif) receptor 10 17 42678889-42683917 Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB011684, HPA048007, HPA069188 Uncertain Supported Endoplasmic reticulum Mixed Mixed adipose tissue: 4.5 CCR7 BLR2, CD197, CDw197, CMKBR7, EBI1 ENSG00000126353 Chemokine (C-C motif) receptor 7 17 40553769-40565472 Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB003796, HPA031383, HPA074467 Supported Supported Mitochondria Head and neck cancer:7.61e-7 (favourable), Cervical cancer:8.03e-6 (favourable), Breast cancer:3.84e-4 (favourable), Testis cancer:7.72e-4 (unfavourable) Mixed Group enriched 6 appendix: 91.9;lymph node: 98.3;spleen: 39.9;tonsil: 80.2 urinary bladder: 12.9 CD14 ENSG00000170458 CD14 molecule 5 140631728-140633701 Cancer-related genes, CD markers, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA001887, HPA002127, CAB033631, CAB072865, CAB072866 Supported Supported Vesicles Renal cancer:6.80e-5 (unfavourable) Expressed in all Expressed in all appendix: 273.9 CD1D ENSG00000158473 CD1d molecule 1 158179947-158184896 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level CAB016107, HPA072662 Uncertain Supported Endoplasmic reticulum Renal cancer:2.12e-5 (unfavourable) Mixed Mixed spleen: 20.9 CD27 S152, TNFRSF7, Tp55 ENSG00000139193 CD27 molecule 12 6444867-6451718 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002420, HPA038936 Supported Head and neck cancer:6.65e-7 (favourable), Renal cancer:1.19e-6 (unfavourable), Cervical cancer:3.77e-5 (favourable), Endometrial cancer:2.90e-4 (favourable), Melanoma:5.50e-4 (favourable) Expressed in all Tissue enhanced lymph node: 142.5;tonsil: 90.3 spleen: 69.5 CD274 B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1 ENSG00000120217 CD274 molecule 9 5450503-5470566 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level CAB030018 Approved Cytosol Colorectal cancer:1.64e-5 (favourable), Breast cancer:8.89e-4 (favourable) Mixed Mixed appendix: 14.4 CD36 FAT, GP3B, GP4, GPIV, SCARB3 ENSG00000135218 CD36 molecule (thrombospondin receptor) 7 80369575-80679277 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA002018, CAB025866 Supported Stomach cancer:4.47e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 1614.0 CD38 ENSG00000004468 CD38 molecule 4 15778275-15853230 Cancer-related genes, CD markers, Enzymes, Predicted intracellular proteins Evidence at protein level CAB002493, HPA022132, CAB025255, HPA052381 Supported Approved Plasma membrane Endometrial cancer:9.68e-4 (favourable) Expressed in all Mixed lymph node,seminal vesicle: 27.3 CD40 Bp50, p50, TNFRSF5 ENSG00000101017 CD40 molecule, TNF receptor superfamily member 5 20 46118272-46129863 Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002495, HPA031567, HPA031568, CAB072868 Supported Renal cancer:4.48e-4 (unfavourable) Expressed in all Expressed in all lymph node: 65.6 CD40LG CD154, CD40L, gp39, hCD40L, HIGM1, IMD3, TNFSF5, TRAP ENSG00000102245 CD40 ligand X 136648193-136660390 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level HPA045827 Supported Mixed Tissue enhanced lymph node: 19.0;tonsil: 14.7 appendix: 10.9 CD44 CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1 ENSG00000026508 CD44 molecule (Indian blood group) 11 35138870-35232402 Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000112, CAB000316, HPA005785 Supported Validated Golgi apparatus
Plasma membrane Renal cancer:1.78e-8 (unfavourable) Expressed in all Expressed in all skin: 505.8 CD46 MCP, MGC26544, MIC10, TLX, TRA2.10 ENSG00000117335 CD46 molecule, complement regulatory protein 1 207752057-207795513 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB010401, HPA016903 Supported Approved Plasma membrane Cervical cancer:8.54e-5 (unfavourable), Stomach cancer:2.38e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 483.7 CD52 CDW52 ENSG00000169442 CD52 molecule 1 26317957-26320523 Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins Evidence at protein level Breast cancer:1.85e-5 (favourable), Endometrial cancer:2.06e-4 (favourable), Head and neck cancer:4.45e-4 (favourable), Renal cancer:5.85e-4 (unfavourable) Expressed in all Tissue enriched 34 epididymis: 43067.6 lymph node: 1271.7 CD59 16.3A5, EJ16, EJ30, EL32, G344, MIC11, MIN1, MIN2, MIN3, MSK21, p18-20 ENSG00000085063 CD59 molecule, complement regulatory protein 11 33698261-33736445 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB001448, HPA026494 Supported Approved Golgi apparatus
Vesicles Renal cancer:1.39e-10 (favourable), Pancreatic cancer:2.92e-5 (unfavourable), Head and neck cancer:3.10e-5 (unfavourable), Cervical cancer:3.81e-5 (unfavourable), Stomach cancer:9.03e-4 (unfavourable) Expressed in all Expressed in all epididymis: 907.3 CD70 CD27L, CD27LG, TNFSF7 ENSG00000125726 CD70 molecule 19 6583183-6604103 Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046582 Uncertain Nucleoplasm Renal cancer:3.22e-4 (unfavourable), Lung cancer:6.29e-4 (unfavourable) Tissue enhanced Tissue enhanced appendix: 4.5 lymph node: 3.9 CD74 DHLAG ENSG00000019582 CD74 molecule, major histocompatibility complex, class II invariant chain 5 150401637-150412929 Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level CAB002506, HPA010592 Supported Supported Golgi apparatus Endometrial cancer:6.53e-6 (favourable), Breast cancer:1.06e-4 (favourable) Expressed in all Expressed in all spleen: 6665.5 CD79A IGA, MB-1 ENSG00000105369 CD79a molecule, immunoglobulin-associated alpha 19 41877120-41881372 Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000019 Supported Head and neck cancer:1.18e-5 (favourable), Renal cancer:2.15e-5 (unfavourable), Breast cancer:8.45e-5 (favourable) Mixed Group enriched 6 appendix: 275.4;lymph node: 522.9;spleen: 324.4;tonsil: 440.3 stomach: 62.7 CD79B B29, IGB ENSG00000007312 CD79b molecule, immunoglobulin-associated beta 17 63928740-63932354 Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level HPA009178, CAB009751 Approved Uncertain Nucleoplasm
Plasma membrane
Cytosol Head and neck cancer:2.35e-4 (favourable) Expressed in all Group enriched 5 appendix: 94.7;lymph node: 315.6;spleen: 160.3;tonsil: 196.1 bone marrow: 36.2 CD82 IA4, KAI1, R2, ST6, TSPAN27 ENSG00000085117 CD82 molecule 11 44564427-44620363 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002508, HPA028900, HPA061418 Supported Approved Vesicles Expressed in all Expressed in all esophagus: 132.1 CD9 BA2, MIC3, MRP-1, P24, TSPAN29 ENSG00000010278 CD9 molecule 12 6199715-6238271 Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB002490 Supported Supported Plasma membrane Renal cancer:6.49e-5 (favourable), Thyroid cancer:8.93e-5 (favourable), Pancreatic cancer:1.59e-4 (unfavourable) Expressed in all Expressed in all esophagus: 1009.8 CDC16 ANAPC6, APC6, CUT9 ENSG00000130177 Cell division cycle 16 13 114234887-114272723 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA042826 Approved Expressed in all Expressed in all testis: 83.4 CDC20 CDC20A, p55CDC ENSG00000117399 Cell division cycle 20 1 43358955-43363203 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004525, HPA045842, HPA055288 Supported Supported Nucleoplasm
Cytosol Renal cancer:0.00e+0 (unfavourable), Liver cancer:4.00e-8 (unfavourable), Pancreatic cancer:1.32e-4 (unfavourable) Expressed in all Tissue enhanced testis: 63.8 tonsil: 46.9 CDC25A ENSG00000164045 Cell division cycle 25A 3 48157146-48188402 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA005855 Uncertain Approved Nucleus
Golgi apparatus
Vesicles Tissue enhanced Tissue enhanced testis: 24.4 bone marrow: 9.3 CDC25B ENSG00000101224 Cell division cycle 25B 20 3786772-3806121 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA038892, HPA038893 Approved Uncertain Nucleoplasm
Cytosol Renal cancer:2.94e-13 (unfavourable), Liver cancer:1.19e-4 (unfavourable), Endometrial cancer:4.76e-4 (unfavourable) Expressed in all Mixed lymph node: 57.4 CDC25C CDC25, PPP1R60 ENSG00000158402 Cell division cycle 25C 5 138285265-138338355 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB003800, HPA066991 Uncertain Supported Nuclear speckles Liver cancer:3.03e-6 (unfavourable), Colorectal cancer:2.49e-4 (favourable), Lung cancer:4.38e-4 (unfavourable) Mixed Tissue enriched 7 testis: 31.7 rectum: 4.4 CDC27 ANAPC3, APC3, D0S1430E, D17S978E, NUC2 ENSG00000004897 Cell division cycle 27 17 47117703-47189422 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB016315, HPA028129, HPA052399 Supported Validated Nucleoplasm Renal cancer:6.39e-5 (unfavourable), Colorectal cancer:1.77e-4 (favourable), Liver cancer:4.38e-4 (unfavourable), Lung cancer:8.15e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 71.1 CDC34 E2-CDC34, UBC3, UBE2R1 ENSG00000099804 Cell division cycle 34 19 531712-542092 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA002382, CAB005109, CAB047311 Approved Supported Nuclear speckles
Cytosol Liver cancer:7.57e-4 (unfavourable) Expressed in all Expressed in all testis: 63.5 CDC37 P50CDC37 ENSG00000105401 Cell division cycle 37 19 10391134-10420121 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA003928, CAB004214 Supported Validated Cytosol Stomach cancer:2.33e-4 (favourable) Expressed in all Expressed in all appendix: 114.0 CDC6 CDC18L ENSG00000094804 Cell division cycle 6 17 40287633-40304657 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA050114, HPA054703 Approved Supported Nucleoplasm
Golgi apparatus
Cytosol Liver cancer:5.96e-8 (unfavourable), Pancreatic cancer:2.90e-4 (unfavourable) Expressed in all Mixed appendix: 15.8 CDC73 C1orf28, FIHP, HRPT1, HRPT2, parafibromin ENSG00000134371 Cell division cycle 73 1 193122017-193253901 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB016359, HPA030772 Supported Supported Nucleus
Cytosol Expressed in all Expressed in all thyroid gland: 32.0 CDH1 CD324, UVO, uvomorulin ENSG00000039068 Cadherin 1, type 1 16 68737225-68835548 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000087, HPA004812, CAB028364, CAB072855, CAB072856, CAB072857 Supported Supported Golgi apparatus
Plasma membrane
Cell Junctions Renal cancer:2.06e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 467.0 thyroid gland: 264.7 CDH11 CAD11, OB ENSG00000140937 Cadherin 11, type 2, OB-cadherin (osteoblast) 16 64943753-65126112 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB013072 Approved Renal cancer:2.48e-9 (unfavourable) Expressed in all Tissue enhanced ovary: 223.0 placenta: 172.7 CDH17 cadherin, HPT-1 ENSG00000079112 Cadherin 17, LI cadherin (liver-intestine) 8 94127171-94217303 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA023614, HPA023616, CAB025143, HPA026556 Supported Supported Cell Junctions Group enriched Group enriched 7 colon: 261.7;duodenum: 323.0;rectum: 272.5;small intestine: 300.5 appendix: 39.2 CDH5 7B4, CD144 ENSG00000179776 Cadherin 5, type 2 (vascular endothelium) 16 66366622-66404786 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB028366 Approved Renal cancer:5.14e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 332.2 lung: 120.6 CDK1 CDC2, CDC28A ENSG00000170312 Cyclin-dependent kinase 1 10 60778331-60794852 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level HPA003387, CAB003799 Uncertain Validated Nucleus
Cytosol Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.10e-6 (unfavourable), Pancreatic cancer:4.15e-6 (unfavourable), Lung cancer:7.88e-4 (unfavourable), Cervical cancer:8.81e-4 (favourable) Expressed in all Mixed lymph node: 48.1 CDK12 CRK7, CRKR, CRKRS, KIAA0904 ENSG00000167258 Cyclin-dependent kinase 12 17 39461511-39564907 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA008038 Supported Supported Nucleus Expressed in all Expressed in all testis: 33.8 CDK2 ENSG00000123374 Cyclin-dependent kinase 2 12 55966769-55972784 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013115, HPA066915 Supported Validated Nucleoplasm
Centrosome
Cytosol Renal cancer:1.46e-10 (unfavourable), Liver cancer:8.61e-5 (unfavourable), Head and neck cancer:9.94e-4 (unfavourable) Expressed in all Expressed in all placenta: 65.0 CDK4 PSK-J3 ENSG00000135446 Cyclin-dependent kinase 4 12 57747727-57756013 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006024, CAB069405 Approved Supported Nucleus
Nuclear membrane
Nucleoli
Cytosol Liver cancer:2.09e-7 (unfavourable), Renal cancer:3.15e-5 (unfavourable) Expressed in all Expressed in all endometrium: 120.2 CDK6 PLSTIRE ENSG00000105810 Cyclin-dependent kinase 6 7 92604921-92836594 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002637, CAB004363 Supported Supported Nucleoplasm
Cytosol Pancreatic cancer:3.86e-6 (unfavourable), Urothelial cancer:2.33e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 33.5 CDK7 CAK, CAK1, CDKN7, MO15, STK1 ENSG00000134058 Cyclin-dependent kinase 7 5 69234795-69277430 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004364, HPA007932 Supported Renal cancer:9.42e-7 (unfavourable), Pancreatic cancer:3.09e-4 (unfavourable) Expressed in all Mixed testis: 24.7 CDKN1A CAP20, CDKN1, CIP1, P21, p21CIP1, p21Cip1/Waf1, SDI1, WAF1 ENSG00000124762 Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 6 36676460-36687339 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB000064, HPA005946, CAB069401 Supported Supported Nucleoplasm
Nuclear bodies Endometrial cancer:3.14e-5 (favourable), Renal cancer:4.95e-5 (favourable), Lung cancer:7.05e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 205.5 CDKN1B KIP1, P27KIP1 ENSG00000111276 Cyclin-dependent kinase inhibitor 1B (p27, Kip1) 12 12715058-12722371 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB003691, CAB021888, HPA059086 Approved Supported Nucleus
Vesicles Liver cancer:3.25e-4 (unfavourable), Colorectal cancer:5.15e-4 (favourable), Renal cancer:8.39e-4 (unfavourable) Expressed in all Expressed in all ovary: 72.9 CDKN1C BWCR, BWS, KIP2, P57 ENSG00000129757 Cyclin-dependent kinase inhibitor 1C (p57, Kip2) 11 2883213-2885881 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA002924 Supported Approved Nucleoplasm
Nuclear bodies
Cytosol Expressed in all Tissue enhanced placenta: 202.0 adipose tissue: 62.4 CDKN2A ARF, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS1, p14, p14ARF, p16, p16INK4a, p19, p19Arf ENSG00000147889 Cyclin-dependent kinase inhibitor 2A 9 21967753-21995301 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000093, CAB000445, CAB018232, HPA047838 Uncertain Validated Nucleoli Endometrial cancer:1.82e-7 (unfavourable), Renal cancer:5.76e-7 (unfavourable), Liver cancer:2.17e-4 (unfavourable), Head and neck cancer:5.19e-4 (favourable) Expressed in all Mixed parathyroid gland: 7.5 CDKN2C INK4C, p18 ENSG00000123080 Cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) 1 50960745-50974633 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005303, CAB018398, HPA019057, HPA019764 Approved Approved Nucleoplasm
Cytosol Renal cancer:1.70e-10 (unfavourable), Liver cancer:1.58e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 80.3 CDX2 CDX3 ENSG00000165556 Caudal type homeobox 2 13 27962137-27971139 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002221, HPA045669, HPA049580 Supported Supported Nucleoplasm Tissue enriched Group enriched 6 colon: 31.4;duodenum: 22.9;rectum: 25.3;small intestine: 30.8 appendix: 4.9 CEACAM5 CD66e, CEA ENSG00000105388 Carcinoembryonic antigen-related cell adhesion molecule 5 19 41708585-41729798 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000021, CAB000022, HPA011041, HPA019758 Supported Supported Plasma membrane Tissue enhanced Tissue enhanced colon: 1030.9;rectum: 1100.3 appendix: 268.1 CEACAM6 CD66c, NCA ENSG00000086548 Carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) 19 41750977-41772208 Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB008370, HPA011041 Supported Mixed Group enriched 6 bone marrow: 110.9;colon: 184.1;esophagus: 174.2;gallbladder: 190.2;lung: 406.1;rectum: 236.9 appendix: 38.9 CEBPA C/EBP-alpha, CEBP ENSG00000245848 CCAAT/enhancer binding protein (C/EBP), alpha 19 33299934-33302564 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA052734, HPA065037, HPA067937 Approved Approved Nucleoplasm
Vesicles Expressed in all Expressed in all adipose tissue: 107.9 CENPF hcp-1 ENSG00000117724 Centromere protein F, 350/400kDa 1 214603195-214664588 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009581, HPA052382 Approved Supported Nucleoplasm Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.29e-5 (unfavourable), Pancreatic cancer:1.39e-4 (unfavourable) Expressed in all Tissue enhanced bone marrow: 17.7;testis: 18.7 lymph node: 10.2 CEP76 C18orf9, FLJ12542, HsT1705 ENSG00000101624 Centrosomal protein 76kDa 18 12661833-12702777 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA039395 Approved Expressed in all Mixed testis: 14.9 CEP89 CCDC123, FLJ14640 ENSG00000121289 Centrosomal protein 89kDa 19 32875925-32971991 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA039382, HPA040056 Uncertain Supported Plasma membrane
Cytosol Liver cancer:8.78e-5 (unfavourable) Expressed in all Mixed fallopian tube: 14.8 CFH ARMD4, ARMS1, FHL1, HF, HF1, HF2, HUS ENSG00000000971 Complement factor H 1 196651878-196747504 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB016385, CAB016769, HPA038922, HPA049176, HPA053326 Supported Approved Vesicles Renal cancer:1.92e-6 (unfavourable) Tissue enriched Tissue enhanced liver: 838.9 gallbladder: 206.0 CFHR1 CFHL, CFHL1, CFHL1P, CFHR1P, FHR1, H36-1, H36-2, HFL1, HFL2 ENSG00000244414 Complement factor H-related 1 1 196819757-196832189 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA038915, HPA038922, HPA040726 Supported Approved Vesicles Liver cancer:8.71e-6 (favourable) Tissue enriched Tissue enriched 144 liver: 1055.2 lymph node: 7.3 CFLAR c-FLIP, CASH, CASP8AP1, Casper, CLARP, FLAME, FLIP, I-FLICE, MRIT ENSG00000003402 CASP8 and FADD-like apoptosis regulator 2 201116104-201176687 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA019044, CAB022157, CAB025216 Uncertain Supported Nucleus
Nuclear bodies
Plasma membrane
Cytosol Head and neck cancer:2.79e-4 (favourable) Expressed in all Expressed in all bone marrow: 160.5 CFTR ABC35, ABCC7, CF, CFTR/MRP, dJ760C5.1, MRP7, TNR-CFTR ENSG00000001626 Cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) 7 117465784-117715971 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB001951, HPA021939 Supported Liver cancer:9.44e-4 (unfavourable) Tissue enhanced Tissue enhanced gallbladder: 89.6;rectum: 50.1 colon: 47.0 CGA FSHA, GPHa, GPHA1, HCG, LHA, TSHA ENSG00000135346 Glycoprotein hormones, alpha polypeptide 6 87085498-87095406 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB023350, HPA029698 Supported Tissue enhanced Tissue enriched 22 placenta: 652.2 stomach: 29.5 CGB CGB3 ENSG00000104827 Chorionic gonadotropin, beta polypeptide 19 49022869-49024333 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000042, CAB010884, HPA038925, HPA038934 Supported Approved Cytosol Tissue enhanced Tissue enriched 18 placenta: 14.9 testis: 0.8 CGB5 HCG ENSG00000189052 Chorionic gonadotropin, beta polypeptide 5 19 49043884-49045311 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA038925, HPA038934 Supported Approved Cytosol Stomach cancer:1.18e-5 (unfavourable), Urothelial cancer:9.47e-4 (unfavourable) Tissue enhanced Tissue enriched 67 placenta: 31.7 pancreas,skin,testis: 0.4 CGB7 CG-beta-a ENSG00000196337 Chorionic gonadotropin, beta polypeptide 7 19 49054275-49058860 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA038925, HPA038934 Supported Approved Cytosol Not detected Tissue enhanced skin: 3.9 testis: 1.1 CGB8 ENSG00000213030 Chorionic gonadotropin, beta polypeptide 8 19 49047638-49049106 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA038925, HPA038934 Supported Approved Cytosol Tissue enhanced Tissue enriched 92 placenta: 29.2 parathyroid gland: 0.3 CHCHD7 COX23, MGC2217 ENSG00000170791 Coiled-coil-helix-coiled-coil-helix domain containing 7 8 56211686-56218798 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA050783 Approved Approved Cell Junctions
Aggresome Endometrial cancer:1.39e-6 (unfavourable), Renal cancer:9.47e-5 (favourable) Expressed in all Expressed in all ovary: 61.5 CHD4 Mi-2b, Mi2-BETA ENSG00000111642 Chromodomain helicase DNA binding protein 4 12 6570083-6607476 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA012008 Supported Validated Nucleus Liver cancer:6.03e-6 (unfavourable) Expressed in all Expressed in all parathyroid gland: 117.2 CHD7 CRG, FLJ20357, FLJ20361, KIAA1416 ENSG00000171316 Chromodomain helicase DNA binding protein 7 8 60678778-60868028 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA053075 Supported Nucleus Endometrial cancer:5.34e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 14.6 CHD8 DUPLIN, HELSNF1, KIAA1564 ENSG00000100888 Chromodomain helicase DNA binding protein 8 14 21385194-21456126 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA052186 Supported Nucleoplasm Liver cancer:4.94e-4 (unfavourable), Ovarian cancer:8.35e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 46.2 CHEK1 CHK1 ENSG00000149554 Checkpoint kinase 1 11 125625136-125676255 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA044364 Approved Nucleoplasm
Vesicles Renal cancer:1.04e-8 (unfavourable), Pancreatic cancer:3.10e-6 (unfavourable), Liver cancer:3.70e-6 (unfavourable), Colorectal cancer:3.62e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 61.6;seminal vesicle: 52.5 testis: 21.8 CHEK2 bA444G7, CDS1, CHK2, HuCds1, PP1425, RAD53 ENSG00000183765 Checkpoint kinase 2 22 28687743-28742422 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA001878, CAB002030 Approved Supported Nucleoplasm
Golgi apparatus Renal cancer:7.80e-9 (unfavourable) Expressed in all Mixed testis: 13.2 CHFR FLJ10796, RNF196 ENSG00000072609 Checkpoint with forkhead and ring finger domains, E3 ubiquitin protein ligase 12 132822187-132956304 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA045768 Uncertain Nuclear bodies
Microtubules Renal cancer:4.21e-9 (unfavourable) Expressed in all Expressed in all testis: 22.8 CHGA ENSG00000100604 Chromogranin A 14 92923080-92935293 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000023, HPA017369, CAB040544, CAB055506, CAB058688 Supported Approved Vesicles Breast cancer:7.85e-5 (favourable), Liver cancer:2.40e-4 (unfavourable), Urothelial cancer:3.99e-4 (unfavourable), Pancreatic cancer:4.07e-4 (favourable) Tissue enhanced Tissue enriched 8 parathyroid gland: 6987.1 adrenal gland: 822.0 CHI3L1 GP39, YKL40 ENSG00000133048 Chitinase 3-like 1 (cartilage glycoprotein-39) 1 203178931-203186749 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA072269 Approved Vesicles Tissue enriched Tissue enhanced appendix: 191.3;cerebral cortex: 267.7;urinary bladder: 185.7 bone marrow: 147.1 CHIC2 BTL ENSG00000109220 Cysteine-rich hydrophobic domain 2 4 54009789-54064690 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA026782 Uncertain Renal cancer:1.56e-4 (unfavourable) Expressed in all Expressed in all testis: 62.9 CHN1 ARHGAP2, CHN, DURS2, n-chimerin, RhoGAP2 ENSG00000128656 Chimerin 1 2 174799363-175005369 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA036111 Approved Cytosol Renal cancer:5.07e-4 (unfavourable) Expressed in all Group enriched 7 cerebral cortex: 640.9;parathyroid gland: 131.0 placenta: 55.5 CHP2 ENSG00000166869 Calcineurin-like EF-hand protein 2 16 23754627-23758951 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB072806 Approved Tissue enhanced Group enriched 10 colon: 121.4;duodenum: 259.0;rectum: 130.7;skin: 144.2;small intestine: 232.0 cervix, uterine: 17.4 CIB2 DFNB48, KIP2, USH1J ENSG00000136425 Calcium and integrin binding family member 2 15 78104606-78131544 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA036697 Approved Renal cancer:6.16e-4 (favourable), Endometrial cancer:7.05e-4 (unfavourable) Expressed in all Mixed testis: 31.5 CIC KIAA0306 ENSG00000079432 Capicua transcriptional repressor 19 42268537-42295797 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB026388, HPA044341, HPA064725 Approved Supported Nucleoplasm
Vesicles Expressed in all Expressed in all testis: 55.0 CIITA C2TA, MHC2TA, NLRA ENSG00000179583 Class II, major histocompatibility complex, transactivator 16 10877198-10932281 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB016084 Approved Approved Nucleoplasm Expressed in all Mixed spleen: 53.8 CKB CKBB ENSG00000166165 Creatine kinase, brain 14 103519659-103523111 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001254, CAB047313 Supported Supported Cytosol Renal cancer:4.02e-8 (favourable) Expressed in all Expressed in all cerebral cortex: 476.4 CKS1B CKS1, ckshs1 ENSG00000173207 CDC28 protein kinase regulatory subunit 1B 1 154974653-154979249 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA003424, HPA030762 Approved Supported Approved Nucleus
Vesicles
Mitochondria
Cytosol Renal cancer:6.03e-7 (unfavourable), Liver cancer:2.94e-5 (unfavourable), Melanoma:3.12e-5 (unfavourable), Thyroid cancer:4.87e-4 (favourable), Pancreatic cancer:6.13e-4 (unfavourable), Endometrial cancer:7.89e-4 (unfavourable) Expressed in all Expressed in all lymph node: 86.0 CKS2 ENSG00000123975 CDC28 protein kinase regulatory subunit 2 9 89311198-89316703 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA003424, HPA030762 Approved Supported Approved Nucleus
Vesicles
Mitochondria
Cytosol Liver cancer:2.51e-6 (unfavourable), Renal cancer:1.78e-5 (unfavourable), Pancreatic cancer:6.85e-4 (unfavourable) Expressed in all Tissue enhanced testis: 339.8 lymph node: 124.3 CLDN3 C7orf1, CPE-R2, CPETR2, HRVP1, RVP1 ENSG00000165215 Claudin 3 7 73768997-73770270 Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002702, HPA014361 Supported Supported Cell Junctions Renal cancer:3.39e-5 (favourable) Mixed Tissue enhanced colon: 89.6;small intestine: 121.9 duodenum: 56.5 CLDN4 CPE-R, CPETR, CPETR1, hCPE-R, WBSCR8 ENSG00000189143 Claudin 4 7 73799542-73832693 Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002610 Supported Supported Plasma membrane Renal cancer:3.46e-10 (favourable), Ovarian cancer:3.28e-4 (unfavourable) Mixed Mixed colon: 212.3 CLDN7 CEPTRL2, CPETRL2, Hs.84359 ENSG00000181885 Claudin 7 17 7259903-7263983 Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB013063, HPA014703, HPA073662 Supported Approved Vesicles
Cell Junctions Renal cancer:8.96e-11 (favourable), Thyroid cancer:1.85e-4 (favourable), Stomach cancer:4.09e-4 (favourable) Expressed in all Mixed small intestine: 357.1 CLEC3B TN, TNA ENSG00000163815 C-type lectin domain family 3, member B 3 45001548-45036071 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB002582, HPA034794 Approved Liver cancer:9.99e-9 (favourable), Head and neck cancer:1.53e-4 (favourable), Pancreatic cancer:5.68e-4 (favourable) Expressed in all Tissue enhanced spleen: 309.1 adipose tissue: 203.5 CLIC1 NCC27, p64CLCP ENSG00000213719 Chloride intracellular channel 1 6 31730581-31739763 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level CAB020825, CAB040557 Supported Supported Cytosol Liver cancer:8.90e-7 (unfavourable), Renal cancer:8.11e-5 (unfavourable) Expressed in all Expressed in all rectum: 71.3 CLIP1 CLIP, CLIP-170, CLIP170, CYLN1, RSN ENSG00000130779 CAP-GLY domain containing linker protein 1 12 122271432-122422632 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004399, HPA026678 Approved Supported Microtubule ends
Cytosol Expressed in all Expressed in all parathyroid gland: 156.2 CLP1 hClp1, HEAB ENSG00000172409 Cleavage and polyadenylation factor I subunit 1 11 57648992-57661868 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA057770 Supported Supported Nucleoplasm Expressed in all Expressed in all bone marrow: 17.1 CLSTN1 CDHR12, CSTN1, KIAA0911 ENSG00000171603 Calsyntenin 1 1 9729026-9824526 Cancer-related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA012412 Approved Renal cancer:4.10e-7 (favourable) Expressed in all Expressed in all cerebral cortex: 382.9 CLTC CLTCL2, Hc ENSG00000141367 Clathrin, heavy chain (Hc) 17 59619689-59696956 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB010389, CAB011571, CAB017155, HPA059143 Approved Validated Endosomes
Lysosomes Urothelial cancer:2.02e-4 (unfavourable), Liver cancer:5.54e-4 (unfavourable), Cervical cancer:7.35e-4 (unfavourable), Colorectal cancer:7.65e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 358.1 CLTCL1 CHC22, CLH22, CLTCL, CLTD ENSG00000070371 Clathrin, heavy chain-like 1 22 19179473-19291716 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA075795 Approved Vesicles Mixed Tissue enhanced skeletal muscle: 24.1;testis: 49.4 bone marrow: 10.5 CLU APOJ, CLI, CLU1, CLU2, KUB1, SGP-2, SP-40, TRPM-2 ENSG00000120885 Clusterin 8 27596917-27615031 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000476, HPA000572, CAB016253 Uncertain Thyroid cancer:7.66e-5 (favourable) Expressed in all Expressed in all epididymis: 10967.7 CNBD1 FLJ35802 ENSG00000176571 Cyclic nucleotide binding domain containing 1 8 86866442-87615219 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA025037, HPA027469, HPA027786 Uncertain Not detected Tissue enriched 12 testis: 11.6 spleen: 0.9 CNBP CNBP1, DM2, RNF163, ZCCHC22, ZNF9 ENSG00000169714 CCHC-type zinc finger, nucleic acid binding protein 3 129169484-129183922 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA063097 Supported Nucleus
Cytosol Pancreatic cancer:3.51e-4 (unfavourable) Expressed in all Expressed in all ovary: 473.3 CNKSR1 CNK, CNK1, KSR ENSG00000142675 Connector enhancer of kinase suppressor of Ras 1 1 26177403-26189886 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA030847 Uncertain Approved Cytosol Urothelial cancer:5.91e-4 (favourable) Mixed Mixed parathyroid gland: 20.3 CNN1 Sm-Calp, SMCC ENSG00000130176 Calponin 1, basic, smooth muscle 19 11538717-11550323 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB000007, HPA014263 Supported Approved Actin filaments Renal cancer:5.43e-6 (unfavourable) Expressed in all Tissue enhanced seminal vesicle: 2086.6;smooth muscle: 3071.6 endometrium: 1724.7 CNOT3 KIAA0691, LENG2, NOT3, NOT3H ENSG00000088038 CCR4-NOT transcription complex, subunit 3 19 54137728-54155681 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA006408 Approved Approved Cytosol Liver cancer:2.22e-4 (unfavourable), Renal cancer:2.77e-4 (unfavourable) Expressed in all Expressed in all testis: 36.1 CNTF HCNTF ENSG00000242689 Ciliary neurotrophic factor 11 58622673-58625733 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019654 Uncertain Approved Vesicles Mixed Tissue enhanced fallopian tube: 7.6 bone marrow: 4.3 CNTRL CEP1, CEP110 ENSG00000119397 Centriolin 9 121074863-121177610 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA020468, HPA020480, HPA051583 Approved Supported Centrosome
Cytosol Head and neck cancer:9.21e-5 (favourable) Expressed in all Tissue enhanced testis: 65.6 lymph node: 29.3 COL11A1 CO11A1, COLL6, STL2 ENSG00000060718 Collagen, type XI, alpha 1 1 102876467-103108496 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA058335 Supported Endoplasmic reticulum Mixed Tissue enriched 6 placenta: 27.9 gallbladder: 4.7 COL17A1 BP180, BPAG2 ENSG00000065618 Collagen, type XVII, alpha 1 10 104031286-104086002 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043673, HPA052963 Supported Breast cancer:1.38e-4 (favourable), Pancreatic cancer:1.86e-4 (unfavourable) Tissue enhanced Tissue enriched 15 skin: 770.5 placenta: 52.8 COL18A1 KNO, KNO1, KS ENSG00000182871 Collagen, type XVIII, alpha 1 21 45405137-45513720 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB001961, HPA011025, HPA036104 Approved Approved Golgi apparatus Liver cancer:6.16e-4 (favourable) Expressed in all Expressed in all cervix, uterine: 129.0 COL1A1 OI4 ENSG00000108821 Collagen, type I, alpha 1 17 50183289-50201632 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA008405, HPA011795 Uncertain Approved Vesicles
Cytosol Renal cancer:7.19e-12 (unfavourable), Lung cancer:4.43e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 1863.2 COL1A2 OI4 ENSG00000164692 Collagen, type I, alpha 2 7 94394561-94431232 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB032650, HPA059738 Approved Supported Endoplasmic reticulum Renal cancer:1.51e-9 (unfavourable) Expressed in all Expressed in all cervix, uterine: 2933.7 COL2A1 AOM, SEDC, STL1 ENSG00000139219 Collagen, type II, alpha 1 12 47972965-48004486 Cancer-related genes, Disease related genes, Predicted secreted proteins Evidence at protein level CAB002214, HPA055753 Supported Approved Nucleoplasm Mixed Group enriched 9 epididymis: 22.6;stomach: 6.0 testis: 1.6 COL4A2 DKFZp686I14213, FLJ22259 ENSG00000134871 Collagen, type IV, alpha 2 13 110305812-110513027 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB010751, HPA029118 Supported Supported Vesicles Renal cancer:3.49e-5 (unfavourable), Urothelial cancer:9.25e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 827.3 smooth muscle: 396.9 COL4A3 ENSG00000169031 Collagen, type IV, alpha 3 (Goodpasture antigen) 2 227164565-227314792 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA042064 Approved Approved Endoplasmic reticulum
Vesicles Renal cancer:2.51e-7 (favourable) Group enriched Tissue enhanced thyroid gland: 26.7 lung: 22.4 COL4A4 CA44 ENSG00000081052 Collagen, type IV, alpha 4 2 227002711-227164113 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Renal cancer:2.30e-13 (favourable) Mixed Mixed thyroid gland: 14.0 COL4A5 ASLN, ATS ENSG00000188153 Collagen, type IV, alpha 5 X 108439844-108697545 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA065449 Uncertain Lipid droplets Renal cancer:2.41e-5 (unfavourable) Expressed in all Mixed endometrium: 75.8 COL5A1 ENSG00000130635 Collagen, type V, alpha 1 9 134641774-134844843 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA030769 Approved Approved Vesicles Renal cancer:2.07e-12 (unfavourable) Expressed in all Mixed cervix, uterine: 157.1 COL5A3 ENSG00000080573 Collagen, type V, alpha 3 19 9959561-10010471 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA048256 Approved Renal cancer:7.17e-8 (unfavourable), Urothelial cancer:6.87e-5 (unfavourable) Expressed in all Tissue enhanced placenta: 47.4 adipose tissue: 30.9 COL6A1 ENSG00000142156 Collagen, type VI, alpha 1 21 45981737-46005050 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA019142, HPA029401 Supported Approved Cytosol Renal cancer:1.07e-8 (unfavourable), Urothelial cancer:4.54e-4 (unfavourable) Expressed in all Mixed placenta: 400.7 COX17 ENSG00000138495 COX17 cytochrome c oxidase copper chaperone 3 119654513-119677454 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA042226, HPA048158 Supported Supported Mitochondria Expressed in all Expressed in all adrenal gland: 115.3 COX6C ENSG00000164919 Cytochrome c oxidase subunit VIc 8 99873200-99894062 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA014295, CAB016244 Supported Validated Mitochondria Expressed in all Expressed in all duodenum: 349.0 CP ENSG00000047457 Ceruloplasmin (ferroxidase) 3 149162410-149222055 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001834, CAB008591 Supported Renal cancer:1.14e-7 (unfavourable) Tissue enhanced Tissue enriched 10 liver: 916.4 cervix, uterine: 95.6 CRABP1 CRABP, CRABP-I, CRABPI, RBP5 ENSG00000166426 Cellular retinoic acid binding protein 1 15 78340324-78348230 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA017203 Approved Endometrial cancer:4.72e-4 (unfavourable) Tissue enhanced Tissue enhanced thyroid gland: 267.9 seminal vesicle: 63.7 CRADD RAIDD ENSG00000169372 CASP2 and RIPK1 domain containing adaptor with death domain 12 93677375-93894840 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB005337 Uncertain Approved Nucleus
Cytosol Renal cancer:4.04e-9 (favourable), Cervical cancer:9.06e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 32.2 CREB1 ENSG00000118260 CAMP responsive element binding protein 1 2 207529737-207603431 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB003803, HPA019150 Supported Validated Nucleoplasm Liver cancer:2.77e-5 (unfavourable) Expressed in all Expressed in all testis: 58.7 CREB3L1 OASIS ENSG00000157613 CAMP responsive element binding protein 3-like 1 11 46277661-46321422 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA024069, CAB026151 Supported Uncertain Plasma membrane
Cytosol Renal cancer:2.97e-4 (unfavourable), Endometrial cancer:3.92e-4 (favourable), Thyroid cancer:8.59e-4 (unfavourable) Expressed in all Mixed stomach: 66.1 CREB3L2 BBF2H7, TCAG_1951439 ENSG00000182158 CAMP responsive element binding protein 3-like 2 7 137874979-138002067 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA015068, HPA015534 Uncertain Supported Nucleoplasm
Endoplasmic reticulum Expressed in all Expressed in all thyroid gland: 109.9 CREBBP CBP, KAT3A, RSTS, RTS ENSG00000005339 CREB binding protein 16 3725054-3880726 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB004212, HPA055861 Supported Validated Nucleoplasm
Nuclear bodies Renal cancer:6.24e-5 (favourable) Expressed in all Expressed in all testis: 60.4 CRLF2 CRL2, TSLPR ENSG00000205755 Cytokine receptor-like factor 2 X 1187549-1212750 Cancer-related genes, Predicted membrane proteins Evidence at protein level Tissue enhanced Tissue enhanced appendix: 2.1;gallbladder: 2.0 bone marrow: 1.0 CRP PTX1 ENSG00000132693 C-reactive protein, pentraxin-related 1 159712289-159714589 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB005036, HPA027367, HPA027396 Supported Renal cancer:4.17e-10 (unfavourable) Tissue enriched Group enriched 68 gallbladder: 173.7;liver: 532.4 endometrium: 5.2 CRTC1 FLJ14027, KIAA0616, MECT1, TORC1 ENSG00000105662 CREB regulated transcription coactivator 1 19 18683677-18782333 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA022035 Approved Supported Nucleoplasm
Nuclear bodies
Plasma membrane
Cytosol Pancreatic cancer:1.80e-5 (favourable), Renal cancer:3.83e-5 (favourable) Expressed in all Expressed in all cerebral cortex: 23.8 CRTC3 FLJ21868 ENSG00000140577 CREB regulated transcription coactivator 3 15 90529925-90645345 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA043735, HPA063691 Uncertain Validated Nucleoplasm
Cytosol Expressed in all Expressed in all ovary: 50.5 CRYAB CRYA2, HSPB5 ENSG00000109846 Crystallin, alpha B 11 111908565-111923722 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002053, CAB040560, HPA057100 Supported Validated Plasma membrane
Cytosol Urothelial cancer:1.70e-5 (unfavourable), Colorectal cancer:4.90e-5 (unfavourable) Group enriched Tissue enhanced heart muscle: 3940.2 cerebral cortex: 1892.7 CSDE1 D1S155E, UNR ENSG00000009307 Cold shock domain containing E1, RNA-binding 1 114716913-114758676 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA018846, HPA052221 Supported Validated Cytosol Expressed in all Expressed in all skeletal muscle: 490.4 CSE1L CAS, CSE1, XPO2 ENSG00000124207 CSE1 chromosome segregation 1-like (yeast) 20 49046246-49096960 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level CAB002140, HPA038059, HPA038060 Supported Validated Nucleoplasm
Cytosol Liver cancer:2.42e-8 (unfavourable), Endometrial cancer:2.91e-5 (unfavourable), Renal cancer:1.89e-4 (unfavourable), Urothelial cancer:6.91e-4 (unfavourable) Expressed in all Expressed in all testis: 158.9 CSF1 M-CSF, MCSF, MGC31930 ENSG00000184371 Colony stimulating factor 1 (macrophage) 1 109910242-109930992 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA076624 Supported Plasma membrane Renal cancer:1.00e-11 (unfavourable), Liver cancer:4.25e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 66.1 CSF1R C-FMS, CD115, CSFR, FMS ENSG00000182578 Colony stimulating factor 1 receptor 5 150053291-150113372 Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB008970, HPA012323 Uncertain Supported Vesicles
Plasma membrane Renal cancer:1.08e-4 (unfavourable), Testis cancer:4.92e-4 (unfavourable) Expressed in all Mixed spleen: 150.2 CSF2 GM-CSF, GMCSF ENSG00000164400 Colony stimulating factor 2 (granulocyte-macrophage) 5 132073790-132076170 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA057404, HPA062006 Validated Vesicles Mixed Tissue enhanced lung: 3.0 urinary bladder: 0.9 CSF2RA CD116, CSF2R ENSG00000198223 Colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) X 1268800-1310381 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB016148 Uncertain Cervical cancer:2.38e-5 (favourable), Head and neck cancer:2.81e-4 (favourable), Testis cancer:5.53e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 93.5 appendix: 36.4 CSF3 C17orf33, G-CSF, GCSF, MGC45931 ENSG00000108342 Colony stimulating factor 3 (granulocyte) 17 40015361-40017813 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA001412, CAB016131 Approved Endometrial cancer:8.45e-4 (favourable) Mixed Tissue enhanced appendix: 19.4;cervix, uterine: 38.0 adipose tissue: 10.2 CSF3R CD114, GCSFR ENSG00000119535 Colony stimulating factor 3 receptor (granulocyte) 1 36466043-36483278 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB017116, HPA048086 Supported Testis cancer:3.79e-4 (unfavourable), Renal cancer:5.72e-4 (unfavourable) Mixed Tissue enhanced appendix: 215.2;bone marrow: 243.8;placenta: 147.0 spleen: 98.2 CSN1S1 CASA, CSN1 ENSG00000126545 Casein alpha s1 4 69931081-69946574 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA035659, HPA057031 Supported Tissue enriched Tissue enriched 85 breast: 1608.6 adipose tissue: 18.9 CSNK1E CKIE, CKIepsilon, HCKIE ENSG00000213923 Casein kinase 1, epsilon 22 38290691-38398522 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB009626, HPA026288 Approved Approved Nucleus
Cytosol Renal cancer:4.67e-6 (unfavourable), Liver cancer:8.20e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 173.6 CSNK2A1 ENSG00000101266 Casein kinase 2, alpha 1 polypeptide 20 473591-543821 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB020680, HPA059206, CAB069395 Approved Supported Nucleoplasm Liver cancer:4.11e-6 (unfavourable) Expressed in all Expressed in all testis: 133.0 CSNK2A2 CSNK2A1 ENSG00000070770 Casein kinase 2, alpha prime polypeptide 16 58157907-58197920 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA077719 Approved Nucleoplasm
Vesicles
Cytosol Head and neck cancer:1.40e-5 (unfavourable), Liver cancer:1.80e-4 (unfavourable) Expressed in all Expressed in all testis: 236.7 CSNK2B ENSG00000204435 Casein kinase 2, beta polypeptide 6 31665236-31670343 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004349, HPA005944, CAB013087, CAB016059 Approved Renal cancer:1.06e-5 (unfavourable) Expressed in all Mixed epididymis: 54.3 CST3 ENSG00000101439 Cystatin C 20 23626706-23638473 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000118, HPA013143 Supported Supported Golgi apparatus
Vesicles Endometrial cancer:1.83e-4 (favourable), Urothelial cancer:8.77e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 1269.6 CST6 ENSG00000175315 Cystatin E/M 11 66011841-66013505 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB019316, HPA044963 Supported Approved Plasma membrane
Cytosol Tissue enhanced Tissue enriched 9 skin: 213.3 breast: 24.7 CSTA STF1, STFA ENSG00000121552 Cystatin A (stefin A) 3 122325244-122341972 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000469, HPA001031, CAB047315 Supported Uncertain Nucleus
Cytosol Renal cancer:2.60e-6 (unfavourable), Head and neck cancer:5.86e-4 (favourable) Expressed in all Group enriched 6 esophagus: 3891.8;tonsil: 868.8 skin: 429.9 CSTB CST6, EPM1, PME, STFB ENSG00000160213 Cystatin B (stefin B) 21 43772512-43776445 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA017380, CAB047320, HPA058557 Supported Supported Nucleoli
Cytosol Liver cancer:6.66e-5 (unfavourable), Renal cancer:2.10e-4 (unfavourable) Expressed in all Tissue enriched 8 esophagus: 1836.3 tonsil: 237.3 CTAG1A ESO1, LAGE2A ENSG00000268651 Cancer/testis antigen 1A X 154585143-154586821 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB013061 Supported Not detected Tissue enriched 39 testis: 4.6 spleen: 0.1 CTAG1B CT6.1, CTAG, CTAG1, ESO1, LAGE2A, LAGE2B, NY-ESO-1 ENSG00000184033 Cancer/testis antigen 1B X 154617604-154619282 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB015453 Supported Not detected Tissue enriched 46 testis: 5.5 spleen: 0.1 CTAG2 CAMEL, CT6.2a, CT6.2b, ESO2, LAGE-1, LAGE-1a, LAGE-1b, LAGE1, MGC138724, MGC3803 ENSG00000126890 Cancer/testis antigen 2 X 154651972-154653579 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA071467 Supported Liver cancer:2.35e-4 (unfavourable) Mixed Group enriched 7 fallopian tube: 2.5;heart muscle: 2.5;placenta: 3.6;skeletal muscle: 1.2;testis: 6.0 pancreas: 0.4 CTCF ENSG00000102974 CCCTC-binding factor (zinc finger protein) 16 67562407-67639183 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA004122, CAB062550, CAB068181, CAB068182 Supported Supported Nucleoplasm Renal cancer:4.06e-4 (favourable), Liver cancer:4.21e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 57.7 CTGF CCN2, IGFBP8 ENSG00000118523 Connective tissue growth factor 6 131948176-131951373 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB005123, HPA031074, HPA031075 Approved Validated Golgi apparatus
Vesicles Stomach cancer:5.04e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 841.0 CTNNB1 armadillo, beta-catenin, CTNNB ENSG00000168036 Catenin (cadherin-associated protein), beta 1, 88kDa 3 41194837-41260096 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000108, CAB001950, HPA029159, HPA029160 Supported Validated Plasma membrane Colorectal cancer:7.54e-4 (favourable) Expressed in all Expressed in all cervix, uterine: 285.2 CTNNBL1 C20orf33, FLJ21108, NAP, NYD-SP19, P14, P14L ENSG00000132792 Catenin, beta like 1 20 37693955-37872129 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA004742, HPA027907 Approved Validated Nucleoplasm Expressed in all Expressed in all testis: 75.0 CTNND1 CTNND, KIAA0384, p120, p120cas, p120ctn ENSG00000198561 Catenin (cadherin-associated protein), delta 1 11 57753243-57819546 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB003837, HPA015954, HPA015955 Supported Validated Plasma membrane Pancreatic cancer:3.02e-4 (unfavourable), Renal cancer:3.54e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 192.9 CTSB ENSG00000164733 Cathepsin B 8 11842524-11869448 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000457, HPA018156 Uncertain Supported Nucleoli
Vesicles Thyroid cancer:5.76e-4 (favourable), Urothelial cancer:9.02e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 2885.5 CTSD CLN10, CPSD ENSG00000117984 Cathepsin D 11 1752752-1763992 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000109, HPA003001 Supported Renal cancer:4.93e-5 (favourable), Colorectal cancer:2.46e-4 (unfavourable) Expressed in all Expressed in all lung: 1071.1 CTSH ACC-4, ACC-5, ACC4, ACC5, CPSB ENSG00000103811 Cathepsin H 15 78921058-78949574 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000458, HPA003524 Supported Supported Vesicles
Cytosol
Cytoplasmic bodies Endometrial cancer:6.90e-4 (favourable) Expressed in all Expressed in all lung: 570.4 CTSL CTSL1, FLJ31037 ENSG00000135047 Cathepsin L 9 87725519-87731393 Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000459 Supported Lung cancer:5.15e-5 (unfavourable), Renal cancer:4.34e-4 (favourable), Glioma:4.94e-4 (unfavourable) Expressed in all Expressed in all placenta: 744.0 CTTN EMS1 ENSG00000085733 Cortactin 11 70398404-70436584 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB011235, HPA057242 Supported Supported Golgi apparatus
Vesicles
Plasma membrane
Cytosol Head and neck cancer:2.19e-6 (unfavourable), Liver cancer:4.45e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 109.3 CUL1 ENSG00000055130 Cullin 1 7 148697914-148801036 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002676, HPA064584 Supported Supported Nucleus
Nucleoli Expressed in all Expressed in all testis: 184.4 CUL2 ENSG00000108094 Cullin 2 10 35008551-35090642 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB002677, HPA024578 Approved Validated Nucleoplasm Liver cancer:8.24e-6 (unfavourable), Renal cancer:9.32e-5 (unfavourable) Expressed in all Expressed in all testis: 64.8 CUL4B ENSG00000158290 Cullin 4B X 120524609-120575794 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003046, HPA011880, CAB017786, HPA058979 Supported Validated Nucleoplasm Expressed in all Expressed in all testis: 68.0 CUL5 VACM-1 ENSG00000166266 Cullin 5 11 108008733-108107776 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA002185, CAB017787 Approved Approved Golgi apparatus
Cytosol Renal cancer:1.06e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 25.5 CUX1 CASP, CDP, CDP/Cut, CDP/Cux, CDP1, Clox, CUT, CUTL1, CUX, Cux/CDP, GOLIM6 ENSG00000257923 Cut-like homeobox 1 7 101815904-102283957 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA003277, HPA003317 Approved Supported Nucleoplasm
Golgi apparatus Renal cancer:5.72e-7 (favourable), Glioma:9.90e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 82.3 CXCL1 FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3, SCYB1 ENSG00000163739 Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 4 73869393-73871242 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Renal cancer:1.60e-4 (unfavourable), Liver cancer:2.91e-4 (unfavourable), Cervical cancer:7.23e-4 (unfavourable), Breast cancer:7.83e-4 (favourable) Expressed in all Tissue enhanced cervix, uterine: 177.9;spleen: 115.0 urinary bladder: 95.4 CXCL10 C7, crg-2, gIP-10, IFI10, INP10, IP-10, mob-1, SCYB10 ENSG00000169245 Chemokine (C-X-C motif) ligand 10 4 76021117-76023497 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Renal cancer:1.16e-6 (unfavourable), Ovarian cancer:1.12e-5 (favourable), Pancreatic cancer:4.61e-4 (unfavourable) Expressed in all Tissue enhanced appendix: 133.1 lymph node: 73.6 CXCL13 ANGIE, ANGIE2, BCA-1, BLC, BLR1L, SCYB13 ENSG00000156234 Chemokine (C-X-C motif) ligand 13 4 77511753-77611834 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA052613 Uncertain Renal cancer:1.16e-10 (unfavourable), Ovarian cancer:5.41e-4 (favourable), Endometrial cancer:5.52e-4 (favourable), Colorectal cancer:9.12e-4 (favourable) Expressed in all Group enriched 7 appendix: 170.3;lymph node: 606.7;spleen: 430.3;tonsil: 411.9 urinary bladder: 60.1 CXCL2 CINC-2a, GRO2, GROb, MGSA-b, MIP-2a, SCYB2 ENSG00000081041 Chemokine (C-X-C motif) ligand 2 4 74097035-74099293 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Renal cancer:2.07e-6 (unfavourable), Breast cancer:5.93e-5 (favourable), Cervical cancer:1.41e-4 (unfavourable) Expressed in all Mixed liver: 110.1 CXCL5 ENA-78, SCYB5 ENSG00000163735 Chemokine (C-X-C motif) ligand 5 4 73995642-73998779 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA065474 Approved Renal cancer:2.45e-5 (unfavourable), Liver cancer:1.39e-4 (unfavourable), Pancreatic cancer:2.23e-4 (unfavourable), Cervical cancer:3.43e-4 (unfavourable) Tissue enhanced Tissue enhanced appendix: 48.8 urinary bladder: 16.0 CXCL8 3-10C, AMCF-I, b-ENAP, GCP-1, GCP1, IL-8, IL8, K60, LECT, LUCT, LYNAP, MDNCF, MONAP, NAF, NAP-1, NAP1, SCYB8, TSG-1 ENSG00000169429 Chemokine (C-X-C motif) ligand 8 4 73740506-73743716 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA057179 Supported Approved Golgi apparatus Renal cancer:3.13e-6 (unfavourable), Cervical cancer:1.18e-5 (unfavourable), Liver cancer:1.19e-5 (unfavourable) Expressed in all Tissue enriched 7 bone marrow: 2079.8 appendix: 297.8 CXCL9 CMK, crg-10, Humig, MIG, SCYB9 ENSG00000138755 Chemokine (C-X-C motif) ligand 9 4 76001275-76007488 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Renal cancer:5.15e-6 (unfavourable), Endometrial cancer:2.07e-4 (favourable), Breast cancer:6.36e-4 (favourable), Ovarian cancer:8.06e-4 (favourable) Expressed in all Tissue enhanced lymph node: 332.0 appendix: 89.3 CXCR1 CD181, CDw128a, CKR-1, CMKAR1, IL8RA ENSG00000163464 Chemokine (C-X-C motif) receptor 1 2 218162845-218166995 Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA031991 Uncertain Mixed Tissue enhanced appendix: 35.7;spleen: 25.4 adipose tissue: 15.5 CXCR2 CD182, CMKAR2, IL8RB ENSG00000180871 Chemokine (C-X-C motif) receptor 2 2 218125289-218137253 Cancer-related genes, CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB016268, HPA031999, HPA032017 Supported Mixed Tissue enhanced appendix: 56.9;spleen: 37.2 esophagus: 30.0 CXCR4 CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R ENSG00000121966 Chemokine (C-X-C motif) receptor 4 2 136114349-136118165 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Renal cancer:1.41e-7 (unfavourable), Ovarian cancer:2.05e-4 (favourable), Stomach cancer:5.67e-4 (unfavourable) Expressed in all Tissue enhanced bone marrow: 772.9 tonsil: 514.7 CYB5R3 DIA1 ENSG00000100243 Cytochrome b5 reductase 3 22 42617840-42649568 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001566 Approved Validated Endoplasmic reticulum Liver cancer:2.13e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 336.2 CYLD CYLD1, KIAA0849, USPL2 ENSG00000083799 Cylindromatosis (turban tumor syndrome) 16 50742050-50801935 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB011713, HPA050095 Approved Supported Nucleoplasm
Microtubule organizing center Expressed in all Expressed in all testis: 70.2 CYP19A1 ARO, ARO1, aromatase, CPV1, CYAR, CYP19, P-450AROM ENSG00000137869 Cytochrome P450, family 19, subfamily A, polypeptide 1 15 51208057-51338610 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000355, HPA051194 Supported Approved Vesicles Mixed Tissue enriched 14 placenta: 173.9 testis: 12.4 CYP1A2 CP12, P3-450 ENSG00000140505 Cytochrome P450, family 1, subfamily A, polypeptide 2 15 74748844-74756202 Cancer-related genes, Enzymes, Predicted membrane proteins Evidence at protein level CAB016531 Supported Group enriched Tissue enriched 168 liver: 268.7 thyroid gland: 1.5 CYP2C19 CPCJ, CYP2C, P450IIC19 ENSG00000165841 Cytochrome P450, family 2, subfamily C, polypeptide 19 10 94762624-94853260 Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA015066 Supported Not detected Tissue enhanced duodenum: 49.7;liver: 125.5 small intestine: 21.2 CYP2E1 CYP2E ENSG00000130649 Cytochrome P450, family 2, subfamily E, polypeptide 1 10 133520406-133561220 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA009128, HPA029564 Supported Tissue enriched Tissue enriched 155 liver: 5312.8 tonsil: 34.3 CYP3A4 CYP3A3 ENSG00000160868 Cytochrome P450, family 3, subfamily A, polypeptide 4 7 99756960-99784265 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB033671, HPA072245 Supported Uncertain Cytosol Tissue enriched Group enriched 200 duodenum: 849.6;liver: 2446.6;small intestine: 990.4 adrenal gland: 7.1 CYP3A5 CP35, P450PCN3, PCN3 ENSG00000106258 Cytochrome P450, family 3, subfamily A, polypeptide 5 7 99648194-99679998 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA072245 Uncertain Cytosol Liver cancer:3.72e-5 (favourable) Tissue enhanced Tissue enhanced duodenum: 117.9;liver: 93.1;small intestine: 191.3 stomach: 79.3 DAD1 OST2 ENSG00000129562 Defender against cell death 1 14 22564905-22589269 Cancer-related genes, Enzymes, Predicted membrane proteins Evidence at protein level HPA028882 Uncertain Approved Cytosol Liver cancer:7.73e-4 (unfavourable) Expressed in all Expressed in all epididymis: 507.2 DAPK1 DAPK ENSG00000196730 Death-associated protein kinase 1 9 87497228-87708633 Cancer-related genes, Enzymes, Predicted membrane proteins Evidence at protein level CAB037302, HPA040472, HPA048436 Approved Supported Centrosome Colorectal cancer:2.48e-5 (unfavourable) Expressed in all Mixed lung: 56.3 DAXX DAP6 ENSG00000204209 Death-domain associated protein 6 33318558-33329269 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB002224, HPA008736, HPA008797, CAB025546, HPA065779 Supported Validated Nucleus
Nuclear bodies Renal cancer:6.32e-7 (unfavourable), Breast cancer:6.05e-4 (favourable) Expressed in all Mixed epididymis: 19.0 DBI ACBD1, ACBP ENSG00000155368 Diazepam binding inhibitor (GABA receptor modulator, acyl-CoA binding protein) 2 119366921-119372560 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA051428 Approved Renal cancer:3.73e-5 (unfavourable), Cervical cancer:5.77e-5 (favourable) Expressed in all Expressed in all breast: 898.4 DCC IGDCC1, NTN1R1 ENSG00000187323 DCC netrin 1 receptor 18 52340172-53535903 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA055376, HPA069552 Supported Approved Golgi apparatus Tissue enhanced Tissue enhanced cerebral cortex: 3.7;testis: 13.4 lung: 2.2 DCDC1 ENSG00000170959 Doublecortin domain containing 1 11 30830369-31369810 Cancer-related genes, Predicted intracellular proteins Evidence at protein level Not detected Tissue enhanced fallopian tube: 6.4;testis: 4.3 gallbladder: 2.8 DCN DSPG2, SLRR1B ENSG00000011465 Decorin 12 91140484-91183123 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA003315, CAB017118, HPA064736, CAB068930 Supported Renal cancer:1.46e-5 (unfavourable) Expressed in all Expressed in all ovary: 3801.6 DCTN1 ENSG00000204843 Dynactin 1 2 74361154-74392087 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009108, HPA034635 Approved Supported Actin filaments
Centrosome
Cytosol Renal cancer:2.34e-7 (favourable) Expressed in all Expressed in all cerebral cortex: 210.5 DDB2 DDBB, FLJ34321, UV-DDB2, XPE ENSG00000134574 Damage-specific DNA binding protein 2, 48kDa 11 47214465-47239240 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB025912, HPA058406 Supported Supported Nucleoplasm
Cell Junctions Endometrial cancer:1.20e-4 (favourable), Cervical cancer:1.58e-4 (favourable), Breast cancer:7.29e-4 (favourable) Expressed in all Expressed in all skin: 53.8 DDIT3 CHOP, CHOP10, GADD153 ENSG00000175197 DNA-damage-inducible transcript 3 12 57516588-57520517 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA058416, HPA068416 Approved Approved Nucleoplasm Liver cancer:6.55e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 263.1 DDX10 HRH-J8 ENSG00000178105 DEAD (Asp-Glu-Ala-Asp) box polypeptide 10 11 108665025-108940930 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA004691 Approved Approved Nucleoli Renal cancer:2.14e-5 (favourable), Liver cancer:2.52e-5 (unfavourable), Pancreatic cancer:5.75e-4 (unfavourable) Expressed in all Expressed in all testis: 29.1 DDX3X DBX, DDX14, DDX3, HLP2 ENSG00000215301 DEAD (Asp-Glu-Ala-Asp) box helicase 3, X-linked X 41333348-41364472 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level HPA001648, HPA005631, HPA059585 Supported Approved Approved Nucleus
Cytosol Expressed in all Expressed in all parathyroid gland: 270.3 DDX5 G17P1, HLR1, p68 ENSG00000108654 DEAD (Asp-Glu-Ala-Asp) box helicase 5 17 64499616-64508199 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005868, HPA020043 Supported Validated Nucleoplasm Colorectal cancer:2.12e-4 (favourable) Expressed in all Expressed in all smooth muscle: 594.4 DDX6 HLR2, RCK ENSG00000110367 DEAD (Asp-Glu-Ala-Asp) box helicase 6 11 118747766-118791149 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB004668, HPA024201, HPA026644 Approved Supported Cytosol
Cytoplasmic bodies Liver cancer:6.56e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 65.6 DEFA1 DEF1, DEFA2, HNP-1, MRS ENSG00000206047 Defensin, alpha 1 8 6977649-6980080 Cancer-related genes, Plasma proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB032548, HPA052517 Supported Not detected Tissue enriched 284 bone marrow: 15680.7 skin: 55.3 DEFA1B ENSG00000240247 Defensin, alpha 1B 8 6996766-7018289 Cancer-related genes, Plasma proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA052517 Supported Not detected Tissue enriched 514 bone marrow: 61211.3 skin: 119.2 DEFA3 DEF3, HNP-3 ENSG00000239839 Defensin, alpha 3, neutrophil-specific 8 6996837-7018301 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA052517 Supported Not detected Tissue enriched 189 bone marrow: 23349.1 spleen: 123.6 DEK D6S231E ENSG00000124795 DEK proto-oncogene 6 18223868-18264823 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB015226, HPA054505, HPA057799 Supported Validated Nucleus Renal cancer:3.45e-4 (unfavourable), Liver cancer:9.65e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 158.3 DES CMD1I, CSM1, CSM2 ENSG00000175084 Desmin 2 219418377-219426739 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000034, HPA018803 Supported Supported Intermediate filaments Renal cancer:5.08e-4 (unfavourable) Expressed in all Tissue enhanced heart muscle: 3865.2;skeletal muscle: 5463.5;smooth muscle: 3556.9 seminal vesicle: 3096.2 DHFR ENSG00000228716 Dihydrofolate reductase 5 80626228-80654983 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB037129, HPA051465 Uncertain Supported Mitochondria Expressed in all Mixed lymph node: 50.1 DHX9 DDX9, LKP, RHA ENSG00000135829 DEAH (Asp-Glu-Ala-His) box helicase 9 1 182839369-182887751 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB011819, HPA028050, HPA055684 Supported Validated Nucleus Liver cancer:3.17e-4 (unfavourable), Melanoma:6.04e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 135.7 DIAPH1 DFNA1, hDIA1, LFHL1 ENSG00000131504 Diaphanous-related formin 1 5 141515016-141619055 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA004916, HPA076913 Approved Approved Plasma membrane Renal cancer:1.29e-5 (favourable), Pancreatic cancer:7.81e-5 (unfavourable) Expressed in all Expressed in all lymph node: 73.7 DIAPH3 AN, AUNA1, DRF3, FLJ34705, NSDAN ENSG00000139734 Diaphanous-related formin 3 13 59665583-60163987 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA032151 Supported Plasma membrane
Microtubules Lung cancer:3.72e-4 (unfavourable), Endometrial cancer:4.18e-4 (unfavourable), Colorectal cancer:9.04e-4 (favourable) Mixed Tissue enriched 7 testis: 33.9 placenta: 5.0 DICER1 Dicer, HERNA, K12H4.8-LIKE, KIAA0928, MNG1 ENSG00000100697 Dicer 1, ribonuclease type III 14 95086228-95158010 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA000694, CAB068185 Approved Supported Cytosol Expressed in all Expressed in all placenta: 32.2 DIS3 dis3p, EXOSC11, KIAA1008, RRP44 ENSG00000083520 DIS3 homolog, exosome endoribonuclease and 3'-5' exoribonuclease 13 72752169-72782096 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA039281, HPA058762 Approved Validated Nucleus
Cytosol Expressed in all Expressed in all testis: 38.5 DLC1 ARHGAP7, DLC-1, HP, p122-RhoGAP, STARD12 ENSG00000164741 DLC1 Rho GTPase activating protein 8 13083361-13604610 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA017753 Uncertain Approved Nucleoplasm
Golgi apparatus
Vesicles Endometrial cancer:1.11e-4 (favourable) Expressed in all Expressed in all lung: 78.7 DMD BMD, DXS142, DXS164, DXS206, DXS230, DXS239, DXS268, DXS269, DXS270, DXS272, MRX85 ENSG00000198947 Dystrophin X 31097677-33339441 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters Evidence at protein level CAB000119, HPA002725, HPA023885 Supported Mixed Mixed seminal vesicle: 54.1 DNAH12 DHC3, DLP12, DNAH12L, DNAH7L, Dnahc3, DNHD2, FLJ40427, FLJ44290, hdhc3, HL-19 ENSG00000174844 Dynein, axonemal, heavy chain 12 3 57293699-57544344 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA037493, HPA058203, HPA061365 Supported Tissue enhanced Tissue enhanced fallopian tube: 16.0;testis: 11.0 lung: 2.7 DNAJC2 MPHOSPH11, MPP11, ZRF1, ZUO1, zuotin ENSG00000105821 DnaJ (Hsp40) homolog, subfamily C, member 2 7 103312474-103344873 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA020454 Approved Supported Cytosol Renal cancer:1.12e-5 (unfavourable) Expressed in all Expressed in all testis: 61.7 DNER bet, UNQ26 ENSG00000187957 Delta/notch-like EGF repeat containing 2 229357629-229714558 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA017320 Approved Liver cancer:1.05e-4 (unfavourable), Renal cancer:3.42e-4 (unfavourable) Tissue enriched Group enriched 7 adrenal gland: 74.9;cerebral cortex: 176.5 salivary gland: 17.4 DNM2 CMT2M, CMTDI1, CMTDIB, DI-CMTB, DYN2, DYNII ENSG00000079805 Dynamin 2 19 10718079-10833488 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA054246 Supported Approved Golgi apparatus
Cytosol Liver cancer:3.63e-4 (unfavourable), Head and neck cancer:8.91e-4 (favourable) Expressed in all Expressed in all colon: 106.7 DNMT3A ENSG00000119772 DNA (cytosine-5-)-methyltransferase 3 alpha 2 25227855-25342590 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB009469, HPA026588 Approved Supported Nucleoplasm Pancreatic cancer:1.18e-4 (favourable), Endometrial cancer:1.55e-4 (unfavourable), Liver cancer:1.58e-4 (unfavourable), Renal cancer:2.49e-4 (unfavourable) Expressed in all Expressed in all placenta: 22.6 DOCK2 KIAA0209 ENSG00000134516 Dedicator of cytokinesis 2 5 169637247-170083382 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA036469 Supported Expressed in all Mixed lymph node: 52.8 DST BP240, BPA, BPAG1, CATX-15, FLJ13425, FLJ21489, FLJ30627, FLJ32235, KIAA0728, MACF2 ENSG00000151914 Dystonin 6 56457987-56954628 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA030200 Uncertain Approved Nucleus
Microtubules
Cytosol Expressed in all Expressed in all skin: 192.5 DUSP1 CL100, HVH1, MKP-1, PTPN10 ENSG00000120129 Dual specificity phosphatase 1 5 172768090-172771195 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB018554, HPA069577 Approved Approved Nucleoli
Cytosol Stomach cancer:3.11e-5 (unfavourable) Expressed in all Expressed in all thyroid gland: 1020.1 DUSP14 MKP-L, MKP6 ENSG00000276023 Dual specificity phosphatase 14 17 37489831-37513501 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019911 Approved Approved Nucleoplasm
Cytosol Renal cancer:6.97e-9 (unfavourable) Expressed in all Tissue enhanced fallopian tube: 5.0 skin: 2.7 DUSP4 HVH2, MKP-2, TYP ENSG00000120875 Dual specificity phosphatase 4 8 29333064-29350668 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA061967 Supported Nucleoplasm Renal cancer:4.19e-4 (unfavourable) Expressed in all Tissue enhanced breast: 29.4 stomach: 28.1 DVL3 KIAA0208 ENSG00000161202 Dishevelled segment polarity protein 3 3 184155388-184173610 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB046486, HPA058265 Approved Approved Intermediate filaments
Midbody ring
Centrosome Renal cancer:1.53e-8 (unfavourable), Prostate cancer:4.77e-5 (unfavourable), Colorectal cancer:1.90e-4 (unfavourable), Liver cancer:8.41e-4 (unfavourable) Expressed in all Expressed in all placenta: 55.0 DYNLL1 DLC1, DLC8, DNCL1, hdlc1, LC8, PIN ENSG00000088986 Dynein, light chain, LC8-type 1 12 120469850-120498493 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA039954 Approved Nucleoplasm
Nuclear bodies
Cytosol Renal cancer:7.97e-7 (unfavourable), Liver cancer:7.33e-5 (unfavourable) Expressed in all Expressed in all fallopian tube: 769.1 DYRK2 ENSG00000127334 Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 12 67648338-67665406 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA027230, HPA056902 Approved Supported Nucleoplasm
Cytosol Expressed in all Expressed in all small intestine: 31.7 E2F1 RBBP3, RBP3 ENSG00000101412 E2F transcription factor 1 20 33675683-33686404 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000329, HPA008003, CAB019308, HPA029735 Approved Validated Nucleoplasm
Centrosome Cervical cancer:9.22e-6 (favourable), Liver cancer:3.83e-5 (unfavourable), Endometrial cancer:4.33e-5 (unfavourable), Renal cancer:8.99e-5 (unfavourable), Thyroid cancer:1.62e-4 (favourable), Pancreatic cancer:4.18e-4 (unfavourable) Expressed in all Tissue enhanced bone marrow: 22.9 testis: 12.7 E2F3 ENSG00000112242 E2F transcription factor 3 6 20401906-20493715 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA065012 Supported Nucleoplasm
Cytosol Renal cancer:1.63e-8 (unfavourable), Ovarian cancer:1.69e-4 (favourable) Expressed in all Mixed thyroid gland: 14.3 E2F5 ENSG00000133740 E2F transcription factor 5, p130-binding 8 85177225-85217158 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transcription factors Evidence at protein level HPA055723 Supported Nucleus
Nucleoli Renal cancer:1.89e-6 (unfavourable) Expressed in all Mixed lymph node: 31.3 EBAG9 EB9, RCAS1 ENSG00000147654 Estrogen receptor binding site associated, antigen, 9 8 109539711-109565996 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA021153, HPA021154, CAB072810, CAB072811, CAB072812 Supported Validated Golgi apparatus Expressed in all Expressed in all thyroid gland: 96.1 EBF1 EBF, OLF1 ENSG00000164330 Early B-cell factor 1 5 158695916-159099761 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA061169 Approved Nucleoplasm
Vesicles Renal cancer:9.62e-7 (unfavourable), Stomach cancer:7.80e-4 (unfavourable) Mixed Tissue enhanced adipose tissue: 41.6 placenta: 16.6 ECT2L ARHGEF32, C6orf91, FBXO49, LFDH ENSG00000203734 Epithelial cell transforming 2 like 6 138795926-138904070 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA035488 Uncertain Not detected Tissue enriched 6 fallopian tube: 18.0 lung: 2.7 EDN1 ET1 ENSG00000078401 Endothelin 1 6 12290363-12297194 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA031976, CAB032500, CAB037291 Approved Approved Nucleus
Nucleoli
Golgi apparatus Expressed in all Mixed lung: 43.6 EEF1A1 EE1A1, EEF1A, EF1A, LENG7 ENSG00000156508 Eukaryotic translation elongation factor 1 alpha 1 6 73515750-73523797 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA051759, HPA053862, HPA056990 Supported Supported Cytosol Liver cancer:5.57e-4 (unfavourable) Expressed in all Expressed in all ovary: 14688.0 EEF2 EEF-2, EF2 ENSG00000167658 Eukaryotic translation elongation factor 2 19 3976056-3985469 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB007795, HPA040534, HPA057351 Approved Validated Plasma membrane
Cytosol Endometrial cancer:1.81e-6 (favourable), Renal cancer:1.25e-5 (favourable) Expressed in all Expressed in all ovary: 1621.9 EFNA1 ECKLG, EPLG1, LERK1, TNFAIP4 ENSG00000169242 Ephrin-A1 1 155127460-155134857 Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB032498 Uncertain Expressed in all Mixed placenta: 123.0 EFNA2 ELF-1, EPLG6, LERK6 ENSG00000099617 Ephrin-A2 19 1286154-1300237 Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB005178 Uncertain Tissue enhanced Group enriched 6 colon: 7.1;duodenum: 8.2;small intestine: 10.8 rectum: 1.5 EFNA5 AF1, EPLG7, LERK7 ENSG00000184349 Ephrin-A5 5 107376889-107670895 Cancer-related genes, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB013282, HPA054047 Approved Approved Vesicles
Cytosol Renal cancer:1.92e-7 (unfavourable), Stomach cancer:3.77e-4 (unfavourable) Mixed Mixed cervix, uterine: 17.1 EFNB1 CFNS, Elk-L, EPLG2, LERK2 ENSG00000090776 Ephrin-B1 X 68828997-68842147 Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB031489, HPA067188 Uncertain Supported Plasma membrane Endometrial cancer:3.32e-5 (unfavourable), Pancreatic cancer:4.29e-4 (unfavourable), Melanoma:8.68e-4 (unfavourable) Expressed in all Mixed adipose tissue: 37.7 EFNB2 EPLG5, Htk-L, HTKL, LERK5, MGC126226, MGC126227, MGC126228 ENSG00000125266 Ephrin-B2 13 106489731-106535114 Cancer-related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA008999, CAB009368 Supported Supported Nucleoplasm
Cytosol Head and neck cancer:3.11e-6 (unfavourable), Pancreatic cancer:8.70e-5 (unfavourable), Lung cancer:8.43e-4 (unfavourable) Expressed in all Mixed placenta: 48.1 EFNB3 EPLG8, LERK-8 ENSG00000108947 Ephrin-B3 17 7705202-7711378 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA001623 Approved Approved Nucleoplasm Endometrial cancer:5.52e-4 (unfavourable), Pancreatic cancer:8.21e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 48.8 endometrium: 17.3 EGF ENSG00000138798 Epidermal growth factor 4 109912884-110012266 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level Mixed Tissue enriched 7 kidney: 121.1 pancreas: 18.5 EGFR ERBB, ERBB1 ENSG00000146648 Epidermal growth factor receptor 7 55019021-55256620 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB000035, HPA001200, HPA018530, CAB068186, CAB073534 Supported Validated Plasma membrane Urothelial cancer:2.04e-5 (unfavourable) Expressed in all Tissue enhanced placenta: 97.3 skin: 58.9 EGR1 AT225, G0S30, KROX-24, NGFI-A, TIS8, ZIF-268, ZNF225 ENSG00000120738 Early growth response 1 5 138465490-138469315 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB019427, HPA029937, HPA029938 Supported Validated Nucleoplasm Expressed in all Expressed in all ovary: 1184.1 EI24 EPG4, PIG8, TP53I8 ENSG00000149547 Etoposide induced 2.4 11 125569216-125584687 Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA047165, HPA051029 Uncertain Supported Endoplasmic reticulum
Golgi apparatus
Cytosol Pancreatic cancer:9.28e-4 (unfavourable) Expressed in all Tissue enriched 9 parathyroid gland: 1098.6 liver: 124.7 EIF2S2 EIF2, EIF2beta, PPP1R67 ENSG00000125977 Eukaryotic translation initiation factor 2, subunit 2 beta, 38kDa 20 34088298-34112332 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB034415, HPA041262, HPA041332 Approved Supported Nucleoli
Endoplasmic reticulum Renal cancer:9.64e-10 (unfavourable), Liver cancer:3.23e-5 (unfavourable), Endometrial cancer:8.74e-4 (unfavourable) Expressed in all Expressed in all placenta: 74.0 EIF3E eIF3-p48, eIF3e, EIF3S6, INT6 ENSG00000104408 Eukaryotic translation initiation factor 3, subunit E 8 108201216-108435333 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA023973 Approved Validated Nuclear bodies
Cytosol Renal cancer:3.06e-7 (unfavourable) Expressed in all Expressed in all ovary: 729.0 EIF3H eIF3-gamma, eIF3-p40, eIF3h, EIF3S3 ENSG00000147677 Eukaryotic translation initiation factor 3, subunit H 8 116642130-116766925 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA023117, HPA023553 Approved Approved Cytosol Breast cancer:5.26e-4 (unfavourable), Cervical cancer:8.07e-4 (unfavourable), Liver cancer:8.34e-4 (unfavourable) Expressed in all Expressed in all ovary: 479.7 EIF4A2 BM-010, DDX2B, EIF4A, EIF4F ENSG00000156976 Eukaryotic translation initiation factor 4A2 3 186783205-186789900 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB011690, HPA068286 Uncertain Approved Cytosol Expressed in all Expressed in all ovary: 724.4 EIF4E EIF4E1, EIF4EL1, EIF4F ENSG00000151247 Eukaryotic translation initiation factor 4E 4 98871684-98930637 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004077, CAB016316, HPA051311 Supported Validated Cytosol
Cytoplasmic bodies Expressed in all Expressed in all testis: 103.0 EIF4EBP1 4E-BP1, PHAS-I ENSG00000187840 Eukaryotic translation initiation factor 4E binding protein 1 8 38030341-38060365 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB005032, CAB005039, HPA023501 Supported Supported Nucleoplasm
Cytosol Renal cancer:0.00e+0 (unfavourable), Endometrial cancer:8.86e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 30.4 EIF4G1 EIF4F, EIF4G, p220, PARK18 ENSG00000114867 Eukaryotic translation initiation factor 4 gamma, 1 3 184314495-184335358 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB014774, HPA028487, HPA043866 Approved Validated Cytosol Liver cancer:7.99e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 206.5 EIF4H KIAA0038, WBSCR1, WSCR1 ENSG00000106682 Eukaryotic translation initiation factor 4H 7 74174245-74197101 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA030542 Approved Approved Nucleoplasm
Nuclear bodies
Cytosol Head and neck cancer:2.15e-4 (unfavourable), Glioma:5.65e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 249.7 EIF5A EIF-5A, EIF5A1, MGC104255, MGC99547 ENSG00000132507 Eukaryotic translation initiation factor 5A 17 7306999-7312463 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level CAB005042, HPA061298 Approved Validated Nucleoplasm
Cytosol Renal cancer:1.63e-5 (unfavourable), Lung cancer:9.04e-4 (unfavourable) Expressed in all Expressed in all esophagus: 437.6 ELANE ELA2, HLE, HNE, NE ENSG00000197561 Elastase, neutrophil expressed 19 851014-856247 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB015409, HPA066836 Supported Group enriched Tissue enriched 320 bone marrow: 1202.2 skin: 3.7 ELF3 EPR-1, ERT, ESE-1, ESX ENSG00000163435 E74-like factor 3 (ets domain transcription factor, epithelial-specific ) 1 202007945-202017188 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA003316, HPA003479 Supported Validated Nucleoplasm Mixed Mixed small intestine: 164.9 ELF4 ELFR, MEF ENSG00000102034 E74-like factor 4 (ets domain transcription factor) X 130064874-130110716 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA058595, HPA060277 Approved Supported Nucleoplasm
Nuclear bodies Renal cancer:6.49e-6 (unfavourable), Urothelial cancer:1.42e-4 (favourable) Expressed in all Mixed placenta: 34.7 ELK3 ERP, NET, SAP2 ENSG00000111145 ELK3, ETS-domain protein (SRF accessory protein 2) 12 96194382-96269835 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA001600 Approved Supported Nucleoplasm
Mitochondria Ovarian cancer:4.93e-4 (unfavourable) Expressed in all Expressed in all spleen: 58.6 ELK4 SAP1 ENSG00000158711 ELK4, ETS-domain protein (SRF accessory protein 1) 1 205597556-205631962 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA028863 Uncertain Supported Nucleoplasm Renal cancer:2.94e-6 (unfavourable), Head and neck cancer:4.65e-4 (favourable) Expressed in all Expressed in all prostate: 41.5 ELL C19orf17, ELL1, Men, PPP1R68 ENSG00000105656 Elongation factor RNA polymerase II 19 18442663-18522127 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA046076 Uncertain Expressed in all Expressed in all testis: 25.3 ELN SVAS, WBS, WS ENSG00000049540 Elastin 7 74027789-74069907 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB010750, HPA018111, HPA056941 Supported Approved Plasma membrane Thyroid cancer:6.29e-4 (unfavourable) Expressed in all Mixed smooth muscle: 124.5 EML4 C2orf2, ELP120, ROPP120 ENSG00000143924 Echinoderm microtubule associated protein like 4 2 42169350-42332548 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA036687, HPA036688, HPA065337 Supported Supported Intermediate filaments
Microtubules
Cytosol Expressed in all Mixed placenta: 50.1 ENC1 ENC-1, KLHL37, NRPB, PIG10, TP53I10 ENSG00000171617 Ectodermal-neural cortex 1 (with BTB domain) 5 74627406-74641424 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA078061 Uncertain Plasma membrane
Cytoplasmic bodies Renal cancer:2.95e-5 (unfavourable), Breast cancer:3.88e-4 (unfavourable) Expressed in all Tissue enriched 15 cerebral cortex: 462.7 gallbladder: 30.9 ENG CD105, END, HHT1, ORW, ORW1 ENSG00000106991 Endoglin 9 127815012-127854756 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB000096, HPA011862, HPA067440, CAB072873 Supported Liver cancer:5.62e-6 (favourable), Renal cancer:4.26e-4 (unfavourable), Head and neck cancer:6.61e-4 (favourable) Expressed in all Expressed in all spleen: 170.7 ENO1 ENO1L1, MBP-1, MPB1, PPH ENSG00000074800 Enolase 1, (alpha) 1 8861002-8879249 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB018614, HPA068284, CAB069394 Supported Validated Nucleoplasm
Plasma membrane
Cytosol Liver cancer:1.30e-8 (unfavourable), Glioma:2.12e-4 (unfavourable) Expressed in all Expressed in all appendix: 789.1 ENO2 ENSG00000111674 Enolase 2 (gamma, neuronal) 12 6913745-6923698 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000063, HPA068284, CAB073539 Supported Approved Nucleus
Plasma membrane
Cytosol Renal cancer:7.89e-11 (unfavourable), Liver cancer:5.15e-4 (unfavourable), Colorectal cancer:6.96e-4 (unfavourable) Expressed in all Tissue enriched 7 cerebral cortex: 432.2 parathyroid gland: 64.5 ENPP2 ATX, PD-IALPHA, PDNP2 ENSG00000136960 Ectonucleotide pyrophosphatase/phosphodiesterase 2 8 119557086-119673453 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA023700, HPA053652 Approved Approved Nucleus
Golgi apparatus
Actin filaments Pancreatic cancer:2.07e-5 (favourable) Expressed in all Expressed in all placenta: 372.6 EP300 KAT3B, p300 ENSG00000100393 E1A binding protein p300 22 41091786-41180079 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB000146, HPA003128, HPA004112 Supported Validated Nucleoplasm Renal cancer:7.45e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 45.3 EPAS1 bHLHe73, HIF2A, HLF, MOP2, PASD2 ENSG00000116016 Endothelial PAS domain protein 1 2 46293667-46386703 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA031200 Approved Nucleoplasm
Cytosol Renal cancer:2.63e-4 (favourable) Expressed in all Expressed in all placenta: 636.7 EPCAM 17-1A, 323/A3, CD326, CO-17A, EGP-2, EGP34, EGP40, Ep-CAM, ESA, GA733-2, HEA125, KS1/4, KSA, Ly74, M4S1, MH99, MIC18, MK-1, MOC31, TACST-1, TACSTD1, TROP1 ENSG00000119888 Epithelial cell adhesion molecule 2 47345158-47387601 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB003809, HPA026761, CAB030012, CAB055098, HPA067463 Supported Supported Plasma membrane Renal cancer:1.04e-6 (favourable), Ovarian cancer:3.30e-4 (favourable) Mixed Tissue enhanced rectum: 691.1;small intestine: 728.8 colon: 672.2 EPHA1 EPH, EPHT, EPHT1 ENSG00000146904 EPH receptor A1 7 143390289-143408892 Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB026144 Approved Renal cancer:1.14e-6 (favourable) Mixed Tissue enriched 24 parathyroid gland: 861.4 esophagus: 36.4 EPHA2 ECK ENSG00000142627 EPH receptor A2 1 16124337-16156087 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level HPA066055 Uncertain Vesicles Expressed in all Tissue enhanced esophagus: 87.1 gallbladder: 44.7 EPHA3 ETK, ETK1, HEK, HEK4, TYRO4 ENSG00000044524 EPH receptor A3 3 89107524-89482134 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB010462 Approved Uncertain Nucleoplasm
Golgi apparatus
Cytosol Renal cancer:3.28e-7 (unfavourable) Mixed Tissue enhanced prostate: 49.0 gallbladder: 29.9 EPHA4 Hek8, TYRO1 ENSG00000116106 EPH receptor A4 2 221418027-221574202 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB028368 Supported Renal cancer:5.67e-4 (favourable), Ovarian cancer:9.56e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 41.8 testis: 22.3 EPHA7 Hek11 ENSG00000135333 EPH receptor A7 6 93240020-93419547 Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB010496 Uncertain Tissue enhanced Tissue enriched 13 parathyroid gland: 250.5 prostate: 19.4 EPHA8 EEK, Hek3 ENSG00000070886 EPH receptor A8 1 22563564-22603594 Cancer-related genes, Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009660, HPA031433 Uncertain Mixed Tissue enhanced adrenal gland: 4.9;spleen: 2.7;testis: 1.9 cerebral cortex: 1.3 EPHB2 DRT, EPHT3, ERK, Hek5, Tyro5 ENSG00000133216 EPH receptor B2 1 22710839-22921500 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB013647, HPA071200 Approved Supported Nucleus
Plasma membrane Endometrial cancer:1.05e-5 (unfavourable), Colorectal cancer:4.98e-4 (favourable) Tissue enhanced Mixed rectum: 27.8 EPHB3 ETK2, Hek2, Tyro6 ENSG00000182580 EPH receptor B3 3 184561784-184582409 Cancer-related genes, Enzymes, Predicted membrane proteins Evidence at protein level HPA007698, HPA008184, CAB034350 Approved Renal cancer:7.88e-5 (unfavourable) Expressed in all Tissue enhanced skin: 45.4 stomach: 17.9 EPHB4 HTK, Tyro11 ENSG00000196411 EPH receptor B4 7 100802565-100827521 Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB013537 Uncertain Colorectal cancer:4.33e-4 (unfavourable), Breast cancer:8.56e-4 (unfavourable), Urothelial cancer:8.84e-4 (unfavourable) Expressed in all Expressed in all placenta: 50.3 EPHX1 EPHX ENSG00000143819 Epoxide hydrolase 1, microsomal (xenobiotic) 1 225810092-225845563 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA020593, HPA048847 Supported Lung cancer:7.02e-5 (favourable), Prostate cancer:1.32e-4 (favourable) Tissue enriched Expressed in all adrenal gland: 1091.2 EPO EP ENSG00000130427 Erythropoietin 7 100720800-100723700 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Predicted secreted proteins Evidence at protein level CAB010336 Supported Renal cancer:2.18e-6 (unfavourable), Liver cancer:5.67e-5 (unfavourable) Group enriched Tissue enhanced cervix, uterine: 2.0;endometrium: 1.7;liver: 1.7 prostate: 1.1 EPOR ENSG00000187266 Erythropoietin receptor 19 11377205-11384342 Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA077613 Uncertain Vesicles Pancreatic cancer:3.17e-5 (favourable) Expressed in all Tissue enhanced parathyroid gland: 52.9 thyroid gland: 18.1 EPS15 AF-1P, MLLT5 ENSG00000085832 Epidermal growth factor receptor pathway substrate 15 1 51354263-51519328 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA008451, CAB010164 Approved Validated Vesicles
Cytosol Cervical cancer:6.44e-4 (unfavourable) Expressed in all Expressed in all testis: 84.3 ERBB2 CD340, HER-2, HER2, NEU, NGL ENSG00000141736 Erb-b2 receptor tyrosine kinase 2 17 39687914-39730426 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555 Approved Supported Plasma membrane
Cytosol Renal cancer:2.41e-14 (favourable), Endometrial cancer:8.99e-8 (unfavourable), Pancreatic cancer:9.17e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 122.9 ERBB2IP ERBIN, LAP2 ENSG00000112851 Erbb2 interacting protein 5 65926475-66082549 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA048606, HPA059863 Approved Supported Nuclear speckles
Plasma membrane Expressed in all Expressed in all testis: 49.9 ERBB3 HER3, LCCS2 ENSG00000065361 Erb-b2 receptor tyrosine kinase 3 12 56079857-56103505 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025331, HPA045396 Uncertain Approved Plasma membrane
Actin filaments Expressed in all Mixed small intestine: 88.5 ERBB4 ALS19, HER4 ENSG00000178568 Erb-b2 receptor tyrosine kinase 4 2 211375717-212538841 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB000276, HPA012016, CAB025522 Approved Tissue enhanced Tissue enhanced fallopian tube: 17.6 cerebral cortex: 7.6 ERC1 CAST2, ELKS, KIAA1081, MGC12974, RAB6IP2 ENSG00000082805 ELKS/RAB6-interacting/CAST family member 1 12 990509-1495933 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA019513, HPA019523, HPA024130 Approved Supported Vesicles
Plasma membrane
Cytosol Urothelial cancer:7.01e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 17.1 ERCC1 RAD10 ENSG00000012061 Excision repair cross-complementation group 1 19 45407333-45478828 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB004390, HPA029773, HPA050182, CAB072859, CAB072860 Supported Validated Nucleoplasm Renal cancer:9.00e-5 (unfavourable), Liver cancer:9.69e-4 (unfavourable) Expressed in all Expressed in all skin: 71.4 ERCC2 EM9, MAG, MGC102762, MGC126218, MGC126219, TFIIH, XPD ENSG00000104884 Excision repair cross-complementation group 2 19 45349837-45370918 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB005375, HPA038057, HPA069266 Approved Supported Nucleoplasm Pancreatic cancer:3.26e-4 (favourable) Expressed in all Expressed in all testis: 16.2 ERCC3 BTF2, GTF2H, RAD25, TFIIH, XPB ENSG00000163161 Excision repair cross-complementation group 3 2 127257290-127294176 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB037153, HPA046077 Approved Validated Nucleoplasm Liver cancer:1.62e-7 (unfavourable), Renal cancer:4.30e-6 (unfavourable) Expressed in all Expressed in all testis: 54.8 ERCC4 FANCQ, RAD1, XPF ENSG00000175595 Excision repair cross-complementation group 4 16 13920157-13952345 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000156, HPA045828 Approved Supported Nucleoplasm
Nuclear bodies Expressed in all Mixed testis: 10.7 ERCC5 ERCM2, XPGC ENSG00000134899 Excision repair cross-complementation group 5 13 102844844-102876001 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA045845, HPA050374 Supported Approved Nucleoplasm Renal cancer:2.96e-6 (unfavourable), Urothelial cancer:6.82e-4 (favourable) Expressed in all Expressed in all spleen: 38.2 ERCC6 ARMD5, CKN2, CSB, RAD26 ENSG00000225830 Excision repair cross-complementation group 6 10 49455368-49539538 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA066830 Supported Nucleus Mixed Mixed parathyroid gland,testis: 10.0 ERG erg-3, p55 ENSG00000157554 V-ets avian erythroblastosis virus E26 oncogene homolog 21 38380027-38661780 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB018377, HPA046598 Approved Approved Nucleoplasm
Cytosol Cervical cancer:6.18e-6 (unfavourable), Renal cancer:3.94e-4 (unfavourable) Expressed in all Expressed in all spleen: 37.3 ESR1 Era, ESR, NR3A1 ENSG00000091831 Estrogen receptor 1 6 151656691-152129619 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000037, HPA000449, HPA000450, CAB055099, CAB072858 Supported Approved Nucleus
Vesicles Endometrial cancer:5.47e-7 (favourable) Group enriched Group enriched 8 breast: 37.4;cervix, uterine: 127.3;endometrium: 179.7;fallopian tube: 105.5;smooth muscle: 75.9 seminal vesicle: 13.5 ESR2 Erb, NR3A2 ENSG00000140009 Estrogen receptor 2 (ER beta) 14 64084232-64338112 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB022544 Approved Nucleoplasm Not detected Tissue enhanced testis: 10.5 adrenal gland: 6.3 ETHE1 HSCO, YF13H12 ENSG00000105755 Ethylmalonic encephalopathy 1 19 43506719-43527244 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA028360, HPA029028, HPA029029 Supported Validated Mitochondria Lung cancer:9.58e-4 (unfavourable) Expressed in all Expressed in all colon: 244.2 ETNK1 EKI, EKI1 ENSG00000139163 Ethanolamine kinase 1 12 22625075-22690665 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010712, HPA029407 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Urothelial cancer:1.75e-4 (favourable), Liver cancer:5.85e-4 (unfavourable) Expressed in all Expressed in all stomach: 45.8 ETV1 ER81 ENSG00000006468 Ets variant 1 7 13891228-13991425 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA077249 Approved Nucleoplasm Expressed in all Tissue enhanced cerebral cortex: 106.6 lung: 43.3 ETV4 E1A-F, E1AF, PEA3 ENSG00000175832 Ets variant 4 17 43527844-43579620 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA005768 Approved Supported Nucleoli Liver cancer:2.48e-4 (unfavourable), Thyroid cancer:7.60e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 29.7 cerebral cortex: 13.7 ETV5 ERM ENSG00000244405 Ets variant 5 3 186046308-186110318 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB009590, HPA063065 Approved Supported Nucleoplasm Liver cancer:7.85e-9 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 112.2 cerebral cortex: 74.9 ETV6 TEL ENSG00000139083 Ets variant 6 12 11649854-11895402 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA000264 Supported Validated Nucleoli
Cytosol Renal cancer:4.66e-8 (unfavourable), Urothelial cancer:1.54e-5 (favourable), Pancreatic cancer:9.38e-5 (unfavourable) Expressed in all Expressed in all bone marrow: 26.5 EWSR1 EWS ENSG00000182944 EWS RNA-binding protein 1 22 29268009-29300525 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004230, HPA051771, HPA062953 Supported Validated Nucleus
Nucleoli Liver cancer:1.27e-6 (unfavourable), Renal cancer:1.21e-5 (unfavourable) Expressed in all Expressed in all testis: 213.0 EXT1 LGCR, LGS, ttv ENSG00000182197 Exostosin glycosyltransferase 1 8 117794490-118111853 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044394 Uncertain Lung cancer:1.20e-5 (unfavourable), Thyroid cancer:4.64e-4 (unfavourable), Cervical cancer:7.04e-4 (unfavourable) Expressed in all Expressed in all duodenum: 32.5 EXT2 SOTV ENSG00000151348 Exostosin glycosyltransferase 2 11 44095549-44245429 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA078409 Supported Golgi apparatus Renal cancer:5.36e-6 (unfavourable), Head and neck cancer:2.50e-4 (unfavourable) Expressed in all Expressed in all placenta: 89.9 EZH1 KIAA0388, KMT6B ENSG00000108799 Enhancer of zeste 1 polycomb repressive complex 2 subunit 17 42700275-42745049 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA005478 Supported Nucleoplasm Expressed in all Expressed in all ovary: 58.5 EZH2 ENX-1, EZH1, KMT6, KMT6A ENSG00000106462 Enhancer of zeste 2 polycomb repressive complex 2 subunit 7 148807383-148884321 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB009589, HPA029131 Supported Supported Nucleoplasm Renal cancer:8.18e-12 (unfavourable), Liver cancer:2.11e-6 (unfavourable), Melanoma:1.96e-4 (unfavourable), Stomach cancer:6.97e-4 (favourable) Expressed in all Tissue enhanced testis: 50.4 bone marrow: 30.0 EZR VIL2 ENSG00000092820 Ezrin 6 158765741-158819412 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004035, HPA021616, CAB047324 Supported Validated Plasma membrane Renal cancer:9.56e-8 (favourable), Pancreatic cancer:1.70e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 528.6 F13A1 F13A ENSG00000124491 Coagulation factor XIII, A1 polypeptide 6 6144085-6321013 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA001804, CAB002155 Supported Renal cancer:6.61e-6 (unfavourable) Expressed in all Expressed in all placenta: 664.9 F13B FXIIIB ENSG00000143278 Coagulation factor XIII, B polypeptide 1 197039191-197067267 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA003827, HPA052139 Supported Liver cancer:6.78e-5 (favourable) Tissue enriched Tissue enriched 108 liver: 122.1 duodenum: 1.1 F2 ENSG00000180210 Coagulation factor II (thrombin) 11 46719180-46739506 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB016780, CAB018650, HPA051476, HPA054698 Supported Renal cancer:6.75e-12 (unfavourable) Tissue enriched Tissue enriched 1471 liver: 627.1 testis: 0.4 F3 CD142 ENSG00000117525 Coagulation factor III (thromboplastin, tissue factor) 1 94529225-94541800 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009438, HPA049292, HPA069132 Approved Validated Vesicles Renal cancer:2.02e-8 (unfavourable), Pancreatic cancer:1.07e-4 (unfavourable) Expressed in all Expressed in all placenta: 189.7 FABP1 L-FABP ENSG00000163586 Fatty acid binding protein 1, liver 2 88122982-88128116 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002305, HPA028275 Supported Approved Nucleoplasm
Cytosol Group enriched Group enriched 7 colon: 4641.2;duodenum: 4243.6;liver: 5656.0;rectum: 3161.5;small intestine: 4603.3 kidney: 599.7 FABP2 I-FABP ENSG00000145384 Fatty acid binding protein 2, intestinal 4 119317250-119322390 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA034607, CAB047325, CAB047326 Supported Approved Plasma membrane
Actin filaments
Cytosol Group enriched Group enriched 12 duodenum: 268.5;small intestine: 565.3 rectum: 34.6 FABP4 A-FABP, aP2 ENSG00000170323 Fatty acid binding protein 4, adipocyte 8 81478419-81483263 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002188, CAB024961 Supported Group enriched Tissue enriched 7 adipose tissue: 3642.8 breast: 553.6 FABP5 E-FABP, KFABP, PA-FABP ENSG00000164687 Fatty acid binding protein 5 (psoriasis-associated) 8 81280363-81284777 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level CAB017831, CAB040577, HPA051895 Supported Supported Plasma membrane
Cytosol Renal cancer:4.69e-10 (unfavourable) Expressed in all Expressed in all esophagus: 1671.2 FADD GIG3, MORT1 ENSG00000168040 Fas (TNFRSF6)-associated via death domain 11 70203163-70207390 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA001464, CAB010209 Supported Supported Nucleoplasm
Cytosol Lung cancer:2.21e-5 (unfavourable), Head and neck cancer:8.22e-5 (unfavourable), Thyroid cancer:3.45e-4 (favourable), Cervical cancer:6.35e-4 (unfavourable) Expressed in all Expressed in all placenta: 20.2 FAF1 CGI-03, hFAF1, HFAF1s, UBXD12, UBXN3A ENSG00000185104 Fas (TNFRSF6) associated factor 1 1 50437028-50960263 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA018253, CAB072814 Approved Validated Nucleus Liver cancer:1.87e-5 (unfavourable) Expressed in all Expressed in all testis: 59.1 FAM129A C1orf24, GIG39, NIBAN ENSG00000135842 Family with sequence similarity 129, member A 1 184790724-184974550 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA028172, HPA028231, HPA028657 Approved Supported Plasma membrane
Cytosol Urothelial cancer:4.52e-4 (unfavourable) Expressed in all Expressed in all heart muscle: 105.0 FAM131B KIAA0773 ENSG00000159784 Family with sequence similarity 131, member B 7 143353400-143362770 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA021371, HPA029992 Validated Nucleoplasm
Cytosol Tissue enriched Tissue enriched 9 cerebral cortex: 64.0 parathyroid gland: 7.4 FAM166A ENSG00000188163 Family with sequence similarity 166, member A 9 137243584-137247770 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA023307 Supported Not detected Tissue enriched 42 testis: 58.6 epididymis: 1.3 FAM46C FLJ20202 ENSG00000183508 Family with sequence similarity 46, member C 1 117605934-117628372 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA054049 Uncertain Approved Nucleoplasm Renal cancer:2.77e-5 (favourable), Endometrial cancer:3.75e-5 (favourable) Expressed in all Mixed testis: 58.4 FANCA FA-H, FAA, FACA, FAH, FANCH ENSG00000187741 Fanconi anemia, complementation group A 16 89737549-89816657 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA063236 Supported Nucleus Mixed Mixed testis: 19.5 FANCC FA3, FAC, FACC ENSG00000158169 Fanconi anemia, complementation group C 9 95099054-95317709 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017793, HPA030771 Approved Supported Nucleoplasm Renal cancer:6.03e-6 (favourable) Expressed in all Mixed testis: 18.1 FANCD2 FA-D2, FACD, FAD, FANCD ENSG00000144554 Fanconi anemia, complementation group D2 3 10026414-10101930 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB016117, HPA063742 Approved Supported Nucleus
Nuclear bodies
Cytosol Ovarian cancer:5.00e-5 (unfavourable) Expressed in all Mixed testis: 21.7 FANCE FACE, FAE ENSG00000112039 Fanconi anemia, complementation group E 6 35452361-35467103 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB014893 Supported Supported Nucleoplasm Liver cancer:2.08e-9 (unfavourable), Endometrial cancer:6.25e-4 (unfavourable) Expressed in all Mixed skin: 16.2 FANCF FAF ENSG00000183161 Fanconi anemia, complementation group F 11 22622519-22626787 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level Liver cancer:2.27e-4 (unfavourable) Expressed in all Mixed fallopian tube: 10.9 FANCG FAG, XRCC9 ENSG00000221829 Fanconi anemia, complementation group G 9 35073835-35080016 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB008105, HPA045335 Approved Supported Nucleoli
Plasma membrane
Cytosol Renal cancer:2.38e-7 (unfavourable), Liver cancer:2.02e-4 (unfavourable) Expressed in all Mixed fallopian tube: 8.5 FAP DPPIV ENSG00000078098 Fibroblast activation protein, alpha 2 162170684-162245151 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA059739 Approved Head and neck cancer:4.82e-4 (unfavourable) Mixed Tissue enhanced endometrium: 50.4 smooth muscle: 37.9 FAS APO-1, APT1, CD95, FAS1, TNFRSF6 ENSG00000026103 Fas cell surface death receptor 10 88990531-89015785 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA027444 Approved Approved Plasma membrane
Cytosol Expressed in all Mixed lung: 39.5 FASLG APT1LG1, CD178, FasL, TNFSF6 ENSG00000117560 Fas ligand (TNF superfamily, member 6) 1 172659018-172666874 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level HPA054959 Approved Renal cancer:1.59e-6 (unfavourable) Mixed Tissue enhanced lymph node: 5.9 spleen: 5.2 FASN FAS, SDR27X1 ENSG00000169710 Fatty acid synthase 17 82078333-82098332 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005192, HPA006461, CAB015417, HPA056108 Supported Validated Plasma membrane
Cytosol Cervical cancer:1.42e-5 (unfavourable), Renal cancer:7.16e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 283.6 FAT1 CDHF7, CDHR8, FAT ENSG00000083857 FAT atypical cadherin 1 4 186587783-186726722 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA001869, HPA023882 Approved Lung cancer:4.22e-4 (unfavourable) Expressed in all Mixed gallbladder: 37.4 FBN2 CCA, DA9 ENSG00000138829 Fibrillin 2 5 128257909-128659185 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA012853, CAB026401 Supported Approved Nucleoplasm
Cytosol Urothelial cancer:7.41e-5 (unfavourable) Mixed Tissue enriched 8 placenta: 117.6 testis: 13.8 FBXO11 FBX11, UBR6 ENSG00000138081 F-box protein 11 2 47789316-47905793 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002690 Uncertain Supported Nucleus Expressed in all Expressed in all testis: 74.9 FBXO6 FBG2, FBS2, FBX6, Fbx6b ENSG00000116663 F-box protein 6 1 11664124-11674354 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA051175 Approved Renal cancer:7.83e-6 (unfavourable), Urothelial cancer:5.90e-4 (favourable), Ovarian cancer:7.12e-4 (favourable) Expressed in all Expressed in all fallopian tube: 21.2 FBXW7 AGO, CDC4, FBW7, FBX30, FBXW6, FLJ11071, SEL-10, SEL10 ENSG00000109670 F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase 4 152321259-152536101 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB013793, CAB029987 Supported Supported Nucleoplasm
Vesicles Renal cancer:1.52e-4 (unfavourable) Expressed in all Expressed in all skin: 87.7 FCER2 CD23, CD23A, CLEC4J, FCE2 ENSG00000104921 Fc fragment of IgE, low affinity II, receptor for (CD23) 19 7688758-7702146 Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002624, HPA008928 Approved Mixed Group enriched 7 appendix: 22.9;lymph node: 48.1;spleen: 53.7;tonsil: 39.4 adipose tissue: 5.7 FCGR2B CD32, CD32B, FCG2, FCGR2 ENSG00000072694 Fc fragment of IgG, low affinity IIb, receptor (CD32) 1 161663147-161678654 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB007796, HPA014730 Supported Renal cancer:8.82e-4 (unfavourable) Mixed Tissue enriched 16 placenta: 571.2 adipose tissue: 36.3 FCRL4 CD307d, FCRH4, IGFP2, IRTA1 ENSG00000163518 Fc receptor-like 4 1 157573749-157598080 Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level HPA054030 Approved Not detected Group enriched 5 appendix: 3.7;lymph node: 4.5;tonsil: 10.1 spleen: 1.2 FEN1 FEN-1, MF1, RAD2 ENSG00000168496 Flap structure-specific endonuclease 1 11 61792637-61797244 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002262, HPA006581, HPA006748 Supported Approved Nucleus
Nucleoli
Plasma membrane
Mitochondria Liver cancer:3.39e-6 (unfavourable), Renal cancer:5.73e-6 (unfavourable), Ovarian cancer:7.85e-4 (favourable), Stomach cancer:9.46e-4 (favourable) Expressed in all Mixed lymph node: 35.2 FES FPS ENSG00000182511 FES proto-oncogene, tyrosine kinase 15 90883695-90895776 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA001376 Approved Approved Nucleus
Vesicles
Cytosol Colorectal cancer:5.78e-4 (unfavourable) Expressed in all Expressed in all spleen: 98.1 FEV Pet-1 ENSG00000163497 FEV (ETS oncogene family) 2 218981087-218985657 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA067679 Supported Approved Nuclear speckles Pancreatic cancer:4.85e-4 (favourable) Group enriched Tissue enhanced adrenal gland: 2.1;duodenum: 3.0;stomach: 2.4 prostate: 1.9 FGA ENSG00000171560 Fibrinogen alpha chain 4 154583126-154590766 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB016776, HPA051370, HPA064755 Supported Renal cancer:4.23e-6 (unfavourable), Liver cancer:7.33e-4 (favourable) Tissue enriched Tissue enriched 246 liver: 9252.8 stomach: 37.6 FGB ENSG00000171564 Fibrinogen beta chain 4 154562956-154571086 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001900, HPA001901, CAB008624 Supported Renal cancer:5.72e-5 (unfavourable) Tissue enriched Tissue enriched 558 liver: 9991.3 kidney: 17.9 FGF1 AFGF, ECGF, ECGF-beta, ECGFA, ECGFB, FGF-alpha, FGFA, GLIO703, HBGF1 ENSG00000113578 Fibroblast growth factor 1 (acidic) 5 142592178-142698070 Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA003265, CAB017519 Supported Validated Nucleoplasm Renal cancer:2.59e-5 (favourable), Thyroid cancer:3.45e-5 (favourable) Tissue enriched Tissue enhanced cerebral cortex: 130.3;kidney: 59.1 heart muscle: 32.8 FGF17 FGF-13 ENSG00000158815 Fibroblast growth factor 17 8 22042398-22048809 Cancer-related genes, Disease related genes, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA052600 Approved Tissue enhanced Mixed adrenal gland,cerebral cortex: 1.8 FGF18 FGF-18, ZFGF5 ENSG00000156427 Fibroblast growth factor 18 5 171419656-171457623 Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA018795 Uncertain Group enriched Tissue enhanced heart muscle: 5.4 adipose tissue,lung: 1.9 FGF19 ENSG00000162344 Fibroblast growth factor 19 11 69698232-69704642 Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA036082 Approved Mixed Tissue enriched 27 gallbladder: 263.2 small intestine: 9.5 FGF2 FGFB ENSG00000138685 Fibroblast growth factor 2 (basic) 4 122826708-122898236 Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB000125 Approved Supported Nucleoplasm
Nuclear bodies Pancreatic cancer:9.85e-4 (unfavourable) Mixed Mixed adipose tissue: 25.4 FGF23 ENSG00000118972 Fibroblast growth factor 23 12 4368227-4379728 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level Not detected Mixed epididymis: 2.0 FGF3 HBGF-3, INT2 ENSG00000186895 Fibroblast growth factor 3 11 69810224-69819024 Cancer-related genes, Disease related genes, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA012692 Uncertain Approved Group enriched Not detected all non-specific tissues: 0.0 FGF4 HBGF-4, HST, HST-1, HSTF1, K-FGF, KFGF ENSG00000075388 Fibroblast growth factor 4 11 69771016-69775403 Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA011209 Uncertain Tissue enriched Not detected testis: 0.4 FGF6 ENSG00000111241 Fibroblast growth factor 6 12 4428155-4445614 Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level Not detected Tissue enriched 8 skeletal muscle: 5.6 esophagus: 0.7 FGF7 KGF ENSG00000140285 Fibroblast growth factor 7 15 49423096-49488775 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA043605 Uncertain Approved Nucleus
Nucleoli Mixed Tissue enhanced gallbladder: 55.6 endometrium: 31.6 FGF8 AIGF ENSG00000107831 Fibroblast growth factor 8 (androgen-induced) 10 101770130-101780369 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level Group enriched Tissue enriched 6 skeletal muscle: 15.7 testis: 2.5 FGF9 ENSG00000102678 Fibroblast growth factor 9 13 21671383-21704498 Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB004392 Uncertain Renal cancer:1.70e-6 (favourable) Tissue enhanced Tissue enhanced kidney: 12.0 adrenal gland: 4.7 FGFBP1 FGFBP, HBP17 ENSG00000137440 Fibroblast growth factor binding protein 1 4 15935569-15938740 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA004332 Supported Pancreatic cancer:5.03e-4 (unfavourable) Tissue enhanced Tissue enriched 7 esophagus: 299.1 skin: 40.3 FGFR1 BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM ENSG00000077782 Fibroblast growth factor receptor 1 8 38411138-38468834 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB033614, HPA056402, HPA076274 Approved Approved Nucleoli Expressed in all Expressed in all gallbladder: 109.6 FGFR1OP FOP ENSG00000213066 FGFR1 oncogene partner 6 166999182-167052713 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA071876 Supported Centrosome Renal cancer:7.32e-4 (unfavourable) Expressed in all Expressed in all testis: 104.8 FGFR2 BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25 ENSG00000066468 Fibroblast growth factor receptor 2 10 121478334-121598458 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB010886, HPA035305, HPA056562 Uncertain Approved Vesicles Cervical cancer:8.79e-4 (favourable), Head and neck cancer:9.32e-4 (favourable) Expressed in all Mixed skin: 97.5 FGFR3 ACH, CD333, CEK2, JTK4 ENSG00000068078 Fibroblast growth factor receptor 3 4 1793307-1808872 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB004231, HPA067204 Supported Supported Endoplasmic reticulum Endometrial cancer:3.77e-4 (unfavourable) Expressed in all Tissue enriched 7 skin: 334.6 cerebral cortex: 49.7 FGFR4 CD334, JTK2 ENSG00000160867 Fibroblast growth factor receptor 4 5 177086886-177098144 Cancer-related genes, CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB005196, HPA027273, HPA027369, HPA028251 Approved Mixed Tissue enhanced lung: 39.1 duodenum: 22.0 FGG ENSG00000171557 Fibrinogen gamma chain 4 154604134-154612967 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA027529, CAB033120 Supported Renal cancer:1.00e-6 (unfavourable) Tissue enriched Tissue enriched 115 liver: 8684.7 lung: 75.3 FH fumarase ENSG00000091483 Fumarate hydratase 1 241497603-241519761 Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB017785, HPA025770, HPA025948, HPA027341 Supported Approved Validated Mitochondria Renal cancer:2.76e-7 (favourable) Expressed in all Expressed in all liver: 141.9 FHIT AP3Aase, FRA3B ENSG00000189283 Fragile histidine triad 3 59749310-61251459 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB002684, HPA018840, HPA018909 Supported Approved Nucleoli fibrillar center
Plasma membrane Renal cancer:1.36e-4 (favourable) Mixed Expressed in all kidney: 26.6 FIGF VEGF-D, VEGFD ENSG00000165197 C-fos induced growth factor (vascular endothelial growth factor D) X 15345591-15384376 Cancer-related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA027342 Uncertain Mixed Tissue enhanced breast: 25.0;lung: 59.2 adipose tissue: 13.2 FIP1L1 DKFZp586K0717, FIP1 ENSG00000145216 Factor interacting with PAPOLA and CPSF1 4 53377643-53460861 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA037475, HPA058202 Supported Validated Nucleoplasm Liver cancer:1.51e-4 (unfavourable) Expressed in all Expressed in all testis: 68.7 FKBP5 FKBP51, FKBP54, P54, PPIase, Ptg-10 ENSG00000096060 FK506 binding protein 5 6 35573585-35728583 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009315, HPA031092, HPA031093, HPA031095 Supported Validated Nucleoplasm Expressed in all Expressed in all adipose tissue: 414.0 FKBP8 FKBP38, FKBPr38 ENSG00000105701 FK506 binding protein 8, 38kDa 19 18531751-18544077 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB025346, HPA045177 Supported Supported Endoplasmic reticulum
Mitochondria
Cytosol Colorectal cancer:1.24e-4 (unfavourable), Pancreatic cancer:7.76e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 355.7 FLCN BHD, MGC17998, MGC23445 ENSG00000154803 Folliculin 17 17212212-17237188 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB015158, HPA028760 Supported Supported Plasma membrane
Cytosol Pancreatic cancer:4.49e-4 (favourable) Expressed in all Expressed in all endometrium: 30.7 FLG ENSG00000143631 Filaggrin 1 152302175-152325203 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002210, HPA027505, HPA030188, HPA030189 Supported Supported Vesicles Tissue enriched Tissue enriched 26 skin: 549.7 breast: 21.0 FLI1 EWSR2, SIC-1 ENSG00000151702 Fli-1 proto-oncogene, ETS transcription factor 11 128686535-128813267 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA073099 Supported Nucleus
Nuclear bodies Renal cancer:4.60e-4 (unfavourable) Expressed in all Tissue enhanced spleen: 48.1 placenta: 16.2 FLT1 FLT, VEGFR1 ENSG00000102755 Fms-related tyrosine kinase 1 13 28300344-28495128 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA011740, HPA014290, CAB068189, CAB068190 Supported Supported Plasma membrane
Actin filaments Renal cancer:2.19e-4 (unfavourable) Expressed in all Tissue enriched 8 placenta: 617.5 thyroid gland: 81.7 FLT3 CD135, FLK2, STK1 ENSG00000122025 Fms-related tyrosine kinase 3 13 28003274-28100592 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA047539 Approved Endoplasmic reticulum Tissue enhanced Tissue enhanced lymph node: 7.1;spleen: 7.8 appendix: 4.0 FLT4 PCL, VEGFR3 ENSG00000037280 Fms-related tyrosine kinase 4 5 180601506-180649624 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB000099 Supported Nuclear speckles
Plasma membrane
Cell Junctions Expressed in all Mixed spleen: 18.6 FMO5 ENSG00000131781 Flavin containing monooxygenase 5 1 147175351-147243050 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012373 Supported Supported Endoplasmic reticulum
Cytosol Renal cancer:1.34e-6 (favourable) Tissue enriched Tissue enhanced liver: 324.2 small intestine: 77.0 FN1 CIG, FINC, GFND2, LETS, MSF ENSG00000115414 Fibronectin 1 2 215360440-215436172 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000126, HPA027066 Supported Renal cancer:3.44e-8 (unfavourable), Stomach cancer:8.82e-5 (unfavourable), Urothelial cancer:3.33e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 4245.7 lung: 1168.8 FNBP1 FBP17, KIAA0554 ENSG00000187239 Formin binding protein 1 9 129887187-130043194 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019691, HPA022119 Supported Renal cancer:8.45e-5 (unfavourable) Expressed in all Expressed in all lymph node: 91.9 FOLH1 FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA ENSG00000086205 Folate hydrolase (prostate-specific membrane antigen) 1 11 49146635-49208670 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB001451, HPA010593 Supported Renal cancer:1.30e-6 (unfavourable), Endometrial cancer:5.24e-5 (favourable), Liver cancer:4.25e-4 (favourable) Tissue enriched Group enriched 6 duodenum: 307.0;prostate: 128.9;small intestine: 93.5 cerebral cortex: 31.1 FOS AP-1, c-fos ENSG00000170345 FBJ murine osteosarcoma viral oncogene homolog 14 75278774-75282230 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA018531 Approved Supported Nucleoplasm Prostate cancer:7.81e-4 (favourable) Expressed in all Expressed in all fallopian tube: 1834.8 FOSL1 fra-1 ENSG00000175592 FOS-like antigen 1 11 65892049-65900573 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB004396, HPA066901 Uncertain Validated Nucleoplasm Renal cancer:6.40e-6 (unfavourable), Pancreatic cancer:9.26e-5 (unfavourable), Lung cancer:1.95e-4 (unfavourable), Head and neck cancer:2.05e-4 (unfavourable), Glioma:2.46e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 35.2;gallbladder: 51.8 urinary bladder: 27.7 FOXA1 HNF3A ENSG00000129514 Forkhead box A1 14 37589984-37596059 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB011595, HPA050505 Supported Supported Nucleoplasm
Nucleoli fibrillar center Urothelial cancer:1.00e-4 (favourable) Tissue enhanced Tissue enhanced prostate: 145.4 breast: 36.3 FOXA2 HNF3B ENSG00000125798 Forkhead box A2 20 22581005-22585455 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB001388, HPA066846 Approved Supported Nucleoplasm
Cell Junctions Endometrial cancer:7.57e-6 (favourable), Pancreatic cancer:2.34e-4 (favourable), Ovarian cancer:6.28e-4 (favourable) Mixed Tissue enhanced cervix, uterine: 21.3;lung: 20.6;stomach: 31.3 liver: 11.5 FOXJ1 FKHL13, HFH-4, HFH4 ENSG00000129654 Forkhead box J1 17 76136333-76141299 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA005714 Supported Renal cancer:2.03e-5 (unfavourable), Breast cancer:9.39e-4 (favourable) Tissue enhanced Tissue enriched 8 fallopian tube: 82.8 lung: 10.4 FOXL2 BPES, BPES1 ENSG00000183770 Forkhead box L2 3 138944224-138947140 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA069613 Supported Supported Nucleus
Cytokinetic bridge Mixed Tissue enhanced endometrium: 12.1;ovary: 29.6;parathyroid gland: 24.2 fallopian tube: 7.6 FOXM1 FKHL16, HFH-11, HNF-3, INS-1, MPHOSPH2, MPP2, TGT3, trident ENSG00000111206 Forkhead box M1 12 2857681-2877155 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB017832, HPA029974 Uncertain Supported Nucleus
Nucleoli
Cytosol Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.95e-6 (unfavourable), Pancreatic cancer:3.03e-5 (unfavourable), Lung cancer:2.92e-4 (unfavourable) Expressed in all Tissue enhanced testis: 39.5 bone marrow: 15.9 FOXO1 FKH1, FKHR, FOXO1A ENSG00000150907 Forkhead box O1 13 40555667-40666597 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA001252, CAB022326 Approved Approved Supported Nucleoplasm
Cytosol Renal cancer:1.33e-5 (favourable), Liver cancer:3.74e-4 (favourable) Expressed in all Expressed in all ovary: 80.5 FOXO3 AF6q21, FKHRL1, FOXO2, FOXO3A ENSG00000118689 Forkhead box O3 6 108559835-108684774 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB004074, HPA063104 Supported Validated Nucleus Expressed in all Expressed in all ovary: 54.9 FOXO4 AFX1, MLLT7 ENSG00000184481 Forkhead box O4 X 71096197-71103535 Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors Evidence at protein level HPA039560, HPA040232 Approved Supported Nuclear speckles
Cytosol Renal cancer:3.46e-4 (favourable), Head and neck cancer:4.61e-4 (favourable) Expressed in all Expressed in all placenta: 171.9 FOXP1 12CC4, hFKH1B, HSPC215, QRF1 ENSG00000114861 Forkhead box P1 3 70954693-71583989 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA003876, CAB011501 Supported Validated Nucleoplasm Expressed in all Expressed in all ovary: 39.5 FOXQ1 HFH1 ENSG00000164379 Forkhead box Q1 6 1312473-1314187 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA059700 Supported Nucleus Prostate cancer:6.68e-4 (favourable) Expressed in all Tissue enhanced stomach: 102.1;urinary bladder: 41.0 skin: 28.3 FRMD7 FLJ43346, NYS, NYS1 ENSG00000165694 FERM domain containing 7 X 132076993-132128020 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA000886 Uncertain Not detected Tissue enhanced endometrium: 2.8;kidney: 3.0;smooth muscle: 3.4 seminal vesicle: 0.7 FSCN1 FLJ38511, p55, SNL ENSG00000075618 Fascin actin-bundling protein 1 7 5592823-5606655 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000121, HPA005723, CAB035991, HPA050654 Supported Supported Plasma membrane
Cytosol Renal cancer:8.15e-7 (unfavourable), Lung cancer:2.28e-4 (unfavourable), Head and neck cancer:5.76e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 85.7 spleen: 55.9 FSHB ENSG00000131808 Follicle stimulating hormone, beta polypeptide 11 30231016-30235261 Cancer-related genes, Disease related genes, Predicted secreted proteins Evidence at protein level CAB023410, HPA069703 Supported Not detected Not detected all non-specific tissues: 0.0 FST FS ENSG00000134363 Follistatin 5 53480409-53487134 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA018155, CAB026025 Uncertain Renal cancer:4.44e-5 (unfavourable) Expressed in all Mixed liver: 32.8 FSTL3 FLRG, FSRP ENSG00000070404 Follistatin-like 3 (secreted glycoprotein) 19 676365-683399 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB024899, HPA045378 Approved Approved Nucleoplasm Lung cancer:4.61e-7 (unfavourable), Ovarian cancer:1.65e-4 (unfavourable), Colorectal cancer:3.01e-4 (unfavourable), Endometrial cancer:3.03e-4 (unfavourable) Expressed in all Expressed in all placenta: 259.7 FTH1 FHC, FTH, FTHL6, PIG15, PLIF ENSG00000167996 Ferritin, heavy polypeptide 1 11 61959718-61967660 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB008623 Approved Approved Microtubules Renal cancer:5.20e-5 (unfavourable), Head and neck cancer:7.56e-5 (unfavourable), Liver cancer:6.18e-4 (unfavourable) Expressed in all Expressed in all appendix: 5085.0 FTL MGC71996, NBIA3 ENSG00000087086 Ferritin, light polypeptide 19 48965301-48966878 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB020769, HPA041602 Supported Approved Cytosol Renal cancer:4.40e-5 (unfavourable) Expressed in all Expressed in all lung: 8051.2 FUBP1 FBP, FUBP ENSG00000162613 Far upstream element (FUSE) binding protein 1 1 77944055-77979110 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006149 Supported Validated Nucleoplasm Liver cancer:9.83e-9 (unfavourable) Expressed in all Expressed in all parathyroid gland: 68.1 FUS ALS6, FUS1, hnRNP-P2, HNRNPP2, TLS ENSG00000089280 FUS RNA binding protein 16 31180110-31194871 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA008784, CAB033036, CAB058691 Supported Validated Nucleoplasm Liver cancer:4.38e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 146.2 FZD1 DKFZp564G072 ENSG00000157240 Frizzled class receptor 1 7 91264364-91271326 Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB013008 Approved Supported Plasma membrane Renal cancer:8.87e-7 (favourable) Expressed in all Mixed thyroid gland: 32.3 FZD2 ENSG00000180340 Frizzled class receptor 2 17 44557459-44559570 Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA057667 Uncertain Approved Nuclear bodies
Cell Junctions Expressed in all Mixed placenta: 4.9 G6PD G6PD1 ENSG00000160211 Glucose-6-phosphate dehydrogenase X 154531391-154547572 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA000247, HPA000834 Supported Approved Vesicles
Microtubule organizing center
Cytosol Liver cancer:9.45e-13 (unfavourable) Expressed in all Expressed in all testis: 107.0 GADD45A DDIT1, GADD45 ENSG00000116717 Growth arrest and DNA-damage-inducible, alpha 1 67685061-67688338 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA053420 Supported Nuclear speckles Renal cancer:8.06e-6 (favourable) Expressed in all Expressed in all thyroid gland: 91.1 GADD45G CR6, DDIT2, GADD45gamma, GRP17 ENSG00000130222 Growth arrest and DNA-damage-inducible, gamma 9 89605013-89606555 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA023606 Approved Approved Nucleus Pancreatic cancer:3.80e-5 (favourable), Endometrial cancer:7.06e-4 (favourable) Expressed in all Mixed adrenal gland: 47.4 GAS1 ENSG00000180447 Growth arrest-specific 1 9 86944363-86947189 Cancer-related genes, Predicted secreted proteins Evidence at protein level CAB024164, HPA036085, HPA066902 Approved Approved Nuclear speckles Thyroid cancer:1.13e-5 (unfavourable), Renal cancer:1.96e-5 (unfavourable), Colorectal cancer:1.55e-4 (unfavourable), Stomach cancer:8.26e-4 (unfavourable) Expressed in all Tissue enhanced endometrium: 110.4 smooth muscle: 73.6 GAS7 KIAA0394, MGC1348 ENSG00000007237 Growth arrest-specific 7 17 9910609-10198551 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA004838, HPA064678 Supported Approved Plasma membrane
Actin filaments
Focal adhesion sites Urothelial cancer:6.89e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 155.2 cervix, uterine: 47.5 GAST GAS ENSG00000184502 Gastrin 17 41712326-41715969 Cancer-related genes, Predicted secreted proteins Evidence at protein level CAB000038 Supported Group enriched Tissue enriched 197 stomach: 11343.0 duodenum: 57.5 GATA1 ERYF1, GATA-1, GF1, NF-E1, NFE1 ENSG00000102145 GATA binding protein 1 (globin transcription factor 1) X 48786554-48794311 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA000232, HPA000233, CAB009195 Supported Not detected Tissue enriched 18 bone marrow: 33.3 testis: 1.8 GATA2 NFE1B ENSG00000179348 GATA binding protein 2 3 128479427-128493185 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA005633, CAB024847 Approved Supported Nucleoplasm Urothelial cancer:5.22e-5 (favourable), Renal cancer:2.04e-4 (favourable) Expressed in all Tissue enhanced seminal vesicle: 76.1 prostate: 60.0 GATA3 HDR ENSG00000107485 GATA binding protein 3 10 8053604-8075198 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB016217, HPA029730, HPA029731 Supported Supported Nucleoplasm Renal cancer:3.13e-4 (unfavourable) Group enriched Tissue enhanced parathyroid gland: 231.0;skin: 149.3 placenta: 44.1 GCLM GLCLR ENSG00000023909 Glutamate-cysteine ligase, modifier subunit 1 93885205-93909456 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB009568, HPA023696, CAB040554 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Liver cancer:9.83e-6 (unfavourable) Expressed in all Expressed in all thyroid gland: 28.1 GDF15 MIC-1, MIC1, NAG-1, PDF, PLAB, PTGFB ENSG00000130513 Growth differentiation factor 15 19 18374731-18389176 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA011191, CAB062554 Supported Supported Golgi apparatus Expressed in all Tissue enhanced placenta: 121.8 prostate: 63.1 GDNF ATF1, ATF2, HFB1-GDNF ENSG00000168621 Glial cell derived neurotrophic factor 5 37812677-37839686 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB005210, HPA070283 Supported Approved Nucleoplasm
Vesicles Mixed Mixed placenta: 6.9 GH1 GH, GH-N, GHN, hGH-N ENSG00000259384 Growth hormone 1 17 63917200-63918838 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA043715 Supported Not detected Tissue enhanced placenta: 1.2 duodenum: 0.7 GH2 GH-V , GH2, GHL, GHV, hGH-V ENSG00000136487 Growth hormone 2 17 63880215-63881935 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA043715 Supported Not detected Tissue enriched 202 placenta: 189.0 smooth muscle: 0.9 GJA1 CX43, GJAL, ODD, ODDD, ODOD, SDTY3 ENSG00000152661 Gap junction protein, alpha 1, 43kDa 6 121435692-121449727 Cancer-related genes, Disease related genes, Predicted membrane proteins Evidence at protein level CAB010753, HPA035097 Supported Approved Stomach cancer:4.99e-5 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 639.4 skin: 470.1 GJB5 CX31.1 ENSG00000189280 Gap junction protein, beta 5, 31.1kDa 1 34755047-34758512 Cancer-related genes, Predicted membrane proteins Evidence at transcript level HPA038146 Uncertain Pancreatic cancer:1.54e-4 (unfavourable) Group enriched Group enriched 6 esophagus: 56.7;skin: 77.6 tonsil: 11.9 GLO1 GLOD1 ENSG00000124767 Glyoxalase I 6 38675925-38703141 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB040541, CAB040542, HPA059791 Supported Supported Nucleoplasm
Plasma membrane
Cytosol Liver cancer:5.21e-4 (unfavourable) Expressed in all Expressed in all prostate: 274.7 GMNN Gem ENSG00000112312 Geminin, DNA replication inhibitor 6 24774931-24786099 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB011458, CAB047327, CAB047328, HPA049977, HPA054597 Supported Validated Nucleoplasm Renal cancer:7.82e-5 (unfavourable), Ovarian cancer:4.13e-4 (favourable), Pancreatic cancer:9.77e-4 (unfavourable) Expressed in all Expressed in all prostate: 70.5 GMPS ENSG00000163655 Guanine monophosphate synthase 3 155870536-155944026 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA046630 Approved Cytosol Liver cancer:8.73e-7 (unfavourable), Endometrial cancer:5.54e-5 (unfavourable), Pancreatic cancer:1.04e-4 (unfavourable) Expressed in all Expressed in all testis: 180.7 GNA11 FBH, FBH2, FHH2, HHC2 ENSG00000088256 Guanine nucleotide binding protein (G protein), alpha 11 (Gq class) 19 3094410-3124004 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA048886 Approved Renal cancer:1.48e-11 (favourable), Liver cancer:4.86e-4 (unfavourable) Expressed in all Expressed in all small intestine: 159.0 GNA13 G13, MGC46138 ENSG00000120063 Guanine nucleotide binding protein (G protein), alpha 13 17 65010715-65056839 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA010087 Approved Supported Cytosol Expressed in all Expressed in all bone marrow: 99.3 GNAI1 ENSG00000127955 Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 7 80133955-80219402 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB022449, HPA042141 Approved Supported Nucleus
Nucleoli
Centrosome Melanoma:5.09e-4 (unfavourable), Stomach cancer:6.47e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 94.8 GNAQ G-ALPHA-q, GAQ ENSG00000156052 Guanine nucleotide binding protein (G protein), q polypeptide 9 77716087-78031458 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB010036, HPA048886 Uncertain Approved Nuclear speckles
Plasma membrane
Cytosol Renal cancer:1.11e-7 (favourable) Expressed in all Expressed in all cerebral cortex: 85.1 GNAS GNAS1, GNASXL, GPSA, NESP, NESP55, SCG6, SgVI ENSG00000087460 GNAS complex locus 20 58839718-58911192 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB010337, HPA018122, HPA027478, HPA028386 Uncertain Supported Nucleoplasm
Plasma membrane
Cytosol Renal cancer:3.49e-4 (unfavourable), Ovarian cancer:8.76e-4 (favourable) Expressed in all Expressed in all thyroid gland: 1471.9 GNB1 ENSG00000078369 Guanine nucleotide binding protein (G protein), beta polypeptide 1 1 1785285-1891117 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA040736 Supported Uncertain Golgi apparatus
Plasma membrane Liver cancer:3.61e-6 (unfavourable) Expressed in all Expressed in all cerebral cortex: 448.5 GNPTAB GNPTA, KIAA1208, MGC4170 ENSG00000111670 N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits 12 101745497-101830938 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017754, HPA042343 Approved Approved Vesicles Endometrial cancer:8.48e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 64.0 GOLGA5 golgin-84, GOLIM5, ret-II, rfg5 ENSG00000066455 Golgin A5 14 92794231-92839963 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000992, HPA063876 Supported Supported Supported Golgi apparatus Expressed in all Expressed in all epididymis: 64.2 GOPC CAL, dJ94G16.2, FIG, GOPC1, PIST ENSG00000047932 Golgi-associated PDZ and coiled-coil motif containing 6 117560269-117602542 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA019477, HPA024018 Approved Validated Golgi apparatus
Cytosol Expressed in all Expressed in all parathyroid gland: 47.0 GOT1 AST1 ENSG00000120053 Glutamic-oxaloacetic transaminase 1, soluble 10 99396870-99430624 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA064532, HPA072629 Supported Supported Nucleoplasm
Cytosol Renal cancer:3.72e-13 (favourable), Cervical cancer:6.23e-4 (favourable) Expressed in all Expressed in all heart muscle: 340.8 GOT2 KAT4, KATIV, mitAAT ENSG00000125166 Glutamic-oxaloacetic transaminase 2, mitochondrial 16 58707131-58734357 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA018139 Supported Renal cancer:2.90e-9 (favourable), Liver cancer:5.75e-5 (favourable), Head and neck cancer:1.61e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 240.3 GPA33 A33 ENSG00000143167 Glycoprotein A33 (transmembrane) 1 167052836-167166479 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018858, CAB025943 Supported Tissue enriched Group enriched 8 colon: 186.8;duodenum: 134.3;rectum: 191.4;small intestine: 133.9 appendix: 19.9 GPC3 DGSX, OCI-5, SDYS, SGB, SGBS, SGBS1 ENSG00000147257 Glypican 3 X 133535745-133985895 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006316 Approved Plasma membrane Stomach cancer:4.83e-4 (unfavourable) Expressed in all Tissue enriched 6 placenta: 838.1 lung: 130.8 GPHN KIAA1385 ENSG00000171723 Gephyrin 14 66507407-67181803 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA003116, CAB004419, HPA024694 Supported Uncertain Cytoplasmic bodies Renal cancer:5.25e-12 (favourable), Urothelial cancer:4.61e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 30.5 GPI AMF, NLK ENSG00000105220 Glucose-6-phosphate isomerase 19 34359480-34402156 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB018655, HPA024305, CAB040563, HPA052171 Supported Supported Nucleoplasm
Plasma membrane
Cytosol Expressed in all Expressed in all parathyroid gland: 308.2 GPS2 ENSG00000132522 G protein pathway suppressor 2 17 7311324-7315564 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA067540 Supported Nucleoplasm Renal cancer:3.42e-5 (unfavourable), Pancreatic cancer:7.50e-5 (favourable) Expressed in all Expressed in all testis: 97.2 GPX1 ENSG00000233276 Glutathione peroxidase 1 3 49357176-49358600 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB011582, HPA044758 Approved Supported Cytosol Endometrial cancer:7.78e-4 (favourable) Expressed in all Expressed in all adipose tissue: 275.5 GPX2 GSHPX-GI ENSG00000176153 Glutathione peroxidase 2 14 64939152-64942905 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA003545 Supported Approved Nucleoplasm
Cytosol Head and neck cancer:5.10e-4 (unfavourable) Mixed Tissue enhanced gallbladder: 699.5;rectum: 466.5 stomach: 338.1 GRB10 ENSG00000106070 Growth factor receptor-bound protein 10 7 50590063-50793462 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB019423, HPA027502, HPA031818 Approved Approved Nuclear membrane
Vesicles Expressed in all Expressed in all thyroid gland: 44.8 GRB2 NCKAP2 ENSG00000177885 Growth factor receptor-bound protein 2 17 75318076-75405709 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB002589, HPA030749, HPA030750 Approved Supported Nucleus Liver cancer:6.04e-7 (unfavourable) Expressed in all Expressed in all appendix: 138.6 GRB7 ENSG00000141738 Growth factor receptor-bound protein 7 17 39737927-39747291 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB005226, HPA057084, CAB073538 Approved Supported Plasma membrane Endometrial cancer:6.60e-7 (unfavourable), Renal cancer:8.23e-5 (favourable), Ovarian cancer:3.10e-4 (unfavourable), Pancreatic cancer:6.90e-4 (unfavourable) Mixed Mixed fallopian tube: 34.9 GRIN2A GluN2A, NMDAR2A ENSG00000183454 Glutamate receptor, ionotropic, N-methyl D-aspartate 2A 16 9753404-10182754 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB022725 Supported Mixed Tissue enriched 5 cerebral cortex: 25.0 testis: 4.7 GSK3A ENSG00000105723 Glycogen synthase kinase 3 alpha 19 42230186-42242625 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB004422, HPA028423 Approved Approved Cytosol Liver cancer:1.13e-4 (unfavourable), Endometrial cancer:4.02e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 74.7 GSN DKFZp313L0718 ENSG00000148180 Gelsolin 9 121207794-121332843 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB010823, CAB016728, CAB036009, HPA054026 Supported Supported Actin filaments Urothelial cancer:1.79e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 1336.6 GSR ENSG00000104687 Glutathione reductase 8 30678061-30727926 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001538, CAB008632 Approved Supported Plasma membrane
Cytosol Liver cancer:3.26e-5 (unfavourable), Colorectal cancer:4.08e-5 (favourable), Renal cancer:1.80e-4 (favourable), Cervical cancer:3.37e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 77.8 GSTM1 GST1, H-B, MU ENSG00000134184 Glutathione S-transferase mu 1 1 109687814-109709039 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB022669, CAB047357, HPA048652, HPA055972, HPA055973 Approved Approved Mitochondria Expressed in all Tissue enhanced liver: 315.8 parathyroid gland: 228.7 GSTM3 GST5 ENSG00000134202 Glutathione S-transferase mu 3 (brain) 1 109733932-109741038 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB017130, HPA035190, CAB040583, HPA055972 Supported Supported Nucleoli
Cytosol Melanoma:1.89e-4 (unfavourable) Expressed in all Expressed in all testis: 718.1 GSTP1 FAEES3, GST3, GSTP ENSG00000084207 Glutathione S-transferase pi 1 11 67583595-67586660 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019779, HPA019869 Approved Supported Mitochondria
Cytosol Expressed in all Expressed in all esophagus: 1064.0 GTF2H1 BTF2, P62, TFIIH ENSG00000110768 General transcription factor IIH, polypeptide 1, 62kDa 11 18322295-18367044 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB004637, HPA046660 Supported Validated Nucleoplasm Liver cancer:5.98e-9 (unfavourable) Expressed in all Expressed in all testis: 60.0 GUSB ENSG00000169919 Glucuronidase, beta 7 65960684-65982314 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA036322, HPA036323 Approved Supported Vesicles Expressed in all Expressed in all breast: 94.1 H3F3A H3.3A, H3F3 ENSG00000163041 H3 histone, family 3A 1 226061851-226072001 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB011481, CAB037178, HPA042570 Supported Supported Nucleoplasm Renal cancer:1.21e-6 (unfavourable) Expressed in all Expressed in all bone marrow: 1218.1 H3F3B H3.3B ENSG00000132475 H3 histone, family 3B (H3.3B) 17 75776434-75785893 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB037166, CAB037187, CAB037221, HPA042570 Supported Validated Nucleoplasm Expressed in all Expressed in all bone marrow: 2838.4 H3F3C H3.5 ENSG00000188375 H3 histone, family 3C 12 31791185-31792241 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA042570 Supported Mixed Tissue enriched 15 testis: 33.6 bone marrow: 2.2 HDAC10 DKFZP761B039 ENSG00000100429 Histone deacetylase 10 22 50245183-50251405 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB045977, HPA056514 Supported Approved Nucleoli fibrillar center Renal cancer:4.74e-11 (unfavourable), Endometrial cancer:2.45e-5 (favourable), Cervical cancer:4.46e-4 (favourable), Pancreatic cancer:9.25e-4 (favourable) Expressed in all Mixed spleen: 9.9 HDAC2 RPD3, YAF1 ENSG00000196591 Histone deacetylase 2 6 113933028-114011308 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005054, HPA011727 Supported Validated Nucleus Liver cancer:5.39e-10 (unfavourable), Breast cancer:7.07e-4 (unfavourable) Expressed in all Expressed in all testis: 142.0 HDAC5 FLJ90614, KIAA0600, NY-CO-9 ENSG00000108840 Histone deacetylase 5 17 44076746-44123702 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB019400, HPA030991 Approved Supported Nuclear speckles
Golgi apparatus
Cytosol Liver cancer:3.12e-5 (unfavourable), Renal cancer:3.30e-5 (favourable), Cervical cancer:6.14e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 59.2 HERPUD1 HERP, KIAA0025, Mif1, SUP ENSG00000051108 Homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 16 56932048-56944863 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB037041, CAB037104, HPA040754, HPA041219 Approved Uncertain Plasma membrane
Cytosol Renal cancer:1.41e-9 (favourable) Expressed in all Expressed in all prostate: 379.0 HEY1 bHLHb31, CHF-2, CHF2, HERP2, HESR-1, HESR1, HRT-1 ENSG00000164683 Hes-related family bHLH transcription factor with YRPW motif 1 8 79764010-79767863 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA055599, HPA063472 Uncertain Approved Nucleoplasm
Nuclear membrane
Cytosol Expressed in all Tissue enhanced cerebral cortex: 96.6 placenta: 28.7 HGF DFNB39, F-TCF, HGFB, HPTA, SF ENSG00000019991 Hepatocyte growth factor (hepapoietin A; scatter factor) 7 81699006-81770438 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB010333, HPA040360, HPA044088 Approved Approved Centrosome
Cytosol Renal cancer:5.59e-4 (unfavourable) Mixed Tissue enriched 16 placenta: 435.4 gallbladder: 27.6 HGFAC HGFA, HGFAP ENSG00000109758 HGF activator 4 3441887-3449495 Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA058279, HPA059076 Supported Renal cancer:9.31e-4 (unfavourable) Tissue enriched Tissue enriched 14 liver: 28.7 testis: 2.0 HIF1A bHLHe78, HIF-1alpha, HIF1, MOP1, PASD8 ENSG00000100644 Hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) 14 61695513-61748259 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA000907, HPA001275, CAB017442 Supported Supported Nucleoplasm
Nuclear bodies
Plasma membrane Expressed in all Expressed in all bone marrow: 292.9 HIP1 ILWEQ ENSG00000127946 Huntingtin interacting protein 1 7 75533300-75738962 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA013606, CAB015334, CAB016402, HPA017964 Supported Validated Vesicles Expressed in all Mixed testis: 35.1 HIP1R FLJ14000, HIP12, HIP3, ILWEQ, KIAA0655 ENSG00000130787 Huntingtin interacting protein 1 related 12 122834453-122862960 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB017187, HPA038135, HPA038136 Approved Validated Vesicles
Plasma membrane
Cytosol Renal cancer:6.50e-7 (favourable), Urothelial cancer:7.26e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 53.3 HIST1H1E H1.4, H1e, H1F4, H1s-4 ENSG00000168298 Histone cluster 1, H1e 6 26156354-26157107 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB011506, HPA055907 Supported Supported Nuclear speckles Mixed Tissue enriched 11 bone marrow: 36.3 lymph node: 3.4 HIST1H2AC H2AFL ENSG00000180573 Histone cluster 1, H2ac 6 26124145-26139116 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA041189 Supported Expressed in all Expressed in all prostate: 56.2 HIST1H3B H3/l, H3FL ENSG00000274267 Histone cluster 1, H3b 6 26031650-26032060 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA042570 Supported Mixed Tissue enriched 6 bone marrow: 6.1 lymph node: 0.9 HIST1H4E H4/j, H4FJ ENSG00000276966 Histone cluster 1, H4e 6 26204552-26206038 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA042201 Supported Renal cancer:2.00e-6 (unfavourable) Expressed in all Mixed prostate: 2.0 HIST1H4I H4/m, H4FM ENSG00000276180 Histone cluster 1, H4i 6 27138588-27139881 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA042201 Supported Renal cancer:1.32e-5 (unfavourable), Cervical cancer:9.70e-4 (favourable) Expressed in all Mixed prostate: 12.1 HK1 ENSG00000156515 Hexokinase 1 10 69269984-69401882 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA007043, HPA007044, CAB010052, HPA011956 Supported Validated Mitochondria Head and neck cancer:3.39e-6 (unfavourable) Expressed in all Expressed in all testis: 152.9 HK2 ENSG00000159399 Hexokinase 2 2 74833981-74893359 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA028587 Approved Renal cancer:1.37e-4 (unfavourable), Liver cancer:3.65e-4 (unfavourable) Expressed in all Mixed epididymis: 79.1 HLA-A ENSG00000206503 Major histocompatibility complex, class I, A 6 29941260-29945884 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB078470 Supported Golgi apparatus
Plasma membrane Ovarian cancer:6.47e-4 (favourable), Endometrial cancer:9.59e-4 (favourable) Expressed in all Mixed gallbladder: 342.4 HLA-B AS ENSG00000234745 Major histocompatibility complex, class I, B 6 31353872-31357188 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB015418 Supported Melanoma:2.90e-4 (favourable) Expressed in all Mixed lung: 1245.1 HLA-G ENSG00000204632 Major histocompatibility complex, class I, G 6 29826967-29831125 Cancer-related genes, Predicted membrane proteins Evidence at protein level CAB016158 Supported Melanoma:3.91e-5 (favourable) Expressed in all Tissue enriched 23 placenta: 14.8 duodenum,testis: 0.6 HLF MGC33822 ENSG00000108924 Hepatic leukemia factor 17 55265012-55325065 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA068156, HPA071210 Validated Nucleus Lung cancer:2.71e-7 (favourable), Renal cancer:3.55e-6 (favourable), Head and neck cancer:1.88e-4 (favourable) Tissue enhanced Mixed cerebral cortex: 65.6 HMGA1 HMGIY ENSG00000137309 High mobility group AT-hook 1 6 34236873-34246231 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB032200 Uncertain Approved Nucleus
Nucleoli Liver cancer:1.29e-6 (unfavourable), Lung cancer:3.36e-4 (unfavourable), Endometrial cancer:7.13e-4 (unfavourable), Pancreatic cancer:8.71e-4 (unfavourable) Expressed in all Expressed in all lymph node: 165.8 HMGA2 BABL, HMGIC, LIPO ENSG00000149948 High mobility group AT-hook 2 12 65824131-65966295 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB017809, HPA039076 Approved Supported Nucleus
Nucleoli Urothelial cancer:2.86e-4 (unfavourable), Head and neck cancer:4.79e-4 (unfavourable) Mixed Mixed testis: 3.7 HMGXB4 HMG2L1, THC211630 ENSG00000100281 HMG box domain containing 4 22 35257452-35295807 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA000725 Approved Colorectal cancer:3.24e-5 (favourable), Pancreatic cancer:1.16e-4 (unfavourable), Liver cancer:4.79e-4 (unfavourable) Expressed in all Expressed in all endometrium: 18.7 HMOX1 bK286B10, HO-1 ENSG00000100292 Heme oxygenase 1 22 35380361-35394214 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000635, CAB017444 Supported Uncertain Golgi apparatus
Plasma membrane Liver cancer:1.59e-4 (unfavourable) Expressed in all Expressed in all spleen: 435.2 HNF1A HCF-1A, HNF1, LFB1, MODY3, TCF1 ENSG00000135100 HNF1 homeobox A 12 120978543-121002512 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB010430, HPA035231 Supported Supported Nucleoplasm Mixed Tissue enhanced duodenum: 15.9;kidney: 10.1;small intestine: 16.0 liver: 5.8 HNRNPA2B1 HNRPA2B1 ENSG00000122566 Heterogeneous nuclear ribonucleoprotein A2/B1 7 26189927-26201529 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001666, HPA005812, CAB012403, HPA065537 Supported Validated Nucleoplasm Liver cancer:1.03e-6 (unfavourable), Renal cancer:8.01e-5 (unfavourable), Prostate cancer:5.12e-4 (unfavourable) Expressed in all Expressed in all lymph node: 762.7 HOOK3 HK3 ENSG00000168172 Hook microtubule-tethering protein 3 8 42896932-43030539 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA024756 Approved Supported Golgi apparatus
Microtubule organizing center
Cytosol Renal cancer:1.32e-4 (unfavourable) Expressed in all Mixed thyroid gland: 36.4 HOXA11 HOX1, HOX1I ENSG00000005073 Homeobox A11 7 27181510-27185223 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA006770, HPA035623 Supported Supported Nucleoplasm Renal cancer:2.57e-5 (unfavourable) Mixed Tissue enhanced endometrium: 96.0;smooth muscle: 67.7 cervix, uterine: 18.3 HOXA13 HOX1, HOX1J ENSG00000106031 Homeobox A13 7 27193503-27200106 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA046098 Approved Nucleoplasm
Intermediate filaments Tissue enhanced Tissue enhanced cervix, uterine: 33.9;placenta: 24.3;prostate: 36.5;seminal vesicle: 32.2 rectum: 13.3 HOXA5 HOX1, HOX1C ENSG00000106004 Homeobox A5 7 27141052-27143668 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA029319 Uncertain Endometrial cancer:2.28e-4 (unfavourable) Mixed Tissue enhanced adrenal gland: 110.5;epididymis: 59.1 fallopian tube: 43.5 HOXA9 HOX1, HOX1G ENSG00000078399 Homeobox A9 7 27162435-27175180 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA061982 Uncertain Supported Nucleus Mixed Mixed kidney: 12.5 HOXC11 HOX3H ENSG00000123388 Homeobox C11 12 53973126-53977643 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA038291 Uncertain Supported Nucleoplasm
Cytosol Mixed Tissue enhanced skin: 2.3 testis: 1.2 HOXC13 HOX3, HOX3G ENSG00000123364 Homeobox C13 12 53938765-53946544 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA051634 Supported Mixed Tissue enriched 7 skin: 4.6 breast: 0.6 HOXD11 HOX4, HOX4F ENSG00000128713 Homeobox D11 2 176104216-176109754 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA055155 Approved Nucleoplasm Mixed Tissue enhanced endometrium: 5.9 colon,smooth muscle: 1.6 HOXD13 HOX4I, SPD ENSG00000128714 Homeobox D13 2 176092891-176095938 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA064064 Supported Nucleus Colorectal cancer:6.95e-5 (unfavourable) Mixed Group enriched 8 cervix, uterine: 7.9;colon: 5.1;prostate: 18.4;rectum: 9.6;seminal vesicle: 24.4 urinary bladder: 1.6 HP ENSG00000257017 Haptoglobin 16 72054592-72061055 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB003787, HPA047750 Supported Approved Vesicles Renal cancer:6.94e-13 (unfavourable) Tissue enriched Tissue enriched 181 liver: 28321.0 bone marrow: 156.1 HPGD SDR36C1 ENSG00000164120 Hydroxyprostaglandin dehydrogenase 15-(NAD) 4 174490177-174523154 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA004919, HPA005679 Supported Supported Nucleoplasm
Cytosol Renal cancer:3.20e-4 (favourable) Tissue enhanced Tissue enhanced urinary bladder: 389.1 stomach: 183.4 HPN TMPRSS1 ENSG00000105707 Hepsin 19 35040506-35066571 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006804 Approved Renal cancer:5.45e-5 (favourable) Tissue enhanced Tissue enhanced kidney: 99.4;liver: 155.0 prostate: 27.9 HRAS HRAS1 ENSG00000174775 Harvey rat sarcoma viral oncogene homolog 11 532242-537287 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB002015, HPA049830 Approved Liver cancer:2.32e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 25.0 HSF1 HSTF1 ENSG00000185122 Heat shock transcription factor 1 8 144291591-144314722 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB004239, HPA008888 Supported Supported Nucleoplasm
Cytosol Liver cancer:4.95e-4 (unfavourable), Endometrial cancer:8.93e-4 (unfavourable) Expressed in all Expressed in all testis: 127.1 HSP90AA1 FLJ31884, Hsp89, Hsp90, HSP90N, HSPC1, HSPCA ENSG00000080824 Heat shock protein 90kDa alpha (cytosolic), class A member 1 14 102080738-102139699 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002058 Approved Supported Cytosol Renal cancer:1.18e-5 (favourable), Liver cancer:3.09e-5 (unfavourable), Breast cancer:5.59e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 1024.3 HSP90AB1 HSPC2, HSPCB ENSG00000096384 Heat shock protein 90kDa alpha (cytosolic), class B member 1 6 44246166-44253888 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005230, HPA055729 Approved Validated Cytosol Ovarian cancer:4.03e-4 (favourable), Renal cancer:9.94e-4 (unfavourable) Expressed in all Expressed in all ovary: 1457.6 HSP90B1 GP96, GRP94, TRA1 ENSG00000166598 Heat shock protein 90kDa beta (Grp94), member 1 12 103930107-103953645 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA003901, CAB005224, HPA008424 Supported Validated Endoplasmic reticulum Renal cancer:1.03e-10 (unfavourable) Expressed in all Expressed in all thyroid gland: 2376.1 HSPA1A HSP70-1, HSPA1 ENSG00000204389 Heat shock 70kDa protein 1A 6 31815464-31817946 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level CAB017451, CAB032815, HPA052504 Supported Uncertain Nucleoplasm
Vesicles Colorectal cancer:1.54e-5 (unfavourable) Expressed in all Mixed adrenal gland: 49.9 HSPA1B HSP70-2 ENSG00000204388 Heat shock 70kDa protein 1B 6 31827735-31830255 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level CAB008640, HPA052504 Approved Uncertain Nucleoplasm
Vesicles Expressed in all Tissue enhanced adrenal gland: 34.3 urinary bladder: 15.0 HSPA1L HSP70-HOM, hum70t ENSG00000204390 Heat shock 70kDa protein 1-like 6 31809619-31815065 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA043285, HPA052504 Supported Uncertain Nucleoplasm
Vesicles Ovarian cancer:1.02e-4 (favourable), Renal cancer:4.63e-4 (favourable) Expressed in all Tissue enriched 8 testis: 9.7 epididymis: 1.1 HSPA2 ENSG00000126803 Heat shock 70kDa protein 2 14 64535905-64546173 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA000798, HPA052504 Approved Approved Uncertain Nucleoplasm
Vesicles Breast cancer:1.78e-4 (favourable), Lung cancer:9.11e-4 (unfavourable) Expressed in all Tissue enhanced testis: 188.7 cerebral cortex: 96.7 HSPA4 HS24/P52, HSPH2 ENSG00000170606 Heat shock 70kDa protein 4 5 133051962-133106449 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA010023, CAB025529 Uncertain Supported Nucleoplasm
Cytosol Liver cancer:4.13e-4 (unfavourable) Expressed in all Expressed in all testis: 116.4 HSPA8 HSC70, HSC71, HSP73, HSPA10 ENSG00000109971 Heat shock 70kDa protein 8 11 123057489-123063230 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002056, HPA052504 Uncertain Uncertain Nucleoplasm
Vesicles Colorectal cancer:6.14e-6 (favourable), Liver cancer:1.93e-4 (unfavourable), Renal cancer:3.81e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 1122.1 HSPB1 CMT2F, Hs.76067, Hsp25, HSP27, HSP28 ENSG00000106211 Heat shock 27kDa protein 1 7 76302544-76304295 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA000497, CAB004439, CAB047330, CAB047331, CAB047332 Supported Validated Plasma membrane
Cytosol Colorectal cancer:9.94e-5 (unfavourable) Expressed in all Expressed in all esophagus: 1622.3 HSPD1 GroEL, HSP60, SPG13 ENSG00000144381 Heat shock 60kDa protein 1 (chaperonin) 2 197486581-197516737 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001523, CAB002775, HPA050025, CAB072816 Supported Validated Mitochondria Endometrial cancer:1.61e-4 (unfavourable), Liver cancer:2.25e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 838.0 HSPE1 CPN10, EPF, GroES, HSP10 ENSG00000115541 Heat shock 10kDa protein 1 2 197499994-197503457 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017366, HPA038755, HPA048272 Supported Expressed in all Expressed in all adrenal gland: 653.6 HSPH1 HSP105A, HSP105B, KIAA0201, NY-CO-25 ENSG00000120694 Heat shock 105kDa/110kDa protein 1 13 31134974-31162388 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB002060, HPA028675, HPA031569 Supported Validated Nucleoplasm
Cytosol Liver cancer:1.41e-5 (unfavourable), Head and neck cancer:4.90e-4 (unfavourable) Expressed in all Expressed in all testis: 123.1 HUWE1 Ib772, KIAA0312, UREB1 ENSG00000086758 HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase X 53532096-53686729 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA002548, CAB022718 Approved Validated Nucleoplasm
Cytosol Expressed in all Expressed in all parathyroid gland: 94.8 IBSP BSP, BSP-II, SP-II ENSG00000029559 Integrin-binding sialoprotein 4 87799581-87812435 Cancer-related genes, Predicted secreted proteins Evidence at protein level Tissue enhanced Tissue enhanced cerebral cortex: 1.6;cervix, uterine: 1.3 gallbladder,placenta: 0.3 ICAM1 BB2, CD54 ENSG00000090339 Intercellular adhesion molecule 1 19 10270835-10286615 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA002126, CAB002142, HPA004877 Supported Uncertain Plasma membrane
Cytosol Renal cancer:1.32e-6 (unfavourable), Breast cancer:7.09e-4 (favourable) Expressed in all Expressed in all lung: 256.0 ID1 bHLHb24, dJ857M17.1.2 ENSG00000125968 Inhibitor of DNA binding 1, dominant negative helix-loop-helix protein 20 31605283-31606515 Cancer-related genes, Plasma proteins, Predicted secreted proteins, Transcription factors Evidence at protein level CAB025915, HPA051456, HPA058518 Approved Validated Nucleoplasm
Golgi apparatus Lung cancer:4.85e-4 (unfavourable) Expressed in all Expressed in all seminal vesicle: 211.5 ID2 bHLHb26, GIG8 ENSG00000115738 Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 2 8678845-8684453 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA027612 Approved Nucleoplasm
Nuclear bodies
Centrosome Head and neck cancer:9.95e-4 (favourable) Expressed in all Tissue enriched 5 parathyroid gland: 1947.2 thyroid gland: 357.9 ID3 bHLHb25, HEIR-1 ENSG00000117318 Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein 1 23557918-23559794 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB021353, HPA024677 Approved Supported Nucleoplasm Endometrial cancer:1.27e-5 (favourable) Expressed in all Mixed seminal vesicle: 90.6 IDH1 ENSG00000138413 Isocitrate dehydrogenase 1 (NADP+), soluble 2 208236227-208266074 Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB033218, HPA035248, HPA057936, CAB062556 Supported Approved Nuclear bodies
Cytosol Renal cancer:2.45e-5 (unfavourable), Liver cancer:6.93e-5 (unfavourable) Expressed in all Expressed in all prostate: 359.5 IDH2 ENSG00000182054 Isocitrate dehydrogenase 2 (NADP+), mitochondrial 15 90083045-90102504 Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA007831 Supported Supported Mitochondria Cervical cancer:5.15e-5 (favourable) Expressed in all Expressed in all skeletal muscle: 450.2 IDO1 IDO, INDO ENSG00000131203 Indoleamine 2,3-dioxygenase 1 8 39902275-39928444 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA023072, HPA023149, HPA027772 Supported Renal cancer:1.12e-7 (unfavourable), Ovarian cancer:3.32e-4 (favourable), Melanoma:5.27e-4 (favourable) Expressed in all Tissue enhanced placenta: 148.0 lymph node: 58.1 IFNA1 IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@ ENSG00000197919 Interferon, alpha 1 9 21409169-21441316 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA047557 Uncertain Not detected Not detected epididymis,urinary bladder: 0.2 IFNA13 ENSG00000233816 Interferon, alpha 13 9 21367424-21368962 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA047557 Uncertain Not detected Not detected epididymis: 0.6 IFNAR1 IFNAR, IFRC ENSG00000142166 Interferon (alpha, beta and omega) receptor 1 21 33324477-33359862 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA018015, HPA029226 Approved Approved Cytosol Expressed in all Expressed in all parathyroid gland: 60.2 IFNAR2 IFNABR ENSG00000159110 Interferon (alpha, beta and omega) receptor 2 21 33229901-33265675 Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB025889 Approved Renal cancer:7.54e-7 (unfavourable) Expressed in all Expressed in all spleen: 59.7 IFNB1 IFB, IFF, IFNB ENSG00000171855 Interferon, beta 1, fibroblast 9 21077105-21077963 Cancer-related genes, Predicted secreted proteins Evidence at protein level CAB009386 Uncertain Not detected Not detected bone marrow: 0.3 IFNG ENSG00000111537 Interferon, gamma 12 68154768-68159747 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB010344 Approved Mixed Tissue enhanced appendix: 4.9;bone marrow: 7.6;lymph node: 8.0 lung: 2.5 IGF1 IGF-I, IGF1A, IGFI ENSG00000017427 Insulin-like growth factor 1 (somatomedin C) 12 102395867-102480645 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA048946 Approved Endometrial cancer:1.04e-4 (favourable) Mixed Tissue enhanced cervix, uterine: 126.3 smooth muscle: 97.4 IGF1R CD221, IGFIR, IGFR, JTK13, MGC18216 ENSG00000140443 Insulin-like growth factor 1 receptor 15 98648971-98964530 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB010268, HPA045563 Uncertain Uncertain Vesicles Renal cancer:3.75e-7 (favourable) Expressed in all Mixed prostate: 24.7 IGF2 C11orf43, FLJ44734, IGF-II ENSG00000167244 Insulin-like growth factor 2 11 2129112-2141238 Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007556, HPA007993 Supported Approved Nucleoplasm
Vesicles Liver cancer:7.12e-4 (favourable) Group enriched Tissue enriched 18 placenta: 3974.6 fallopian tube: 220.1 IGF2R CD222, CIMPR, M6P-R, MPR1, MPRI ENSG00000197081 Insulin-like growth factor 2 receptor 6 159969099-160113507 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009661, HPA011332 Supported Validated Golgi apparatus
Vesicles Cervical cancer:2.92e-5 (unfavourable), Breast cancer:3.01e-4 (unfavourable), Urothelial cancer:6.08e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 49.5 IGFBP2 IBP2 ENSG00000115457 Insulin-like growth factor binding protein 2, 36kDa 2 216632828-216664436 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA077723 Approved Endoplasmic reticulum Renal cancer:2.22e-5 (unfavourable), Melanoma:2.43e-4 (unfavourable) Expressed in all Expressed in all seminal vesicle: 276.7 IGFBP3 BP-53, IBP3 ENSG00000146674 Insulin-like growth factor binding protein 3 7 45912245-45921874 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB010360 Approved Nucleoplasm
Vesicles
Cytosol Renal cancer:5.07e-7 (unfavourable), Colorectal cancer:1.08e-4 (unfavourable), Liver cancer:1.64e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 2649.6 endometrium: 881.5 IKBKB IKK-beta, IKK2, IKKB, NFKBIKB ENSG00000104365 Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta 8 42271302-42332653 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA001249, CAB004447 Approved Approved Cytosol Urothelial cancer:1.46e-6 (favourable) Expressed in all Mixed parathyroid gland: 18.8 IKZF1 hIk-1, Hs.54452, IKAROS, LyF-1, PPP1R92, ZNFN1A1 ENSG00000185811 IKAROS family zinc finger 1 (Ikaros) 7 50304124-50405101 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level CAB009247, HPA035221, HPA035222 Supported Approved Nucleoplasm
Nucleoli
Vesicles Cervical cancer:2.02e-4 (favourable), Breast cancer:4.28e-4 (favourable), Head and neck cancer:8.63e-4 (favourable) Expressed in all Tissue enhanced lymph node: 84.0;tonsil: 58.0 appendix: 55.9 IL10 CSIF, IL-10, IL10A, TGIF ENSG00000136634 Interleukin 10 1 206767602-206772494 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB013120 Approved Mixed Tissue enhanced appendix: 8.9 adipose tissue: 7.4 IL11 AGIF, IL-11 ENSG00000095752 Interleukin 11 19 55364389-55370463 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA044955 Uncertain Mitochondria Pancreatic cancer:7.50e-4 (unfavourable) Mixed Tissue enhanced appendix: 5.8;endometrium: 5.2;gallbladder: 4.9 placenta,skin: 1.7 IL12A CLMF, IL-12A, NFSK, NKSF1, p35 ENSG00000168811 Interleukin 12A 3 159988750-159996019 Cancer-related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA001886 Uncertain Mixed Tissue enhanced esophagus: 4.0 fallopian tube: 3.2 IL13 ALRH, BHR1, IL-13, MGC116786, MGC116788, MGC116789, P600 ENSG00000169194 Interleukin 13 5 132656263-132661110 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA042421 Approved Plasma membrane
Cytosol Not detected Tissue enriched 10 testis: 19.9 gallbladder: 2.0 IL13RA2 CD213a2, CT19, IL-13R, IL13BP ENSG00000123496 Interleukin 13 receptor, alpha 2 X 115003975-115019977 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level HPA055552 Approved Nucleus
Nucleoli Liver cancer:3.55e-4 (favourable) Tissue enhanced Tissue enriched 8 testis: 52.5 prostate: 6.5 IL15 IL-15, MGC9721 ENSG00000164136 Interleukin 15 4 141636599-141733987 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB004457, HPA037738 Uncertain Supported Nucleoplasm
Nuclear speckles Mixed Tissue enhanced breast: 45.7 spleen: 19.1 IL16 FLJ16806, FLJ42735, HsT19289, IL-16, LCF, prIL-16 ENSG00000172349 Interleukin 16 15 81159575-81314058 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005247, HPA018467 Supported Approved Nuclear speckles
Plasma membrane
Cytosol Expressed in all Tissue enhanced lymph node: 156.4;tonsil: 128.4 spleen: 120.1 IL17A CTLA8, IL-17, IL-17A, IL17 ENSG00000112115 Interleukin 17A 6 52186387-52190638 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA052258 Uncertain Not detected Tissue enhanced appendix: 1.0;tonsil: 1.4;urinary bladder: 1.6 gallbladder: 0.3 IL17B IL-17B, IL-20, MGC138900, MGC138901, NIRF, ZCYTO7 ENSG00000127743 Interleukin 17B 5 149371324-149404202 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA042441 Uncertain Mixed Tissue enhanced breast: 4.1 smooth muscle: 3.5 IL18 IGIF, IL-18, IL-1g, IL1F4 ENSG00000150782 Interleukin 18 11 112143251-112164117 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003980, CAB007772 Supported Approved Nucleus
Golgi apparatus
Cytosol Colorectal cancer:2.78e-4 (favourable) Expressed in all Tissue enhanced esophagus: 133.6;skin: 171.9 lymph node: 73.1 IL1A IL-1A, IL1, IL1-ALPHA, IL1F1 ENSG00000115008 Interleukin 1, alpha 2 112773915-112784590 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level Lung cancer:1.54e-4 (unfavourable), Stomach cancer:4.03e-4 (unfavourable), Cervical cancer:9.52e-4 (unfavourable) Tissue enhanced Tissue enhanced esophagus: 12.8;testis: 18.6 tonsil: 7.7 IL1B IL-1B, IL1-BETA, IL1F2 ENSG00000125538 Interleukin 1, beta 2 112829751-112836903 Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level Renal cancer:7.49e-5 (unfavourable), Cervical cancer:1.31e-4 (unfavourable) Mixed Tissue enhanced appendix: 69.5;bone marrow: 106.7 adipose tissue: 52.7 IL1R1 CD121A, D2S1473, IL1R, IL1RA ENSG00000115594 Interleukin 1 receptor, type I 2 102064544-102179874 Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA001237, HPA005823, CAB007779, HPA029560 Approved Validated Vesicles Renal cancer:6.92e-6 (unfavourable) Expressed in all Expressed in all cervix, uterine: 244.6 IL1R2 CD121b, IL1RB ENSG00000115590 Interleukin 1 receptor, type II 2 101991844-102028544 Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA027597, HPA027598 Approved Renal cancer:5.58e-12 (unfavourable) Mixed Mixed appendix: 51.2 IL1RN ICIL-1RA, IL-1RN, IL1F3, IL1RA, IRAP, MGC10430 ENSG00000136689 Interleukin 1 receptor antagonist 2 113107214-113134016 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001482, CAB009633 Supported Renal cancer:2.66e-6 (unfavourable), Endometrial cancer:3.00e-4 (unfavourable), Pancreatic cancer:6.85e-4 (unfavourable), Testis cancer:8.23e-4 (unfavourable) Expressed in all Tissue enhanced esophagus: 1248.5 tonsil: 301.6 IL2 IL-2, TCGF ENSG00000109471 Interleukin 2 4 122451470-122456725 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB010310 Uncertain Not detected Not detected rectum,small intestine,tonsil: 0.3 IL21R CD360 ENSG00000103522 Interleukin 21 receptor 16 27402162-27452042 Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level HPA042296 Uncertain Uncertain Plasma membrane
Cytosol Head and neck cancer:7.29e-4 (favourable) Mixed Tissue enhanced appendix: 16.4;lymph node: 29.2;tonsil: 18.0 spleen: 7.7 IL24 C49A, FISP, IL-24, IL10B, mda-7, Mob-5, ST16 ENSG00000162892 Interleukin 24 1 206897443-206904139 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB025972 Uncertain Breast cancer:5.09e-4 (favourable) Mixed Group enriched 5 appendix: 17.9;lymph node: 37.6;spleen: 30.0;tonsil: 28.5 urinary bladder: 5.6 IL2RA CD25, IDDM10, IL2R ENSG00000134460 Interleukin 2 receptor, alpha 10 6010689-6062325 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002419, HPA054622 Supported Renal cancer:2.08e-9 (unfavourable) Mixed Tissue enhanced adipose tissue: 23.9;appendix: 20.4;lymph node: 20.7 tonsil: 12.5 IL2RB CD122, IL15RB ENSG00000100385 Interleukin 2 receptor, beta 22 37125838-37175054 Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA062657 Supported Renal cancer:3.50e-7 (unfavourable), Endometrial cancer:3.18e-5 (favourable), Colorectal cancer:6.76e-4 (favourable) Expressed in all Tissue enhanced spleen: 68.3 placenta: 52.4 IL2RG CD132, CIDX, IMD4, SCIDX1 ENSG00000147168 Interleukin 2 receptor, gamma X 71107404-71112108 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046641, HPA049691 Supported Approved Vesicles Renal cancer:2.28e-7 (unfavourable), Endometrial cancer:1.73e-4 (favourable) Expressed in all Tissue enhanced lymph node: 277.4;tonsil: 290.2 appendix: 188.7 IL4 BCGF-1, BCGF1, BSF1, IL-4, MGC79402 ENSG00000113520 Interleukin 4 5 132673986-132682676 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Not detected Tissue enhanced parathyroid gland: 2.2 fallopian tube: 1.0 IL4R CD124 ENSG00000077238 Interleukin 4 receptor 16 27313668-27364778 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB004451, HPA050124 Supported Approved Cytosol Renal cancer:1.23e-5 (unfavourable), Endometrial cancer:6.43e-4 (favourable) Expressed in all Expressed in all lymph node: 139.5 IL5 EDF, IL-5, TRF ENSG00000113525 Interleukin 5 5 132541444-132556838 Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB010304 Approved Not detected Tissue enriched 9 testis: 9.7 epididymis: 1.1 IL6 BSF2, HGF, HSF, IFNB2, IL-6 ENSG00000136244 Interleukin 6 7 22725884-22732002 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB023406, CAB072821 Supported Approved Vesicles Renal cancer:1.10e-11 (unfavourable) Mixed Tissue enhanced adipose tissue: 135.4 urinary bladder: 76.8 IL6R CD126 ENSG00000160712 Interleukin 6 receptor 1 154405193-154469450 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Pancreatic cancer:1.65e-4 (favourable) Expressed in all Expressed in all appendix: 34.4 IL6ST CD130, GP130 ENSG00000134352 Interleukin 6 signal transducer 5 55935095-55994993 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010558, CAB025784 Uncertain Supported Golgi apparatus
Plasma membrane Renal cancer:5.05e-4 (unfavourable) Expressed in all Expressed in all placenta: 327.1 IL7 IL-7 ENSG00000104432 Interleukin 7 8 78675743-78805523 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA019590 Approved Renal cancer:2.69e-4 (unfavourable) Mixed Mixed skin: 10.2 IL7R CD127 ENSG00000168685 Interleukin 7 receptor 5 35852695-35879603 Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB010215 Approved Supported Plasma membrane Expressed in all Expressed in all appendix: 188.9 IL9 HP40, IL-9, P40 ENSG00000145839 Interleukin 9 5 135892246-135895827 Cancer-related genes, Predicted secreted proteins Evidence at transcript level Not detected Tissue enhanced cerebral cortex: 1.7 skin: 0.5 ILF3 DRBP76, MPHOSPH4, MPP4, NF90, NFAR-1 ENSG00000129351 Interleukin enhancer binding factor 3, 90kDa 19 10654261-10692417 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001897 Supported Supported Nucleoplasm
Nucleoli
Mitochondria Melanoma:1.57e-4 (unfavourable), Renal cancer:9.65e-4 (unfavourable) Expressed in all Expressed in all testis: 149.2 ILK ENSG00000166333 Integrin-linked kinase 11 6603708-6610874 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004041, HPA048437 Supported Validated Cell Junctions
Focal adhesion sites Renal cancer:2.44e-4 (favourable) Expressed in all Expressed in all seminal vesicle: 554.5 ING1 p24ING1c, p33, p33ING1, p33ING1b, p47, p47ING1a ENSG00000153487 Inhibitor of growth family, member 1 13 110712736-110723339 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB016136, CAB017773, HPA052591 Approved Approved Nucleoplasm
Cytosol Endometrial cancer:5.81e-4 (favourable) Expressed in all Expressed in all ovary: 20.9 INHBA ENSG00000122641 Inhibin, beta A 7 41685114-41703108 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA020031 Uncertain Renal cancer:7.91e-8 (unfavourable), Cervical cancer:1.46e-5 (unfavourable), Head and neck cancer:4.34e-4 (unfavourable), Lung cancer:7.72e-4 (unfavourable) Expressed in all Tissue enhanced endometrium: 28.7;gallbladder: 35.0 lung: 16.4 INHBB ENSG00000163083 Inhibin, beta B 2 120346143-120351808 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA049218 Uncertain Nucleoplasm Thyroid cancer:1.02e-4 (favourable), Colorectal cancer:1.44e-4 (unfavourable), Renal cancer:3.02e-4 (unfavourable) Expressed in all Tissue enhanced testis: 27.1 adipose tissue: 24.8 INPPL1 SHIP2 ENSG00000165458 Inositol polyphosphate phosphatase-like 1 11 72223701-72239105 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA037601 Approved Supported Golgi apparatus
Cytosol Liver cancer:7.37e-4 (unfavourable) Expressed in all Expressed in all spleen: 65.5 INS IDDM1, IDDM2 ENSG00000254647 Insulin 11 2159779-2161341 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB000048, HPA004932, CAB012098, CAB053843 Supported Tissue enriched Tissue enriched 27 pancreas: 1850.8 skin: 68.1 INTS12 INT12, PHF22, SBBI22 ENSG00000138785 Integrator complex subunit 12 4 105682627-105895986 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA035772, HPA041814 Approved Approved Nucleoplasm
Nuclear bodies
Plasma membrane
Cytosol Liver cancer:2.67e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 33.5 IPO7 Imp7, RANBP7 ENSG00000205339 Importin 7 11 9384622-9448126 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level HPA019002, HPA056590 Approved Approved Validated Nucleoplasm
Cytosol Pancreatic cancer:8.38e-6 (unfavourable), Cervical cancer:4.98e-4 (unfavourable), Liver cancer:6.57e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 89.6 IRF1 MAR ENSG00000125347 Interferon regulatory factor 1 5 132481609-132490798 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB011662, HPA063131 Supported Supported Nucleoplasm
Cytosol Renal cancer:1.09e-7 (unfavourable) Expressed in all Expressed in all spleen: 137.5 IRF4 LSIRF, MUM1 ENSG00000137265 Interferon regulatory factor 4 6 391739-411447 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA002038, HPA002698, CAB013508 Supported Supported Nucleoplasm Head and neck cancer:1.64e-6 (favourable), Breast cancer:6.44e-4 (favourable) Tissue enriched Tissue enhanced lymph node: 27.4 tonsil: 25.0 IRF6 LPS, OFC6, VWS, VWS1 ENSG00000117595 Interferon regulatory factor 6 1 209785623-209806175 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA063121, HPA076162 Approved Validated Nucleus
Cytosol Renal cancer:0.00e+0 (favourable) Mixed Mixed skin: 84.2 IRS2 ENSG00000185950 Insulin receptor substrate 2 13 109752698-109786568 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB016944, HPA054664 Approved Supported Aggresome
Cytosol Expressed in all Mixed bone marrow: 33.0 ITGA1 CD49a, VLA1 ENSG00000213949 Integrin, alpha 1 5 52787896-52959210 Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA042555 Uncertain Approved Endoplasmic reticulum Renal cancer:2.24e-4 (unfavourable) Expressed in all Mixed spleen: 78.9 ITGA2 CD49B ENSG00000164171 Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 5 52989326-53094779 Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB017690, HPA060991, HPA063556 Supported Approved Nucleus
Cytosol Pancreatic cancer:1.02e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 24.3 ITGA2B CD41, CD41B, GP2B, PPP1R93 ENSG00000005961 Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) 17 44372180-44389505 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB018611, HPA031168, HPA031169, HPA031170, HPA031171 Supported Uncertain Nucleoplasm
Cell Junctions
Cytosol Mixed Tissue enhanced bone marrow: 11.2;epididymis: 28.6 testis: 4.4 ITGA3 CD49c, GAP-B3, MSK18, VCA-2, VLA3a ENSG00000005884 Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) 17 50055968-50090481 Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008572, CAB018594 Supported Supported Plasma membrane Pancreatic cancer:5.95e-5 (unfavourable), Head and neck cancer:1.36e-4 (unfavourable), Cervical cancer:6.75e-4 (unfavourable) Expressed in all Mixed lung: 99.1 ITGA4 CD49D ENSG00000115232 Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) 2 181457202-181536187 Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA064041 Approved Golgi apparatus
Vesicles Renal cancer:3.08e-5 (unfavourable), Head and neck cancer:8.29e-4 (favourable) Mixed Tissue enhanced spleen: 68.6 appendix: 51.2 ITGA5 CD49e, FNRA ENSG00000161638 Integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 12 54395261-54419460 Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA002642, CAB009008 Supported Renal cancer:1.32e-8 (unfavourable), Cervical cancer:4.07e-6 (unfavourable), Liver cancer:2.23e-5 (unfavourable), Lung cancer:2.44e-4 (unfavourable), Head and neck cancer:2.91e-4 (unfavourable), Colorectal cancer:8.43e-4 (unfavourable), Thyroid cancer:8.89e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 482.6 ITGA6 CD49f ENSG00000091409 Integrin, alpha 6 2 172427354-172506282 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB009009, HPA012696, HPA027582 Supported Renal cancer:2.35e-11 (favourable), Head and neck cancer:1.03e-4 (unfavourable) Expressed in all Expressed in all placenta: 114.3 ITGAM CD11B, CR3A, MAC-1 ENSG00000169896 Integrin, alpha M (complement component 3 receptor 3 subunit) 16 31259990-31332892 Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA002274, CAB025091, CAB072870 Supported Renal cancer:6.93e-5 (unfavourable), Liver cancer:3.43e-4 (unfavourable), Testis cancer:6.93e-4 (unfavourable) Expressed in all Tissue enhanced bone marrow: 130.4 appendix: 37.1 ITGAV CD51, MSK8, VNRA, VTNR ENSG00000138448 Integrin, alpha V 2 186590065-186680901 Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002499, HPA004856 Supported Approved Focal adhesion sites
Cytosol Stomach cancer:1.05e-6 (unfavourable), Liver cancer:2.08e-4 (unfavourable), Pancreatic cancer:5.07e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 187.7 ITGB1 CD29, FNRB, GPIIA, MDF2, MSK12 ENSG00000150093 Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) 10 32900319-33005792 Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB003434 Approved Supported Endoplasmic reticulum
Plasma membrane
Focal adhesion sites Lung cancer:3.36e-6 (unfavourable), Cervical cancer:5.01e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 1058.2 ITGB3 CD61, GP3A, GPIIIa ENSG00000259207 Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 17 47253846-47311816 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA027852 Supported Group enriched Tissue enhanced thyroid gland: 95.1 smooth muscle: 36.3 ITGB4 CD104 ENSG00000132470 Integrin, beta 4 17 75721328-75757818 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002422, CAB005258, HPA036348, HPA036349 Supported Supported Nucleus
Plasma membrane
Cell Junctions Pancreatic cancer:6.39e-4 (unfavourable), Lung cancer:7.18e-4 (unfavourable) Expressed in all Mixed skin: 84.4 ITGB5 ENSG00000082781 Integrin, beta 5 3 124761948-124901418 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001820, CAB022050 Approved Approved Plasma membrane
Mitochondria Pancreatic cancer:1.40e-4 (unfavourable) Expressed in all Expressed in all placenta: 116.8 ITGB6 ENSG00000115221 Integrin, beta 6 2 160099666-160271888 Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA023626, CAB073536 Approved Uncertain Nucleoplasm
Cell Junctions
Centrosome Pancreatic cancer:5.03e-6 (unfavourable) Mixed Tissue enhanced lung: 66.9 urinary bladder: 31.3 ITGB7 ENSG00000139626 Integrin, beta 7 12 53191318-53207307 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA042277 Approved Plasma membrane
Cytosol Mixed Mixed spleen: 32.8 ITGB8 ENSG00000105855 Integrin, beta 8 7 20330702-20415754 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA027796, HPA027797 Approved Approved Plasma membrane
Cytosol Renal cancer:1.77e-4 (favourable) Mixed Mixed cerebral cortex: 30.9 ITIH4 H4P, IHRP, ITIHL1 ENSG00000055955 Inter-alpha-trypsin inhibitor heavy chain family, member 4 3 52812975-52831479 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001835, HPA003948, CAB072872 Supported Approved Vesicles Tissue enriched Tissue enriched 71 liver: 983.2 skeletal muscle: 13.8 ITK EMT, LYK, PSCTK2 ENSG00000113263 IL2-inducible T-cell kinase 5 157142933-157255191 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level Mixed Tissue enhanced appendix: 20.9;lymph node: 33.6;tonsil: 23.0 spleen: 14.0 ITPKB IP3-3KB, IP3KB ENSG00000143772 Inositol-trisphosphate 3-kinase B 1 226631690-226739323 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA030273, HPA072923 Uncertain Approved Nucleus Head and neck cancer:1.72e-5 (favourable), Lung cancer:6.65e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 61.8 JAK1 JAK1A, JAK1B, JTK3 ENSG00000162434 Janus kinase 1 1 64833229-64966504 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013088 Approved Renal cancer:2.67e-4 (favourable), Colorectal cancer:2.81e-4 (favourable), Breast cancer:9.63e-4 (favourable) Expressed in all Expressed in all lymph node: 117.1 JAK2 JTK10 ENSG00000096968 Janus kinase 2 9 4985033-5128183 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013089, HPA040820, HPA043870 Approved Supported Nucleoplasm
Plasma membrane
Focal adhesion sites Expressed in all Mixed appendix: 25.4 JAK3 JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK ENSG00000105639 Janus kinase 3 19 17824780-17848071 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA070314 Supported Approved Cytosol Renal cancer:2.89e-14 (unfavourable), Cervical cancer:6.42e-5 (favourable) Expressed in all Tissue enhanced appendix: 49.9;lymph node: 47.2 tonsil: 28.2 JAZF1 DKFZp761K2222, TIP27, ZNF802 ENSG00000153814 JAZF zinc finger 1 7 27830573-28180743 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB019271, HPA066967 Approved Supported Nucleus
Nucleoli fibrillar center Expressed in all Expressed in all adrenal gland: 113.6 JKAMP C14orf100, CDA06, HSPC213, HSPC327, JAMP ENSG00000050130 JNK1/MAPK8-associated membrane protein 14 59484443-59505410 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA031172, HPA071650 Supported Approved Nucleoplasm
Vesicles Liver cancer:3.09e-6 (unfavourable), Renal cancer:1.36e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 74.7 JTB hJT ENSG00000143543 Jumping translocation breakpoint 1 153974269-153977688 Cancer-related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA006514 Approved Approved Vesicles
Actin filaments Renal cancer:6.65e-9 (unfavourable), Ovarian cancer:7.87e-4 (favourable) Expressed in all Expressed in all epididymis: 114.3 JUN AP-1, c-Jun ENSG00000177606 Jun proto-oncogene 1 58780788-58784327 Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB003801, CAB007780, HPA059474 Supported Validated Nucleoplasm Expressed in all Expressed in all thyroid gland: 312.9 JUND AP-1 ENSG00000130522 Jun D proto-oncogene 19 18279760-18281622 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB005268, HPA063029 Supported Supported Nucleus Breast cancer:6.15e-5 (favourable) Expressed in all Expressed in all bone marrow: 278.3 JUP CTNNG, DP3, DPIII, PDGB, PKGB ENSG00000173801 Junction plakoglobin 17 41754604-41786931 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002139, HPA032047 Supported Validated Vesicles
Plasma membrane
Cell Junctions Renal cancer:2.06e-10 (favourable) Expressed in all Group enriched 6 esophagus: 493.6;skin: 787.3 fallopian tube: 112.6 KALRN ARHGEF24, DUET, duo, HAPIP, Hs.8004, Kalirin, TRAD ENSG00000160145 Kalirin, RhoGEF kinase 3 124080023-124726325 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011913, CAB026456 Approved Supported Nucleoplasm
Cytosol Mixed Tissue enhanced cerebral cortex: 51.5 spleen: 12.0 KAT2B GCN5, GCN5L, P/CAF, PCAF ENSG00000114166 K(lysine) acetyltransferase 2B 3 20040023-20154404 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB004526, HPA055839 Supported Approved Nucleus Expressed in all Expressed in all parathyroid gland: 83.6 KAT6A MOZ, MYST3, RUNXBP2, ZC2HC6A, ZNF220 ENSG00000083168 K(lysine) acetyltransferase 6A 8 41929479-42051990 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB017023, HPA063266, HPA065052 Supported Approved Nucleoli
Nuclear speckles
Cytosol Expressed in all Expressed in all parathyroid gland: 33.9 KAT6B Morf, MOZ2, MYST4, qkf, querkopf, ZC2HC6B ENSG00000156650 K(lysine) acetyltransferase 6B 10 74825582-75032622 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA006104 Supported Approved Nucleus
Nuclear bodies Renal cancer:4.82e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 17.0 KCNJ5 CIR, GIRK4, KATP1, Kir3.4, LQT13 ENSG00000120457 Potassium channel, inwardly rectifying subfamily J, member 5 11 128891356-128921035 Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA014722, HPA017353, CAB022569 Supported Mixed Tissue enhanced adrenal gland: 85.2 spleen: 19.1 KDM5A JARID1A, RBBP2 ENSG00000073614 Lysine (K)-specific demethylase 5A 12 280129-389454 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA006201 Approved Nuclear bodies
Cytosol Expressed in all Expressed in all testis: 42.5 KDM5C DXS1272E, JARID1C, MRX13, SMCX, XE169 ENSG00000126012 Lysine (K)-specific demethylase 5C X 53191321-53225422 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA038244, HPA046147 Validated Nucleoplasm
Cytosol Liver cancer:2.11e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 65.5 KDM6A UTX ENSG00000147050 Lysine (K)-specific demethylase 6A X 44873177-45112602 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA000568, HPA001165, HPA002111 Supported Approved Nucleoli Expressed in all Expressed in all bone marrow: 41.1 KDR CD309, FLK1, VEGFR, VEGFR2 ENSG00000128052 Kinase insert domain receptor 4 55078477-55125589 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB004028 Approved Supported Plasma membrane Renal cancer:7.26e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 118.2 thyroid gland: 54.5 KDSR DHSR, FVT1, SDR35C1 ENSG00000119537 3-ketodihydrosphingosine reductase 18 63327726-63367510 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB003673, HPA044884 Approved Renal cancer:9.53e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 45.6 KEAP1 INrf2, KIAA0132, KLHL19, MGC10630, MGC1114, MGC20887, MGC4407, MGC9454 ENSG00000079999 Kelch-like ECH-associated protein 1 19 10486120-10503741 Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA005558, CAB025337 Approved Supported Nucleoplasm
Microtubule organizing center
Cytosol Cervical cancer:3.28e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 49.4 KEL CD238, ECE3 ENSG00000197993 Kell blood group, metallo-endopeptidase 7 142941114-142962681 Blood group antigen proteins, Cancer-related genes, CD markers, Enzymes, Predicted membrane proteins Evidence at protein level Mixed Tissue enhanced bone marrow: 14.6;testis: 19.4 lymph node: 6.5 KIAA1109 FLJ21404, FSA, KIAA1371, Tweek ENSG00000138688 KIAA1109 4 122152333-122362758 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038076 Approved Approved Nucleoplasm
Centrosome Renal cancer:4.33e-8 (favourable) Expressed in all Expressed in all parathyroid gland: 128.4 KIAA1549 ENSG00000122778 KIAA1549 7 138831381-138981318 Cancer-related genes, Disease related genes, Predicted membrane proteins Evidence at protein level HPA019560 Approved Approved Nuclear membrane
Intermediate filaments Renal cancer:3.93e-7 (favourable) Mixed Mixed seminal vesicle: 10.4 KIF2A HK2, KIF2 ENSG00000068796 Kinesin heavy chain member 2A 5 62306162-62537249 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA004715, HPA004716 Approved Validated Nucleus
Nucleoli
Centrosome Liver cancer:3.17e-6 (unfavourable), Renal cancer:3.81e-5 (unfavourable), Colorectal cancer:1.70e-4 (favourable), Head and neck cancer:5.45e-4 (favourable) Expressed in all Expressed in all testis: 91.5 KIF2C CT139, KNSL6, MCAK ENSG00000142945 Kinesin family member 2C 1 44739818-44767767 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006219 Supported Nucleoplasm
Centrosome Renal cancer:0.00e+0 (unfavourable), Liver cancer:3.07e-7 (unfavourable), Pancreatic cancer:6.86e-4 (unfavourable) Expressed in all Tissue enriched 7 testis: 134.4 bone marrow: 20.4 KIF5B KNS, KNS1 ENSG00000170759 Kinesin family member 5B 10 32009010-32056431 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009846, HPA037589, HPA037590 Approved Validated Microtubule organizing center
Cytosol Expressed in all Expressed in all parathyroid gland: 184.2 KIFC3 ENSG00000140859 Kinesin family member C3 16 57758217-57863053 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA021240 Uncertain Expressed in all Expressed in all skin: 98.9 KISS1 ENSG00000170498 KiSS-1 metastasis-suppressor 1 204190341-204196486 Cancer-related genes, Disease related genes, Predicted secreted proteins Evidence at protein level CAB017775, HPA035542 Supported Approved Vesicles Urothelial cancer:6.29e-6 (favourable) Tissue enhanced Tissue enriched 86 placenta: 328.0 stomach: 3.8 KIT C-Kit, CD117, PBT, SCFR ENSG00000157404 V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 4 54657918-54740715 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB003288, HPA004471, CAB068253, CAB072867, HPA073252 Supported Supported Plasma membrane Renal cancer:5.63e-4 (favourable) Mixed Tissue enhanced breast: 133.8 thyroid gland: 78.4 KITLG FPH2, Kitl, KL-1, MGF, SCF, SF ENSG00000049130 KIT ligand 12 88492793-88580851 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level HPA070395 Approved Approved Vesicles Renal cancer:5.81e-7 (favourable), Liver cancer:4.01e-4 (unfavourable) Expressed in all Mixed lung: 24.2 KLF4 EZF, GKLF ENSG00000136826 Kruppel-like factor 4 (gut) 9 107484852-107490482 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA002926 Supported Supported Nucleoplasm Renal cancer:3.93e-5 (favourable) Expressed in all Expressed in all esophagus: 129.0 KLF5 BTEB2, CKLF, IKLF ENSG00000102554 Kruppel-like factor 5 (intestinal) 13 73054976-73077542 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA040398 Approved Supported Nucleoplasm
Golgi apparatus
Vesicles Pancreatic cancer:2.55e-4 (unfavourable) Expressed in all Tissue enhanced skin: 280.2 esophagus: 217.1 KLF6 BCD1, COPEB, CPBP, GBF, PAC1, ST12, Zf9 ENSG00000067082 Kruppel-like factor 6 10 3775996-3785281 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB013529, HPA069585 Supported Approved Nucleus
Nucleoli fibrillar center
Vesicles
Cytosol Renal cancer:2.28e-4 (favourable) Expressed in all Expressed in all thyroid gland: 321.3 KLHL8 KIAA1378 ENSG00000145332 Kelch-like family member 8 4 87160103-87240314 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA013856, HPA017762 Approved Validated Nucleoplasm Renal cancer:1.53e-5 (favourable) Expressed in all Expressed in all epididymis: 72.6 KLK10 NES1, PRSSL1 ENSG00000129451 Kallikrein-related peptidase 10 19 51012739-51020175 Cancer-related genes, Enzymes, Predicted secreted proteins Evidence at protein level HPA017195 Uncertain Plasma membrane
Cytosol Pancreatic cancer:6.46e-5 (unfavourable), Breast cancer:8.32e-4 (favourable) Mixed Tissue enhanced esophagus: 138.7;skin: 52.8 tonsil: 47.4 KLK11 PRSS20, TLSP ENSG00000167757 Kallikrein-related peptidase 11 19 51022216-51028039 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB026340 Approved Endometrial cancer:3.78e-4 (favourable), Pancreatic cancer:4.17e-4 (unfavourable) Mixed Tissue enhanced esophagus: 226.6;skin: 214.5 prostate: 107.3 KLK13 KLK-L4 ENSG00000167759 Kallikrein-related peptidase 13 19 51056206-51065114 Cancer-related genes, Enzymes, Predicted secreted proteins Evidence at protein level HPA062136 Supported Tissue enhanced Tissue enriched 9 esophagus: 403.9 tonsil: 46.8 KLK14 KLK-L6 ENSG00000129437 Kallikrein-related peptidase 14 19 51077495-51084245 Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB026228 Uncertain Tissue enhanced Tissue enriched 5 skin: 10.3 breast: 2.0 KLK15 ACO, HSRNASPH, prostinogen ENSG00000174562 Kallikrein-related peptidase 15 19 50825289-50837213 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA019802 Uncertain Tissue enhanced Tissue enhanced colon: 3.4;salivary gland: 2.4 adrenal gland: 1.8 KLK2 ENSG00000167751 Kallikrein-related peptidase 2 19 50861568-50880567 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA000764 Supported Tissue enriched Tissue enriched 174 prostate: 850.1 testis: 4.8 KLK3 APS, PSA ENSG00000142515 Kallikrein-related peptidase 3 19 50854915-50860764 Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000070, HPA000764 Supported Tissue enriched Tissue enriched 369 prostate: 12913.7 seminal vesicle: 34.9 KLK4 EMSP, EMSP1, KLK-L1, PRSS17, PSTS ENSG00000167749 Kallikrein-related peptidase 4 19 50906352-50910738 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA051839 Supported Tissue enriched Tissue enriched 36 prostate: 395.8 skin: 10.9 KLK5 KLK-L2, SCTE ENSG00000167754 Kallikrein-related peptidase 5 19 50943303-50953093 Cancer-related genes, Enzymes, Predicted secreted proteins Evidence at protein level HPA014343, CAB025503, CAB026341 Supported Urothelial cancer:3.85e-6 (unfavourable), Endometrial cancer:2.33e-4 (unfavourable), Lung cancer:9.79e-4 (unfavourable) Tissue enhanced Tissue enriched 6 skin: 213.9 breast: 37.5 KLK6 Bssp, Klk7, neurosin, PRSS18, PRSS9 ENSG00000167755 Kallikrein-related peptidase 6 19 50958631-50969673 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA051837 Supported Nucleoplasm
Nuclear membrane
Cytokinetic bridge Endometrial cancer:1.38e-5 (unfavourable), Urothelial cancer:1.27e-4 (unfavourable), Pancreatic cancer:7.82e-4 (unfavourable), Lung cancer:8.85e-4 (unfavourable) Tissue enhanced Group enriched 5 cerebral cortex: 79.0;esophagus: 63.2;fallopian tube: 44.3;tonsil: 32.5 kidney: 10.1 KLK7 PRSS6, SCCE ENSG00000169035 Kallikrein-related peptidase 7 19 50976482-50984099 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA018994, CAB026342, HPA062126 Supported Supported Plasma membrane Endometrial cancer:8.06e-5 (unfavourable), Pancreatic cancer:1.16e-4 (unfavourable) Tissue enhanced Group enriched 5 esophagus: 68.9;skin: 220.0 fallopian tube: 27.6 KLK8 HNP, neuropsin, ovasin, PRSS19, TADG14 ENSG00000129455 Kallikrein-related peptidase 8 19 50996007-51002711 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB019393, HPA035761 Supported Approved Vesicles Pancreatic cancer:1.10e-4 (unfavourable), Endometrial cancer:2.31e-4 (unfavourable), Lung cancer:5.72e-4 (unfavourable), Urothelial cancer:6.17e-4 (unfavourable) Tissue enhanced Group enriched 6 esophagus: 78.1;fallopian tube: 20.6;skin: 97.0 breast: 10.9 KLK9 KLK-L3 ENSG00000213022 Kallikrein-related peptidase 9 19 51003111-51009634 Cancer-related genes, Enzymes, Predicted secreted proteins Evidence at transcript level CAB025049 Uncertain Tissue enriched Not detected skin,tonsil: 0.8 KLRK1 CD314, D12S2489E, KLR, NKG2-D, NKG2D ENSG00000213809 Killer cell lectin-like receptor subfamily K, member 1 12 10372353-10391874 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level CAB021896, HPA068877 Supported Supported Plasma membrane Not detected Tissue enhanced lymph node: 35.7;spleen: 53.6 tonsil: 16.7 KMT2A ALL-1, CXXC7, HRX, HTRX1, MLL, MLL1A, TRX1 ENSG00000118058 Lysine (K)-specific methyltransferase 2A 11 118436490-118526832 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB017794, CAB024270, HPA044910 Supported Supported Nucleoplasm
Cytosol Expressed in all Expressed in all parathyroid gland: 31.1 KMT2B CXXC10, HRX2, KIAA0304, MLL1B, MLL2, MLL4, TRX2, WBP7 ENSG00000272333 Lysine (K)-specific methyltransferase 2B 19 35718019-35738878 Cancer-related genes, Enzymes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA006487 Approved Nucleoplasm
Cytosol Expressed in all Expressed in all testis: 28.8 KMT2C HALR, KIAA1506, MLL3 ENSG00000055609 Lysine (K)-specific methyltransferase 2C 7 152134922-152436005 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA074736 Supported Nucleoplasm Renal cancer:8.01e-6 (favourable) Expressed in all Expressed in all skin: 25.8 KMT2D ALR, CAGL114, MLL2, MLL4, TNRC21 ENSG00000167548 Lysine (K)-specific methyltransferase 2D 12 49018975-49059774 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA035977 Approved Approved Nucleus
Plasma membrane
Cytosol Expressed in all Expressed in all parathyroid gland: 45.7 KRAS KRAS1, KRAS2 ENSG00000133703 Kirsten rat sarcoma viral oncogene homolog 12 25204789-25250936 Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA049830 Approved Renal cancer:2.75e-5 (favourable), Pancreatic cancer:3.59e-4 (unfavourable) Expressed in all Expressed in all rectum: 34.1 KRT13 CK13, K13, MGC161462, MGC3781 ENSG00000171401 Keratin 13, type I 17 41500981-41505705 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000133, HPA030877 Supported Validated Intermediate filaments Renal cancer:1.45e-6 (unfavourable), Pancreatic cancer:1.02e-4 (unfavourable) Group enriched Tissue enriched 20 esophagus: 35268.3 tonsil: 1800.1 KRT14 EBS3, EBS4 ENSG00000186847 Keratin 14, type I 17 41582279-41586921 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000134, HPA000452, HPA000539, HPA023040 Supported Supported Intermediate filaments Breast cancer:2.66e-4 (favourable) Group enriched Tissue enriched 19 skin: 7966.8 breast: 417.5 KRT15 CK15, K15, K1CO ENSG00000171346 Keratin 15, type I 17 41513743-41522529 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA023910, HPA024554 Supported Supported Nucleoplasm
Intermediate filaments Breast cancer:4.50e-4 (favourable) Tissue enhanced Group enriched 8 breast: 320.0;esophagus: 787.5;skin: 1012.3 prostate: 84.8 KRT17 PCHC1 ENSG00000128422 Keratin 17, type I 17 41619437-41624842 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000029, HPA000452, HPA000453, HPA000539, HPA045062 Supported Supported Intermediate filaments Breast cancer:4.44e-4 (favourable), Renal cancer:5.74e-4 (unfavourable) Expressed in all Tissue enhanced breast: 219.7;seminal vesicle: 223.4;urinary bladder: 334.2 prostate: 106.2 KRT18 ENSG00000111057 Keratin 18, type I 12 52948871-52952901 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB000008, CAB000030, HPA001605 Supported Validated Cytosol Pancreatic cancer:1.78e-4 (unfavourable), Lung cancer:5.06e-4 (unfavourable) Expressed in all Mixed placenta: 654.2 KRT19 CK19, K19, K1CS, MGC15366 ENSG00000171345 Keratin 19, type I 17 41523617-41528308 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000031, HPA002465 Supported Supported Intermediate filaments Renal cancer:2.98e-5 (unfavourable), Pancreatic cancer:6.82e-5 (unfavourable) Mixed Mixed urinary bladder: 705.5 KRT4 CK4, CYK4, K4 ENSG00000170477 Keratin 4, type II 12 52806549-52814551 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002154, HPA034881 Supported Validated Intermediate filaments Ovarian cancer:3.26e-4 (unfavourable), Urothelial cancer:6.26e-4 (unfavourable) Group enriched Tissue enriched 24 esophagus: 14911.0 tonsil: 623.1 KRT8 CARD2, CK8, CYK8, K2C8, K8, KO ENSG00000170421 Keratin 8, type II 12 52897187-52949954 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000131, CAB001696, HPA049866 Supported Supported Intermediate filaments Pancreatic cancer:1.51e-4 (unfavourable) Mixed Tissue enhanced small intestine: 1505.1 duodenum: 1149.4 KTN1 CG1, KIAA0004 ENSG00000126777 Kinectin 1 (kinesin receptor) 14 55559072-55701526 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003178, CAB015331, HPA017876 Supported Validated Endoplasmic reticulum Renal cancer:1.01e-6 (favourable), Head and neck cancer:6.83e-5 (unfavourable), Liver cancer:3.76e-4 (unfavourable) Expressed in all Expressed in all testis: 269.6 LALBA LYZL7 ENSG00000167531 Lactalbumin, alpha- 12 48567684-48570066 Cancer-related genes, Predicted secreted proteins Evidence at protein level CAB026343, HPA029855, HPA029856 Supported Tissue enriched Tissue enriched 572 breast: 2487.9 testis: 4.3 LAMB1 CLM ENSG00000091136 Laminin, beta 1 7 107923799-108003255 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA004056, HPA004132, CAB004256 Supported Liver cancer:2.07e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 261.4 adipose tissue: 160.4 LAMC1 LAMB2 ENSG00000135862 Laminin, gamma 1 (formerly LAMB2) 1 183023460-183145592 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001908, HPA001909, CAB004486, CAB078163 Supported Approved Endoplasmic reticulum
Plasma membrane Urothelial cancer:8.85e-5 (unfavourable) Expressed in all Tissue enhanced placenta: 330.2 smooth muscle: 145.7 LASP1 Lasp-1, MLN50 ENSG00000002834 LIM and SH3 protein 1 17 38869859-38921770 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA012072, CAB022049 Supported Supported Plasma membrane
Focal adhesion sites
Cytosol Liver cancer:2.41e-4 (unfavourable), Endometrial cancer:4.57e-4 (unfavourable) Expressed in all Expressed in all small intestine: 185.0 LCK ENSG00000182866 LCK proto-oncogene, Src family tyrosine kinase 1 32251239-32286165 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA003494, CAB003816 Supported Approved Golgi apparatus Endometrial cancer:2.96e-6 (favourable), Renal cancer:2.60e-5 (unfavourable), Melanoma:5.65e-5 (favourable), Head and neck cancer:2.91e-4 (favourable) Mixed Tissue enhanced appendix: 68.8;lymph node: 127.7;tonsil: 75.1 spleen: 55.2 LCN1 MGC71975, PMFA, TLC, TP, VEGP ENSG00000160349 Lipocalin 1 9 135521438-135526532 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Tissue enhanced Group enriched 5 fallopian tube: 3.0;seminal vesicle: 12.1 prostate: 1.4 LCP1 CP64, L-PLASTIN, LC64P, PLS2 ENSG00000136167 Lymphocyte cytosolic protein 1 (L-plastin) 13 46125920-46211871 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019493, CAB020673 Supported Approved Plasma membrane
Actin filaments
Cytosol Expressed in all Expressed in all lymph node: 622.1 LCTL FLJ33279, KLG, KLPH ENSG00000188501 Lactase-like 15 66547179-66565979 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA071640 Approved Endoplasmic reticulum
Plasma membrane Group enriched Mixed cerebral cortex: 1.0 LDHA ENSG00000134333 Lactate dehydrogenase A 11 18394388-18408425 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB015336 Approved Supported Vesicles
Cytosol Renal cancer:9.69e-9 (unfavourable), Liver cancer:3.26e-8 (unfavourable), Lung cancer:2.27e-6 (unfavourable), Pancreatic cancer:8.09e-6 (unfavourable), Cervical cancer:2.78e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 499.8 LEP OB, OBS ENSG00000174697 Leptin 7 128241284-128257628 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB010490 Approved Tissue enhanced Tissue enriched 11 adipose tissue: 321.7 breast: 29.4 LEPR CD295, OBR ENSG00000116678 Leptin receptor 1 65420652-65641559 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030899 Approved Vesicles Tissue enriched Mixed liver: 69.9 LGALS3 GALIG, LGALS2, MAC-2 ENSG00000131981 Lectin, galactoside-binding, soluble, 3 14 55124110-55145413 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003162, CAB005191 Supported Supported Nucleoplasm
Plasma membrane
Cytosol Expressed in all Expressed in all colon: 886.8 LGALS3BP 90K, BTBD17B, CyCAP, gp90, M2BP, MAC-2-BP, TANGO10B ENSG00000108679 Lectin, galactoside-binding, soluble, 3 binding protein 17 78971238-78980109 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA000554, CAB002158 Supported Renal cancer:1.07e-6 (unfavourable) Expressed in all Expressed in all gallbladder: 324.9 LGALS4 GAL4 ENSG00000171747 Lectin, galactoside-binding, soluble, 4 19 38801671-38813364 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB025653, HPA031184, HPA031185, HPA031186 Supported Renal cancer:2.28e-4 (unfavourable), Urothelial cancer:3.21e-4 (favourable) Group enriched Tissue enhanced colon: 749.2;duodenum: 541.6;rectum: 652.0;small intestine: 503.3 gallbladder: 139.4 LGI1 EPITEMPIN, EPT, ETL1, IB1099 ENSG00000108231 Leucine-rich, glioma inactivated 1 10 93757809-93798174 Cancer-related genes, Disease related genes, Predicted secreted proteins Evidence at protein level Group enriched Tissue enriched 11 cerebral cortex: 51.3 esophagus: 4.7 LGMN LGMN1, PRSC1 ENSG00000100600 Legumain 14 92703807-92748702 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA000799, HPA001426 Supported Approved Cytosol Renal cancer:4.70e-4 (favourable) Expressed in all Expressed in all placenta: 357.3 LHB CGB4, hLHB, LSH-B ENSG00000104826 Luteinizing hormone beta polypeptide 19 49015980-49017090 Cancer-related genes, Disease related genes, Predicted secreted proteins Evidence at protein level CAB022241, CAB022707, HPA038925, HPA038934 Supported Approved Cytosol Pancreatic cancer:6.78e-4 (unfavourable) Mixed Tissue enhanced duodenum: 3.3;pancreas: 4.8;testis: 3.1 skin: 0.8 LHFP MGC22429 ENSG00000183722 Lipoma HMGIC fusion partner 13 39342892-39603528 Cancer-related genes, Disease related genes, Predicted membrane proteins Evidence at protein level HPA058975 Approved Approved Nucleoli Renal cancer:1.20e-7 (unfavourable), Urothelial cancer:2.30e-4 (unfavourable) Expressed in all Mixed placenta: 195.0 LHX1 LIM-1, LIM1 ENSG00000273706 LIM homeobox 1 17 36936785-36944612 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at transcript level CAB002770 Uncertain Endometrial cancer:3.63e-5 (unfavourable) Tissue enhanced Tissue enriched 6 kidney: 1.3 fallopian tube: 0.2 LIF CDF, DIA, HILDA ENSG00000128342 Leukemia inhibitory factor 22 30240447-30246851 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA018844, CAB025985 Approved Validated Cytosol Renal cancer:6.78e-8 (unfavourable), Cervical cancer:9.01e-4 (unfavourable) Expressed in all Tissue enhanced gallbladder: 75.8 urinary bladder: 43.5 LIFR CD118 ENSG00000113594 Leukemia inhibitory factor receptor alpha 5 38474963-38608354 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA004478, CAB010252 Approved Approved Nuclear speckles
Golgi apparatus Renal cancer:1.40e-7 (favourable), Lung cancer:1.92e-4 (favourable) Mixed Mixed thyroid gland: 71.7 LIG4 ENSG00000174405 Ligase IV, DNA, ATP-dependent 13 108207439-108218368 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA001334 Supported Approved Nucleoplasm
Plasma membrane
Cytosol Expressed in all Mixed cerebral cortex: 20.1 LIMK1 LIMK ENSG00000106683 LIM domain kinase 1 7 74082933-74122525 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA028064, HPA028516 Approved Supported Nuclear speckles
Cytosol Renal cancer:6.63e-8 (unfavourable), Liver cancer:7.79e-6 (unfavourable), Colorectal cancer:4.95e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 39.6 LMNA CMD1A, HGPS, LGMD1B, LMN1, LMNL1, PRO1 ENSG00000160789 Lamin A/C 1 156082573-156140089 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004022, HPA006660 Supported Expressed in all Expressed in all gallbladder: 344.5 LMO1 RBTN1, RHOM1, TTG1 ENSG00000166407 LIM domain only 1 (rhombotin 1) 11 8224304-8268716 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level Tissue enriched Tissue enhanced skeletal muscle: 10.1;skin: 5.9 testis: 2.0 LMO2 RBTN2, RBTNL1, RHOM2, TTG2 ENSG00000135363 LIM domain only 2 (rhombotin-like 1) 11 33858576-33892289 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB016258, HPA029285 Approved Approved Nucleoplasm
Cytosol Liver cancer:3.12e-4 (favourable) Expressed in all Mixed spleen: 26.2 LPP ENSG00000145012 LIM domain containing preferred translocation partner in lipoma 3 188153284-188890671 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA011133, HPA017342 Supported Validated Focal adhesion sites
Cytosol Expressed in all Expressed in all smooth muscle: 116.9 LRIG3 FLJ90440, KIAA3016 ENSG00000139263 Leucine-rich repeats and immunoglobulin-like domains 3 12 58872149-58920522 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010773 Approved Approved Cytosol Expressed in all Tissue enhanced thyroid gland: 97.1 skin: 33.1 LRP1B LRP-DIT, LRPDIT ENSG00000168702 Low density lipoprotein receptor-related protein 1B 2 140231423-142131701 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA069094, HPA074788 Approved Uncertain Vesicles Tissue enhanced Tissue enhanced cerebral cortex: 16.5;thyroid gland: 9.6 epididymis: 2.7 LRP6 ADCAD2 ENSG00000070018 Low density lipoprotein receptor-related protein 6 12 12116025-12267012 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB004490, HPA029925 Supported Expressed in all Mixed parathyroid gland: 16.2 LRRK2 DKFZp434H2111, FLJ45829, PARK8, RIPK7, ROCO2 ENSG00000188906 Leucine-rich repeat kinase 2 12 40196744-40369285 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA014293, CAB037160 Approved Approved Nucleus
Vesicles Renal cancer:3.02e-6 (favourable) Group enriched Tissue enhanced lung: 78.2 parathyroid gland: 22.9 LSM14A C19orf13, DKFZP434D1335, FAM61A, RAP55, RAP55A ENSG00000257103 LSM14A mRNA processing body assembly factor 19 34172504-34229515 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA017961 Approved Supported Cytosol
Cytoplasmic bodies Expressed in all Mixed thyroid gland: 37.3 LTA LT, TNFB, TNFSF1 ENSG00000226979 Lymphotoxin alpha 6 31572054-31574324 Cancer-related genes, Disease related genes, Predicted secreted proteins Evidence at protein level HPA007729 Uncertain Mixed Tissue enhanced lymph node: 1.6;spleen: 1.0 tonsil: 0.7 LTA4H ENSG00000111144 Leukotriene A4 hydrolase 12 96000828-96043520 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA008399, CAB015221, HPA017017 Supported Supported Nucleoplasm
Cytosol Lung cancer:8.96e-4 (favourable), Breast cancer:9.79e-4 (favourable) Expressed in all Expressed in all lung: 283.6 LTB p33, TNFC, TNFSF3 ENSG00000227507 Lymphotoxin beta (TNF superfamily, member 3) 6 31580525-31582522 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA048884 Approved Approved Centrosome Renal cancer:3.31e-7 (unfavourable), Endometrial cancer:2.36e-6 (favourable), Head and neck cancer:1.74e-4 (favourable) Expressed in all Group enriched 8 appendix: 19.4;lymph node: 22.5;spleen: 26.4;tonsil: 10.6 bone marrow: 2.6 LTBR D12S370, TNF-R-III, TNFCR, TNFR-RP, TNFR2-RP, TNFRSF3 ENSG00000111321 Lymphotoxin beta receptor (TNFR superfamily, member 3) 12 6375045-6391571 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB026202 Uncertain Approved Golgi apparatus Liver cancer:5.13e-4 (unfavourable), Renal cancer:5.92e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 88.1 LTF HLF2 ENSG00000012223 Lactotransferrin 3 46435645-46485234 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB008646, CAB016201, HPA057177, HPA059976 Supported Renal cancer:6.30e-5 (favourable) Expressed in all Tissue enhanced bone marrow: 2808.6;cervix, uterine: 1024.2 seminal vesicle: 526.7 LUM LDC, SLRR2D ENSG00000139329 Lumican 12 91102629-91111831 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Renal cancer:1.75e-6 (unfavourable) Expressed in all Tissue enhanced gallbladder: 932.2 placenta: 597.0 LYL1 bHLHa18 ENSG00000104903 Lymphoblastic leukemia associated hematopoiesis regulator 1 19 13099033-13103161 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA075004 Approved Golgi apparatus Renal cancer:3.89e-4 (unfavourable) Expressed in all Tissue enhanced bone marrow: 22.9;spleen: 21.2 appendix: 14.8 LYN JTK8 ENSG00000254087 LYN proto-oncogene, Src family tyrosine kinase 8 55879813-56014168 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA001231, CAB004492 Supported Supported Golgi apparatus
Vesicles
Plasma membrane Renal cancer:3.43e-4 (unfavourable) Expressed in all Tissue enhanced spleen: 163.6 appendix: 133.8 LZTR1 BTBD29, LZTR-1 ENSG00000099949 Leucine-zipper-like transcription regulator 1 22 20979462-20999038 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA068772, HPA071248 Approved Approved Nucleus Liver cancer:5.15e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 25.5 MAD2L1 HSMAD2, MAD2 ENSG00000164109 MAD2 mitotic arrest deficient-like 1 (yeast) 4 120055608-120067074 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003348 Uncertain Approved Nucleoplasm Renal cancer:3.07e-11 (unfavourable), Liver cancer:5.15e-5 (unfavourable), Lung cancer:2.17e-4 (unfavourable) Expressed in all Mixed lymph node: 4.6 MAD2L2 MAD2B, POLZ2, REV7 ENSG00000116670 MAD2 mitotic arrest deficient-like 2 (yeast) 1 11674480-11691650 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB008110, HPA024176 Approved Supported Nucleoli
Cytosol Expressed in all Expressed in all testis: 73.5 MAF c-MAF ENSG00000178573 V-maf avian musculoaponeurotic fibrosarcoma oncogene homolog 16 79585843-79600714 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB010296, HPA028289 Approved Renal cancer:3.74e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 147.2 small intestine: 93.1 MAFB KRML ENSG00000204103 V-maf avian musculoaponeurotic fibrosarcoma oncogene homolog B 20 40685848-40689240 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA005653 Approved Approved Nucleus
Nucleoli Endometrial cancer:5.64e-4 (unfavourable) Expressed in all Tissue enriched 7 parathyroid gland: 677.4 spleen: 103.7 MAGEA3 CT1.3, HIP8, HYPD, MAGE3, MGC14613 ENSG00000221867 Melanoma antigen family A3 X 152698752-152702347 Cancer-related genes, Predicted intracellular proteins Evidence at protein level Liver cancer:3.58e-4 (unfavourable) Mixed Tissue enriched 28 testis: 12.8 placenta: 0.4 MAGEA4 CT1.4, MAGE-41, MAGE-X2, MAGE4, MAGE4A, MAGE4B, MGC21336 ENSG00000147381 Melanoma antigen family A4 X 151912509-151925170 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA021942, CAB040535 Supported Approved Nuclear speckles
Cytosol Mixed Tissue enriched 7 testis: 44.8 placenta: 6.6 MAGEA6 CT1.6, MAGE6 ENSG00000197172 Melanoma antigen family A6 X 152766136-152769747 Cancer-related genes, Predicted intracellular proteins Evidence at protein level Liver cancer:1.93e-4 (unfavourable) Mixed Tissue enriched 22 testis: 10.9 endometrium: 0.4 MAGEB5 CT3.3, MAGE-B5 ENSG00000188408 Melanoma antigen family B5 X 26216169-26218270 Cancer-related genes, Predicted intracellular proteins Evidence at transcript level HPA052627 Uncertain Not detected Not detected testis: 0.8 MAGEB6 CT3.4, FLJ40242, MAGE-B6, MAGEB6A ENSG00000176746 Melanoma antigen family B6 X 26192440-26195646 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA041853 Approved Tissue enhanced Tissue enriched 58 testis: 5.7 all non-specific tissues: 0.0 MAGEC1 CT7, CT7.1, MAGE-C1, MGC39366 ENSG00000155495 Melanoma antigen family C1 X 141903894-141909388 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA004622, CAB015452 Supported Approved Nucleoplasm
Cytosol Tissue enhanced Tissue enriched 133 testis: 13.3 all non-specific tissues: 0.0 MAGEC2 CT10, MAGE-C2, MAGEE1 ENSG00000046774 Melanoma antigen family C2 X 142202345-142205290 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA062230 Supported Supported Nucleus
Nucleoli
Cytosol Tissue enhanced Tissue enriched 368 testis: 36.7 all non-specific tissues: 0.0 MAGEC3 CT7.2, HCA2, MAGE-C3 ENSG00000165509 Melanoma antigen family C3 X 141838316-141897832 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA052067 Approved Tissue enriched Tissue enhanced testis: 1.0 cerebral cortex: 0.6 MAGED1 DLXIN-1, NRAGE ENSG00000179222 Melanoma antigen family D1 X 51803007-51902357 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA043645 Approved Cytosol Thyroid cancer:3.25e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 194.4 MAGED2 11B6, BCG1, HCA10, JCL-1, MAGE-D2, MAGED, MGC8386 ENSG00000102316 Melanoma antigen family D2 X 54807599-54816012 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA031572, HPA031573 Supported Validated Nucleus
Nucleoli
Cytosol Pancreatic cancer:2.82e-4 (favourable), Ovarian cancer:2.88e-4 (favourable), Stomach cancer:9.43e-4 (unfavourable) Expressed in all Expressed in all prostate: 313.4 MAGI1 AIP3, BAIAP1, BAP1, MAGI-1, TNRC19, WWP3 ENSG00000151276 Membrane associated guanylate kinase, WW and PDZ domain containing 1 3 65353525-66038834 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA031851, HPA031852, HPA031853 Approved Validated Nucleoplasm
Cell Junctions Renal cancer:4.55e-8 (favourable) Expressed in all Mixed thyroid gland: 18.8 MALT1 MLT, PCASP1 ENSG00000172175 MALT1 paracaspase 18 58671386-58754477 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB004494, HPA048432 Supported Supported Nucleoli
Cytosol Expressed in all Expressed in all lymph node: 34.4 MAML2 KIAA1819, MAM3 ENSG00000184384 Mastermind-like transcriptional coactivator 2 11 95976598-96343180 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA035223 Approved Supported Nucleoplasm
Nuclear bodies
Cytosol Renal cancer:1.90e-4 (favourable), Pancreatic cancer:3.89e-4 (unfavourable) Expressed in all Mixed placenta: 17.4 MAP2K1 MAPKK1, MEK1, PRKMK1 ENSG00000169032 Mitogen-activated protein kinase kinase 1 15 66386817-66492312 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB003834, HPA026430 Approved Validated Plasma membrane
Cytosol Glioma:2.68e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 144.8 MAP2K2 MEK2, PRKMK2 ENSG00000126934 Mitogen-activated protein kinase kinase 2 19 4090321-4124129 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB003835, HPA051993 Supported Validated Cytosol Stomach cancer:5.43e-5 (favourable), Cervical cancer:3.72e-4 (favourable), Head and neck cancer:7.98e-4 (favourable) Expressed in all Expressed in all duodenum: 138.7 MAP2K4 JNKK1, MEK4, MKK4, PRKMK4, SERK1 ENSG00000065559 Mitogen-activated protein kinase kinase 4 17 12020824-12143830 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB007751, HPA060074 Supported Approved Nucleoplasm
Cell Junctions Expressed in all Expressed in all cerebral cortex: 64.2 MAP3K1 MAPKKK1, MEKK, MEKK1 ENSG00000095015 Mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase 5 56815574-56896152 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level CAB004500, HPA046509 Approved Approved Cytosol Expressed in all Mixed spleen: 28.7 MAP3K13 LZK, MEKK13 ENSG00000073803 Mitogen-activated protein kinase kinase kinase 13 3 185282941-185489097 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA016497, HPA036691, HPA036692 Uncertain Approved Nucleoplasm
Microtubule organizing center
Cytosol Endometrial cancer:1.28e-5 (unfavourable), Pancreatic cancer:7.27e-5 (unfavourable), Ovarian cancer:1.11e-4 (favourable) Expressed in all Expressed in all epididymis: 68.4 MAP3K3 MAPKKK3, MEKK3 ENSG00000198909 Mitogen-activated protein kinase kinase kinase 3 17 63622415-63696303 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB007764, HPA035410, HPA035411 Uncertain Approved Nucleoplasm Endometrial cancer:1.13e-4 (unfavourable) Expressed in all Expressed in all spleen: 42.3 MAP3K4 KIAA0213, MAPKKK4, MEKK4, MTK1 ENSG00000085511 Mitogen-activated protein kinase kinase kinase 4 6 160991727-161117385 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA007625 Uncertain Approved Cytosol Expressed in all Expressed in all endometrium: 15.3 MAP4K3 GLK, MAPKKKK3, RAB8IPL1 ENSG00000011566 Mitogen-activated protein kinase kinase kinase kinase 3 2 39249266-39437312 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA030380 Approved Approved Centrosome Expressed in all Expressed in all thyroid gland: 40.7 MAPK1 ERK, ERK2, MAPK2, p41mapk, PRKM1, PRKM2 ENSG00000100030 Mitogen-activated protein kinase 1 22 21754500-21867680 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA003995, CAB004229, HPA005700, HPA030069 Approved Liver cancer:4.95e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 132.8 MAPK14 CSBP1, CSBP2, CSPB1, Mxi2, p38, PRKM14, PRKM15 ENSG00000112062 Mitogen-activated protein kinase 14 6 36027677-36111236 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB010285, CAB040578, HPA051825 Approved Supported Nuclear speckles Expressed in all Expressed in all placenta: 62.7 MAPK3 ERK1, p44erk1, p44mapk, PRKM3 ENSG00000102882 Mitogen-activated protein kinase 3 16 30114105-30123506 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB002683, HPA003995, HPA005700, HPA030069 Approved Approved Nucleoplasm Liver cancer:1.11e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 134.1 MAPK7 BMK1, ERK5, PRKM7 ENSG00000166484 Mitogen-activated protein kinase 7 17 19377721-19383544 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB018561, HPA031031 Uncertain Validated Nucleus
Cytosol Liver cancer:1.86e-4 (unfavourable) Expressed in all Mixed testis: 10.7 MAPK8 JNK, JNK1, PRKM8, SAPK1 ENSG00000107643 Mitogen-activated protein kinase 8 10 48306639-48439360 Cancer-related genes, Enzymes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB004463, CAB069396 Approved Liver cancer:8.66e-4 (unfavourable), Renal cancer:8.66e-4 (favourable) Expressed in all Expressed in all testis: 34.9 MAPK8IP1 IB1, JIP-1, JIP1, PRKM8IP ENSG00000121653 Mitogen-activated protein kinase 8 interacting protein 1 11 45885651-45906465 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA058921, HPA070332 Supported Plasma membrane Renal cancer:1.23e-11 (favourable) Expressed in all Tissue enriched 5 cerebral cortex: 177.7 parathyroid gland: 32.6 MAPKAPK2 ENSG00000162889 Mitogen-activated protein kinase-activated protein kinase 2 1 206684944-206734283 Cancer-related genes, Enzymes, Predicted membrane proteins Evidence at protein level CAB010297, HPA045556, HPA063708, HPA064435 Approved Supported Nucleoplasm
Centrosome Renal cancer:4.58e-6 (unfavourable), Liver cancer:1.93e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 113.2 MAST2 KIAA0807, MAST205 ENSG00000086015 Microtubule associated serine/threonine kinase 2 1 45786987-46036124 Cancer-related genes, Enzymes, Predicted membrane proteins Evidence at protein level HPA039722, HPA040155 Approved Approved Cytosol Renal cancer:6.85e-13 (unfavourable), Liver cancer:4.31e-8 (unfavourable) Expressed in all Expressed in all testis: 78.5 MATK CHK, CTK, DKFZp434N1212, HHYLTK, HYL, HYLTK, Lsk, MGC1708, MGC2101 ENSG00000007264 Megakaryocyte-associated tyrosine kinase 19 3777970-3802129 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA004847 Approved Breast cancer:5.27e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 22.1 spleen: 20.2 MAX bHLHd4, bHLHd5, bHLHd6, bHLHd7, bHLHd8 ENSG00000125952 MYC associated factor X 14 65006174-65102695 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000328, HPA003474 Supported Supported Nucleoplasm
Golgi apparatus
Vesicles Thyroid cancer:2.12e-4 (favourable), Renal cancer:5.57e-4 (unfavourable) Expressed in all Expressed in all spleen: 80.2 MBD1 CXXC3, PCM1 ENSG00000141644 Methyl-CpG binding domain protein 1 18 50266882-50281774 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB009017, CAB036003 Approved Supported Nucleus Prostate cancer:1.70e-6 (unfavourable), Liver cancer:5.08e-6 (unfavourable) Expressed in all Expressed in all testis: 109.0 MBD2 ENSG00000134046 Methyl-CpG binding domain protein 2 18 54151601-54224788 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB037282, HPA067582, HPA067615 Approved Validated Nucleoplasm Colorectal cancer:6.49e-4 (favourable) Expressed in all Expressed in all thyroid gland: 50.3 MBD4 MED1 ENSG00000129071 Methyl-CpG binding domain 4 DNA glycosylase 3 129430944-129440179 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA002031 Supported Supported Nuclear speckles Renal cancer:2.73e-6 (unfavourable), Pancreatic cancer:2.18e-4 (unfavourable), Prostate cancer:4.75e-4 (unfavourable) Expressed in all Expressed in all lymph node: 77.5 MCL1 BCL2L3, Mcl-1 ENSG00000143384 Myeloid cell leukemia 1 1 150574551-150579738 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002781, HPA008455, HPA031125, CAB068195 Approved Validated Mitochondria Renal cancer:7.16e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 662.8 MCM2 BM28, CCNL1, cdc19, CDCL1, D3S3194, KIAA0030 ENSG00000073111 Minichromosome maintenance complex component 2 3 127598223-127622436 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000303, HPA031495, HPA031496 Supported Validated Nucleoplasm
Cytosol Liver cancer:1.51e-7 (unfavourable), Cervical cancer:4.66e-4 (favourable) Expressed in all Mixed bone marrow: 38.6 MCM3 ENSG00000112118 Minichromosome maintenance complex component 3 6 52264009-52284881 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002162, HPA004789, HPA004790 Supported Validated Nucleoplasm Thyroid cancer:3.13e-5 (favourable), Melanoma:4.40e-5 (unfavourable), Liver cancer:1.40e-4 (unfavourable), Cervical cancer:1.89e-4 (favourable) Expressed in all Expressed in all lymph node: 81.8 MCM5 CDC46 ENSG00000100297 Minichromosome maintenance complex component 5 22 35400063-35425430 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000101, HPA000845, HPA052880 Supported Validated Nucleoplasm Cervical cancer:2.81e-6 (favourable), Renal cancer:3.58e-5 (unfavourable), Liver cancer:1.78e-4 (unfavourable), Lung cancer:3.95e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 88.7 MCM7 CDC47, MCM2, PPP1R104 ENSG00000166508 Minichromosome maintenance complex component 7 7 100092728-100101940 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002163, HPA003898, CAB016312 Supported Validated Nucleoplasm Cervical cancer:1.28e-4 (favourable), Liver cancer:2.18e-4 (unfavourable) Expressed in all Expressed in all lymph node: 41.9 MDC1 Em:AB023051.5, KIAA0170, NFBD1 ENSG00000137337 Mediator of DNA-damage checkpoint 1 6 30699807-30717889 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA006915 Supported Supported Nucleoplasm
Nuclear bodies Expressed in all Tissue enhanced testis: 9.7 skin: 3.3 MDH1 ENSG00000014641 Malate dehydrogenase 1, NAD (soluble) 2 63588609-63607197 Cancer-related genes, Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA027296, CAB047333, HPA054276 Uncertain Supported Centrosome
Cytosol Endometrial cancer:7.13e-4 (unfavourable), Renal cancer:9.95e-4 (favourable) Expressed in all Expressed in all heart muscle: 736.3 MDK FLJ27379, MK, NEGF2 ENSG00000110492 Midkine (neurite growth-promoting factor 2) 11 46380756-46383837 Cancer-related genes, Predicted secreted proteins Evidence at protein level CAB010055, HPA057126 Uncertain Approved Vesicles Renal cancer:3.06e-6 (unfavourable), Glioma:9.54e-4 (unfavourable) Expressed in all Expressed in all ovary: 524.0 MDM2 HDM2, MGC5370 ENSG00000135679 MDM2 proto-oncogene, E3 ubiquitin protein ligase 12 68808172-68850686 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB000086, CAB016303 Supported Supported Nucleus Endometrial cancer:4.51e-7 (favourable), Cervical cancer:3.23e-4 (favourable) Expressed in all Expressed in all rectum: 44.3 MDM4 HDMX, MDMX ENSG00000198625 MDM4, p53 regulator 1 204516379-204558120 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA018919, HPA048821 Approved Supported Nucleus Renal cancer:7.06e-6 (unfavourable), Urothelial cancer:2.49e-4 (favourable), Prostate cancer:9.87e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 37.5 MECOM EVI1, MDS1, MDS1-EVI1, PRDM3 ENSG00000085276 MDS1 and EVI1 complex locus 3 169083499-169663618 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA046537 Supported Supported Nuclear speckles Pancreatic cancer:2.59e-4 (unfavourable) Mixed Mixed stomach: 66.8 MECP2 MRX16, MRX79, RTT ENSG00000169057 Methyl CpG binding protein 2 X 154021573-154137103 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA000593, HPA001341, CAB037264 Supported Supported Nucleus Renal cancer:7.32e-9 (favourable), Endometrial cancer:8.35e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 29.4 MED1 CRSP1, CRSP200, DRIP230, PBP, PPARBP, PPARGBP, RB18A, TRAP220, TRIP2 ENSG00000125686 Mediator complex subunit 1 17 39404285-39451286 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017696, HPA052818 Approved Supported Nucleoplasm Expressed in all Expressed in all parathyroid gland: 56.9 MED12 CAGH45, FGS1, HOPA, KIAA0192, OKS, OPA1, TNRC11, TRAP230 ENSG00000184634 Mediator complex subunit 12 X 71118556-71142454 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA003184, HPA003185 Supported Approved Nucleoplasm Expressed in all Expressed in all spleen: 27.1 MED13 KIAA0593, THRAP1, TRAP240 ENSG00000108510 Mediator complex subunit 13 17 61942605-62065282 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA067939 Supported Nucleus Colorectal cancer:1.43e-4 (favourable) Expressed in all Expressed in all testis: 35.5 MED17 CRSP6, CRSP77, DRIP80, TRAP80 ENSG00000042429 Mediator complex subunit 17 11 93784227-93814695 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA064236 Approved Vesicles Liver cancer:4.04e-6 (unfavourable), Breast cancer:4.94e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 26.5 MED23 CRSP130, CRSP3, DRIP130, Sur2 ENSG00000112282 Mediator complex subunit 23 6 131573966-131628229 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA070341 Approved Nucleoplasm
Vesicles Expressed in all Expressed in all parathyroid gland: 31.6 MEF2A RSRFC4, RSRFC9 ENSG00000068305 Myocyte enhancer factor 2A 15 99565417-99716466 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB004499, HPA046597 Approved Supported Nucleoplasm Renal cancer:6.93e-4 (favourable), Stomach cancer:7.96e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 68.4 MEN1 ENSG00000133895 Multiple endocrine neoplasia I 11 64803510-64811294 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA030342 Uncertain Supported Nucleoplasm
Cytosol Stomach cancer:6.31e-5 (favourable), Liver cancer:1.08e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 22.2 MET DFNB97, HGFR, RCCP2 ENSG00000105976 MET proto-oncogene, receptor tyrosine kinase 7 116672390-116798386 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB005282, CAB018577, HPA055607 Uncertain Supported Plasma membrane
Cytosol Pancreatic cancer:1.21e-7 (unfavourable), Head and neck cancer:6.75e-4 (unfavourable) Expressed in all Mixed placenta: 38.7 METTL14 KIAA1627 ENSG00000145388 Methyltransferase like 14 4 118685368-118715433 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA038002 Supported Supported Nucleoplasm Renal cancer:1.46e-5 (favourable) Expressed in all Expressed in all testis: 23.5 MFGE8 BA46, EDIL1, hP47, HsT19888, MFG-E8, OAcGD3S, SED1, SPAG10 ENSG00000140545 Milk fat globule-EGF factor 8 protein 15 88898683-88913411 Cancer-related genes, Predicted secreted proteins Evidence at protein level CAB002753, HPA002807 Uncertain Approved Cytosol Renal cancer:6.06e-9 (unfavourable), Stomach cancer:3.08e-4 (unfavourable) Expressed in all Expressed in all heart muscle: 288.2 MGA FLJ12634, KIAA0518, MAD5, MXD5 ENSG00000174197 MGA, MAX dimerization protein 15 41621224-41773081 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors Evidence at protein level HPA042278, HPA058183 Approved Supported Nucleoplasm
Cytosol Expressed in all Expressed in all testis: 16.0 MGMT ENSG00000170430 O-6-methylguanine-DNA methyltransferase 10 129467184-129768007 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB002786, HPA032135, HPA032136 Approved Validated Nucleoplasm Liver cancer:1.54e-4 (favourable), Cervical cancer:9.42e-4 (favourable) Expressed in all Expressed in all fallopian tube: 25.8 MIA CD-RAP ENSG00000261857 Melanoma inhibitory activity 19 40771648-40777490 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA031950 Supported Breast cancer:2.08e-4 (favourable) Tissue enriched Tissue enhanced breast: 62.4;stomach: 51.0 salivary gland: 18.6 MICALCL FLJ14966 ENSG00000133808 MICAL C-terminal like 11 12276080-12359144 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA039895, HPA040438 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Mixed Tissue enhanced skin: 17.3;testis: 13.3 lung: 10.3 MIF GIF, GLIF ENSG00000240972 Macrophage migration inhibitory factor (glycosylation-inhibiting factor) 22 23894004-23895227 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003868, CAB005284 Approved Approved Nucleoplasm
Cytosol Expressed in all Expressed in all cerebral cortex: 40.6 MITF bHLHe32, MI, WS2, WS2A ENSG00000187098 Microphthalmia-associated transcription factor 3 69739435-69968337 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002578, HPA003259 Supported Renal cancer:8.35e-10 (favourable) Group enriched Tissue enhanced cervix, uterine: 80.4;endometrium: 78.8 smooth muscle: 68.6 MKI67 MIB-, PPP1R105 ENSG00000148773 Marker of proliferation Ki-67 10 128096659-128126385 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000058, HPA000451, HPA001164, CAB068198 Supported Validated Nucleus
Nucleoli
Nuclear bodies Renal cancer:0.00e+0 (unfavourable), Liver cancer:3.61e-6 (unfavourable), Pancreatic cancer:9.47e-5 (unfavourable) Expressed in all Tissue enhanced bone marrow: 28.9 lymph node: 18.1 MKL1 BSAC, KIAA1438, MAL, MRTF-A ENSG00000196588 Megakaryoblastic leukemia (translocation) 1 22 40410281-40636702 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA030782 Approved Supported Nucleoplasm
Cytosol Renal cancer:1.58e-7 (unfavourable) Expressed in all Expressed in all bone marrow: 51.3 MLF1 ENSG00000178053 Myeloid leukemia factor 1 3 158571163-158607252 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA069479 Approved Nucleoplasm
Cytosol Endometrial cancer:2.15e-5 (unfavourable), Stomach cancer:5.54e-4 (unfavourable) Mixed Tissue enriched 6 testis: 667.3 heart muscle: 104.2 MLH1 COCA2, FCC2, HNPCC, HNPCC2 ENSG00000076242 MutL homolog 1 3 36993332-37050918 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013294, HPA052707, HPA060714, CAB070868 Supported Validated Nucleoplasm Liver cancer:8.24e-5 (unfavourable) Expressed in all Expressed in all testis: 59.7 MLLT1 ENL, LTG19, YEATS1 ENSG00000130382 Myeloid/lymphoid or mixed-lineage leukemia; translocated to, 1 19 6210379-6279948 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA031166 Approved Supported Nucleoplasm Head and neck cancer:6.03e-5 (favourable) Expressed in all Expressed in all placenta: 61.2 MLLT10 AF10 ENSG00000078403 Myeloid/lymphoid or mixed-lineage leukemia; translocated to, 10 10 21524675-21743630 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA005747 Supported Supported Nucleoplasm Head and neck cancer:8.75e-4 (favourable) Expressed in all Expressed in all testis: 176.8 MLLT11 AF1Q ENSG00000213190 Myeloid/lymphoid or mixed-lineage leukemia; translocated to, 11 1 151057758-151068497 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA000540 Uncertain Supported Nucleoplasm
Cytosol Renal cancer:4.25e-12 (unfavourable), Endometrial cancer:4.26e-5 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 122.9 parathyroid gland: 26.9 MLLT3 AF-9, AF9, YEATS3 ENSG00000171843 Myeloid/lymphoid or mixed-lineage leukemia; translocated to, 3 9 20341665-20622543 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA001824 Approved Approved Nucleoplasm
Cytosol Renal cancer:1.84e-4 (favourable) Expressed in all Mixed thyroid gland: 40.4 MLLT4 AF-6, AF6 ENSG00000130396 Myeloid/lymphoid or mixed-lineage leukemia; translocated to, 4 6 167826922-167972023 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB013496, HPA030212, HPA030213, HPA030214, HPA030215, HPA049868 Approved Validated Nucleoplasm
Plasma membrane
Cell Junctions Breast cancer:7.43e-5 (unfavourable) Expressed in all Expressed in all esophagus: 111.1 MLLT6 AF17, FLJ23480 ENSG00000275023 Myeloid/lymphoid or mixed-lineage leukemia; translocated to, 6 17 38705542-38729803 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA004021 Approved Approved Nucleus Head and neck cancer:3.98e-4 (favourable), Breast cancer:4.18e-4 (favourable), Pancreatic cancer:7.41e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 35.2 MME CALLA, CD10, NEP ENSG00000196549 Membrane metallo-endopeptidase 3 155024124-155183729 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000013, HPA052583, HPA056072 Supported Mixed Tissue enhanced duodenum: 440.1;kidney: 381.4;small intestine: 410.3 prostate: 151.9 MMP1 CLG ENSG00000196611 Matrix metallopeptidase 1 11 102789920-102798160 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA004920 Supported Vesicles Renal cancer:9.86e-10 (unfavourable), Liver cancer:4.22e-6 (unfavourable), Cervical cancer:4.66e-4 (unfavourable) Tissue enhanced Tissue enhanced appendix: 39.7;gallbladder: 126.6 urinary bladder: 30.2 MMP10 STMY2 ENSG00000166670 Matrix metallopeptidase 10 11 102770503-102780628 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level CAB002159 Uncertain Approved Plasma membrane
Cytosol Urothelial cancer:7.12e-4 (favourable) Tissue enhanced Tissue enriched 39 endometrium: 443.1 appendix: 11.3 MMP11 STMY3 ENSG00000099953 Matrix metallopeptidase 11 22 23768226-23784316 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level CAB002593, HPA068864 Approved Renal cancer:2.62e-4 (unfavourable) Expressed in all Group enriched 9 cervix, uterine: 30.9;endometrium: 122.3;placenta: 27.9 smooth muscle: 6.4 MMP12 HME ENSG00000262406 Matrix metallopeptidase 12 11 102862736-102875034 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level Liver cancer:1.42e-4 (unfavourable) Expressed in all Tissue enhanced appendix: 55.9;urinary bladder: 29.8 tonsil: 17.9 MMP13 CLG3 ENSG00000137745 Matrix metallopeptidase 13 11 102942995-102955734 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Tissue enhanced Tissue enhanced lung: 1.5;urinary bladder: 1.4 appendix,testis: 0.3 MMP14 MT1-MMP ENSG00000157227 Matrix metallopeptidase 14 (membrane-inserted) 14 22836557-22849027 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009918, HPA051432 Approved Approved Intermediate filaments
Cytosol Renal cancer:1.34e-4 (unfavourable), Ovarian cancer:9.48e-4 (unfavourable) Expressed in all Mixed endometrium: 236.1 MMP15 MT2-MMP, MTMMP2, SMCP-2 ENSG00000102996 Matrix metallopeptidase 15 (membrane-inserted) 16 58025566-58046901 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002611, HPA040390 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:8.54e-8 (favourable), Urothelial cancer:3.08e-4 (favourable) Expressed in all Tissue enhanced thyroid gland: 69.9 duodenum: 39.8 MMP16 C8orf57, DKFZp761D112, MT3-MMP ENSG00000156103 Matrix metallopeptidase 16 (membrane-inserted) 8 88032009-88328025 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA023693 Uncertain Approved Vesicles
Cytosol Tissue enhanced Tissue enhanced cerebral cortex: 9.6 gallbladder: 4.2 MMP2 CLG4, CLG4A, TBE-1 ENSG00000087245 Matrix metallopeptidase 2 16 55389700-55506691 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001939, CAB002788 Approved Uncertain Vesicles
Cytosol Expressed in all Tissue enhanced gallbladder: 1688.5 urinary bladder: 944.6 MMP3 STMY, STMY1 ENSG00000149968 Matrix metallopeptidase 3 11 102835801-102843803 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA007875 Uncertain Approved Vesicles Pancreatic cancer:4.09e-4 (unfavourable), Cervical cancer:9.73e-4 (unfavourable) Tissue enhanced Tissue enhanced appendix: 26.9;endometrium: 58.7 urinary bladder: 9.2 MMP7 MPSL1, PUMP-1 ENSG00000137673 Matrix metallopeptidase 7 11 102520508-102530753 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB025869, HPA051358 Supported Approved Nucleoplasm
Vesicles Liver cancer:2.53e-4 (unfavourable), Lung cancer:3.38e-4 (unfavourable) Expressed in all Tissue enhanced gallbladder: 824.4 breast: 201.5 MMP8 CLG1 ENSG00000118113 Matrix metallopeptidase 8 11 102711795-102727050 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA021221, HPA022935 Supported Tissue enriched Tissue enriched 103 bone marrow: 336.3 endometrium: 3.2 MMP9 CLG4B ENSG00000100985 Matrix metallopeptidase 9 20 46008908-46016561 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000348, HPA001238, HPA063909, CAB068199, CAB068200, CAB068201 Supported Approved Cytosol Renal cancer:4.05e-5 (unfavourable), Endometrial cancer:2.55e-4 (favourable), Liver cancer:7.19e-4 (unfavourable) Expressed in all Tissue enhanced bone marrow: 253.0;lymph node: 119.4 appendix: 85.4 MN1 MGCR, MGCR1, MGCR1-PEN ENSG00000169184 Meningioma (disrupted in balanced translocation) 1 22 27748277-27801498 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA003072 Approved Approved Nucleoplasm Mixed Tissue enhanced skeletal muscle: 22.0 cerebral cortex: 6.4 MNX1 HB9, HLXB9, HOXHB9, SCRA1 ENSG00000130675 Motor neuron and pancreas homeobox 1 7 156994051-157010651 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA071717 Approved Nucleus
Nucleoli
Cytosol Mixed Tissue enhanced duodenum: 7.5;small intestine: 6.8 colon: 3.8 MORC4 FLJ11565, ZCW4, ZCWCC2 ENSG00000133131 MORC family CW-type zinc finger 4 X 106813871-107000244 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA000395, HPA015547, HPA050250 Supported Validated Nucleoplasm Breast cancer:3.56e-5 (unfavourable) Expressed in all Expressed in all placenta: 113.4 MPL CD110, TPOR ENSG00000117400 MPL proto-oncogene, thrombopoietin receptor 1 43337807-43352772 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA007619 Uncertain Plasma membrane Not detected Tissue enhanced testis: 1.8 ovary: 1.3 MPO ENSG00000005381 Myeloperoxidase 17 58269856-58280935 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000059, HPA021147, HPA061464 Supported Supported Nucleus
Vesicles Tissue enhanced Tissue enriched 81 bone marrow: 2504.1 salivary gland: 30.8 MRE11A ATLD, MRE11 ENSG00000020922 MRE11 homolog A, double strand break repair nuclease 11 94415578-94493908 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002691, CAB004081 Supported Validated Nucleoplasm Liver cancer:7.14e-4 (unfavourable) Expressed in all Expressed in all endometrium: 18.8 MSH2 COCA1, HNPCC, HNPCC1 ENSG00000095002 MutS homolog 2 2 47402969-47562311 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009572, CAB070867 Supported Approved Nucleoplasm
Vesicles Liver cancer:1.72e-9 (unfavourable), Endometrial cancer:4.44e-4 (unfavourable), Pancreatic cancer:4.63e-4 (unfavourable) Expressed in all Expressed in all testis: 32.6 MSH6 GTBP ENSG00000116062 MutS homolog 6 2 47695530-47810101 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009091, HPA028376, HPA028446 Supported Supported Nucleoplasm
Golgi apparatus
Vesicles Renal cancer:1.06e-7 (unfavourable), Endometrial cancer:1.34e-4 (unfavourable), Liver cancer:7.86e-4 (unfavourable) Expressed in all Expressed in all ovary: 74.4 MSI2 ENSG00000153944 Musashi RNA-binding protein 2 17 57255851-57684685 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB022300 Approved Supported Cytosol Renal cancer:9.22e-8 (favourable), Stomach cancer:2.00e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 117.6 MSLN CAK1, MPF ENSG00000102854 Mesothelin 16 643262-768865 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002216, HPA017172 Supported Approved Nucleoplasm
Vesicles Renal cancer:5.91e-4 (favourable), Pancreatic cancer:6.66e-4 (unfavourable) Tissue enhanced Group enriched 9 fallopian tube: 440.6;lung: 105.4 epididymis: 29.2 MSMB IGBF, MSP, MSPB, PN44, PRPS, PSP, PSP-94, PSP57, PSP94 ENSG00000263639 Microseminoprotein, beta- 10 46033307-46046269 Cancer-related genes, Disease related genes, Predicted secreted proteins Evidence at protein level CAB026357, HPA051257 Supported Urothelial cancer:7.19e-4 (favourable) Tissue enriched Tissue enriched 32 prostate: 18712.1 stomach: 590.2 MSN ENSG00000147065 Moesin X 65588377-65741931 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA000263, CAB010898, HPA011135, HPA011227, CAB047336, CAB047338 Supported Validated Plasma membrane Renal cancer:1.60e-5 (unfavourable) Expressed in all Expressed in all lung: 421.4 MSR1 CD204, SCARA1 ENSG00000038945 Macrophage scavenger receptor 1 8 16107878-16567490 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000272, CAB032491 Supported Expressed in all Tissue enhanced lung: 188.3 gallbladder: 50.3 MST1 D3F15S2, DNF15S2, HGFL, MSP, NF15S2 ENSG00000173531 Macrophage stimulating 1 3 49683947-49689501 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA024036 Uncertain Pancreatic cancer:7.14e-4 (favourable) Tissue enriched Tissue enhanced liver: 143.1 duodenum: 52.7 MT1A MT1, MT1S ENSG00000205362 Metallothionein 1A 16 56638666-56750276 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB002161, CAB013056 Approved Expressed in all Tissue enhanced adipose tissue: 254.9 liver: 58.8 MT1G MT1, MT1K ENSG00000125144 Metallothionein 1G 16 56666731-56668065 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Renal cancer:1.67e-7 (unfavourable) Expressed in all Tissue enhanced kidney: 2338.0;thyroid gland: 4892.9 liver: 1261.9 MTA1 ENSG00000182979 Metastasis associated 1 14 105419820-105470729 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB004508, HPA005544 Supported Validated Nucleoplasm
Cytosol Pancreatic cancer:9.48e-5 (favourable), Liver cancer:4.62e-4 (unfavourable) Expressed in all Expressed in all testis: 35.8 MTCP1 P13MTCP1, p8MTCP1 ENSG00000214827 Mature T-cell proliferation 1 X 155061622-155147937 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA032040 Approved Nucleoplasm
Plasma membrane Renal cancer:4.52e-8 (unfavourable) Mixed Mixed testis: 8.7 MTOR FLJ44809, FRAP, FRAP1, FRAP2, RAFT1, RAPT1 ENSG00000198793 Mechanistic target of rapamycin (serine/threonine kinase) 1 11106535-11262507 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB069425, HPA071227 Approved Approved Vesicles
Cytosol Renal cancer:1.49e-5 (favourable) Expressed in all Expressed in all testis: 62.0 MUC1 ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM ENSG00000185499 Mucin 1, cell surface associated 1 155185824-155192916 Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000036, CAB001986, HPA004179, HPA007235, HPA008855 Supported Validated Vesicles
Plasma membrane Pancreatic cancer:4.60e-4 (unfavourable) Expressed in all Tissue enhanced lung: 447.5;stomach: 650.2 cervix, uterine: 286.5 MUC17 ENSG00000169876 Mucin 17, cell surface associated 7 101020072-101058745 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA031634 Supported Group enriched Group enriched 8 duodenum: 22.4;small intestine: 43.3 rectum: 3.9 MUTYH MYH ENSG00000132781 MutY DNA glycosylase 1 45329163-45340470 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA008732 Uncertain Supported Nucleus Liver cancer:4.76e-8 (unfavourable), Renal cancer:7.25e-5 (unfavourable) Expressed in all Mixed thyroid gland: 10.7 MVP LRP, VAULT1 ENSG00000013364 Major vault protein 16 29820394-29848039 Cancer-related genes, Predicted intracellular proteins, Transporters Evidence at protein level HPA002321, CAB002752, CAB022717, HPA064740 Supported Validated Cytosol Renal cancer:5.49e-5 (favourable), Breast cancer:4.51e-4 (favourable) Expressed in all Expressed in all small intestine: 169.1 MXI1 bHLHc11, MAD2, MXD2, MXI ENSG00000119950 MAX interactor 1, dimerization protein 10 110207605-110287365 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA035319, HPA056762 Approved Supported Nucleus
Nucleoli Renal cancer:1.02e-5 (unfavourable), Prostate cancer:9.17e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 88.4 MXRA5 DKFZp564I1922 ENSG00000101825 Matrix-remodelling associated 5 X 3308565-3346641 Cancer-related genes, Disease related genes, Predicted secreted proteins Evidence at protein level HPA000508 Uncertain Uncertain Mitochondria Glioma:2.56e-4 (unfavourable), Urothelial cancer:8.94e-4 (unfavourable) Expressed in all Tissue enhanced cervix, uterine: 56.8 skin: 35.3 MYB c-myb ENSG00000118513 V-myb avian myeloblastosis viral oncogene homolog 6 135181315-135219173 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB017704 Approved Approved Nucleus
Plasma membrane Prostate cancer:9.65e-4 (favourable), Stomach cancer:9.87e-4 (favourable) Tissue enhanced Tissue enhanced breast: 25.9;rectum: 29.6 colon: 25.7 MYBL2 B-MYB, BMYB ENSG00000101057 V-myb avian myeloblastosis viral oncogene homolog-like 2 20 43667019-43716496 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB017114, HPA030530, HPA055416 Uncertain Validated Nucleoplasm
Cytosol Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.11e-7 (unfavourable), Endometrial cancer:9.73e-4 (unfavourable) Tissue enriched Tissue enhanced bone marrow: 57.1;lymph node: 68.1;tonsil: 51.7 appendix: 33.8 MYC bHLHe39, c-Myc, MYCC ENSG00000136997 V-myc avian myelocytomatosis viral oncogene homolog 8 127735434-127741434 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000084, CAB010307, HPA055893, HPA066556 Supported Validated Nucleoplasm Renal cancer:5.49e-8 (unfavourable), Urothelial cancer:4.96e-5 (unfavourable), Ovarian cancer:7.52e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 144.4 MYCL bHLHe38, LMYC, MYCL1 ENSG00000116990 V-myc avian myelocytomatosis viral oncogene lung carcinoma derived homolog 1 39895426-39902256 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA063132 Supported Nucleus Lung cancer:4.49e-4 (favourable) Expressed in all Tissue enhanced skin: 41.7 urinary bladder: 24.6 MYCN bHLHe37, MYCNOT, N-myc, NMYC ENSG00000134323 V-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog 2 15940564-15947007 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA057420 Approved Nucleus
Nucleoli Tissue enhanced Tissue enhanced placenta: 9.6 cerebral cortex: 5.3 MYD88 ENSG00000172936 Myeloid differentiation primary response 88 3 38138478-38143022 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009104 Approved Supported Vesicles
Mitochondria
Cytosol Breast cancer:8.45e-4 (favourable) Expressed in all Mixed appendix: 57.6 MYH11 SMHC, SMMHC ENSG00000133392 Myosin, heavy chain 11, smooth muscle 16 15703135-15857033 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002302, HPA014539, HPA015310 Supported Approved Plasma membrane
Cytosol Liver cancer:1.10e-5 (favourable) Tissue enhanced Tissue enhanced seminal vesicle: 1365.9;smooth muscle: 1008.5 prostate: 841.6 MYH9 DFNA17, EPSTS, FTNS, MHA, NMHC-II-A, NMMHCA ENSG00000100345 Myosin, heavy chain 9, non-muscle 22 36281281-36388018 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001644, CAB015386 Supported Approved Plasma membrane
Actin filaments
Cytosol Expressed in all Expressed in all spleen: 313.7 MYO5A GS1, MYH12, MYO5, MYR12 ENSG00000197535 Myosin VA 15 52307283-52529050 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001356 Approved Approved Focal adhesion sites
Microtubule organizing center Urothelial cancer:4.22e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 94.6 MYOCD MYCD ENSG00000141052 Myocardin 17 12665890-12768949 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB046485 Approved Mixed Tissue enhanced seminal vesicle: 28.6 smooth muscle: 22.7 MYOD1 bHLHc1, MYF3, MYOD, PUM ENSG00000129152 Myogenic differentiation 1 11 17719568-17722131 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA051362 Supported Nucleoplasm
Nuclear bodies
Cytosol Tissue enhanced Tissue enriched 12 skeletal muscle: 9.0 prostate: 0.7 MYOG bHLHc3, MYF4 ENSG00000122180 Myogenin (myogenic factor 4) 1 203083132-203086036 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA028336, HPA038093 Approved Supported Nucleoplasm Group enriched Tissue enriched 12 skeletal muscle: 31.7 prostate: 2.7 NAB2 MADER ENSG00000166886 NGFI-A binding protein 2 (EGR1 binding protein 2) 12 57088894-57095476 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004510, HPA027464 Approved Approved Nucleus
Cytosol Renal cancer:9.38e-6 (unfavourable), Breast cancer:7.41e-4 (favourable) Expressed in all Expressed in all ovary: 39.3 NACA NACA1 ENSG00000196531 Nascent polypeptide-associated complex alpha subunit 12 56712428-56731628 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA073152, HPA073648 Approved Cytosol Renal cancer:4.58e-11 (unfavourable) Expressed in all Expressed in all ovary: 2544.0 NAGA D22S674 ENSG00000198951 N-acetylgalactosaminidase, alpha- 22 42058354-42070842 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA000649 Supported Expressed in all Expressed in all parathyroid gland: 62.5 NAIP BIRC1, NLRB1 ENSG00000249437 NLR family, apoptosis inhibitory protein 5 70968483-71025114 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA042438 Approved Not detected Mixed appendix,spleen: 3.9 NAMPT PBEF, PBEF1 ENSG00000105835 Nicotinamide phosphoribosyltransferase 7 106248285-106286326 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB034349, HPA047776, HPA057722 Approved Approved Nuclear speckles
Cell Junctions Renal cancer:2.49e-6 (unfavourable), Pancreatic cancer:1.51e-4 (unfavourable), Cervical cancer:4.78e-4 (unfavourable), Head and neck cancer:8.81e-4 (unfavourable) Expressed in all Expressed in all appendix: 792.4 NAT2 AAC2 ENSG00000156006 N-acetyltransferase 2 (arylamine N-acetyltransferase) 8 18391245-18401218 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA043704 Uncertain Colorectal cancer:4.61e-5 (favourable) Tissue enhanced Group enriched 13 colon: 14.7;duodenum: 33.6;liver: 62.2;rectum: 14.2;small intestine: 27.7 smooth muscle: 2.3 NAV3 KIAA0938, POMFIL1 ENSG00000067798 Neuron navigator 3 12 77830905-78213008 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA032111, HPA032112, CAB037063 Uncertain Approved Nuclear membrane
Cytosol Mixed Tissue enhanced cerebral cortex: 23.1;ovary: 22.9 spleen: 12.1 NBN AT-V1, AT-V2, ATV, NBS, NBS1 ENSG00000104320 Nibrin 8 89933336-90003228 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA001429, CAB003836 Supported Approved Nucleoplasm
Golgi apparatus Lung cancer:5.46e-5 (unfavourable), Pancreatic cancer:4.20e-4 (unfavourable) Expressed in all Expressed in all appendix: 38.1 NBPF1 FLJ20719, KIAA1693 ENSG00000219481 Neuroblastoma breakpoint family, member 1 1 16562319-16613562 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA038748, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050 Approved Approved Vesicles Renal cancer:1.06e-4 (favourable) Expressed in all Mixed testis: 21.8 NBPF10 AG1 ENSG00000271425 Neuroblastoma breakpoint family, member 10 1 146064699-146144942 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA038748, HPA038752, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050 Approved Approved Vesicles Not detected Expressed in all skin: 38.4 NCAM1 CD56, NCAM ENSG00000149294 Neural cell adhesion molecule 1 11 112961247-113278436 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000142, CAB018071, HPA039835 Supported Validated Plasma membrane
Cytosol Pancreatic cancer:9.11e-6 (favourable), Renal cancer:8.20e-4 (unfavourable) Tissue enriched Tissue enhanced cerebral cortex: 335.9 adrenal gland: 87.0 NCKIPSD AF3P21, DIP1, ORF1, SPIN90, WASLBP, WISH ENSG00000213672 NCK interacting protein with SH3 domain 3 48673844-48686364 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB019267, HPA050005 Validated Plasma membrane
Cytosol Renal cancer:1.20e-5 (favourable), Liver cancer:8.57e-4 (unfavourable) Expressed in all Tissue enriched 9 parathyroid gland: 300.2 cerebral cortex: 35.1 NCOA1 bHLHe74, F-SRC-1, KAT13A, NCoA-1, RIP160, SRC1 ENSG00000084676 Nuclear receptor coactivator 1 2 24491914-24770702 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB019402, HPA070213, HPA070520 Supported Validated Nucleoplasm
Plasma membrane
Cytosol Expressed in all Expressed in all parathyroid gland: 58.0 NCOA2 bHLHe75, GRIP1, KAT13C, NCoA-2, TIF2 ENSG00000140396 Nuclear receptor coactivator 2 8 70109762-70403805 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA060243 Supported Nucleoplasm
Nuclear bodies Renal cancer:5.08e-4 (favourable) Expressed in all Expressed in all epididymis: 35.4 NCOA3 ACTR, AIB1, bHLHe42, CAGH16, KAT13B, p/CIP, RAC3, SRC-3, SRC3, TNRC16, TRAM-1 ENSG00000124151 Nuclear receptor coactivator 3 20 47501902-47656877 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB009800, HPA024210 Supported Supported Nucleoplasm
Cytosol Liver cancer:8.09e-4 (unfavourable) Expressed in all Expressed in all lymph node: 45.3 NCOA4 ARA70, DKFZp762E1112, ELE1, PTC3, RFG ENSG00000266412 Nuclear receptor coactivator 4 10 46005088-46030714 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA051260, HPA065208 Uncertain Approved Nucleoli
Golgi apparatus
Cytosol Renal cancer:8.04e-6 (favourable), Glioma:2.88e-4 (favourable) Expressed in all Expressed in all duodenum: 253.9 NCOR1 hCIT529I10, hN-CoR, KIAA1047, MGC104216, N-CoR, PPP1R109, TRAC1 ENSG00000141027 Nuclear receptor corepressor 1 17 16029157-16218185 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA043246, HPA050288, HPA051168, CAB072830 Supported Validated Nucleoplasm
Cytosol Renal cancer:7.92e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 84.0 NCOR2 CTG26, SMRT, SMRTE, TNRC14, TRAC-1 ENSG00000196498 Nuclear receptor corepressor 2 12 124324415-124567589 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA001928 Approved Supported Nucleoplasm Expressed in all Expressed in all cerebral cortex: 81.4 NDRG1 CAP43, DRG1, NDR1, RTP, TDD5 ENSG00000104419 N-myc downstream regulated 1 8 133237171-133302022 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006881 Approved Supported Microtubules
Cytosol Liver cancer:1.47e-4 (unfavourable), Renal cancer:4.13e-4 (unfavourable), Glioma:7.24e-4 (unfavourable) Expressed in all Expressed in all prostate: 487.4 NEB NEB177D, NEM2 ENSG00000183091 Nebulin 2 151485336-151734487 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA016601 Supported Tissue enhanced Tissue enriched 110 skeletal muscle: 3274.3 prostate: 29.6 NEDD4L KIAA0439, NEDD4-2, RSP5 ENSG00000049759 Neural precursor cell expressed, developmentally down-regulated 4-like, E3 ubiquitin protein ligase 18 58044367-58401540 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA024618, HPA064730 Approved Approved Focal adhesion sites Renal cancer:6.55e-15 (favourable) Expressed in all Expressed in all prostate: 69.9 NEDD8 Nedd-8 ENSG00000129559 Neural precursor cell expressed, developmentally down-regulated 8 14 24216852-24232454 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004082 Approved Supported Nucleoplasm
Cytosol Expressed in all Expressed in all parathyroid gland: 548.6 NEO1 HsT17534, IGDCC2, NGN, NTN1R2 ENSG00000067141 Neogenin 1 15 73051710-73305206 Cancer-related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB009320, HPA027804, HPA027805, HPA027806 Uncertain Approved Nucleoplasm
Golgi apparatus
Plasma membrane Renal cancer:4.39e-4 (favourable) Expressed in all Mixed parathyroid gland: 100.9 NF1 ENSG00000196712 Neurofibromin 1 17 31094927-31382116 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA045502 Uncertain Approved Mitochondria Expressed in all Expressed in all parathyroid gland: 31.9 NF2 merlin ENSG00000186575 Neurofibromin 2 (merlin) 22 29603556-29698598 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003097, CAB005385 Supported Validated Nucleus
Plasma membrane
Cytosol Renal cancer:2.89e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 57.6 NFATC2 NF-ATP, NFAT1, NFATp ENSG00000101096 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 20 51386957-51562831 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA008789, CAB018567, HPA024369 Supported Supported Nucleoplasm
Cytosol Renal cancer:1.57e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 26.8 NFE2L2 NRF2 ENSG00000116044 Nuclear factor, erythroid 2-like 2 2 177227595-177392697 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA002990, CAB020317, HPA043438 Supported Approved Nucleus
Plasma membrane
Cytosol Renal cancer:2.26e-4 (favourable) Expressed in all Expressed in all esophagus: 267.9 NFIB NFI-RED, NFIB2, NFIB3 ENSG00000147862 Nuclear factor I/B 9 14081843-14398983 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA003956 Supported Supported Nucleus
Nucleoli fibrillar center Renal cancer:3.53e-4 (favourable) Expressed in all Mixed breast: 44.4 NFKB1 KBF1, NF-kappaB, NF-kB1, NFkappaB, NFKB-p50, p105, p50 ENSG00000109320 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 4 102501329-102617302 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors Evidence at protein level CAB004031, HPA027305 Supported Supported Nucleoplasm
Cytosol Renal cancer:1.76e-4 (favourable) Expressed in all Expressed in all bone marrow: 57.0 NFKB2 LYT-10, NF-kB2, p105, p52 ENSG00000077150 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) 10 102394110-102402529 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA008422, CAB022098, HPA023900 Supported Approved Nucleoplasm
Cytosol Renal cancer:6.69e-12 (unfavourable), Melanoma:8.45e-5 (favourable), Colorectal cancer:3.86e-4 (unfavourable) Expressed in all Expressed in all appendix: 72.8 NFKBIA IkappaBalpha, IKBA, MAD-3, NFKBI ENSG00000100906 Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 14 35401511-35404749 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB003815, HPA029207 Approved Validated Cytosol Breast cancer:1.33e-5 (favourable) Expressed in all Expressed in all bone marrow: 713.0 NFKBIE IKBE ENSG00000146232 Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon 6 44258166-44265788 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA002692, HPA005941, CAB010272 Supported Supported Nucleus
Nucleoli fibrillar center
Cytosol Renal cancer:1.37e-6 (unfavourable), Breast cancer:1.72e-5 (favourable), Liver cancer:3.50e-4 (unfavourable), Urothelial cancer:8.07e-4 (favourable) Expressed in all Mixed appendix: 26.8 NGF NGFB ENSG00000134259 Nerve growth factor (beta polypeptide) 1 115285918-115338236 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level Renal cancer:8.08e-7 (unfavourable), Head and neck cancer:1.80e-4 (unfavourable) Mixed Tissue enhanced ovary: 12.3 smooth muscle: 5.9 NGFR CD271, p75NTR, TNFRSF16 ENSG00000064300 Nerve growth factor receptor 17 49495293-49515017 Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB000143, CAB001995, HPA004765 Supported Approved Nucleoplasm
Plasma membrane Urothelial cancer:3.40e-4 (unfavourable) Expressed in all Mixed adipose tissue: 32.2 NIN ENSG00000100503 Ninein (GSK3B interacting protein) 14 50719763-50831121 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA005939, HPA070691 Supported Validated Nucleus
Nucleoli
Centrosome Expressed in all Mixed lymph node: 48.1 NKX2-1 BCH, NKX2A, TITF1, TTF-1, TTF1 ENSG00000136352 NK2 homeobox 1 14 36516392-36521149 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000078, CAB053633, HPA074316 Supported Uncertain Golgi apparatus
Vesicles Group enriched Group enriched 174 lung: 102.0;thyroid gland: 103.6 stomach: 0.5 NKX3-1 BAPX2, NKX3.1, NKX3A ENSG00000167034 NK3 homeobox 1 8 23678693-23682927 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level Tissue enriched Tissue enriched 12 prostate: 517.0 testis: 44.8 NLRP3 AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1, FCAS, FCU, MWS, NALP3, PYPAF1 ENSG00000162711 NLR family, pyrin domain containing 3 1 247416156-247449108 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA012878 Uncertain Mixed Tissue enhanced bone marrow: 34.5 appendix: 14.9 NME1 NDPKA, NM23, NM23-H1 ENSG00000239672 NME/NM23 nucleoside diphosphate kinase 1 17 51153536-51162428 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA008467, CAB040571, HPA041113 Supported Validated Nucleoplasm
Cytosol Renal cancer:2.07e-9 (unfavourable), Liver cancer:2.60e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 89.5 NME1-NME2 NM23-LV, NMELV ENSG00000011052 NME1-NME2 readthrough 17 51153590-51171744 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB002169, HPA008467, HPA041113 Approved Supported Cytosol Glioma:8.99e-4 (favourable) Expressed in all Expressed in all appendix: 50.0 NONO NMT55, NRB54, P54, P54NRB, PPP1R114 ENSG00000147140 Non-POU domain containing, octamer-binding X 71283192-71301168 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB022069, HPA054094, HPA054559 Supported Validated Nucleoplasm Endometrial cancer:9.29e-4 (unfavourable) Expressed in all Expressed in all ovary: 245.1 NOS1 nNOS, NOS ENSG00000089250 Nitric oxide synthase 1 (neuronal) 12 117208142-117452170 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002167, HPA058312 Uncertain Supported Nucleoplasm
Plasma membrane Mixed Tissue enhanced skeletal muscle: 12.9 cerebral cortex: 3.0 NOS2 HEP-NOS, iNOS, NOS, NOS2A ENSG00000007171 Nitric oxide synthase 2, inducible 17 27756766-27800499 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002014 Approved Tissue enhanced Group enriched 5 appendix: 19.6;colon: 7.2;duodenum: 12.6;rectum: 10.0;small intestine: 24.6;urinary bladder: 6.7 smooth muscle: 2.5 NOS3 ECNOS, eNOS ENSG00000164867 Nitric oxide synthase 3 (endothelial cell) 7 150990995-151014588 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002168 Supported Renal cancer:3.63e-4 (unfavourable) Expressed in all Tissue enriched 7 spleen: 73.1 adipose tissue: 10.7 NOTCH1 TAN1 ENSG00000148400 Notch 1 9 136494444-136545862 Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB008112, CAB022466, HPA067168 Supported Approved Nucleoplasm Renal cancer:5.45e-4 (unfavourable) Expressed in all Expressed in all skin: 24.0 NOTCH2 ENSG00000134250 Notch 2 1 119911553-120069626 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046392, HPA048743 Uncertain Supported Nucleoplasm
Plasma membrane Ovarian cancer:5.24e-4 (unfavourable), Pancreatic cancer:9.48e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 46.5 NOTCH3 CADASIL, CASIL ENSG00000074181 Notch 3 19 15159038-15200981 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB005393, HPA044392 Approved Supported Nucleoplasm
Actin filaments
Cytosol Renal cancer:2.53e-7 (unfavourable), Endometrial cancer:5.92e-4 (unfavourable) Expressed in all Mixed skin: 93.5 NPM1 B23, NPM ENSG00000181163 Nucleophosmin (nucleolar phosphoprotein B23, numatrin) 5 171387116-171411137 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA011384, CAB012983 Supported Validated Nucleus
Nucleoli Renal cancer:2.89e-6 (unfavourable), Liver cancer:4.82e-6 (unfavourable), Head and neck cancer:7.48e-4 (unfavourable) Expressed in all Expressed in all ovary: 1797.0 NQO1 DHQU, DIA4, DTD, NMOR1, QR1 ENSG00000181019 NAD(P)H dehydrogenase, quinone 1 16 69706996-69726951 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA007308, CAB012421 Supported Validated Cytosol Head and neck cancer:1.45e-4 (unfavourable) Expressed in all Tissue enhanced breast: 371.7;stomach: 559.0 gallbladder: 321.6 NR0B1 AHC, AHCH, DAX1, DSS, NR0B1 ENSG00000169297 Nuclear receptor subfamily 0, group B, member 1 X 30304206-30309598 Cancer-related genes, Disease related genes, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA070839 Supported Nucleoplasm Tissue enhanced Group enriched 7 adrenal gland: 27.9;testis: 34.9 ovary: 4.2 NR1H2 LXR-b, NER, NER-I, RIP15, UNR ENSG00000131408 Nuclear receptor subfamily 1, group H, member 2 19 50329653-50382982 Cancer-related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA056838, HPA070212 Uncertain Approved Nucleoplasm Colorectal cancer:9.86e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 87.8 NR4A2 HZF-3, NOT, NURR1, RNR1, TINUR ENSG00000153234 Nuclear receptor subfamily 4, group A, member 2 2 156324432-156342348 Cancer-related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA000543, CAB010481 Uncertain Supported Nuclear speckles Expressed in all Tissue enhanced adrenal gland: 175.5 ovary: 95.2 NR4A3 CHN, CSMF, MINOR, NOR1 ENSG00000119508 Nuclear receptor subfamily 4, group A, member 3 9 99821855-99866891 Cancer-related genes, Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA043360 Uncertain Breast cancer:5.97e-4 (favourable) Mixed Tissue enhanced adrenal gland: 89.5 urinary bladder: 43.5 NRAS N-ras ENSG00000213281 Neuroblastoma RAS viral (v-ras) oncogene homolog 1 114704469-114716894 Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB010157, HPA049830 Uncertain Liver cancer:3.03e-7 (unfavourable), Pancreatic cancer:1.36e-4 (unfavourable), Renal cancer:7.87e-4 (unfavourable) Expressed in all Expressed in all placenta: 39.1 NRG1 GGF, HGL, HRG, NDF, NRG1-IT2 ENSG00000157168 Neuregulin 1 8 31639386-32767959 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010964 Uncertain Approved Nucleoplasm Tissue enhanced Mixed thyroid gland: 19.9 NRG2 Don-1, HRG2, NTAK ENSG00000158458 Neuregulin 2 5 139846779-140043299 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA038935, HPA047973 Uncertain Supported Nucleus
Nucleoli Mixed Tissue enhanced parathyroid gland: 13.1 ovary: 10.2 NRG3 ENSG00000185737 Neuregulin 3 10 81875314-82987179 Cancer-related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level Group enriched Tissue enhanced cerebral cortex: 30.4 fallopian tube: 7.3 NRP1 CD304, NRP, VEGF165R ENSG00000099250 Neuropilin 1 10 33177492-33336262 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB004511, HPA030278 Approved Uncertain Mitochondria Stomach cancer:1.22e-5 (unfavourable), Cervical cancer:7.10e-5 (unfavourable), Renal cancer:3.87e-4 (unfavourable), Glioma:7.78e-4 (unfavourable) Expressed in all Expressed in all placenta: 193.5 NRP2 VEGF165R2 ENSG00000118257 Neuropilin 2 2 205681990-205798133 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA039980, HPA054974 Approved Supported Vesicles
Plasma membrane Renal cancer:7.68e-7 (unfavourable), Urothelial cancer:7.80e-5 (unfavourable) Expressed in all Mixed smooth muscle: 83.5 NSD1 ARA267, FLJ22263, KMT3B, STO ENSG00000165671 Nuclear receptor binding SET domain protein 1 5 177133025-177300215 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA048431, HPA070333 Supported Nucleus
Plasma membrane Expressed in all Expressed in all testis: 43.2 NT5C2 cN-II, GMP, NT5B, PNT5, SPG65 ENSG00000076685 5'-nucleotidase, cytosolic II 10 103088017-103193306 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA003751 Approved Expressed in all Expressed in all thyroid gland: 118.9 NTF3 NGF2 ENSG00000185652 Neurotrophin 3 12 5432112-5521536 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA032001 Approved Mixed Tissue enhanced ovary: 13.5 spleen: 6.3 NTF4 GLC1O, NT-4/5, NTF5 ENSG00000225950 Neurotrophin 4 19 49055793-49065076 Cancer-related genes, Disease related genes, Predicted secreted proteins Evidence at protein level HPA049376 Approved Golgi apparatus Mixed Tissue enhanced skin: 36.6 seminal vesicle: 10.3 NTHL1 NTH1, OCTS3 ENSG00000065057 Nth-like DNA glycosylase 1 16 2039815-2047866 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB025152 Supported Expressed in all Expressed in all fallopian tube: 21.1 NTN1 NTN1L ENSG00000065320 Netrin 1 17 9021542-9244000 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA056419 Approved Mixed Mixed heart muscle: 23.7 NTN4 ENSG00000074527 Netrin 4 12 95657807-95791152 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA049832 Approved Renal cancer:8.12e-9 (favourable), Urothelial cancer:6.67e-5 (favourable), Pancreatic cancer:9.50e-4 (unfavourable) Expressed in all Tissue enhanced spleen: 250.0 kidney: 117.8 NTRK1 MTC, TRK, TRKA ENSG00000198400 Neurotrophic tyrosine kinase, receptor, type 1 1 156815640-156881850 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB004606, HPA035799, HPA076570 Approved Uncertain Vesicles
Cytosol Tissue enhanced Tissue enriched 6 adrenal gland: 9.6 testis: 1.6 NTRK2 TRKB ENSG00000148053 Neurotrophic tyrosine kinase, receptor, type 2 9 84668551-85027070 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA007637 Approved Approved Cytosol Group enriched Tissue enhanced cerebral cortex: 441.0;thyroid gland: 214.8 breast: 81.9 NTRK3 TRKC ENSG00000140538 Neurotrophic tyrosine kinase, receptor, type 3 15 87859751-88256768 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009233, HPA027484, HPA048065 Supported Supported Nuclear membrane
Nucleoli Tissue enhanced Tissue enhanced cerebral cortex: 39.7 testis: 15.2 NUDT1 MTH1 ENSG00000106268 Nudix (nucleoside diphosphate linked moiety X)-type motif 1 7 2242222-2251146 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA012636 Approved Approved Cytosol Renal cancer:1.30e-7 (unfavourable), Liver cancer:4.44e-4 (unfavourable) Expressed in all Expressed in all testis: 50.7 NUMA1 ENSG00000137497 Nuclear mitotic apparatus protein 1 11 72002864-72080693 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019841, HPA019859, HPA029912 Supported Validated Nucleoplasm Renal cancer:7.92e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 243.4 NUMB C14orf41 ENSG00000133961 Numb homolog (Drosophila) 14 73275107-73463642 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB011478 Approved Approved Cell Junctions
Cytosol Renal cancer:2.32e-6 (favourable) Expressed in all Expressed in all lung: 78.1 NUP210L ENSG00000143552 Nucleoporin 210kDa-like 1 153992685-154155116 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA047195, HPA064245, HPA066707 Supported Approved Nuclear bodies Not detected Tissue enriched 93 testis: 47.5 seminal vesicle: 0.5 NUP214 CAIN, CAN, D9S46E, N214 ENSG00000126883 Nucleoporin 214kDa 9 131125561-131234670 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA048789 Supported Nucleus
Vesicles
Focal adhesion sites Renal cancer:2.39e-5 (favourable) Expressed in all Expressed in all testis: 122.9 NUP93 KIAA0095 ENSG00000102900 Nucleoporin 93kDa 16 56730105-56850286 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA017937 Uncertain Liver cancer:1.72e-6 (unfavourable) Expressed in all Expressed in all testis: 74.3 NUP98 NUP96 ENSG00000110713 Nucleoporin 98kDa 11 3671083-3797792 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA074810 Supported Nucleoplasm
Vesicles Expressed in all Expressed in all testis: 150.1 NUTM1 C15orf55, DKFZp434O192, FAM22H, NUT ENSG00000184507 NUT midline carcinoma, family member 1 15 34343315-34357737 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA040421 Approved Not detected Tissue enriched 78 testis: 22.5 duodenum,skin: 0.2 NUTM2A FAM22A ENSG00000184923 NUT family member 2A 10 87225448-87236908 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA064635 Uncertain Nuclear bodies Not detected Mixed skin: 1.9 NUTM2B bA119F19.1, FAM22B ENSG00000188199 NUT family member 2B 10 79703227-79714681 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA064635 Uncertain Nuclear bodies Not detected Mixed testis: 2.2 ODAM APin, FLJ20513 ENSG00000109205 Odontogenic, ameloblast asssociated 4 70196496-70204576 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA036543 Supported Nucleoplasm
Cytosol Mixed Tissue enriched 14 salivary gland: 136.9 smooth muscle: 10.0 OGG1 HMMH, HOGG1, MUTM, OGH1 ENSG00000114026 8-oxoguanine DNA glycosylase 3 9749944-9788219 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA027514, CAB047301 Approved Validated Nucleoplasm Liver cancer:5.77e-5 (unfavourable), Renal cancer:2.65e-4 (favourable) Expressed in all Expressed in all lymph node: 31.0 OLIG2 BHLHB1, bHLHe19, OLIGO2, PRKCBP2, RACK17 ENSG00000205927 Oligodendrocyte lineage transcription factor 2 21 33025845-33029196 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA003254, CAB019381 Supported Uncertain Nucleoplasm
Plasma membrane Tissue enriched Tissue enriched 239 cerebral cortex: 91.2 duodenum: 0.3 OMA1 FLJ33782, MPRP-1, YKR087C, ZMPOMA1 ENSG00000162600 OMA1 zinc metallopeptidase 1 58415384-58546802 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA055120 Approved Approved Nucleoplasm
Mitochondria Breast cancer:1.63e-4 (favourable), Colorectal cancer:7.70e-4 (favourable), Lung cancer:8.52e-4 (favourable) Expressed in all Expressed in all prostate: 32.2 OMD osteoadherin, SLRR2C ENSG00000127083 Osteomodulin 9 92414245-92424461 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA005731 Approved Mixed Mixed cervix, uterine: 36.2 OR4A16 OR4A16Q ENSG00000181961 Olfactory receptor, family 4, subfamily A, member 16 11 55343201-55344187 Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins No evidence Not detected Not detected testis: 0.1 OR51E2 PSGR ENSG00000167332 Olfactory receptor, family 51, subfamily E, member 2 11 4680171-4697854 Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at transcript level Tissue enriched Tissue enriched 7 prostate: 38.9 placenta: 5.8 OR52N1 ENSG00000181001 Olfactory receptor, family 52, subfamily N, member 1 11 5787854-5788816 Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins No evidence HPA054028 Uncertain Not detected Not detected adipose tissue: 0.1 ORM1 ENSG00000229314 Orosomucoid 1 9 114323056-114326475 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB006265, HPA046438, HPA047725, HPA057726 Approved Approved Golgi apparatus
Vesicles Renal cancer:2.35e-4 (unfavourable) Tissue enriched Tissue enriched 69 liver: 10546.0 bone marrow: 152.7 OSM MGC20461 ENSG00000099985 Oncostatin M 22 30262829-30266840 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Renal cancer:1.03e-5 (unfavourable) Mixed Tissue enhanced bone marrow: 78.8 appendix: 20.6 OTUD7A C15orf16, CEZANNE2, OTUD7 ENSG00000169918 OTU deubiquitinase 7A 15 31475398-31870789 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA044554 Uncertain Approved Nucleoli
Cytosol Mixed Tissue enhanced cerebral cortex: 13.5 testis: 5.1 P2RY8 P2Y8 ENSG00000182162 Purinergic receptor P2Y, G-protein coupled, 8 X 1462572-1537107 Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA003631 Supported Head and neck cancer:7.80e-5 (favourable), Liver cancer:1.73e-4 (favourable), Pancreatic cancer:6.54e-4 (favourable) Expressed in all Tissue enhanced lymph node: 43.1 tonsil: 29.0 PABPC1 PAB1, PABP1, PABPC2, PABPL1 ENSG00000070756 Poly(A) binding protein, cytoplasmic 1 8 100685816-100722809 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB011536, HPA045423, HPA067156 Supported Supported Cytosol Renal cancer:5.70e-12 (unfavourable), Glioma:1.35e-4 (favourable), Liver cancer:5.80e-4 (unfavourable) Expressed in all Expressed in all esophagus: 1155.5 PAFAH1B2 ENSG00000168092 Platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (30kDa) 11 117144267-117176894 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA051836 Approved Supported Nucleoli
Plasma membrane
Cytosol Pancreatic cancer:7.79e-5 (unfavourable), Lung cancer:3.07e-4 (unfavourable), Ovarian cancer:4.25e-4 (favourable), Liver cancer:9.44e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 68.4 PAGE4 CT16.7, GAGEC1, PAGE-4 ENSG00000101951 P antigen family, member 4 (prostate associated) X 49829260-49833973 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA023880 Supported Approved Golgi apparatus
Vesicles Group enriched Group enriched 6 epididymis: 1431.1;placenta: 2026.4 prostate: 279.7 PALB2 FANCN, FLJ21816 ENSG00000083093 Partner and localizer of BRCA2 16 23603160-23641310 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB014895, HPA057000 Approved Supported Nucleoplasm Pancreatic cancer:2.35e-5 (unfavourable), Colorectal cancer:2.83e-5 (favourable) Expressed in all Mixed testis: 14.4 PAPD5 TRF4-2 ENSG00000121274 PAP associated domain containing 5 16 50152918-50235310 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA042968, HPA048225 Uncertain Renal cancer:1.85e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 27.1 PAPPA ASBABP2, DIPLA1, IGFBP-4ase, PAPA, PAPP-A, PAPPA1 ENSG00000182752 Pregnancy-associated plasma protein A, pappalysin 1 9 116153804-116402322 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA001667, CAB016724 Supported Uncertain Plasma membrane
Cytosol Mixed Tissue enriched 7 placenta: 103.9 parathyroid gland: 14.6 PARP1 ADPRT, PARP, PPOL ENSG00000143799 Poly (ADP-ribose) polymerase 1 1 226360691-226408079 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000147, CAB003839, CAB003840, HPA045168, CAB075726, CAB075727 Supported Validated Nucleus Renal cancer:1.35e-5 (unfavourable), Liver cancer:3.40e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 195.1 PARVB CGI-56 ENSG00000188677 Parvin, beta 22 43999211-44172949 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA062601 Approved Cytosol Expressed in all Expressed in all skeletal muscle: 68.6 PATZ1 dJ400N23, MAZR, PATZ, RIAZ, ZBTB19, ZNF278, ZSG ENSG00000100105 POZ (BTB) and AT hook containing zinc finger 1 22 31325804-31346232 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA047893, HPA048315 Approved Supported Nucleoplasm Renal cancer:8.54e-8 (favourable), Urothelial cancer:7.79e-6 (favourable), Glioma:6.53e-5 (favourable), Lung cancer:8.71e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 39.8 PAX3 HUP2, WS1 ENSG00000135903 Paired box 3 2 222199888-222298996 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA063659, HPA069000 Uncertain Supported Nucleoplasm Tissue enriched Group enriched 9 breast: 1.2;skeletal muscle: 1.1;skin: 3.2;testis: 2.4 prostate: 0.2 PAX5 BSAP ENSG00000196092 Paired box 5 9 36833275-37034185 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB026269, CAB026869, HPA056394, HPA068498 Supported Approved Nucleoplasm
Vesicles
Cytosol Mixed Tissue enhanced lymph node: 49.1;spleen: 26.7;tonsil: 35.2 appendix: 20.2 PAX7 Hup1 ENSG00000009709 Paired box 7 1 18631006-18748866 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level Group enriched Group enriched 7 cerebral cortex: 1.4;skeletal muscle: 2.2 esophagus,testis: 0.2 PAX8 ENSG00000125618 Paired box 8 2 113215997-113278950 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA030062, HPA064554 Validated Nucleoplasm Endometrial cancer:1.75e-5 (unfavourable) Group enriched Tissue enriched 10 thyroid gland: 642.7 kidney: 65.0 PBRM1 BAF180, PB1 ENSG00000163939 Polybromo 1 3 52545352-52685917 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA015629, HPA059373 Uncertain Supported Nucleoplasm Expressed in all Expressed in all thyroid gland: 44.5 PBX1 ENSG00000185630 Pre-B-cell leukemia homeobox 1 1 164555584-164899296 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA003505, HPA003881, CAB018768 Supported Validated Nucleoplasm Mixed Expressed in all endometrium: 246.5 PCBP1 hnRNP-E1, hnRNP-X, HNRPE1, HNRPX ENSG00000169564 Poly(rC) binding protein 1 2 70087454-70089203 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB037113, HPA043803, HPA068497 Supported Validated Nuclear speckles
Cytoplasmic bodies Renal cancer:1.71e-5 (favourable) Expressed in all Expressed in all spleen: 288.8 PCM1 PTC4 ENSG00000078674 Pericentriolar material 1 8 17922840-18029944 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA023370, HPA023374, CAB058695 Supported Validated Nuclear membrane
Centrosome
Cytosol Expressed in all Expressed in all testis: 275.8 PCNA ENSG00000132646 Proliferating cell nuclear antigen 20 5114953-5126626 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000148, HPA030521, HPA030522, HPA030523 Supported Supported Nucleoplasm
Nuclear bodies Renal cancer:3.03e-6 (unfavourable), Cervical cancer:1.86e-5 (favourable), Liver cancer:2.61e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 223.6 PCSK7 LPC, PC7, PC8, SPC7 ENSG00000160613 Proprotein convertase subtilisin/kexin type 7 11 117204337-117232525 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043181, HPA052957 Uncertain Nucleus
Nuclear membrane
Nucleoli Expressed in all Expressed in all smooth muscle: 305.0 PDAP1 HASPP28, PAP, PAP1 ENSG00000106244 PDGFA associated protein 1 7 99392048-99408829 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB021103, HPA050294, HPA060836 Approved Validated Plasma membrane
Cytosol Liver cancer:6.67e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 37.3 PDCD1LG2 B7-DC, bA574F11.2, Btdc, CD273, PD-L2, PDL2 ENSG00000197646 Programmed cell death 1 ligand 2 9 5510570-5571254 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level HPA013411 Approved Approved Cytosol Renal cancer:1.15e-4 (unfavourable) Mixed Tissue enhanced spleen: 21.8 lymph node: 12.2 PDCD2L MGC13096 ENSG00000126249 Programmed cell death 2-like 19 34404384-34426168 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA052181 Approved Uncertain Mitochondria Renal cancer:1.23e-5 (unfavourable), Liver cancer:5.81e-4 (unfavourable) Expressed in all Mixed testis: 17.6 PDE4DIP CMYA2, KIAA0454, KIAA0477, MMGL ENSG00000178104 Phosphodiesterase 4D interacting protein 1 148808181-149048286 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA008162, HPA012678 Uncertain Supported Golgi apparatus Expressed in all Expressed in all skeletal muscle: 769.6 PDGFA PDGF-A, PDGF1 ENSG00000197461 Platelet-derived growth factor alpha polypeptide 7 497258-520296 Cancer-related genes, Candidate cardiovascular disease genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB005579 Uncertain Approved Vesicles
Microtubule organizing center Glioma:1.51e-4 (unfavourable), Head and neck cancer:1.78e-4 (unfavourable), Urothelial cancer:8.67e-4 (unfavourable) Expressed in all Expressed in all placenta: 39.1 PDGFB SIS, SSV ENSG00000100311 Platelet-derived growth factor beta polypeptide 22 39223359-39244751 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB011604, HPA011972, CAB018341 Supported Approved Vesicles Lung cancer:3.67e-5 (unfavourable) Expressed in all Tissue enhanced placenta: 59.5 lung: 28.7 PDGFRA CD140a, GAS9, PDGFR2 ENSG00000134853 Platelet-derived growth factor receptor, alpha polypeptide 4 54229097-54298247 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA004947, CAB018143 Supported Supported Nucleus
Plasma membrane
Cell Junctions Renal cancer:9.79e-6 (unfavourable), Head and neck cancer:9.33e-4 (favourable) Expressed in all Expressed in all ovary: 222.0 PDGFRB CD140b, JTK12, PDGFR, PDGFR1 ENSG00000113721 Platelet-derived growth factor receptor, beta polypeptide 5 150113837-150155872 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB003842, CAB018144, HPA028499 Approved Approved Vesicles
Cytosol Renal cancer:5.87e-8 (unfavourable), Urothelial cancer:8.11e-4 (unfavourable) Expressed in all Mixed gallbladder: 194.6 PDSS2 bA59I9.3, C6orf210 ENSG00000164494 Prenyl (decaprenyl) diphosphate synthase, subunit 2 6 107152557-107459564 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA029685, HPA029686 Approved Validated Cytosol Renal cancer:3.75e-7 (favourable), Breast cancer:1.34e-5 (unfavourable), Colorectal cancer:5.74e-5 (favourable) Expressed in all Expressed in all prostate: 23.6 PDZD4 FLJ34125, KIAA1444, LU1, PDZK4, PDZRN4L ENSG00000067840 PDZ domain containing 4 X 153802166-153830565 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA003878 Approved Pancreatic cancer:2.96e-5 (favourable) Tissue enhanced Tissue enriched 9 cerebral cortex: 123.9 seminal vesicle: 13.6 PER1 PER, RIGUI ENSG00000179094 Period circadian clock 1 17 8140472-8156506 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA047947, HPA067064 Supported Nucleoplasm
Cytosol Stomach cancer:1.94e-4 (unfavourable), Liver cancer:2.56e-4 (favourable), Cervical cancer:3.89e-4 (favourable) Expressed in all Expressed in all thyroid gland: 70.1 PF4 CXCL4, SCYB4 ENSG00000163737 Platelet factor 4 4 73981077-73982124 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB026008, HPA052485 Supported Tissue enhanced Group enriched 5 bone marrow: 53.9;spleen: 13.7 placenta: 6.4 PGC ENSG00000096088 Progastricsin (pepsinogen C) 6 41736711-41754109 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA031717, HPA031718 Supported Supported Nucleus Tissue enhanced Tissue enriched 16 stomach: 22057.0 duodenum: 1339.7 PGF D12S1900, PGFL, PLGF, PlGF-2, SHGC-10760 ENSG00000119630 Placental growth factor 14 74941834-74955784 Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA041624 Approved Nucleoplasm
Mitochondria
Cytosol Renal cancer:1.33e-6 (unfavourable), Liver cancer:1.40e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 70.9;thyroid gland: 64.4 cervix, uterine: 29.9 PGR NR3C3, PR ENSG00000082175 Progesterone receptor 11 101029624-101130524 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000068, HPA004751, HPA008428, HPA017176, CAB055100 Supported Endometrial cancer:5.76e-8 (favourable) Group enriched Group enriched 6 cervix, uterine: 95.8;endometrium: 171.3;fallopian tube: 52.8;smooth muscle: 113.5 ovary: 19.4 PHF20 C20orf104, dJ1121G12.1, TDRD20A ENSG00000025293 PHD finger protein 20 20 35771974-35950381 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA029619, HPA029620, HPA029621 Approved Supported Nucleoplasm
Nuclear membrane
Cytosol Liver cancer:2.49e-4 (unfavourable) Expressed in all Expressed in all testis: 26.0 PHF6 BFLS, BORJ, CENP-31, KIAA1823, MGC14797 ENSG00000156531 PHD finger protein 6 X 134373253-134428791 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA001023 Supported Validated Nucleus
Nucleoli Liver cancer:3.38e-4 (unfavourable), Pancreatic cancer:9.96e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 41.2 PHLDA1 DT1P1B11, PHRIP, TDAG51 ENSG00000139289 Pleckstrin homology-like domain, family A, member 1 12 76025447-76033932 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB016160, HPA019000, HPA063520 Approved Supported Nucleoli Expressed in all Mixed salivary gland: 69.1 PHOX2B NBPhox, Phox2b, PMX2B ENSG00000109132 Paired-like homeobox 2b 4 41744082-41748970 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA074325 Supported Nucleoplasm Not detected Tissue enriched 8 adrenal gland: 10.4 small intestine: 1.2 PICALM CALM, CLTH ENSG00000073921 Phosphatidylinositol binding clathrin assembly protein 11 85957684-86069882 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA019053, HPA019061 Supported Supported Vesicles Renal cancer:2.02e-6 (favourable), Pancreatic cancer:6.61e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 291.7 PIGR ENSG00000162896 Polymeric immunoglobulin receptor 1 206928518-206946466 Cancer-related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA006154, CAB009454, HPA012012 Supported Uncertain Nucleus
Nucleoli
Cytosol Breast cancer:1.22e-5 (favourable), Renal cancer:5.08e-5 (favourable), Endometrial cancer:2.57e-4 (favourable) Tissue enhanced Tissue enhanced colon: 1721.7;duodenum: 2732.8 rectum: 1357.3 PIK3CA PI3K ENSG00000121879 Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha 3 179148114-179240093 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA009985, CAB017804 Approved Approved Cytosol Expressed in all Mixed parathyroid gland: 23.9 PIK3CB PIK3C1 ENSG00000051382 Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta 3 138652699-138834938 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB031938, HPA064207 Approved Supported Nucleoplasm
Nucleoli
Midbody Pancreatic cancer:3.99e-5 (unfavourable), Liver cancer:6.42e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 88.7 PIK3CG ENSG00000105851 Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma 7 106865278-106907145 Cancer-related genes, Enzymes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA069976 Supported Plasma membrane Mixed Tissue enhanced bone marrow: 28.2 lymph node: 22.2 PIK3R1 GRB1, p85, p85-ALPHA ENSG00000145675 Phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 5 68215720-68301821 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA001216, CAB004268 Approved Approved Cytosol Liver cancer:8.09e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 133.3 PIK3R2 p85, P85B ENSG00000105647 Phosphoinositide-3-kinase, regulatory subunit 2 (beta) 19 18153118-18170540 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA069291 Approved Approved Golgi apparatus Mixed Expressed in all cerebral cortex: 47.4 PIK3R3 p55 ENSG00000117461 Phosphoinositide-3-kinase, regulatory subunit 3 (gamma) 1 46040140-46133036 Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA005751, HPA071988 Approved Approved Nucleoplasm
Vesicles Endometrial cancer:1.93e-4 (favourable), Head and neck cancer:3.62e-4 (favourable) Expressed in all Mixed testis: 46.2 PIM1 PIM ENSG00000137193 Pim-1 proto-oncogene, serine/threonine kinase 6 37170203-37175426 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA003941, CAB017040 Uncertain Supported Nucleoli
Cytosol Endometrial cancer:9.73e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 134.1 PIM2 ENSG00000102096 Pim-2 proto-oncogene, serine/threonine kinase X 48913182-48919024 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000285 Approved Approved Cytosol Renal cancer:1.17e-11 (unfavourable), Cervical cancer:4.05e-5 (favourable) Tissue enriched Mixed lymph node: 130.6 PIM3 ENSG00000198355 Pim-3 proto-oncogene, serine/threonine kinase 22 49960513-49964080 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA068758 Supported Cytosol Renal cancer:8.09e-4 (favourable), Ovarian cancer:9.68e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 61.3 PIN1 dod ENSG00000127445 Peptidylprolyl cis/trans isomerase, NIMA-interacting 1 19 9835257-9849682 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB004528, CAB009326, HPA068650 Approved Validated Nucleoplasm
Cytosol Renal cancer:7.80e-5 (favourable), Pancreatic cancer:3.25e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 137.3 PIP4K2B PIP5K2B, PIP5KIIB, PIP5KIIbeta ENSG00000276293 Phosphatidylinositol-5-phosphate 4-kinase, type II, beta 17 38765689-38800126 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA047875, HPA062220 Approved Supported Nucleoplasm Thyroid cancer:1.36e-4 (favourable), Liver cancer:4.54e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 51.8 PIP5K1A ENSG00000143398 Phosphatidylinositol-4-phosphate 5-kinase, type I, alpha 1 151197949-151249536 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA029366 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Renal cancer:4.16e-7 (unfavourable) Expressed in all Expressed in all testis: 69.4 PKM OIP3, PK3, PKM2, THBP1 ENSG00000067225 Pyruvate kinase, muscle 15 72199029-72231822 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB019421, HPA029501 Uncertain Validated Cytosol Liver cancer:2.74e-6 (unfavourable), Pancreatic cancer:5.17e-5 (unfavourable), Head and neck cancer:1.30e-4 (unfavourable), Lung cancer:2.85e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 1492.7 PLAG1 ZNF912 ENSG00000181690 Pleiomorphic adenoma gene 1 8 56160904-56211324 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA072290 Approved Nuclear speckles Mixed Mixed ovary: 5.9 PLAT ENSG00000104368 Plasminogen activator, tissue 8 42175233-42207724 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA003412, CAB009335 Supported Approved Actin filaments Renal cancer:4.95e-4 (unfavourable), Breast cancer:7.57e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 695.5 urinary bladder: 141.1 PLAU UPA, URK ENSG00000122861 Plasminogen activator, urokinase 10 73909177-73917497 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA008719 Approved Approved Plasma membrane
Cytosol Pancreatic cancer:1.32e-4 (unfavourable), Head and neck cancer:2.70e-4 (unfavourable), Endometrial cancer:3.38e-4 (favourable), Renal cancer:3.51e-4 (unfavourable), Lung cancer:4.04e-4 (unfavourable) Expressed in all Expressed in all appendix: 61.3 PLAUR CD87, UPAR, URKR ENSG00000011422 Plasminogen activator, urokinase receptor 19 43646095-43670547 Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA050843, CAB073533 Uncertain Supported Plasma membrane Renal cancer:7.83e-9 (unfavourable), Lung cancer:2.33e-5 (unfavourable) Expressed in all Expressed in all bone marrow: 429.4 PLCG1 NCKAP3, PLC-II, PLC1, PLC148, PLCgamma1 ENSG00000124181 Phospholipase C, gamma 1 20 41136960-41196801 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB004277, HPA036681, HPA036682 Approved Supported Cytosol Pancreatic cancer:4.72e-4 (favourable) Expressed in all Expressed in all endometrium: 47.4 PLCG2 ENSG00000197943 Phospholipase C, gamma 2 (phosphatidylinositol-specific) 16 81739097-81962693 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB004280, HPA020099, HPA020100 Supported Approved Vesicles Renal cancer:4.88e-4 (favourable), Head and neck cancer:6.71e-4 (favourable) Expressed in all Tissue enhanced lymph node: 79.9 tonsil: 68.3 PLEC EBS1, PCN, PLEC1, PLTN ENSG00000178209 Plectin 8 143915147-143976734 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB003847, HPA025967, HPA029906 Supported Validated Intermediate filaments
Focal adhesion sites
Cytosol Renal cancer:7.98e-6 (unfavourable), Colorectal cancer:4.29e-4 (unfavourable), Lung cancer:5.33e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 94.9 PLG ENSG00000122194 Plasminogen 6 160702238-160753315 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000668, CAB016678, HPA021602, HPA048823, HPA053770 Supported Uncertain Vesicles Renal cancer:4.22e-4 (favourable) Tissue enriched Tissue enriched 6 liver: 1748.3 kidney: 310.9 PLK1 PLK ENSG00000166851 Polo-like kinase 1 16 23677656-23690367 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA051638, HPA053229 Approved Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.70e-7 (unfavourable), Lung cancer:2.28e-5 (unfavourable), Pancreatic cancer:4.12e-4 (unfavourable) Expressed in all Tissue enhanced testis: 44.0 lymph node: 33.2 PLP1 GPM6C, PLP, SPG2 ENSG00000123560 Proteolipid protein 1 X 103773718-103792619 Cancer-related genes, Disease related genes, Predicted membrane proteins, Transporters Evidence at protein level HPA004128 Supported Group enriched Tissue enriched 30 cerebral cortex: 3225.1 parathyroid gland: 106.1 PMEPA1 STAG1, TMEPAI ENSG00000124225 Prostate transmembrane protein, androgen induced 1 20 57648392-57711536 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA072291 Supported Vesicles Renal cancer:2.87e-7 (unfavourable), Lung cancer:4.73e-5 (unfavourable), Cervical cancer:2.45e-4 (unfavourable), Urothelial cancer:7.60e-4 (unfavourable) Expressed in all Tissue enhanced cervix, uterine: 145.4;prostate: 181.8 endometrium: 60.1 PML MYL, RNF71, TRIM19 ENSG00000140464 Promyelocytic leukemia 15 73994673-74047812 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA008312, CAB010194, CAB016304 Supported Validated Nuclear bodies Renal cancer:6.27e-8 (unfavourable), Breast cancer:3.24e-4 (favourable), Pancreatic cancer:3.29e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 45.0 PMP22 GAS3, HNPP, Sp110 ENSG00000109099 Peripheral myelin protein 22 17 15229777-15265326 Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Renal cancer:1.73e-4 (unfavourable) Expressed in all Expressed in all placenta,small intestine: 314.4 PMS1 MLH2, PMSL1 ENSG00000064933 PMS1 homolog 1, mismatch repair system component 2 189784085-189877629 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB010233, HPA031013 Approved Supported Nucleoplasm
Nuclear bodies Renal cancer:1.86e-6 (unfavourable), Liver cancer:2.38e-6 (unfavourable), Urothelial cancer:3.73e-4 (favourable) Expressed in all Expressed in all testis: 84.8 PMS2 HNPCC4, H_DJ0042M02.9, MLH4, PMSL2 ENSG00000122512 PMS1 homolog 2, mismatch repair system component 7 5973239-6009125 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB010235, HPA044400, HPA066490, HPA070310 Approved Validated Nucleoplasm
Cytosol Renal cancer:1.23e-5 (favourable) Expressed in all Mixed cerebral cortex: 20.0 PNMT PENT ENSG00000141744 Phenylethanolamine N-methyltransferase 17 39667981-39670475 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017029, HPA043412, HPA051005 Supported Uncertain Vesicles Endometrial cancer:3.95e-5 (unfavourable) Tissue enhanced Tissue enriched 8 adrenal gland: 227.7 seminal vesicle: 28.8 POLE POLE1 ENSG00000177084 Polymerase (DNA directed), epsilon, catalytic subunit 12 132623753-132687365 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA058210, HPA067385 Validated Nucleus
Plasma membrane Renal cancer:3.19e-8 (unfavourable), Melanoma:1.44e-4 (unfavourable) Expressed in all Expressed in all testis: 22.0 POMC ACTH, CLIP, LPH, MSH, NPP, POC ENSG00000115138 Proopiomelanocortin 2 25160853-25168903 Cancer-related genes, Disease related genes, Predicted secreted proteins Evidence at protein level CAB002762, HPA046135, HPA063644 Supported Pancreatic cancer:5.70e-4 (favourable) Tissue enriched Tissue enhanced testis: 6.8 pancreas: 5.2 PON1 ESA, PON ENSG00000005421 Paraoxonase 1 7 95297676-95324707 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters Evidence at protein level HPA001610 Uncertain Liver cancer:7.24e-7 (favourable) Tissue enriched Tissue enriched 69 liver: 234.0 adrenal gland: 3.3 POSTN OSF-2, periostin, PN ENSG00000133110 Periostin, osteoblast specific factor 13 37562583-37598844 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA012306 Supported Approved Nucleoplasm
Golgi apparatus Renal cancer:1.83e-7 (unfavourable), Lung cancer:2.93e-4 (unfavourable), Stomach cancer:4.86e-4 (unfavourable) Expressed in all Mixed skin: 247.0 POT1 DKFZp586D211, hPot1 ENSG00000128513 Protection of telomeres 1 7 124822386-124929983 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA068538 Supported Nucleus Expressed in all Mixed thyroid gland: 21.5 POTEF A26C1B, POTE2alpha, POTEACTIN ENSG00000196604 POTE ankyrin domain family, member F 2 130073535-130129222 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA041264, HPA041271, HPA042822, HPA043260 Uncertain Not detected Tissue enriched 5 testis: 2.2 prostate: 0.4 POU2AF1 OBF1 ENSG00000110777 POU class 2 associating factor 1 11 111352252-111455630 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB011193 Approved Cervical cancer:1.63e-4 (favourable), Breast cancer:1.68e-4 (favourable), Head and neck cancer:3.59e-4 (favourable) Mixed Tissue enhanced lymph node: 103.0;tonsil: 97.6 appendix: 57.6 POU2F2 OCT2, OTF2 ENSG00000028277 POU class 2 homeobox 2 19 42086110-42196585 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002513, HPA040368, HPA062096, HPA064404 Supported Supported Nucleoplasm Renal cancer:7.57e-11 (unfavourable) Mixed Group enriched 6 appendix: 37.8;lymph node: 62.5;spleen: 37.2;tonsil: 45.5 urinary bladder: 8.1 POU5F1 MGC22487, OCT3, Oct4, OTF3 ENSG00000204531 POU class 5 homeobox 1 6 31164337-31180731 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB025600, CAB026380, HPA058267 Approved Supported Nucleoplasm
Cytosol Urothelial cancer:2.04e-5 (favourable) Tissue enriched Mixed small intestine: 5.8 PPA2 FLJ20459 ENSG00000138777 Pyrophosphatase (inorganic) 2 4 105369077-105474081 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA030888, HPA031671, HPA031672 Supported Approved Nucleus
Mitochondria Renal cancer:1.27e-11 (favourable), Breast cancer:2.98e-4 (unfavourable), Colorectal cancer:6.60e-4 (favourable) Expressed in all Expressed in all kidney: 21.6 PPARG NR1C3, PPARG1, PPARG2, PPARgamma ENSG00000132170 Peroxisome proliferator-activated receptor gamma 3 12287368-12434356 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB004282, HPA051239, HPA063663 Approved Validated Nucleus
Vesicles Renal cancer:1.59e-8 (favourable), Liver cancer:3.41e-5 (unfavourable), Urothelial cancer:5.52e-5 (favourable) Expressed in all Tissue enhanced adipose tissue: 172.8 placenta: 58.6 PPARGC1A PGC1, PGC1A, PPARGC1 ENSG00000109819 Peroxisome proliferator-activated receptor gamma, coactivator 1 alpha 4 23755041-23904089 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA063136 Supported Nucleoplasm Renal cancer:1.49e-14 (favourable), Liver cancer:3.35e-6 (favourable), Thyroid cancer:5.80e-4 (unfavourable) Tissue enhanced Mixed kidney: 28.9 PPFIBP1 hSGT2, hSgt2p, L2, SGT2 ENSG00000110841 PTPRF interacting protein, binding protein 1 (liprin beta 1) 12 27523431-27695564 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001924 Uncertain Approved Plasma membrane
Cytosol Renal cancer:5.11e-7 (favourable), Pancreatic cancer:2.56e-4 (unfavourable), Lung cancer:5.11e-4 (unfavourable), Endometrial cancer:6.29e-4 (unfavourable) Expressed in all Expressed in all ovary: 106.2 PPM1D PP2C-DELTA, Wip1 ENSG00000170836 Protein phosphatase, Mg2+/Mn2+ dependent, 1D 17 60600183-60666280 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA022277 Uncertain Approved Endoplasmic reticulum Colorectal cancer:3.52e-4 (favourable), Liver cancer:4.27e-4 (unfavourable) Expressed in all Mixed testis: 9.8 PPP1R15A GADD34 ENSG00000087074 Protein phosphatase 1, regulatory subunit 15A 19 48872392-48876057 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB018395, HPA020240 Approved Uncertain Vesicles Liver cancer:1.95e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 358.8 PPP2R1A PP2A-Aalpha, PR65A ENSG00000105568 Protein phosphatase 2, regulatory subunit A, alpha 19 52190039-52229533 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB018599 Approved Cytosol Renal cancer:1.20e-4 (favourable), Liver cancer:1.76e-4 (unfavourable), Lung cancer:2.50e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 205.2 PPP6C PP6 ENSG00000119414 Protein phosphatase 6, catalytic subunit 9 125146573-125189939 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA050940 Uncertain Renal cancer:4.50e-6 (favourable) Expressed in all Expressed in all thyroid gland: 52.4 PPY PNP ENSG00000108849 Pancreatic polypeptide 17 43940804-43942468 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB016735, HPA032122 Supported Tissue enriched Group enriched 7 epididymis: 7.6;pancreas: 35.3;parathyroid gland: 33.0;rectum: 8.4;skin: 8.3 colon: 2.6 PRCC RCCP1 ENSG00000143294 Papillary renal cell carcinoma (translocation-associated) 1 156750610-156800817 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017151, HPA019463, HPA019481 Supported Validated Nuclear speckles Renal cancer:8.99e-15 (unfavourable), Thyroid cancer:3.72e-4 (unfavourable), Endometrial cancer:5.55e-4 (unfavourable), Liver cancer:8.63e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 54.7 PRDM1 BLIMP1, PRDI-BF1 ENSG00000057657 PR domain containing 1, with ZNF domain 6 106086320-106109939 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA030033 Approved Approved Nucleus
Nucleoli Renal cancer:9.81e-5 (unfavourable) Expressed in all Tissue enhanced esophagus: 61.3 endometrium: 30.1 PRDM13 ENSG00000112238 PR domain containing 13 6 99606730-99615578 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA070592 Uncertain Not detected Not detected all non-specific tissues: 0.0 PRDM16 KIAA1675, MEL1, MGC166915, PFM13 ENSG00000142611 PR domain containing 16 1 3069168-3438621 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA050343, HPA060467 Validated Nucleoplasm Thyroid cancer:4.70e-5 (unfavourable) Mixed Mixed duodenum: 7.8 PRDX2 MGC4104, NKEFB, PRP, PRX2, PRXII, TDPX1, TSA ENSG00000167815 Peroxiredoxin 2 19 12796820-12801859 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB008713 Approved Renal cancer:5.66e-11 (favourable) Expressed in all Expressed in all adrenal gland: 471.1 PRDX4 AOE37-2 ENSG00000123131 Peroxiredoxin 4 X 23664262-23686399 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB008659, CAB027389, CAB047362 Supported Supported Endoplasmic reticulum
Cytosol Renal cancer:1.33e-6 (unfavourable) Expressed in all Expressed in all pancreas: 239.4 PRF1 HPLH2, P1, PFP ENSG00000180644 Perforin 1 (pore forming protein) 10 70597348-70602775 Cancer-related genes, Disease related genes, Predicted secreted proteins Evidence at protein level CAB002436, HPA037940 Approved Approved Cytosol Renal cancer:1.08e-5 (unfavourable), Endometrial cancer:2.09e-4 (favourable), Head and neck cancer:3.54e-4 (favourable) Expressed in all Tissue enhanced spleen: 54.5 lymph node: 21.2 PRKAR1A CNC1, PRKAR1, TSE1 ENSG00000108946 Protein kinase, cAMP-dependent, regulatory, type I, alpha 17 68511780-68551319 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB019378, HPA049979 Approved Approved Cytosol Expressed in all Expressed in all parathyroid gland: 555.0 PRKCA PKCA ENSG00000154229 Protein kinase C, alpha 17 66302636-66810743 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB003844, HPA006563, HPA006564, CAB016290 Approved Validated Plasma membrane
Cytosol Expressed in all Mixed cerebral cortex: 45.1 PRKCB PKCB, PRKCB1, PRKCB2 ENSG00000166501 Protein kinase C, beta 16 23836001-24220611 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB003843, HPA048321, HPA054203 Approved Supported Nucleoplasm
Cytosol Mixed Tissue enhanced cerebral cortex: 125.8 spleen: 65.5 PRKCD ENSG00000163932 Protein kinase C, delta 3 53156009-53192717 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA001863, HPA001890, CAB010469, CAB013225 Supported Validated Endoplasmic reticulum
Golgi apparatus
Cytosol Liver cancer:2.24e-4 (unfavourable), Lung cancer:9.01e-4 (favourable) Expressed in all Mixed adrenal gland: 70.7 PRKCE ENSG00000171132 Protein kinase C, epsilon 2 45651345-46187990 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB001948, HPA044496, HPA054252 Supported Approved Vesicles Renal cancer:2.63e-7 (favourable), Endometrial cancer:2.42e-4 (unfavourable), Lung cancer:9.62e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 48.5 parathyroid gland: 20.3 PRKCH PKC-L, PKCL, PRKCL ENSG00000027075 Protein kinase C, eta 14 61187559-61550976 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA026294, HPA053709 Approved Approved Plasma membrane
Cytosol Head and neck cancer:8.55e-6 (favourable) Expressed in all Expressed in all lymph node: 62.3 PRKCI DXS1179E, PKCI ENSG00000163558 Protein kinase C, iota 3 170222365-170305981 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA026574, HPA038635 Approved Validated Microtubules
Cytokinetic bridge
Cytosol Endometrial cancer:3.93e-6 (unfavourable), Pancreatic cancer:1.22e-4 (unfavourable), Liver cancer:3.02e-4 (unfavourable), Renal cancer:3.10e-4 (favourable) Expressed in all Expressed in all thyroid gland: 39.6 PRKCQ ENSG00000065675 Protein kinase C, theta 10 6427143-6580301 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA065279, HPA073098 Supported Microtubule organizing center Thyroid cancer:5.27e-4 (unfavourable) Mixed Tissue enhanced skeletal muscle: 43.0 thyroid gland: 24.8 PRKDC DNA-PKcs, DNAPK, DNPK1, HYRC, HYRC1, p350, XRCC7 ENSG00000253729 Protein kinase, DNA-activated, catalytic polypeptide 8 47773108-47960183 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB005167, HPA035174 Supported Validated Nucleoplasm Endometrial cancer:1.03e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 30.0 PRL ENSG00000172179 Prolactin 6 22287244-22297501 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB023353, HPA042416, HPA062017 Supported Uncertain Cytosol Not detected Group enriched 8 endometrium: 10.7;placenta: 27.1 testis: 2.2 PROC ENSG00000115718 Protein C (inactivator of coagulation factors Va and VIIIa) 2 127418427-127429246 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA005550, CAB016721, CAB016792 Supported Tissue enriched Tissue enriched 12 liver: 139.9 kidney: 12.0 PRPF8 hPrp8, Prp8, PRPC8, RP13, SNRNP220 ENSG00000174231 Pre-mRNA processing factor 8 17 1650629-1684882 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009941, CAB015457 Supported Validated Nucleoplasm Expressed in all Expressed in all parathyroid gland: 92.7 PRRX1 PHOX1, PMX1 ENSG00000116132 Paired related homeobox 1 1 170662728-170739419 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA051084 Uncertain Supported Nucleus
Nucleoli Renal cancer:6.60e-10 (unfavourable) Mixed Mixed cervix, uterine: 135.2 PRSS1 TRY1 ENSG00000204983 Protease, serine, 1 (trypsin 1) 7 142749468-142763997 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB025487, CAB025538, HPA062452, HPA063471 Supported Endometrial cancer:6.41e-6 (unfavourable), Thyroid cancer:4.91e-4 (favourable), Ovarian cancer:7.05e-4 (favourable) Tissue enriched Tissue enriched 316 pancreas: 81582.7 ovary: 257.8 PSCA ENSG00000167653 Prostate stem cell antigen 8 142670308-142682724 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030783, HPA056418 Approved Supported Plasma membrane Pancreatic cancer:5.60e-5 (unfavourable) Tissue enriched Tissue enhanced stomach: 1662.7;urinary bladder: 357.0 prostate: 312.0 PSEN1 AD3, FAD, PS1, S182 ENSG00000080815 Presenilin 1 14 73136418-73223691 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB006844, HPA030760, HPA067496 Approved Approved Nucleus
Golgi apparatus
Cell Junctions Renal cancer:1.52e-8 (favourable), Liver cancer:1.99e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 66.1 PSIP1 LEDGF, p52, p75, PSIP2 ENSG00000164985 PC4 and SFRS1 interacting protein 1 9 15464066-15511019 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013718, HPA019697 Supported Validated Nucleoplasm Expressed in all Expressed in all cerebral cortex: 161.8 PSMD4 AF, AF-1, Rpn10, S5A ENSG00000159352 Proteasome 26S subunit, non-ATPase 4 1 151254703-151267479 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA038807, HPA039252, CAB047300 Supported Validated Nucleoplasm
Cytosol Renal cancer:6.66e-10 (unfavourable) Expressed in all Expressed in all testis: 173.5 PTCH1 BCNS, NBCCS, PTCH ENSG00000185920 Patched 1 9 95442980-95517057 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB013717, HPA075072 Uncertain Approved Golgi apparatus Mixed Tissue enhanced cervix, uterine: 41.6 endometrium: 27.2 PTCH2 ENSG00000117425 Patched 2 1 44819844-44843063 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level Pancreatic cancer:5.74e-5 (favourable) Tissue enhanced Tissue enriched 6 parathyroid gland: 200.3 salivary gland: 32.3 PTEN BZS, MHAM, MMAC1, PTEN1, TEP1 ENSG00000171862 Phosphatase and tensin homolog 10 87863113-87971930 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB004076, HPA031335 Uncertain Supported Nucleoplasm
Cytosol Renal cancer:7.35e-4 (unfavourable) Expressed in all Mixed testis: 59.0 PTGS1 COX1, PGHS-1, PTGHS ENSG00000095303 Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) 9 122370530-122395703 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA002834, CAB020315 Supported Supported Golgi apparatus
Vesicles Renal cancer:8.68e-4 (unfavourable), Urothelial cancer:9.35e-4 (unfavourable) Expressed in all Tissue enhanced skin: 161.9 esophagus: 85.8 PTGS2 COX2 ENSG00000073756 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 1 186671791-186680427 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level CAB000113, HPA001335 Approved Supported Endoplasmic reticulum Renal cancer:9.79e-4 (unfavourable) Mixed Tissue enhanced seminal vesicle: 178.8 cervix, uterine: 98.8 PTH PTH1 ENSG00000152266 Parathyroid hormone 11 13492055-13496181 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000072, CAB023409, CAB026363, HPA048540 Supported Not detected Tissue enriched 24434 parathyroid gland: 58263.3 heart muscle: 2.3 PTHLH HHM, PLP, PTHR, PTHRP ENSG00000087494 Parathyroid hormone-like hormone 12 27958084-27972705 Cancer-related genes, Disease related genes, Predicted secreted proteins Evidence at protein level HPA035982 Approved Approved Supported Nucleoplasm
Golgi apparatus
Cytosol Renal cancer:1.82e-9 (unfavourable), Liver cancer:3.37e-4 (unfavourable) Tissue enhanced Tissue enhanced breast: 23.9 esophagus: 18.1 PTK2 FADK, FAK, FAK1, PPP1R71 ENSG00000169398 Protein tyrosine kinase 2 8 140657900-141002216 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA001842, CAB004036, HPA029671 Approved Supported Vesicles
Focal adhesion sites
Cytosol Breast cancer:3.21e-4 (unfavourable), Endometrial cancer:9.11e-4 (unfavourable) Expressed in all Expressed in all placenta: 106.5 PTN HBGF8, HBNF, NEGF1 ENSG00000105894 Pleiotrophin 7 137227341-137343865 Cancer-related genes, Predicted secreted proteins Evidence at protein level CAB017685 Uncertain Renal cancer:1.35e-4 (favourable) Tissue enriched Tissue enhanced parathyroid gland: 713.3 cerebral cortex: 270.4 PTPN11 BPTP3, NS1, PTP2C, SH-PTP2, SHP-2, SHP2 ENSG00000179295 Protein tyrosine phosphatase, non-receptor type 11 12 112418351-112509913 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB005377 Approved Supported Nucleus
Nucleoli
Actin filaments
Cytosol Expressed in all Expressed in all cerebral cortex: 124.6 PTPRB PTPB ENSG00000127329 Protein tyrosine phosphatase, receptor type, B 12 70515866-70637440 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB004782, HPA067868 Uncertain Approved Vesicles
Plasma membrane
Cell Junctions Renal cancer:1.02e-4 (favourable), Liver cancer:6.05e-4 (favourable) Expressed in all Mixed lung: 54.1 PTPRC CD45, GP180, LCA, T200 ENSG00000081237 Protein tyrosine phosphatase, receptor type, C 1 198638671-198757283 Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000052, HPA000440, CAB002800, CAB056154, CAB068221 Supported Renal cancer:2.42e-4 (unfavourable) Expressed in all Expressed in all lymph node: 378.0 PTPRK R-PTP-kappa ENSG00000152894 Protein tyrosine phosphatase, receptor type, K 6 127968779-128520674 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054056, HPA054822 Uncertain Supported Vesicles
Plasma membrane
Cell Junctions Renal cancer:9.33e-5 (favourable), Pancreatic cancer:1.99e-4 (unfavourable) Expressed in all Mixed gallbladder: 27.9 PTPRO GLEPP1, NPHS6, PTP-oc, PTP-U2, PTPU2 ENSG00000151490 Protein tyrosine phosphatase, receptor type, O 12 15322397-15597399 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA034525 Supported Tissue enhanced Tissue enhanced rectum: 33.5 cerebral cortex: 21.8 PTTG1 EAP1, HPTTG, PTTG, securin, TUTR1 ENSG00000164611 Pituitary tumor-transforming 1 5 160421822-160428744 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB008373, HPA008890, HPA045034 Supported Supported Nucleoli
Cytosol Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.62e-6 (unfavourable) Expressed in all Tissue enhanced testis: 284.3 tonsil: 125.0 PURA PUR-ALPHA, PUR1, PURALPHA ENSG00000185129 Purine-rich element binding protein A 5 140107777-140125619 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level Renal cancer:4.77e-5 (favourable) Expressed in all Mixed parathyroid gland: 26.4 PWWP2A KIAA1935 ENSG00000170234 PWWP domain containing 2A 5 160061801-160119423 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA046733, HPA058233 Uncertain Supported Nucleoplasm
Focal adhesion sites Urothelial cancer:3.51e-4 (favourable), Renal cancer:3.70e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 15.4 PZP CPAMD6 ENSG00000126838 Pregnancy-zone protein 12 9148840-9208370 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA041403, HPA041471 Supported Tissue enhanced Tissue enriched 12 liver: 46.1 testis: 3.8 QKI QK3 ENSG00000112531 QKI, KH domain containing, RNA binding 6 163414000-163578596 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA019123, CAB022602 Supported Supported Supported Nucleoplasm Renal cancer:2.31e-5 (unfavourable), Liver cancer:1.27e-4 (unfavourable), Stomach cancer:3.69e-4 (unfavourable) Tissue enriched Expressed in all cerebral cortex: 360.6 RAB11FIP3 eferin, KIAA0665, Rab11-FIP3 ENSG00000090565 RAB11 family interacting protein 3 (class II) 16 425619-523011 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA028088, HPA028631, HPA030086 Approved Supported Vesicles
Cytokinetic bridge
Microtubule organizing center Pancreatic cancer:3.16e-5 (favourable), Liver cancer:9.87e-5 (unfavourable), Endometrial cancer:1.22e-4 (favourable), Renal cancer:7.99e-4 (favourable) Expressed in all Expressed in all kidney: 56.8 RAB18 ENSG00000099246 RAB18, member RAS oncogene family 10 27504174-27542237 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA025928 Uncertain Expressed in all Expressed in all cerebral cortex: 88.2 RAB25 CATX-8 ENSG00000132698 RAB25, member RAS oncogene family 1 156061160-156070514 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA010872, CAB033645 Approved Uncertain Cell Junctions
Cytosol Renal cancer:1.38e-6 (favourable) Mixed Tissue enhanced esophagus: 298.6 skin: 169.3 RAB40A Rar-2, RAR2A ENSG00000172476 RAB40A, member RAS oncogene family X 103499750-103519489 Cancer-related genes, Predicted intracellular proteins Evidence at transcript level Mixed Tissue enhanced epididymis: 9.2 esophagus: 7.6 RABEP1 neurocrescin, RAB5EP, rabaptin-5, RABPT5 ENSG00000029725 Rabaptin, RAB GTPase binding effector protein 1 17 5282265-5385812 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB004549, HPA019669, HPA024235, HPA024691 Supported Validated Vesicles Pancreatic cancer:6.43e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 89.9 RAC1 p21-Rac1, Rac-1, TC-25 ENSG00000136238 Ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) 7 6374523-6403977 Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB035994, HPA047820 Approved Approved Nucleus
Nucleoli
Cytosol Liver cancer:1.74e-5 (unfavourable), Pancreatic cancer:4.57e-5 (unfavourable), Renal cancer:2.11e-4 (unfavourable), Lung cancer:4.59e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 282.4 RAD21 hHR21, KIAA0078, SCC1 ENSG00000164754 RAD21 cohesin complex component 8 116845935-116874866 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA020044, CAB022065 Supported Validated Nucleoplasm Liver cancer:1.71e-4 (unfavourable) Expressed in all Expressed in all testis: 161.7 RAD23A HHR23A, MGC111083 ENSG00000179262 RAD23 homolog A, nucleotide excision repair protein 19 12945855-12953642 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA053901, HPA057003, HPA065599 Supported Supported Nucleoplasm
Cytosol Expressed in all Expressed in all skeletal muscle: 334.2 RAD23B HHR23B, HR23B, P58 ENSG00000119318 RAD23 homolog B, nucleotide excision repair protein 9 107283137-107332194 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA029718, HPA029720, CAB033868 Supported Supported Nucleoplasm
Cytosol Head and neck cancer:2.58e-4 (unfavourable), Lung cancer:6.71e-4 (unfavourable) Expressed in all Expressed in all placenta: 110.0 RAD51 BRCC5, FANCR, HsRad51, HsT16930, RAD51A, RECA ENSG00000051180 RAD51 recombinase 15 40694774-40732339 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB010381, HPA039310 Approved Validated Nucleoli
Mitochondria
Cytosol Breast cancer:7.94e-4 (unfavourable), Liver cancer:9.33e-4 (unfavourable) Expressed in all Tissue enhanced testis: 45.1 lymph node,tonsil: 13.2 RAD51B hREC2, R51H2, RAD51L1, REC2 ENSG00000182185 RAD51 paralog B 14 67819779-68730218 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB016191, HPA051869 Supported Approved Nucleoplasm
Nuclear bodies Mixed Mixed epididymis: 11.3 RAD51D HsTRAD, R51H3, RAD51L3, Trad ENSG00000185379 RAD51 paralog D 17 35092208-35121522 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level Renal cancer:7.20e-9 (unfavourable), Pancreatic cancer:3.35e-6 (favourable), Endometrial cancer:5.37e-5 (favourable) Expressed in all Mixed cerebral cortex: 9.6 RAD52 ENSG00000002016 RAD52 homolog, DNA repair protein 12 912077-990053 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA028957 Approved Nuclear speckles
Plasma membrane Renal cancer:2.22e-6 (unfavourable) Expressed in all Expressed in all thyroid gland: 13.5 RAD54B RDH54 ENSG00000197275 RAD54 homolog B (S. cerevisiae) 8 94371960-94475109 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA007087 Uncertain Mixed Mixed fallopian tube: 10.6 RAF1 c-Raf, CRAF, Raf-1 ENSG00000132155 Raf-1 proto-oncogene, serine/threonine kinase 3 12583601-12664226 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA002640, CAB019291 Approved Approved Nuclear speckles Expressed in all Expressed in all parathyroid gland: 100.1 RALGDS RalGEF, RGDS, RGF ENSG00000160271 Ral guanine nucleotide dissociation stimulator 9 133097720-133149334 Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA025961, CAB032582 Approved Approved Nucleus Cervical cancer:4.19e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 53.0 RANBP17 ENSG00000204764 RAN binding protein 17 5 170861870-171300015 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA029568, HPA029569 Uncertain Approved Nuclear membrane
Nuclear bodies
Cytosol Mixed Tissue enhanced testis: 5.0 thyroid gland: 1.7 RANBP2 ADANE, ANE1, NUP358 ENSG00000153201 RAN binding protein 2 2 108719481-108785811 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA018437, HPA023960, CAB034063, HPA049497, HPA051675, HPA067564 Supported Validated Nuclear membrane
Vesicles Expressed in all Expressed in all parathyroid gland: 73.6 RANBP3 ENSG00000031823 RAN binding protein 3 19 5916139-5978142 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA043375, HPA043389 Supported Validated Nucleoplasm Endometrial cancer:1.22e-5 (favourable), Pancreatic cancer:4.14e-4 (favourable), Thyroid cancer:8.14e-4 (favourable) Expressed in all Expressed in all testis: 60.1 RAP1GDS1 SmgGDS ENSG00000138698 RAP1, GTP-GDP dissociation stimulator 1 4 98261384-98443861 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA019060 Approved Supported Cytosol Renal cancer:2.00e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 94.1 RARA NR1B1, RAR ENSG00000131759 Retinoic acid receptor, alpha 17 40309192-40357643 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA058282 Supported Nucleus
Cytosol Endometrial cancer:2.60e-4 (favourable) Expressed in all Expressed in all gallbladder: 68.9 RARB HAP, NR1B2, RRB2 ENSG00000077092 Retinoic acid receptor, beta 3 25174332-25597932 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002617, HPA004174 Supported Validated Nucleoplasm Renal cancer:3.43e-5 (favourable) Expressed in all Mixed placenta: 20.5 RARG NR1B3, RARC ENSG00000172819 Retinoic acid receptor, gamma 12 53210567-53232980 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA053883 Supported Supported Nucleoplasm Renal cancer:3.08e-6 (unfavourable), Endometrial cancer:3.68e-6 (unfavourable) Expressed in all Tissue enhanced skin: 143.7 esophagus: 77.6 RASA1 CM-AVM, GAP, p120GAP, p120RASGAP, RASA ENSG00000145715 RAS p21 protein activator (GTPase activating protein) 1 5 87267888-87391931 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB007789, HPA036393, HPA064556 Supported Expressed in all Expressed in all placenta: 136.1 RB1 OSRC, PPP1R130, RB ENSG00000139687 Retinoblastoma 1 13 48303751-48481986 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000095, CAB016687, HPA050082 Supported Validated Nucleoplasm Ovarian cancer:6.92e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 36.0 RBBP4 lin-53, NURF55, RbAp48 ENSG00000162521 Retinoblastoma binding protein 4 1 32651142-32686211 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB006264, HPA060710, HPA060724 Supported Validated Nucleoplasm Liver cancer:1.89e-6 (unfavourable), Melanoma:6.45e-4 (unfavourable) Expressed in all Expressed in all testis: 138.1 RBL1 cp107, p107, PRB1 ENSG00000080839 Retinoblastoma-like 1 20 36996349-37095995 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054962, HPA056525 Supported Validated Nucleoplasm Renal cancer:2.52e-6 (unfavourable) Expressed in all Mixed bone marrow: 9.2 RBL2 p130, Rb2 ENSG00000103479 Retinoblastoma-like 2 16 53433977-53491649 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB016547, HPA019703 Supported Approved Nucleus
Nucleoli
Cytosol Renal cancer:3.57e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 158.3 RBM10 DXS8237E, GPATC9, GPATCH9, KIAA0122, ZRANB5 ENSG00000182872 RNA binding motif protein 10 X 47144869-47186813 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA034972, HPA057372 Approved Validated Nuclear speckles Pancreatic cancer:2.86e-6 (favourable), Cervical cancer:6.71e-4 (favourable) Expressed in all Expressed in all ovary: 35.1 RBM15 OTT, OTT1 ENSG00000162775 RNA binding motif protein 15 1 110338506-110346681 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB015201, HPA019824, HPA049642 Supported Validated Nucleoplasm Renal cancer:1.37e-4 (unfavourable), Liver cancer:7.61e-4 (unfavourable), Stomach cancer:7.97e-4 (favourable) Expressed in all Mixed bone marrow: 27.9 RBM6 3G2, DEF-3, DEF3, g16, NY-LU-12 ENSG00000004534 RNA binding motif protein 6 3 49940007-50100045 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA026272, HPA027164 Supported Approved Nuclear speckles
Cytoplasmic bodies Urothelial cancer:5.13e-5 (favourable), Pancreatic cancer:1.41e-4 (favourable), Renal cancer:8.83e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 82.3 RBMX hnRNP-G, HNRNPG, RNMX ENSG00000147274 RNA binding motif protein, X-linked X 136848004-136880764 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA057707 Supported Approved Nucleoplasm Liver cancer:5.16e-6 (unfavourable) Expressed in all Expressed in all ovary: 296.1 RBP4 ENSG00000138207 Retinol binding protein 4, plasma 10 93591687-93601744 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001641, CAB004555 Supported Liver cancer:1.74e-8 (favourable), Endometrial cancer:1.50e-4 (unfavourable) Tissue enriched Tissue enriched 10 liver: 6086.1 adipose tissue: 630.4 RECQL4 RecQ4 ENSG00000160957 RecQ helicase-like 4 8 144511288-144517845 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB017800, HPA025821 Supported Validated Nucleus Liver cancer:1.91e-4 (unfavourable) Expressed in all Mixed testis: 17.4 REL c-Rel, I-Rel ENSG00000162924 V-rel avian reticuloendotheliosis viral oncogene homolog 2 60881521-60931610 Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors Evidence at protein level CAB004404 Uncertain Mixed Mixed bone marrow: 29.9 RELA NFKB3, p65 ENSG00000173039 V-rel avian reticuloendotheliosis viral oncogene homolog A 11 65653596-65663094 Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors Evidence at protein level CAB004264, CAB005030, HPA063461 Supported Validated Cytosol Renal cancer:5.66e-4 (unfavourable), Liver cancer:9.18e-4 (unfavourable) Expressed in all Expressed in all endometrium: 62.1 RELB REL-B ENSG00000104856 V-rel avian reticuloendotheliosis viral oncogene homolog B 19 45001430-45038198 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB007753, HPA040506 Approved Supported Nucleoplasm
Cytosol Renal cancer:2.99e-6 (unfavourable), Breast cancer:1.55e-4 (favourable) Expressed in all Expressed in all appendix: 25.8 RET CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51 ENSG00000165731 Ret proto-oncogene 10 43077027-43130351 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002581, HPA008356, HPA008495, CAB018342 Approved Supported Supported Vesicles
Plasma membrane
Cytosol Endometrial cancer:5.02e-4 (unfavourable) Tissue enhanced Tissue enriched 5 parathyroid gland: 146.8 adrenal gland: 29.2 RHEB RHEB2 ENSG00000106615 Ras homolog enriched in brain 7 151466012-151520120 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB019436 Uncertain Liver cancer:9.08e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 207.8 RHOA ARH12, ARHA, Rho12, RhoA, RHOH12 ENSG00000067560 Ras homolog family member A 3 49359145-49412998 Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB005052 Approved Supported Cytosol Renal cancer:3.21e-6 (favourable), Colorectal cancer:3.08e-4 (favourable), Liver cancer:9.15e-4 (unfavourable) Expressed in all Expressed in all lung: 592.9 RHOB ARH6, ARHB, MST081, RhoB, RHOH6 ENSG00000143878 Ras homolog family member B 2 20447074-20449445 Cancer-related genes, Predicted intracellular proteins Evidence at protein level Renal cancer:4.23e-4 (favourable) Expressed in all Expressed in all adrenal gland: 714.3 RHOC ARH9, ARHC, RhoC ENSG00000155366 Ras homolog family member C 1 112701106-112707434 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA051461 Uncertain Renal cancer:3.65e-5 (unfavourable), Liver cancer:2.68e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 685.6 RHOH ARHH, RhoH, TTF ENSG00000168421 Ras homolog family member H 4 40191053-40246967 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA030345 Uncertain Mixed Tissue enhanced lymph node: 99.6;tonsil: 80.6 appendix: 49.4 RIT1 MGC125864, MGC125865, RIBB, RIT, ROC1 ENSG00000143622 Ras-like without CAAX 1 1 155897808-155911404 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA053249 Approved Liver cancer:8.64e-6 (unfavourable) Expressed in all Expressed in all bone marrow: 50.6 RMI2 BLAP18, C16orf75, MGC24665 ENSG00000175643 RecQ mediated genome instability 2 16 11249619-11351762 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA040995 Uncertain Supported Nuclear speckles
Cytosol Liver cancer:2.77e-5 (unfavourable), Cervical cancer:5.69e-5 (favourable) Expressed in all Mixed lymph node: 37.3 RNF213 C17orf27, KIAA1554, KIAA1618, MYMY2, NET57 ENSG00000173821 Ring finger protein 213 17 80260866-80398786 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003347, HPA026790 Approved Supported Cytosol Endometrial cancer:4.65e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 66.8 RNF43 DKFZp781H0392, FLJ20315, URCC ENSG00000108375 Ring finger protein 43 17 58352500-58417595 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA008079 Uncertain Renal cancer:6.04e-9 (favourable) Tissue enhanced Mixed duodenum: 24.1 ROS1 c-ros-1, MCF3, ROS ENSG00000047936 ROS proto-oncogene 1 , receptor tyrosine kinase 6 117288300-117425855 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA049098, HPA072424 Uncertain Approved Vesicles Tissue enriched Group enriched 18 epididymis: 69.7;lung: 47.3 seminal vesicle: 3.2 RPA2 ENSG00000117748 Replication protein A2, 32kDa 1 27891524-27914746 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB016538, HPA026306, HPA026309 Supported Validated Nucleoplasm
Nuclear bodies Cervical cancer:4.33e-4 (favourable), Head and neck cancer:8.12e-4 (favourable) Expressed in all Expressed in all testis: 103.3 RPGR COD1, CORDX1, CRD, RP15, RP3 ENSG00000156313 Retinitis pigmentosa GTPase regulator X 38269163-38327564 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001593, HPA073455 Uncertain Supported Golgi apparatus Expressed in all Expressed in all fallopian tube: 23.0 RPL10 DXS648, DXS648E, FLJ23544, L10, NOV, QM ENSG00000147403 Ribosomal protein L10 X 154389955-154409168 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins Evidence at protein level CAB010339, HPA011311 Supported Validated Endoplasmic reticulum
Cytosol Renal cancer:7.67e-6 (unfavourable) Expressed in all Expressed in all ovary: 9655.2 RPL22 EAP, L22 ENSG00000116251 Ribosomal protein L22 1 6181269-6209389 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins Evidence at protein level Expressed in all Expressed in all ovary: 1344.6 RPL27 L27 ENSG00000131469 Ribosomal protein L27 17 42998273-43002959 Cancer-related genes, Predicted intracellular proteins, Ribosomal proteins Evidence at protein level HPA002649 Approved Renal cancer:7.80e-8 (unfavourable) Expressed in all Expressed in all lymph node: 2459.3 RPL5 L5, PPP1R135 ENSG00000122406 Ribosomal protein L5 1 92832025-92841924 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins Evidence at protein level HPA043717 Approved Renal cancer:6.81e-5 (unfavourable) Expressed in all Expressed in all ovary: 4031.6 RPN1 OST1 ENSG00000163902 Ribophorin I 3 128619970-128681075 Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB009748, HPA026828, HPA051520 Supported Validated Endoplasmic reticulum Liver cancer:4.80e-4 (unfavourable) Expressed in all Expressed in all epididymis: 416.3 RPS15 MGC111130, RIG, S15 ENSG00000115268 Ribosomal protein S15 19 1438358-1440494 Cancer-related genes, Predicted intracellular proteins, Ribosomal proteins Evidence at protein level HPA054510, HPA057793 Supported Approved Endoplasmic reticulum
Cytosol Expressed in all Expressed in all ovary: 1335.1 RPS2 LLREP3, S2 ENSG00000140988 Ribosomal protein S2 16 1962052-1964860 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins Evidence at protein level HPA055133 Approved Approved Endoplasmic reticulum
Cytosol Renal cancer:3.04e-7 (unfavourable), Liver cancer:7.70e-4 (unfavourable) Expressed in all Expressed in all ovary: 3061.1 RPS3 FLJ26283, FLJ27450, MGC87870, S3 ENSG00000149273 Ribosomal protein S3 11 75399486-75422280 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins Evidence at protein level HPA063339 Uncertain Supported Endoplasmic reticulum
Cytosol Renal cancer:6.92e-6 (unfavourable) Expressed in all Expressed in all ovary: 3526.1 RPS6KA1 HU-1, p90Rsk, RSK, RSK1 ENSG00000117676 Ribosomal protein S6 kinase, 90kDa, polypeptide 1 1 26529761-26575030 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB003852, HPA007981 Approved Supported Nucleus
Cytosol Endometrial cancer:7.20e-7 (favourable), Renal cancer:1.84e-4 (favourable), Stomach cancer:4.58e-4 (favourable), Urothelial cancer:8.33e-4 (favourable) Expressed in all Mixed small intestine: 39.7 RPS6KA3 CLS, HU-3, MRX19, RSK, RSK2 ENSG00000177189 Ribosomal protein S6 kinase, 90kDa, polypeptide 3 X 20149911-20267100 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA003221, CAB003853, CAB013520 Approved Approved Nucleus
Nucleoli
Cytosol Expressed in all Expressed in all parathyroid gland: 91.0 RSBN1L FLJ42526, FLJ45813, MGC71764 ENSG00000187257 Round spermatid basic protein 1-like 7 77696443-77783022 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA020406, HPA020413 Approved Supported Nuclear speckles
Plasma membrane Lung cancer:3.74e-4 (favourable) Expressed in all Expressed in all testis: 47.0 RSPO2 MGC35555 ENSG00000147655 R-spondin 2 8 107899316-108083648 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA024764, CAB025900, HPA053068 Approved Mixed Tissue enhanced cerebral cortex: 20.3;placenta: 25.6 prostate: 14.7 RSPO3 FLJ14440, THSD2 ENSG00000146374 R-spondin 3 6 127118604-127197765 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA029957 Approved Mixed Tissue enhanced endometrium: 102.8;smooth muscle: 102.3 placenta: 72.8 RUNX1 AML1, AMLCR1, CBFA2, PEBP2A2 ENSG00000159216 Runt-related transcription factor 1 21 34787801-36004667 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA004176, HPA037912 Supported Validated Nucleoplasm
Vesicles Renal cancer:3.44e-15 (unfavourable) Expressed in all Mixed breast: 33.8 RUNX1T1 AML1T1, CBFA2T1, CDR, ETO, MTG8, ZMYND2 ENSG00000079102 Runt-related transcription factor 1; translocated to, 1 (cyclin D-related) 8 91954967-92103286 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA049852, HPA070951 Approved Approved Nucleoplasm Mixed Mixed cervix, uterine: 12.9 RXRA NR2B1 ENSG00000186350 Retinoid X receptor, alpha 9 134317098-134440585 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB004565, CAB005352 Supported Supported Nucleus
Golgi apparatus Renal cancer:5.58e-4 (unfavourable), Pancreatic cancer:7.02e-4 (favourable) Expressed in all Mixed esophagus: 25.9 RXRB H-2RIIBP, NR2B2, RCoR-1 ENSG00000204231 Retinoid X receptor, beta 6 33193588-33200688 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002003, HPA063653 Approved Supported Nucleus Expressed in all Mixed epididymis: 15.5 RXRG NR2B3 ENSG00000143171 Retinoid X receptor, gamma 1 165400917-165445355 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002615 Uncertain Thyroid cancer:9.40e-5 (favourable) Group enriched Tissue enhanced skeletal muscle: 16.7 cervix, uterine: 4.6 S100A1 S100-alpha, S100A ENSG00000160678 S100 calcium binding protein A1 1 153627926-153632039 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002599, HPA006462 Supported Endometrial cancer:1.12e-4 (unfavourable), Renal cancer:3.08e-4 (unfavourable) Group enriched Group enriched 5 heart muscle: 1764.2;skeletal muscle: 996.0 thyroid gland: 267.1 S100A2 CAN19, S100L ENSG00000196754 S100 calcium binding protein A2 1 153561108-153567890 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB002600, CAB047340, HPA062451 Supported Supported Nucleus
Nucleoli
Plasma membrane
Cytosol Pancreatic cancer:2.04e-4 (unfavourable) Expressed in all Tissue enhanced esophagus: 1487.6;tonsil: 385.6 urinary bladder: 368.6 S100A4 18A2, 42A, CAPL, FSP1, MTS1, P9KA, PEL98 ENSG00000196154 S100 calcium binding protein A4 1 153543613-153550136 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002618, HPA007973, CAB027387, CAB058698, CAB068227, CAB068228 Supported Validated Plasma membrane Head and neck cancer:4.03e-5 (favourable), Renal cancer:2.90e-4 (unfavourable) Expressed in all Expressed in all lung: 990.8 S100A6 2A9, CABP, CACY, PRA ENSG00000197956 S100 calcium binding protein A6 1 153534599-153536244 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002601, HPA007575, CAB040549 Supported Validated Cytosol Urothelial cancer:7.56e-4 (favourable) Expressed in all Expressed in all lung: 1681.2 S100A7 PSOR1, S100A7c ENSG00000143556 S100 calcium binding protein A7 1 153457744-153460701 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB001453, HPA006997, CAB033766 Supported Group enriched Group enriched 6 skin: 325.1;tonsil: 921.8 esophagus: 96.4 S100A8 60B8AG, CAGA, CFAG, CGLA, MRP8, P8 ENSG00000143546 S100 calcium binding protein A8 1 153390032-153391188 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002791, HPA024372 Supported Supported Intermediate filaments Renal cancer:8.94e-7 (unfavourable) Expressed in all Group enriched 9 bone marrow: 14952.4;esophagus: 12812.0;tonsil: 5078.4 appendix: 1261.4 S100A9 60B8AG, CAGB, CFAG, CGLB, LIAG, MAC387, MIF, MRP14, NIF, P14 ENSG00000163220 S100 calcium binding protein A9 1 153357854-153361027 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA004193, CAB009441 Supported Supported Nucleoplasm
Cell Junctions
Cytosol Liver cancer:1.13e-6 (unfavourable), Renal cancer:8.10e-4 (unfavourable) Expressed in all Group enriched 6 bone marrow: 21012.0;esophagus: 24343.4 tonsil: 4079.1 S100B S100beta ENSG00000160307 S100 calcium binding protein B 21 46598962-46605208 Cancer-related genes, Candidate cardiovascular disease genes, Predicted intracellular proteins Evidence at protein level CAB000073, HPA015768, CAB078196 Supported Approved Nucleus
Vesicles Group enriched Group enriched 9 adipose tissue: 208.2;cerebral cortex: 628.0 seminal vesicle: 49.1 S1PR1 CD363, D1S3362, edg-1, EDG1 ENSG00000170989 Sphingosine-1-phosphate receptor 1 1 101236888-101241518 Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level CAB010104, HPA075568 Supported Supported Vesicles Urothelial cancer:8.78e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 86.5 SAA2 ENSG00000134339 Serum amyloid A2 11 18239223-18248643 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Renal cancer:1.30e-8 (unfavourable) Tissue enriched Tissue enhanced adipose tissue: 708.4;cervix, uterine: 411.1;liver: 580.7 appendix: 215.3 SACS ARSACS, DKFZp686B15167, DNAJC29, KIAA0730, PPP1R138, SPAX6 ENSG00000151835 Sacsin molecular chaperone 13 23328823-23433728 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017714 Uncertain Renal cancer:6.21e-6 (unfavourable), Endometrial cancer:9.04e-4 (unfavourable) Mixed Tissue enhanced parathyroid gland: 31.6 cerebral cortex: 16.0 SART1 Ara1, SNRNP110, Snu66 ENSG00000175467 Squamous cell carcinoma antigen recognized by T cells 1 11 65961689-65979828 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA031188, HPA031189, HPA031190 Supported Validated Nuclear speckles
Golgi apparatus Expressed in all Expressed in all spleen: 32.9 SBDS CGI-97, FLJ10917, SDS, SWDS ENSG00000126524 Shwachman-Bodian-Diamond syndrome 7 66987677-66995601 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA028891 Approved Supported Nucleus
Cytosol Breast cancer:1.49e-4 (unfavourable), Head and neck cancer:3.65e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 238.7 SCGB1A1 CC10, CC16, CCSP, UGB ENSG00000149021 Secretoglobin, family 1A, member 1 (uteroglobin) 11 62405103-62423195 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB025686, HPA031828 Supported Tissue enriched Tissue enriched 9 lung: 4755.1 fallopian tube: 513.6 SCGB1D2 LIPB, LPHB ENSG00000124935 Secretoglobin, family 1D, member 2 11 62242210-62244808 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA035318 Approved Endometrial cancer:3.46e-6 (favourable), Renal cancer:8.03e-6 (favourable) Group enriched Group enriched 9 breast: 1426.3;cervix, uterine: 5141.6 epididymis: 377.9 SCGB2A1 LPHC, MGB2, MGC71973, UGB3 ENSG00000124939 Secretoglobin, family 2A, member 1 11 62208668-62213939 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA034584 Supported Endometrial cancer:1.54e-8 (favourable), Colorectal cancer:1.22e-4 (favourable), Renal cancer:6.36e-4 (favourable) Group enriched Group enriched 6 cervix, uterine: 2835.4;epididymis: 1634.2 fallopian tube: 376.7 SCGB2A2 MGB1, MGC71974, UGB2 ENSG00000110484 Secretoglobin, family 2A, member 2 11 62270155-62273156 Cancer-related genes, Predicted secreted proteins Evidence at protein level CAB026270 Supported Endometrial cancer:9.57e-8 (favourable) Tissue enriched Tissue enriched 7 breast: 3633.4 cervix, uterine: 504.4 SDC1 CD138, SDC, SYND1, syndecan ENSG00000115884 Syndecan 1 2 20200797-20225433 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB002424, HPA006185 Approved Approved Focal adhesion sites Breast cancer:2.22e-4 (unfavourable), Glioma:8.05e-4 (unfavourable) Expressed in all Tissue enhanced esophagus: 251.7;skin: 288.6 liver: 144.9 SDC4 amphiglycan, ryudocan, SYND4 ENSG00000124145 Syndecan 4 20 45325288-45348424 Cancer-related genes, Predicted membrane proteins, Transporters Evidence at protein level HPA005716, CAB013240 Supported Approved Golgi apparatus
Plasma membrane Renal cancer:2.44e-7 (favourable), Thyroid cancer:2.67e-4 (favourable), Pancreatic cancer:4.20e-4 (unfavourable) Expressed in all Expressed in all lung: 250.5 SDHAF2 C11orf79, FLJ20487, PGL2, SDH5 ENSG00000167985 Succinate dehydrogenase complex assembly factor 2 11 61430042-61447529 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA039464, HPA039732 Supported Supported Nucleoli
Mitochondria
Cytosol Expressed in all Expressed in all fallopian tube: 35.7 SDHB SDH, SDH1 ENSG00000117118 Succinate dehydrogenase complex, subunit B, iron sulfur (Ip) 1 17018722-17054170 Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA002868, CAB009822, CAB068233, CAB068234, CAB068235 Supported Supported Nucleoplasm
Plasma membrane
Mitochondria Renal cancer:2.93e-7 (favourable) Expressed in all Expressed in all kidney: 213.3 SDHC CYB560, PGL3 ENSG00000143252 Succinate dehydrogenase complex, subunit C, integral membrane protein, 15kDa 1 161314257-161375340 Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Renal cancer:2.20e-4 (favourable) Expressed in all Expressed in all kidney: 187.3 SDHD PGL, PGL1 ENSG00000204370 Succinate dehydrogenase complex, subunit D, integral membrane protein 11 112086773-112120013 Cancer-related genes, Citric acid cycle related proteins, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA045727 Approved Renal cancer:1.99e-10 (favourable) Expressed in all Expressed in all kidney: 303.5 SELE CD62E, ELAM, ELAM1, ESEL ENSG00000007908 Selectin E 1 169722641-169764705 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002143 Supported Mixed Tissue enhanced parathyroid gland: 44.4;prostate: 40.0 urinary bladder: 28.6 SELL CD62L, hLHRc, LAM-1, LAM1, Leu-8, LNHR, LSEL, Lyam-1, LYAM1, PLNHR ENSG00000188404 Selectin L 1 169690667-169711698 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002144, HPA051972 Supported Uncertain Cytosol Renal cancer:4.96e-5 (unfavourable), Cervical cancer:2.25e-4 (favourable), Ovarian cancer:3.14e-4 (favourable), Breast cancer:3.76e-4 (favourable), Head and neck cancer:6.43e-4 (favourable) Expressed in all Tissue enhanced lymph node: 258.2;spleen: 222.6;tonsil: 185.9 appendix: 157.5 SELP CD62, CD62P, GMP140, GRMP, PADGEM, PSEL ENSG00000174175 Selectin P (granule membrane protein 140kDa, antigen CD62) 1 169588849-169630193 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002145, HPA002655, HPA005990 Supported Head and neck cancer:3.12e-4 (favourable) Mixed Mixed smooth muscle: 20.4 SEMA3B LUCA-1, SemA, sema5, SEMAA, semaV ENSG00000012171 Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B 3 50267558-50277546 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Breast cancer:1.27e-4 (favourable) Expressed in all Mixed adrenal gland: 75.9 SEPT12 FLJ25410 ENSG00000140623 Septin 12 16 4777669-4788521 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA041128 Uncertain Microtubules Tissue enhanced Tissue enriched 667 testis: 107.9 bone marrow: 0.1 SEPT2 DIFF6, hNedd5, KIAA0158, NEDD5, Pnutl3 ENSG00000168385 Septin 2 2 241315100-241354027 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017190, HPA018481 Supported Supported Nucleus
Actin filaments
Cytosol Liver cancer:3.66e-4 (unfavourable), Glioma:4.32e-4 (favourable) Expressed in all Expressed in all thyroid gland: 368.1 SEPT5 H5, HCDCREL-1, PNUTL1 ENSG00000184702 Septin 5 22 19714464-19724772 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB016120, HPA029095, HPA063885 Supported Approved Nucleoplasm
Actin filaments
Cytosol Renal cancer:6.87e-6 (unfavourable) Expressed in all Expressed in all parathyroid gland: 378.7 SEPT6 KIAA0128, MGC16619, MGC20339, SEP2, SEPT2 ENSG00000125354 Septin 6 X 119615724-119693370 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003459, HPA005665 Supported Expressed in all Mixed lymph node: 142.3 SEPT9 AF17q25, KIAA0991, MSF, MSF1, PNUTL4, SeptD1 ENSG00000184640 Septin 9 17 77280569-77500596 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA042564, HPA050627 Approved Validated Actin filaments Liver cancer:1.61e-5 (unfavourable) Expressed in all Expressed in all lymph node: 272.5 SERPINA1 A1A, A1AT, AAT, alpha-1-antitrypsin, alpha1AT, PI, PI1 ENSG00000197249 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 14 94376747-94390693 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA000927, HPA001292, CAB013211, CAB016648, CAB073396 Supported Validated Vesicles Breast cancer:1.61e-5 (favourable), Colorectal cancer:5.86e-4 (favourable) Tissue enriched Tissue enriched 19 liver: 15340.0 lung: 799.2 SERPINA3 AACT, ACT, alpha-1-antichymotrypsin ENSG00000196136 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 14 94612384-94624055 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA000893, HPA002560, CAB016647 Supported Breast cancer:8.92e-4 (favourable) Mixed Group enriched 5 cervix, uterine: 133.1;liver: 607.5 gallbladder: 69.4 SERPINA5 PAI3, PCI, PLANH3, PROCI ENSG00000188488 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 14 94561442-94593120 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA056919 Approved Mitochondria Endometrial cancer:7.72e-4 (favourable) Tissue enhanced Tissue enhanced adrenal gland: 516.7;liver: 406.5;testis: 816.1 gallbladder: 251.6 SERPINB13 headpin, HUR7, hurpin, PI13 ENSG00000197641 Serpin peptidase inhibitor, clade B (ovalbumin), member 13 18 63586989-63604639 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA052630, HPA057129 Supported Approved Nuclear speckles
Cytosol Tissue enhanced Tissue enriched 9 esophagus: 185.3 tonsil: 21.6 SERPINB2 HsT1201, PAI2, PLANH2 ENSG00000197632 Serpin peptidase inhibitor, clade B (ovalbumin), member 2 18 63871692-63903890 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA015480 Supported Approved Golgi apparatus Urothelial cancer:1.55e-5 (unfavourable) Tissue enhanced Group enriched 6 esophagus: 261.7;placenta: 69.7;skin: 106.0;tonsil: 75.5 bone marrow: 22.3 SERPINB3 HsT1196, SCC, SCCA1, T4-A ENSG00000057149 Serpin peptidase inhibitor, clade B (ovalbumin), member 3 18 63637719-63661963 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB018772, CAB036006, CAB036007, HPA048341, HPA049988, HPA055992 Supported Approved Plasma membrane
Cytosol Pancreatic cancer:3.19e-4 (unfavourable) Tissue enhanced Group enriched 6 cervix, uterine: 297.6;esophagus: 851.2 urinary bladder: 90.5 SERPINB4 LEUPIN, PI11, SCCA-2, SCCA1, SCCA2 ENSG00000206073 Serpin peptidase inhibitor, clade B (ovalbumin), member 4 18 63637259-63644298 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA048341, HPA049988, HPA055992 Supported Pancreatic cancer:5.48e-4 (unfavourable) Tissue enhanced Group enriched 6 esophagus: 98.6;urinary bladder: 20.1 skin: 9.4 SERPINE1 PAI, PAI1, PLANH1 ENSG00000106366 Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 7 101127089-101139266 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA050039 Approved Approved Cytosol Renal cancer:5.88e-8 (unfavourable), Stomach cancer:3.27e-6 (unfavourable), Lung cancer:4.41e-6 (unfavourable), Head and neck cancer:2.84e-5 (unfavourable), Colorectal cancer:2.82e-4 (unfavourable), Cervical cancer:5.01e-4 (unfavourable), Urothelial cancer:5.51e-4 (unfavourable) Expressed in all Tissue enhanced gallbladder: 581.0;placenta: 595.2 adipose tissue: 213.2 SERPINF1 EPC-1, PEDF, PIG35 ENSG00000132386 Serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1 17 1761959-1777574 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA005825 Approved Renal cancer:1.40e-8 (unfavourable), Cervical cancer:5.49e-4 (favourable) Expressed in all Expressed in all gallbladder: 742.8 SET 2PP2A, IPP2A2, PHAPII ENSG00000119335 SET nuclear proto-oncogene 9 128683424-128696400 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005232, HPA063683 Supported Supported Nucleoplasm
Lipid droplets Liver cancer:9.41e-7 (unfavourable) Expressed in all Expressed in all lymph node: 366.1 SETBP1 KIAA0437, SEB ENSG00000152217 SET binding protein 1 18 44680173-45068510 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA049022, HPA057259 Uncertain Supported Nucleus
Nuclear bodies
Cytosol Renal cancer:6.34e-8 (favourable) Mixed Expressed in all seminal vesicle: 13.8 SETD2 FLJ23184, HIF-1, HYPB, KIAA1732, KMT3A ENSG00000181555 SET domain containing 2 3 47016429-47163967 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA042451 Approved Approved Nuclear speckles
Cytosol Renal cancer:7.99e-6 (favourable), Melanoma:8.19e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 30.5 SETDB1 ESET, KG1T, KIAA0067, KMT1E, TDRD21 ENSG00000143379 SET domain, bifurcated 1 1 150926263-150964744 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018142, HPA058484 Uncertain Validated Nucleoplasm
Cytosol Renal cancer:4.25e-4 (unfavourable), Liver cancer:8.88e-4 (unfavourable) Expressed in all Expressed in all testis: 46.1 SF3B1 Hsh155, Prp10, PRPF10, SAP155, SF3b155 ENSG00000115524 Splicing factor 3b, subunit 1, 155kDa 2 197389784-197435091 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA050275 Approved Validated Nuclear speckles Expressed in all Expressed in all endometrium: 345.5 SFN YWHAS ENSG00000175793 Stratifin 1 26863138-26864457 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB006268, HPA011105, CAB040552 Supported Supported Cytosol Renal cancer:7.45e-6 (unfavourable), Liver cancer:5.68e-5 (unfavourable), Endometrial cancer:1.92e-4 (favourable), Pancreatic cancer:6.01e-4 (unfavourable) Expressed in all Group enriched 8 esophagus: 1094.4;skin: 1158.9 tonsil: 137.8 SFPQ PPP1R140, PSF ENSG00000116560 Splicing factor proline/glutamine-rich 1 35176378-35193148 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB009886, HPA047513, HPA054689 Supported Validated Nucleoplasm Liver cancer:7.91e-13 (unfavourable), Breast cancer:9.56e-5 (favourable) Expressed in all Expressed in all bone marrow: 135.7 SGK1 SGK ENSG00000118515 Serum/glucocorticoid regulated kinase 1 6 134169246-134318112 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB022085, CAB025148, HPA051251 Approved Supported Nuclear speckles
Cytosol Cervical cancer:5.26e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 778.6 SH2B3 IDDM20, LNK ENSG00000111252 SH2B adaptor protein 3 12 111405948-111451623 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA005483 Approved Approved Nucleoplasm Renal cancer:6.20e-4 (unfavourable) Expressed in all Expressed in all spleen: 51.9 SH3GL1 CNSA1, EEN, MGC111371, SH3D2B, SH3P8 ENSG00000141985 SH3-domain GRB2-like 1 19 4360370-4400547 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA021485 Approved Validated Cytosol Renal cancer:9.36e-8 (unfavourable), Liver cancer:1.10e-4 (unfavourable), Cervical cancer:1.50e-4 (favourable), Endometrial cancer:1.86e-4 (favourable) Expressed in all Expressed in all esophagus: 115.0 SHBG ABP, MGC126834, MGC138391, TEBG ENSG00000129214 Sex hormone-binding globulin 17 7613946-7633383 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Tissue enriched Tissue enhanced liver: 32.9;testis: 13.8 small intestine: 7.6 SHTN1 KIAA1598, shootin-1, shootin1 ENSG00000187164 Shootin 1 10 116881482-117126586 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA037942, HPA037943 Supported Approved Nucleus
Plasma membrane
Cytosol Urothelial cancer:5.08e-6 (unfavourable), Prostate cancer:5.07e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 36.2 parathyroid gland: 18.6 SIN3A DKFZP434K2235, KIAA0700 ENSG00000169375 SIN3 transcription regulator family member A 15 75369379-75455842 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004506, HPA047213, HPA062123 Supported Validated Nucleoplasm Expressed in all Expressed in all testis: 55.4 SIRT2 SIR2L ENSG00000068903 Sirtuin 2 19 38878555-38899862 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB004573, HPA011165 Approved Approved Nucleus
Nucleoli
Cytosol Endometrial cancer:7.20e-7 (unfavourable) Expressed in all Expressed in all cerebral cortex: 84.2 SIRT4 SIR2L4 ENSG00000089163 Sirtuin 4 12 120302316-120313249 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA029691, HPA029692 Approved Renal cancer:1.75e-4 (favourable) Mixed Mixed testis: 9.5 SKP2 FBL1, FBXL1, p45 ENSG00000145604 S-phase kinase-associated protein 2, E3 ubiquitin protein ligase 5 36151989-36184319 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB013491, CAB013533, HPA051196, HPA054633 Approved Supported Nucleus
Cytosol Renal cancer:4.77e-15 (unfavourable), Melanoma:3.72e-7 (unfavourable), Ovarian cancer:8.57e-4 (favourable) Expressed in all Tissue enriched 6 placenta: 83.9 lymph node: 13.9 SLC19A1 FOLT ENSG00000173638 Solute carrier family 19 (folate transporter), member 1 21 45493572-45544411 Cancer-related genes, Predicted membrane proteins, Transporters Evidence at protein level HPA024802 Approved Approved Plasma membrane Renal cancer:1.07e-10 (unfavourable), Cervical cancer:4.15e-4 (unfavourable) Expressed in all Mixed duodenum: 22.6 SLC1A3 EA6, EAAT1, GLAST ENSG00000079215 Solute carrier family 1 (glial high affinity glutamate transporter), member 3 5 36606355-36688334 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002573, HPA037467, HPA037468 Supported Approved Nucleoli
Mitochondria Tissue enriched Tissue enriched 16 cerebral cortex: 519.6 adipose tissue: 31.7 SLC26A3 CLD, DRA ENSG00000091138 Solute carrier family 26 (anion exchanger), member 3 7 107765467-107803225 Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA036055 Approved Tissue enriched Tissue enhanced colon: 1092.5;duodenum: 594.0;rectum: 974.8 seminal vesicle: 183.9 SLC2A1 CSE, DYT18, DYT9, GLUT, GLUT1, HTLVR ENSG00000117394 Solute carrier family 2 (facilitated glucose transporter), member 1 1 42925375-42959173 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002759, HPA031345, HPA058494 Supported Supported Validated Plasma membrane Renal cancer:4.55e-9 (unfavourable), Liver cancer:3.65e-8 (unfavourable), Pancreatic cancer:4.39e-5 (unfavourable), Lung cancer:1.09e-4 (unfavourable), Urothelial cancer:4.05e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 133.9 skin: 31.3 SLC34A2 NAPI-3B ENSG00000157765 Solute carrier family 34 (type II sodium/phosphate cotransporter), member 2 4 25655301-25678748 Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA037989 Supported Tissue enhanced Tissue enriched 10 lung: 1127.5 fallopian tube: 111.7 SLC3A2 4F2, 4F2HC, 4T2HC, CD98, CD98HC, MDU1, NACAE ENSG00000168003 Solute carrier family 3 (amino acid transporter heavy chain), member 2 11 62856102-62888875 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB010455, HPA017980 Supported Supported Nucleus
Plasma membrane
Cytosol Urothelial cancer:1.48e-4 (unfavourable), Liver cancer:8.17e-4 (unfavourable), Renal cancer:8.22e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 424.3 SLC44A3 CTL3, MGC45474 ENSG00000143036 Solute carrier family 44, member 3 1 94820342-94895246 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA047433 Approved Renal cancer:7.63e-5 (favourable) Expressed in all Mixed rectum: 39.1 SLC45A3 IPCA-2, IPCA-6, IPCA-8, PCANAP2, PCANAP6, PCANAP8, prostein ENSG00000158715 Solute carrier family 45, member 3 1 205657851-205680459 Cancer-related genes, Predicted membrane proteins, Transporters Evidence at protein level HPA019073, HPA019075 Supported Approved Nucleoplasm
Vesicles Endometrial cancer:4.04e-5 (unfavourable), Urothelial cancer:7.33e-5 (favourable) Tissue enriched Tissue enriched 25 prostate: 430.6 stomach: 16.9 SLC4A5 NBC4 ENSG00000188687 Solute carrier family 4 (sodium bicarbonate cotransporter), member 5 2 74216242-74343414 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036621 Approved Tissue enriched Group enriched 9 testis: 25.5;thyroid gland: 40.5 skin: 3.7 SLPI ALK1, ALP, BLPI, HUSI, HUSI-I, WAP4, WFDC4 ENSG00000124107 Secretory leukocyte peptidase inhibitor 20 45252239-45254564 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB002303, HPA027774 Supported Approved Golgi apparatus Renal cancer:6.91e-5 (unfavourable) Expressed in all Tissue enriched 10 cervix, uterine: 40728.5 seminal vesicle: 4274.8 SMAD1 JV4-1, MADH1, MADR1 ENSG00000170365 SMAD family member 1 4 145481194-145558079 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB005389 Approved Supported Nucleus
Plasma membrane
Cytosol Expressed in all Expressed in all parathyroid gland: 69.4 SMAD2 JV18-1, MADH2, MADR2 ENSG00000175387 SMAD family member 2 18 47808957-47931146 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level CAB025507, HPA067203, CAB073546 Approved Supported Nucleus
Nucleoli
Cytosol Liver cancer:9.44e-5 (unfavourable) Expressed in all Expressed in all thyroid gland: 126.1 SMAD3 HsT17436, JV15-2, MADH3 ENSG00000166949 SMAD family member 3 15 67063763-67195195 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB008094, HPA046386, HPA067203, CAB069409 Approved Validated Nucleoplasm
Cytosol Pancreatic cancer:2.48e-4 (unfavourable) Expressed in all Expressed in all esophagus: 54.4 SMAD4 DPC4, MADH4 ENSG00000141646 SMAD family member 4 18 51028394-51085045 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA019154 Approved Supported Nucleoplasm
Centrosome
Cytosol Renal cancer:1.92e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 38.7 SMARCA4 BAF190, BRG1, FLJ39786, hSNF2b, SNF2, SNF2-BETA, SNF2L4, SNF2LB, SWI2 ENSG00000127616 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 19 10961001-11065395 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004208 Supported Supported Nucleoplasm Liver cancer:1.11e-4 (unfavourable) Expressed in all Expressed in all testis: 39.5 SMARCB1 BAF47, hSNFS, Ini1, PPP1R144, RDT, Sfh1p, SNF5, SNF5L1, Snr1 ENSG00000099956 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 22 23786963-23834516 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009196, HPA018248, HPA019127 Supported Supported Nucleoplasm
Nucleoli fibrillar center Renal cancer:1.14e-6 (favourable), Liver cancer:6.52e-4 (unfavourable) Expressed in all Expressed in all testis: 51.2 SMARCD1 BAF60A, CRACD1, Rsc6p ENSG00000066117 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 1 12 50084972-50100712 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA004101 Supported Approved Nucleoplasm
Vesicles Liver cancer:2.53e-8 (unfavourable) Expressed in all Expressed in all parathyroid gland: 84.7 SMARCE1 BAF57 ENSG00000073584 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1 17 40624962-40648508 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA003916, CAB037318 Supported Supported Nucleoplasm Expressed in all Expressed in all endometrium: 72.9 SMC1A DXS423E, KIAA0178, SB1.8, SMC1L1, Smcb ENSG00000072501 Structural maintenance of chromosomes 1A X 53374149-53422728 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA005499, CAB025404 Supported Validated Nucleoplasm
Cytosol Expressed in all Expressed in all parathyroid gland: 51.8 SMC3 BAM, bamacan, CSPG6, HCAP, SMC3L1 ENSG00000108055 Structural maintenance of chromosomes 3 10 110567691-110604636 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA037411, HPA043206 Uncertain Supported Nucleoplasm Expressed in all Expressed in all testis: 94.5 SMO FZD11, SMOH ENSG00000128602 Smoothened, frizzled class receptor 7 129188872-129213545 Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB011446 Approved Expressed in all Mixed ovary: 30.3 SMYD3 KMT3E, ZMYND1, ZNFN3A1 ENSG00000185420 SET and MYND domain containing 3 1 245749342-246507312 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB012229, HPA045821, HPA054352 Approved Approved Golgi apparatus
Vesicles Expressed in all Expressed in all thyroid gland: 26.9 SND1 p100, TDRD11 ENSG00000197157 Staphylococcal nuclease and tudor domain containing 1 7 127652180-128092609 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002529, HPA002632, CAB019323 Supported Validated Cytosol Endometrial cancer:1.95e-4 (favourable) Expressed in all Expressed in all placenta: 121.5 SNX25 SBBI31 ENSG00000109762 Sorting nexin 25 4 185204237-185370185 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA036928 Uncertain Approved Vesicles Expressed in all Expressed in all lung: 42.7 SOCS1 Cish1, JAB, SOCS-1, SSI-1, TIP3 ENSG00000185338 Suppressor of cytokine signaling 1 16 11254405-11256179 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB010355, HPA074108 Approved Supported Nucleoplasm
Cytoplasmic bodies Renal cancer:1.08e-6 (unfavourable), Head and neck cancer:1.10e-4 (favourable) Expressed in all Tissue enhanced appendix: 20.0 lymph node: 15.9 SOD1 ALS, ALS1, IPOA ENSG00000142168 Superoxide dismutase 1, soluble 21 31659622-31668931 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA001401, CAB008670 Supported Supported Nucleus
Plasma membrane
Cytosol Expressed in all Expressed in all liver: 767.7 SOD2 ENSG00000112096 Superoxide dismutase 2, mitochondrial 6 159669057-159762529 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA001814, CAB002013 Supported Renal cancer:1.72e-4 (unfavourable) Expressed in all Expressed in all appendix: 750.9 SOS1 GF1, GINGF, HGF ENSG00000115904 Son of sevenless homolog 1 (Drosophila) 2 38981396-39124345 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB005396, HPA012613 Uncertain Uncertain Nucleus
Nucleoli
Cytosol Expressed in all Expressed in all parathyroid gland: 40.3 SOX1 ENSG00000182968 SRY (sex determining region Y)-box 1 13 112067647-112070488 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level Group enriched Group enriched 8 cerebral cortex: 3.6;testis: 1.5 skin: 0.3 SOX17 ENSG00000164736 SRY (sex determining region Y)-box 17 8 54457935-54460888 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB025594, HPA068399 Supported Approved Nucleoplasm Endometrial cancer:2.76e-4 (favourable) Group enriched Tissue enhanced cervix, uterine: 30.1;endometrium: 32.1;fallopian tube: 30.1 adipose tissue: 14.7 SOX2 ENSG00000181449 SRY (sex determining region Y)-box 2 3 181711924-181714436 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB010648, HPA045725 Approved Supported Nucleoplasm Tissue enhanced Tissue enriched 8 cerebral cortex: 118.3 esophagus: 14.9 SOX9 CMD1, CMPD1, SRA1 ENSG00000125398 SRY (sex determining region Y)-box 9 17 72121020-72126420 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA001758, CAB022456, CAB068240 Supported Validated Nucleoplasm Lung cancer:2.07e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 61.5 SP1 ENSG00000185591 Sp1 transcription factor 12 53380176-53416446 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000330, HPA001853, HPA012292 Supported Validated Nucleoplasm Pancreatic cancer:1.43e-4 (unfavourable) Expressed in all Expressed in all endometrium: 53.9 SPARC ON ENSG00000113140 Secreted protein, acidic, cysteine-rich (osteonectin) 5 151661096-151687165 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB002306, HPA002989, HPA003020 Supported Renal cancer:3.53e-5 (unfavourable) Expressed in all Expressed in all placenta: 3224.6 SPARCL1 MAST9 ENSG00000152583 SPARC-like 1 (hevin) 4 87473335-87531061 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB026225, HPA067641 Approved Approved Endoplasmic reticulum Urothelial cancer:3.33e-4 (unfavourable), Colorectal cancer:4.06e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 2041.4 SPATA6 FLJ10007, SRF-1, SRF1 ENSG00000132122 Spermatogenesis associated 6 1 48295372-48472208 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA028234 Approved Nucleoplasm
Golgi apparatus
Vesicles Mixed Tissue enhanced testis: 88.4 fallopian tube: 24.3 SPECC1 CYTSB, FLJ36955, HCMOGT-1, NSP ENSG00000128487 Sperm antigen with calponin homology and coiled-coil domains 1 17 20009344-20319026 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA021421, HPA021430 Approved Lung cancer:1.06e-5 (unfavourable) Expressed in all Expressed in all testis: 67.2 SPEN KIAA0929, MINT, RBM15C, SHARP ENSG00000065526 Spen family transcriptional repressor 1 15847864-15940460 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA015825, HPA050257 Supported Validated Nucleoplasm Expressed in all Expressed in all parathyroid gland: 38.3 SPINK1 PCTT, PSTI, Spink3, TATI ENSG00000164266 Serine peptidase inhibitor, Kazal type 1 5 147824568-147831786 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB026366, HPA027498 Supported Renal cancer:5.44e-7 (unfavourable), Urothelial cancer:2.15e-5 (favourable) Tissue enhanced Tissue enriched 8 pancreas: 7130.5 stomach: 935.1 SPINT1 HAI, MANSC2 ENSG00000166145 Serine peptidase inhibitor, Kunitz type 1 15 40844018-40858207 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA006903 Uncertain Uncertain Plasma membrane
Cytosol Renal cancer:1.37e-7 (favourable), Breast cancer:6.97e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 219.8 SPINT2 HAI-2, Kop ENSG00000167642 Serine peptidase inhibitor, Kunitz type, 2 19 38244035-38292614 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA011101, CAB018969 Approved Uncertain Plasma membrane
Intermediate filaments
Cytosol Renal cancer:3.41e-4 (favourable) Expressed in all Mixed thyroid gland: 536.5 SPOP BTBD32, TEF2 ENSG00000121067 Speckle-type POZ protein 17 49598884-49678234 Cancer-related genes, Predicted intracellular proteins Evidence at protein level Liver cancer:6.88e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 120.3 SPP1 BNSP, BSPI, ETA-1, OPN ENSG00000118785 Secreted phosphoprotein 1 4 87975650-87983426 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB002212, HPA027540, HPA027541 Approved Supported Golgi apparatus Liver cancer:2.84e-6 (unfavourable), Pancreatic cancer:5.89e-4 (unfavourable), Cervical cancer:9.52e-4 (unfavourable) Expressed in all Tissue enhanced gallbladder: 4002.0;kidney: 2385.1;placenta: 4016.3 cerebral cortex: 797.1 SPRR1B GADD33, SPRR1 ENSG00000169469 Small proline-rich protein 1B 1 153031202-153032900 Cancer-related genes, Predicted intracellular proteins Evidence at protein level Pancreatic cancer:7.64e-5 (unfavourable), Lung cancer:7.66e-5 (unfavourable), Urothelial cancer:7.28e-4 (unfavourable) Group enriched Tissue enriched 6 esophagus: 2466.0 tonsil: 422.7 SPRR3 ENSG00000163209 Small proline-rich protein 3 1 153001747-153003856 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA044467 Supported Pancreatic cancer:6.27e-5 (unfavourable) Tissue enhanced Tissue enriched 10 esophagus: 22163.5 tonsil: 2312.3 SPRY1 hSPRY1 ENSG00000164056 Sprouty RTK signaling antagonist 1 4 123396795-123403760 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB013538, HPA051369, HPA070554 Approved Approved Nucleoplasm
Golgi apparatus
Cytosol Expressed in all Expressed in all gallbladder: 132.5 SRC ASV, c-src, SRC1 ENSG00000197122 SRC proto-oncogene, non-receptor tyrosine kinase 20 37344685-37406050 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004023, HPA030875 Approved Validated Plasma membrane
Cytosol Liver cancer:4.90e-5 (unfavourable), Urothelial cancer:5.22e-5 (favourable), Renal cancer:1.22e-4 (unfavourable), Prostate cancer:1.63e-4 (unfavourable) Expressed in all Mixed gallbladder,small intestine: 43.7 SRD5A1 ENSG00000145545 Steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1) 5 6633343-6674386 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA051402 Approved Endometrial cancer:8.73e-6 (unfavourable) Expressed in all Mixed skin: 17.1 SRD5A2 ENSG00000277893 Steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2) 2 31522480-31581067 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level Group enriched Group enriched 11 epididymis: 27.4;fallopian tube: 31.2;liver: 30.6;prostate: 25.3;seminal vesicle: 24.2 testis: 2.4 SRGAP3 ARHGAP14, KIAA0411, MEGAP, SRGAP2, WRP ENSG00000196220 SLIT-ROBO Rho GTPase activating protein 3 3 8980591-9363053 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA036959, HPA044074 Supported Approved Nucleoplasm Mixed Tissue enhanced cerebral cortex: 26.6;fallopian tube: 17.3 cervix, uterine: 7.9 SRSF2 PR264, SC-35, SC35, SFRS2, SFRS2A ENSG00000161547 Serine/arginine-rich splicing factor 2 17 76734115-76737374 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA049905 Supported Approved Nucleus
Cytosol Liver cancer:3.53e-8 (unfavourable), Renal cancer:1.05e-7 (unfavourable), Endometrial cancer:8.73e-4 (unfavourable), Urothelial cancer:9.87e-4 (favourable) Expressed in all Expressed in all lymph node: 128.8 SRSF3 SFRS3, SRp20 ENSG00000112081 Serine/arginine-rich splicing factor 3 6 36594353-36605600 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB012986, HPA056981 Supported Supported Nucleoplasm Liver cancer:6.22e-5 (unfavourable), Ovarian cancer:1.37e-4 (favourable), Melanoma:1.95e-4 (unfavourable), Renal cancer:2.02e-4 (unfavourable), Colorectal cancer:2.56e-4 (favourable) Expressed in all Expressed in all lymph node: 141.5 SS18 SSXT, SYT ENSG00000141380 Synovial sarcoma translocation, chromosome 18 18 26016253-26091217 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA055741, HPA059539 Supported Approved Nucleoplasm
Cytosol Renal cancer:4.86e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 74.4 SS18L1 KIAA0693 ENSG00000184402 Synovial sarcoma translocation gene on chromosome 18-like 1 20 62143795-62182484 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB011827, HPA059046 Approved Supported Nucleoplasm
Cytosol Head and neck cancer:8.00e-5 (favourable), Lung cancer:3.74e-4 (favourable) Expressed in all Expressed in all skin: 23.7 SST SMST ENSG00000157005 Somatostatin 3 187668906-187670399 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000075, HPA019472 Supported Supported Endometrial cancer:1.93e-5 (unfavourable) Group enriched Tissue enhanced cerebral cortex: 212.6;duodenum: 387.3;stomach: 304.0 small intestine: 145.4 SSX1 CT5.1 ENSG00000126752 Synovial sarcoma, X breakpoint 1 X 48255317-48267444 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA045683 Supported Approved Nucleus
Nucleoli Tissue enhanced Tissue enriched 32 testis: 12.7 thyroid gland: 0.3 SSX2 CT5.2a, HD21, HOM-MEL-40, MGC119055, MGC15364, MGC3884, SSX ENSG00000241476 Synovial sarcoma, X breakpoint 2 X 52644567-52707189 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA045683, CAB046020 Supported Not detected Tissue enriched 112 testis: 46.0 thyroid gland: 0.4 SSX2B CT5.2b ENSG00000268447 Synovial sarcoma, X breakpoint 2B X 52751132-52790305 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA045683 Supported Approved Nucleus
Nucleoli Not detected Tissue enriched 22 testis: 14.9 thyroid gland: 0.6 SSX4 CT5.4 ENSG00000268009 Synovial sarcoma, X breakpoint 4 X 48383516-48393347 Cancer-related genes, Predicted intracellular proteins Evidence at transcript level HPA045683 Approved Not detected Tissue enriched 15 testis: 3.8 fallopian tube: 0.2 ST14 HAI, MT-SP1, PRSS14, SNC19, TMPRSS14 ENSG00000149418 Suppression of tumorigenicity 14 (colon carcinoma) 11 130159562-130210376 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA047014 Approved Nucleoplasm
Vesicles Renal cancer:5.03e-11 (favourable) Expressed in all Mixed small intestine: 152.0 STAG2 SA-2, SA2, SCC3B ENSG00000101972 Stromal antigen 2 X 123960212-124422664 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002857 Supported Expressed in all Expressed in all parathyroid gland: 110.6 STARD3 es64, MLN64 ENSG00000131748 StAR-related lipid transfer (START) domain containing 3 17 39637065-39663484 Cancer-related genes, Predicted membrane proteins, Transporters Evidence at protein level CAB017021 Uncertain Liver cancer:3.60e-5 (unfavourable), Renal cancer:7.70e-4 (unfavourable) Expressed in all Expressed in all testis: 33.3 STAT3 APRF ENSG00000168610 Signal transducer and activator of transcription 3 (acute-phase response factor) 17 42313324-42388568 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA001671, CAB003859, HPA058603, CAB068241, CAB068242 Supported Supported Nucleoplasm
Cytosol Expressed in all Expressed in all gallbladder: 127.9 STAT4 ENSG00000138378 Signal transducer and activator of transcription 4 2 191029576-191151596 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA001860, CAB013108 Approved Renal cancer:1.07e-8 (unfavourable), Pancreatic cancer:5.88e-4 (favourable) Mixed Tissue enhanced testis: 50.3 spleen: 18.8 STAT5A MGF, STAT5 ENSG00000126561 Signal transducer and activator of transcription 5A 17 42287547-42311943 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB003860, HPA027873, HPA042128, HPA049883, HPA051156 Approved Validated Nucleoplasm
Cytosol Breast cancer:5.87e-4 (favourable) Expressed in all Expressed in all adipose tissue: 90.2 STAT5B ENSG00000173757 Signal transducer and activator of transcription 5B 17 42199168-42276707 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB004298, HPA042128, HPA049883, HPA051156 Approved Renal cancer:2.39e-5 (favourable), Pancreatic cancer:1.63e-4 (favourable), Endometrial cancer:9.37e-4 (favourable) Expressed in all Expressed in all endometrium: 70.8 STAT6 D12S1644, IL-4-STAT ENSG00000166888 Signal transducer and activator of transcription 6, interleukin-4 induced 12 57095408-57132139 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA001861 Approved Validated Nucleoplasm
Cytosol Urothelial cancer:1.14e-4 (favourable), Endometrial cancer:1.69e-4 (favourable), Thyroid cancer:7.76e-4 (favourable) Expressed in all Expressed in all skin: 164.0 STEAP1 PRSS24, STEAP ENSG00000164647 Six transmembrane epithelial antigen of the prostate 1 7 90154375-90164829 Cancer-related genes, Predicted membrane proteins, Transporters Evidence at protein level HPA030985 Uncertain Tissue enriched Tissue enhanced prostate: 124.2 appendix: 41.5 STIL MCPH7, SIL ENSG00000123473 SCL/TAL1 interrupting locus 1 47250139-47314147 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA046543 Approved Plasma membrane
Cytosol Pancreatic cancer:1.33e-4 (unfavourable) Mixed Mixed testis: 12.5 STK11 LKB1, PJS ENSG00000118046 Serine/threonine kinase 11 19 1177558-1228435 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB016231, HPA017254, CAB022105, HPA067481 Approved Supported Nucleoplasm
Cytosol Endometrial cancer:3.69e-5 (favourable), Head and neck cancer:1.96e-4 (favourable) Expressed in all Expressed in all testis: 70.3 STK19 D6S60, G11, RP1 ENSG00000204344 Serine/threonine kinase 19 6 31971091-31982821 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA031510, HPA031511, HPA068559 Uncertain Supported Nuclear speckles Melanoma:1.18e-4 (unfavourable) Expressed in all Mixed testis: 1.0 STMN1 C1orf215, FLJ32206, Lag, LAP18, OP18, PP17, PP19, PR22, SMN ENSG00000117632 Stathmin 1 1 25884181-25906991 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB010107 Approved Supported Cytosol Liver cancer:9.90e-7 (unfavourable) Expressed in all Expressed in all cerebral cortex: 1042.5 STRAP MAWD, pt-wd, UNRIP ENSG00000023734 Serine/threonine kinase receptor associated protein 12 15882391-15903478 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA027320, HPA055557, HPA073876 Approved Validated Nucleoplasm
Cytosol Liver cancer:6.83e-6 (unfavourable), Urothelial cancer:5.10e-4 (unfavourable), Thyroid cancer:9.07e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 144.6 STRN SG2NA ENSG00000115808 Striatin, calmodulin binding protein 2 36843640-36966472 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA017286 Approved Approved Nucleoplasm
Cytosol Renal cancer:2.27e-4 (favourable) Expressed in all Expressed in all esophagus: 23.9 STT3A ITM1, MGC9042, STT3-A, TMC ENSG00000134910 STT3A, subunit of the oligosaccharyltransferase complex (catalytic) 11 125591712-125625215 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA030735 Approved Uncertain Nucleoplasm
Vesicles
Cytosol Endometrial cancer:1.32e-4 (favourable), Liver cancer:3.57e-4 (unfavourable), Renal cancer:4.96e-4 (unfavourable) Expressed in all Tissue enriched 6 parathyroid gland: 1111.5 epididymis: 173.1 STX2 EPIM, EPM, STX2A, STX2B, STX2C ENSG00000111450 Syntaxin 2 12 130789600-130839266 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA038189, HPA069176 Uncertain Approved Nucleus
Cytosol Renal cancer:5.15e-5 (unfavourable) Expressed in all Expressed in all testis: 35.1 SUFU PRO1280, SUFUH, SUFUXL ENSG00000107882 Suppressor of fused homolog (Drosophila) 10 102503987-102633535 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA008700 Supported Supported Nucleus Expressed in all Mixed parathyroid gland: 15.8 SULT1E1 EST, STE ENSG00000109193 Sulfotransferase family 1E, estrogen-preferring, member 1 4 69810780-69860152 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA028213, HPA028728, CAB047344 Supported Cervical cancer:4.06e-4 (favourable) Mixed Group enriched 7 duodenum: 28.4;liver: 18.7;skin: 7.6;small intestine: 30.3 adrenal gland: 3.1 SUZ12 CHET9, JJAZ1, KIAA0160 ENSG00000178691 SUZ12 polycomb repressive complex 2 subunit 17 31937018-32001045 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA057436 Approved Approved Nucleus
Nucleoli
Nuclear bodies Expressed in all Expressed in all testis: 50.5 SYK ENSG00000165025 Spleen tyrosine kinase 9 90801787-90898549 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA001384, CAB007773 Supported Approved Vesicles
Plasma membrane
Cytosol Expressed in all Mixed parathyroid gland: 94.2 SYNE1 8B, ARCA1, C6orf98, CPG2, dJ45H2.2, enaptin, KIAA0796, MYNE1, Nesp1, Nesprin-1, SCAR8, SYNE-1B ENSG00000131018 Spectrin repeat containing, nuclear envelope 1 6 152121684-152637801 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019113 Approved Supported Nucleoplasm
Nuclear membrane Mixed Expressed in all parathyroid gland: 58.0 TAF1 BA2R, CCG1, CCGS, DYT3, DYT3/TAF1, KAT4, NSCL2, TAF2A, TAFII250 ENSG00000147133 TAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 250kDa X 71366239-71532374 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA001075, CAB016283 Supported Validated Nucleoplasm Renal cancer:6.03e-4 (unfavourable), Lung cancer:6.54e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 25.7 TAF15 hTAFII68, Npl3, RBP56, TAF2N ENSG00000270647 TAF15 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 68kDa 17 35713791-35864615 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA052059, HPA063647 Supported Validated Nucleoplasm Expressed in all Expressed in all lymph node: 61.9 TAGLN DKFZp686P11128, SM22, SMCC, TAGLN1, WS3-10 ENSG00000149591 Transgelin 11 117199321-117204782 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB001447, HPA019467 Supported Approved Microtubules
Mitochondria
Cytosol Renal cancer:2.12e-7 (unfavourable) Expressed in all Expressed in all smooth muscle: 11751.0 TAL1 bHLHa17, SCL, TCL5 ENSG00000162367 T-cell acute lymphocytic leukemia 1 1 47216290-47232220 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB017805, HPA047866 Approved Approved Nucleus Mixed Tissue enhanced bone marrow: 17.7 placenta: 10.0 TAL2 bHLHa19 ENSG00000186051 T-cell acute lymphocytic leukemia 2 9 105662457-105663112 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA030886 Uncertain Approved Cytosol Renal cancer:2.69e-4 (favourable) Tissue enhanced Group enriched 5 kidney: 3.4;skeletal muscle: 4.8 epididymis: 0.8 TAP1 ABCB2, D6S114E, PSF1, RING4 ENSG00000168394 Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 6 32845209-32853978 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB009516, HPA072354 Approved Supported Endoplasmic reticulum
Microtubule organizing center Renal cancer:6.58e-5 (unfavourable), Ovarian cancer:4.07e-4 (favourable), Colorectal cancer:9.01e-4 (favourable) Expressed in all Mixed appendix: 20.6 TBC1D12 KIAA0608 ENSG00000108239 TBC1 domain family, member 12 10 94402504-94535930 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA038277, HPA038645 Uncertain Approved Nucleoplasm
Nuclear speckles Colorectal cancer:1.79e-5 (favourable) Expressed in all Mixed parathyroid gland: 19.1 TBL1XR1 C21, DC42, FLJ12894, IRA1, TBLR1 ENSG00000177565 Transducin (beta)-like 1 X-linked receptor 1 3 177019355-177197396 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019182 Supported Approved Nucleoplasm Liver cancer:1.08e-7 (unfavourable), Renal cancer:4.25e-5 (unfavourable), Glioma:7.23e-5 (favourable) Expressed in all Expressed in all thyroid gland: 61.2 TBX3 TBX3-ISO, UMS, XHL ENSG00000135111 T-box 3 12 114670254-114684164 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA005799 Approved Nucleoplasm
Cytosol Urothelial cancer:3.28e-4 (favourable) Expressed in all Tissue enhanced adrenal gland: 201.8 prostate: 114.3 TCEA1 GTF2S, SII, TCEA, TF2S, TFIIS ENSG00000187735 Transcription elongation factor A (SII), 1 8 53966552-54022529 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA043786 Approved Supported Nucleus
Nucleoli Renal cancer:3.75e-5 (unfavourable) Expressed in all Expressed in all thyroid gland: 199.1 TCEB1 SIII ENSG00000154582 Transcription elongation factor B (SIII), polypeptide 1 (15kDa, elongin C) 8 73939169-73972287 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA078113 Approved Cell Junctions Breast cancer:6.48e-4 (unfavourable) Expressed in all Expressed in all testis: 162.2 TCF12 bHLHb20, HEB, HsT17266, HTF4 ENSG00000140262 Transcription factor 12 15 56918623-57299281 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors Evidence at protein level CAB004432, HPA065827 Approved Supported Nucleoplasm
Nuclear speckles Renal cancer:5.24e-5 (unfavourable), Melanoma:8.89e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 115.4 TCF3 bHLHb21, E2A, E47, ITF1, MGC129647, MGC129648, VDIR ENSG00000071564 Transcription factor 3 19 1609290-1652605 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB018351, HPA049808, HPA062476 Approved Validated Nucleoplasm Renal cancer:1.53e-4 (unfavourable), Liver cancer:2.46e-4 (unfavourable) Expressed in all Expressed in all lymph node: 104.6 TCF7 TCF-1 ENSG00000081059 Transcription factor 7 (T-cell specific, HMG-box) 5 134114711-134151865 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB019403, HPA058863, HPA070505 Supported Validated Nucleoplasm Expressed in all Tissue enhanced lymph node: 111.6 appendix: 74.8 TCF7L2 TCF-4, TCF4 ENSG00000148737 Transcription factor 7-like 2 (T-cell specific, HMG-box) 10 112950250-113167678 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB013535, HPA038800 Supported Supported Nucleoplasm
Nuclear bodies Expressed in all Expressed in all endometrium: 33.6 TCL1A TCL1 ENSG00000100721 T-cell leukemia/lymphoma 1A 14 95709967-95714196 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB004045, HPA016604 Supported Tissue enriched Tissue enhanced lymph node: 328.5;tonsil: 204.6 spleen: 79.4 TCP11L2 MGC40368 ENSG00000166046 T-complex 11, testis-specific-like 2 12 106301929-106347015 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA039483, HPA042188 Uncertain Supported Nuclear speckles Head and neck cancer:9.52e-4 (favourable) Mixed Expressed in all fallopian tube: 26.2 TDRD10 DKFZp434M202 ENSG00000163239 Tudor domain containing 10 1 154502219-154548147 Cancer-related genes, Predicted intracellular proteins Evidence at transcript level HPA054327 Approved Vesicles Thyroid cancer:8.04e-5 (favourable) Tissue enhanced Tissue enriched 12 testis: 76.9 lung: 6.3 TDRD6 bA446F17.4, CT41.2, NY-CO-45, SPATA36 ENSG00000180113 Tudor domain containing 6 6 46687875-46704319 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level Tissue enhanced Tissue enhanced testis: 42.6;thyroid gland: 20.3 spleen: 7.2 TEK CD202b, TIE-2, TIE2, VMCM, VMCM1 ENSG00000120156 TEK tyrosine kinase, endothelial 9 27109141-27230175 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB010359, HPA073265 Approved Supported Plasma membrane
Microtubule organizing center Liver cancer:2.31e-5 (favourable), Renal cancer:7.81e-4 (favourable) Expressed in all Tissue enhanced placenta: 65.3 lung: 42.7 TERT EST2, hEST2, TCS1, TP2, TRT ENSG00000164362 Telomerase reverse transcriptase 5 1253147-1295069 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA054641, HPA065897 Validated Nucleoplasm Mixed Not detected lymph node,testis: 0.5 TET1 bA119F7.1, CXXC6, KIAA1676, LCX ENSG00000138336 Tet methylcytosine dioxygenase 1 10 68560656-68694482 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB014886, HPA019032, HPA057273 Approved Supported Nucleus
Nuclear membrane Tissue enriched Mixed parathyroid gland: 2.4 TET2 FLJ20032, KIAA1546 ENSG00000168769 Tet methylcytosine dioxygenase 2 4 105145875-105279816 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA043135 Supported Approved Nucleoplasm Mixed Mixed bone marrow: 15.8 TF PRO1557, PRO2086 ENSG00000091513 Transferrin 3 133745956-133779006 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001527, HPA005692, CAB009538 Supported Uncertain Mitochondria Renal cancer:2.35e-13 (unfavourable), Breast cancer:4.05e-4 (favourable) Tissue enriched Tissue enriched 14 liver: 5384.6 cerebral cortex: 386.9 TFAP2B AP2-B ENSG00000008196 Transcription factor AP-2 beta (activating enhancer binding protein 2 beta) 6 50818723-50847613 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA034683, HPA062942 Approved Approved Nucleoplasm Tissue enriched Tissue enhanced epididymis: 38.7 breast: 9.5 TFDP1 Dp-1, DP1, DRTF1 ENSG00000198176 Transcription factor Dp-1 13 113584721-113641470 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB033605, HPA044754, HPA068909 Supported Validated Nucleoplasm Liver cancer:1.03e-4 (unfavourable), Stomach cancer:6.17e-4 (favourable), Renal cancer:7.57e-4 (favourable) Expressed in all Expressed in all bone marrow: 100.1 TFDP2 Dp-2 ENSG00000114126 Transcription factor Dp-2 (E2F dimerization partner 2) 3 141944428-142149544 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB018396 Supported Supported Nucleus
Vesicles Cervical cancer:6.32e-4 (favourable), Renal cancer:9.84e-4 (favourable) Expressed in all Expressed in all testis: 127.0 TFE3 bHLHe33, TFEA ENSG00000068323 Transcription factor binding to IGHM enhancer 3 X 49028726-49043486 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA023881 Approved Supported Nucleoplasm
Cytosol Renal cancer:2.19e-8 (unfavourable), Liver cancer:6.03e-5 (unfavourable) Expressed in all Expressed in all seminal vesicle: 24.2 TFEB bHLHe35, TCFEB ENSG00000112561 Transcription factor EB 6 41683978-41736259 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA049532 Supported Nucleoplasm Renal cancer:1.06e-5 (favourable), Pancreatic cancer:4.77e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 53.4 TFF1 BCEI, D21S21, HP1.A, HPS2, pNR-2, pS2 ENSG00000160182 Trefoil factor 1 21 42362282-42366594 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB002170, HPA003425 Supported Breast cancer:5.00e-4 (favourable), Endometrial cancer:5.67e-4 (favourable) Group enriched Tissue enriched 32 stomach: 6481.5 gallbladder: 204.1 TFF2 SML1 ENSG00000160181 Trefoil factor 2 21 42346357-42351128 Cancer-related genes, Predicted secreted proteins Evidence at protein level CAB025834, HPA036705 Supported Liver cancer:1.99e-4 (unfavourable) Group enriched Group enriched 29 duodenum: 1057.0;stomach: 5161.6 gallbladder: 107.8 TFG FLJ36137, SPG57, TF6 ENSG00000114354 TRK-fused gene 3 100709331-100748966 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019473, HPA052206 Approved Approved Vesicles
Cytosol Pancreatic cancer:1.50e-4 (unfavourable), Liver cancer:5.48e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 161.6 TFPT amida, FB1, INO80F ENSG00000105619 TCF3 (E2A) fusion partner (in childhood Leukemia) 19 54107013-54115675 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA034958, HPA058534 Approved Supported Nucleoplasm
Nuclear membrane Pancreatic cancer:3.13e-4 (favourable), Colorectal cancer:5.13e-4 (unfavourable), Liver cancer:5.25e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 10.6 TFRC CD71, p90, TFR1 ENSG00000072274 Transferrin receptor 3 196027183-196082189 Cancer-related genes, CD markers, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000153, HPA028598 Supported Supported Endosomes
Lysosomes Liver cancer:1.15e-4 (unfavourable), Thyroid cancer:2.96e-4 (unfavourable), Cervical cancer:3.67e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 157.6 TG AITD3, TGN ENSG00000042832 Thyroglobulin 8 132866958-133134903 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000077, HPA002740, CAB056155 Supported Tissue enriched Tissue enriched 1097 thyroid gland: 15544.0 gallbladder: 14.1 TGFA ENSG00000163235 Transforming growth factor, alpha 2 70447280-70554193 Cancer-related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA042297 Approved Approved Vesicles Pancreatic cancer:1.20e-5 (unfavourable), Thyroid cancer:1.52e-4 (favourable) Expressed in all Mixed esophagus: 27.4 TGFB1 CED, DPD1, TGFB, TGFbeta ENSG00000105329 Transforming growth factor, beta 1 19 41301587-41353911 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000361, CAB073543 Approved Uncertain Cytosol Renal cancer:1.19e-8 (unfavourable), Head and neck cancer:3.38e-4 (unfavourable) Expressed in all Expressed in all spleen: 86.1 TGFB2 ENSG00000092969 Transforming growth factor, beta 2 1 218346235-218444619 Cancer-related genes, Disease related genes, Predicted secreted proteins Evidence at protein level Expressed in all Tissue enhanced prostate: 28.3 placenta: 20.2 TGFB3 ARVD, ARVD1 ENSG00000119699 Transforming growth factor, beta 3 14 75958099-75982991 Cancer-related genes, Disease related genes, Predicted secreted proteins Evidence at protein level HPA063582 Approved Vesicles Renal cancer:4.01e-7 (unfavourable) Expressed in all Mixed placenta: 84.3 TGFBR2 MFS2 ENSG00000163513 Transforming growth factor, beta receptor II (70/80kDa) 3 30606502-30694142 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level CAB073537 Supported Plasma membrane Expressed in all Expressed in all adipose tissue: 290.3 TGFBR3 betaglycan, BGCAN ENSG00000069702 Transforming growth factor, beta receptor III 1 91680343-91906335 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA008257, CAB018971 Supported Approved Cytosol Thyroid cancer:3.14e-4 (unfavourable), Endometrial cancer:3.36e-4 (unfavourable), Head and neck cancer:4.84e-4 (favourable), Renal cancer:4.99e-4 (favourable) Expressed in all Expressed in all ovary: 99.5 TGIF1 HPE4, TGIF ENSG00000177426 TGFB-induced factor homeobox 1 18 3411608-3459978 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA062160 Supported Nucleoplasm Pancreatic cancer:6.47e-4 (unfavourable) Expressed in all Expressed in all epididymis: 159.9 TGM4 TGP ENSG00000163810 Transglutaminase 4 3 44874608-44914990 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA032072, CAB033571 Supported Tissue enriched Tissue enriched 463 prostate: 688.5 adrenal gland: 1.4 TGM7 TGMZ ENSG00000159495 Transglutaminase 7 15 43276280-43302255 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at transcript level Tissue enriched Group enriched 6 testis: 1.5;tonsil: 1.5 esophagus: 0.2 THBS1 THBS, THBS-1, TSP, TSP-1, TSP1 ENSG00000137801 Thrombospondin 1 15 39581079-39599466 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB033678, HPA059756 Approved Approved Plasma membrane Renal cancer:8.47e-5 (unfavourable), Stomach cancer:8.50e-4 (unfavourable) Expressed in all Expressed in all appendix: 585.7 THBS2 TSP2 ENSG00000186340 Thrombospondin 2 6 169215780-169254044 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB017716, HPA044304 Approved Approved Nuclear speckles
Plasma membrane
Cytosol Renal cancer:3.77e-6 (unfavourable) Expressed in all Tissue enhanced gallbladder: 113.8 endometrium: 71.0 THBS4 ENSG00000113296 Thrombospondin 4 5 79991311-80083287 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB004597, HPA042426 Approved Approved Vesicles Urothelial cancer:3.33e-4 (unfavourable) Expressed in all Group enriched 5 adipose tissue: 234.3;heart muscle: 92.7;smooth muscle: 384.5 thyroid gland: 44.6 THPO MGDF, MPLLG, TPO ENSG00000090534 Thrombopoietin 3 184371935-184378144 Cancer-related genes, Disease related genes, Predicted secreted proteins Evidence at protein level Renal cancer:2.48e-6 (unfavourable) Tissue enriched Tissue enhanced liver: 8.9 testis: 3.9 THRA AR7, EAR-7.1/EAR-7.2, ERBA, ERBA1, NR1A1, THRA1, THRA2, THRA3 ENSG00000126351 Thyroid hormone receptor, alpha 17 40058290-40093867 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA009654, CAB023349 Uncertain Supported Cytosol Renal cancer:6.05e-8 (favourable), Lung cancer:1.84e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 239.6 THRAP3 TRAP150 ENSG00000054118 Thyroid hormone receptor associated protein 3 1 36224416-36305357 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA012041, CAB017472, HPA063765 Supported Validated Nuclear speckles Stomach cancer:5.36e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 97.5 THRB ERBA-BETA, ERBA2, GRTH, NR1A2, PRTH, THR1, THRB1, THRB2 ENSG00000151090 Thyroid hormone receptor, beta 3 24117160-24495282 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002008, CAB002009, HPA061035 Approved Supported Nuclear bodies Renal cancer:9.46e-8 (favourable) Mixed Mixed cerebral cortex: 36.4 TIE1 JTK14, TIE ENSG00000066056 Tyrosine kinase with immunoglobulin-like and EGF-like domains 1 1 43300993-43323108 Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA045769 Approved Vesicles Expressed in all Tissue enhanced placenta: 70.1 lung: 40.1 TIMM17A TIM17, TIM17A ENSG00000134375 Translocase of inner mitochondrial membrane 17 homolog A (yeast) 1 201955491-201970661 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA010083 Approved Supported Nucleoplasm
Mitochondria Breast cancer:1.98e-5 (unfavourable) Expressed in all Expressed in all thyroid gland: 62.9 TIMP1 CLGI, EPO, TIMP ENSG00000102265 TIMP metallopeptidase inhibitor 1 X 47582313-47586789 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB022360, HPA053417 Approved Approved Golgi apparatus Renal cancer:2.90e-11 (unfavourable), Colorectal cancer:2.09e-4 (unfavourable) Expressed in all Expressed in all appendix: 2083.7 TIMP2 CSC-21K ENSG00000035862 TIMP metallopeptidase inhibitor 2 17 78852977-78925387 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB010203 Approved Expressed in all Expressed in all ovary: 1176.3 TIMP3 SFD ENSG00000100234 TIMP metallopeptidase inhibitor 3 22 32801701-32863043 Cancer-related genes, Disease related genes, Predicted secreted proteins Evidence at protein level Ovarian cancer:1.90e-5 (unfavourable), Renal cancer:1.50e-4 (favourable) Mixed Tissue enhanced placenta: 1428.9 adipose tissue: 727.5 TJP2 DFNA51, X104, ZO-2, ZO2 ENSG00000119139 Tight junction protein 2 9 69121264-69255208 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001813, CAB009228 Supported Validated Plasma membrane
Cell Junctions
Cytosol Renal cancer:1.78e-14 (favourable) Expressed in all Expressed in all parathyroid gland: 136.2 TK1 ENSG00000167900 Thymidine kinase 1, soluble 17 78174075-78187233 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004683 Approved Renal cancer:6.50e-11 (unfavourable), Lung cancer:3.03e-5 (unfavourable), Liver cancer:6.87e-4 (unfavourable) Expressed in all Mixed bone marrow: 45.8 TLX1 HOX11, TCL3 ENSG00000107807 T-cell leukemia homeobox 1 10 101130505-101137789 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level Colorectal cancer:7.32e-4 (unfavourable) Mixed Tissue enriched 5 spleen: 32.5 salivary gland: 6.1 TLX3 HOX11L2, RNX ENSG00000164438 T-cell leukemia homeobox 3 5 171309284-171312134 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA074512 Approved Nucleoplasm
Centrosome Tissue enhanced Not detected all non-specific tissues: 0.0 TMF1 ARA160, TMF ENSG00000144747 TATA element modulatory factor 1 3 69019827-69052303 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA008729 Approved Supported Golgi apparatus Expressed in all Expressed in all testis: 59.3 TMPRSS2 PRSS10 ENSG00000184012 Transmembrane protease, serine 2 21 41464551-41531116 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034493, HPA035787 Supported Supported Nucleoplasm
Cell Junctions Renal cancer:7.86e-6 (favourable), Endometrial cancer:2.56e-4 (favourable) Tissue enriched Tissue enhanced prostate: 495.7 stomach: 142.5 TMPRSS3 DFNB10, DFNB8 ENSG00000160183 Transmembrane protease, serine 3 21 42371890-42396846 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level Colorectal cancer:3.64e-4 (unfavourable), Renal cancer:8.24e-4 (unfavourable) Mixed Tissue enhanced fallopian tube: 34.9 stomach: 14.5 TNC DFNA56, HXB, MGC167029, TN ENSG00000041982 Tenascin C 9 115019578-115118257 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB004592, HPA004823 Approved Expressed in all Tissue enhanced appendix: 243.6;smooth muscle: 522.1 adipose tissue: 77.9 TNF DIF, TNF-alpha, TNFA, TNFSF2 ENSG00000232810 Tumor necrosis factor 6 31575567-31578336 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level Mixed Tissue enhanced bone marrow: 3.7 lymph node: 1.3 TNFAIP2 B94, EXOC3L3 ENSG00000185215 Tumor necrosis factor, alpha-induced protein 2 14 103123442-103137439 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level CAB004598, HPA030624 Supported Approved Nucleus
Nuclear membrane
Golgi apparatus
Cytosol Stomach cancer:2.79e-5 (favourable), Urothelial cancer:7.17e-5 (favourable), Renal cancer:4.10e-4 (unfavourable) Expressed in all Expressed in all urinary bladder: 211.4 TNFAIP3 A20, OTUD7C ENSG00000118503 Tumor necrosis factor, alpha-induced protein 3 6 137867188-137883312 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002116 Approved Approved Centrosome
Cytosol Renal cancer:6.05e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 345.8 TNFRSF10A Apo2, CD261, DR4, TRAILR-1 ENSG00000104689 Tumor necrosis factor receptor superfamily, member 10a 8 23190452-23225126 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level HPA050958, HPA054475 Approved Supported Nucleoplasm Pancreatic cancer:1.00e-4 (unfavourable) Expressed in all Mixed lymph node: 16.1 TNFRSF10B CD262, DR5, KILLER, TRAIL-R2, TRICK2A, TRICKB ENSG00000120889 Tumor necrosis factor receptor superfamily, member 10b 8 23020133-23069179 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA023625 Approved Renal cancer:1.76e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 33.4 TNFRSF10C CD263, DcR1, LIT, TRAILR3, TRID ENSG00000173535 Tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain 8 23084355-23117437 Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB025635 Supported Mixed Tissue enhanced appendix: 22.4 spleen: 18.5 TNFRSF10D CD264, DcR2, TRAILR4, TRUNDD ENSG00000173530 Tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain 8 23135588-23164030 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level HPA070971 Approved Plasma membrane
Actin filaments Cervical cancer:1.70e-4 (unfavourable) Expressed in all Mixed gallbladder: 12.7 TNFRSF11B OCIF, OPG, TR1 ENSG00000164761 Tumor necrosis factor receptor superfamily, member 11b 8 118923557-118952200 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Urothelial cancer:3.88e-4 (unfavourable), Cervical cancer:6.22e-4 (unfavourable), Renal cancer:6.79e-4 (favourable) Expressed in all Tissue enriched 5 thyroid gland: 139.8 kidney: 25.5 TNFRSF12A CD266, FN14, TweakR ENSG00000006327 Tumor necrosis factor receptor superfamily, member 12A 16 3018445-3022383 Cancer-related genes, CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007853 Approved Approved Plasma membrane
Cytosol Head and neck cancer:5.50e-4 (unfavourable), Renal cancer:8.78e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 195.6 TNFRSF14 ATAR, CD270, HVEA, HVEM, LIGHTR, TR2 ENSG00000157873 Tumor necrosis factor receptor superfamily, member 14 1 2555639-2565382 Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA006404, CAB026150, CAB030007 Approved Approved Cytosol
Rods & Rings Urothelial cancer:7.79e-6 (favourable), Endometrial cancer:8.01e-6 (favourable), Breast cancer:4.39e-5 (favourable) Expressed in all Expressed in all duodenum: 46.7 TNFRSF17 BCM, BCMA, CD269, TNFRSF13A ENSG00000048462 Tumor necrosis factor receptor superfamily, member 17 16 11965107-11968068 Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Head and neck cancer:1.58e-6 (favourable), Breast cancer:1.35e-5 (favourable) Mixed Tissue enhanced tonsil: 38.2 lymph node: 31.4 TNFRSF1A CD120a, TNF-R, TNF-R-I, TNF-R55, TNFAR, TNFR1, TNFR60 ENSG00000067182 Tumor necrosis factor receptor superfamily, member 1A 12 6328757-6342114 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA004102, CAB010309 Approved Renal cancer:2.70e-7 (unfavourable), Head and neck cancer:3.68e-4 (unfavourable), Endometrial cancer:8.22e-4 (favourable) Expressed in all Expressed in all gallbladder: 140.8 TNFRSF1B CD120b, p75, TNF-R-II, TNF-R75, TNFBR, TNFR2, TNFR80 ENSG00000028137 Tumor necrosis factor receptor superfamily, member 1B 1 12167003-12209228 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA004796 Approved Renal cancer:8.35e-5 (unfavourable), Testis cancer:8.68e-4 (unfavourable) Expressed in all Tissue enhanced appendix: 103.0 spleen: 79.2 TNFRSF4 ACT35, CD134, OX40, TXGP1L ENSG00000186827 Tumor necrosis factor receptor superfamily, member 4 1 1211326-1214138 Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level CAB016128 Supported Head and neck cancer:3.50e-6 (favourable), Renal cancer:4.52e-6 (unfavourable), Liver cancer:6.03e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 9.7;appendix: 8.6 lymph node: 7.2 TNFRSF8 CD30, D1S166E, KI-1 ENSG00000120949 Tumor necrosis factor receptor superfamily, member 8 1 12063377-12144207 Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000016, HPA032081, HPA032082 Approved Tissue enriched Tissue enhanced appendix: 4.3 adipose tissue: 3.1 TNFRSF9 4-1BB, CD137, ILA ENSG00000049249 Tumor necrosis factor receptor superfamily, member 9 1 7915894-7943165 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level HPA071425 Approved Nucleoli
Plasma membrane Renal cancer:2.69e-8 (unfavourable) Mixed Tissue enhanced lymph node: 11.2;tonsil: 7.4 appendix: 5.3 TNFSF10 Apo-2L, CD253, TL2, TRAIL ENSG00000121858 Tumor necrosis factor (ligand) superfamily, member 10 3 172505508-172523507 Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054938 Uncertain Approved Microtubules Pancreatic cancer:9.43e-4 (unfavourable) Expressed in all Expressed in all lung: 260.2 TNFSF11 CD254, ODF, OPGL, RANKL, TRANCE ENSG00000120659 Tumor necrosis factor (ligand) superfamily, member 11 13 42562736-42608013 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009193, HPA045142 Supported Mixed Tissue enhanced lymph node: 17.6 appendix: 6.5 TNFSF13 APRIL, CD256 ENSG00000161955 Tumor necrosis factor (ligand) superfamily, member 13 17 7558292-7561608 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA004863 Uncertain Renal cancer:1.30e-9 (favourable), Glioma:8.28e-4 (unfavourable) Expressed in all Expressed in all lung: 150.0 TNFSF13B BAFF, BLYS, CD257, TALL-1, TALL1, THANK, TNFSF20 ENSG00000102524 Tumor necrosis factor (ligand) superfamily, member 13b 13 108251240-108308484 Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009188 Approved Renal cancer:2.53e-11 (unfavourable) Expressed in all Mixed appendix: 36.2 TNFSF4 CD252, gp34, OX-40L, TXGP1 ENSG00000117586 Tumor necrosis factor (ligand) superfamily, member 4 1 173183734-173207313 Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA059579 Approved Approved Nucleus
Vesicles Expressed in all Tissue enhanced testis: 7.5 appendix: 3.2 TNFSF8 CD153, CD30LG ENSG00000106952 Tumor necrosis factor (ligand) superfamily, member 8 9 114893343-114930595 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at transcript level Mixed Tissue enhanced lymph node: 34.8;tonsil: 27.8 appendix: 25.1 TNK2 ACK, ACK1, p21cdc42Hs ENSG00000061938 Tyrosine kinase, non-receptor, 2 3 195863364-195911945 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA041954 Approved Approved Cytosol Urothelial cancer:1.00e-4 (favourable), Renal cancer:1.30e-4 (unfavourable), Endometrial cancer:8.96e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 109.8 TOM1 ENSG00000100284 Target of myb1 membrane trafficking protein 22 35299275-35347994 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA000818, HPA001749 Approved Approved Plasma membrane
Microtubule organizing center
Cytosol Endometrial cancer:2.20e-5 (favourable), Renal cancer:3.72e-5 (favourable) Expressed in all Expressed in all esophagus: 54.8 TOP1 ENSG00000198900 Topoisomerase (DNA) I 20 41028818-41124487 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB009058, HPA019039 Supported Supported Nucleus
Nucleoli fibrillar center Liver cancer:6.42e-4 (unfavourable) Expressed in all Expressed in all lymph node: 71.8 TOP2A TOP2 ENSG00000131747 Topoisomerase (DNA) II alpha 17 40388516-40417950 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002448, HPA006458, HPA026773 Supported Validated Nucleus
Nucleoli Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.92e-6 (unfavourable), Pancreatic cancer:3.83e-5 (unfavourable), Lung cancer:4.99e-4 (unfavourable) Expressed in all Tissue enhanced testis: 108.0 lymph node: 48.2 TOP3A TOP3, ZGRF7 ENSG00000177302 Topoisomerase (DNA) III alpha 17 18271428-18315007 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB002449 Approved Pancreatic cancer:1.39e-4 (favourable), Prostate cancer:4.59e-4 (unfavourable) Expressed in all Expressed in all testis: 24.9 TP53 LFS1, p53 ENSG00000141510 Tumor protein p53 17 7661779-7687550 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors, Transporters Evidence at protein level CAB002973, CAB039238, CAB039239, HPA051244, CAB072876 Supported Validated Nucleoplasm Endometrial cancer:1.35e-4 (favourable), Prostate cancer:5.01e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 50.3 TP53BP1 53BP1, p202, TDRD30 ENSG00000067369 Tumor protein p53 binding protein 1 15 43403061-43510728 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB004083, HPA008788, HPA022133 Supported Validated Nucleoplasm
Nuclear bodies Expressed in all Expressed in all parathyroid gland: 49.6 TP53BP2 53BP2, ASPP2, PPP1R13A ENSG00000143514 Tumor protein p53 binding protein 2 1 223779899-223845972 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA021603, HPA050429 Supported Validated Cell Junctions
Cytosol Expressed in all Expressed in all thyroid gland: 34.4 TPD52 D52, hD52, N8L ENSG00000076554 Tumor protein D52 8 80034745-80231232 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA028427, HPA062167 Supported Approved Golgi apparatus
Cytosol Renal cancer:4.77e-6 (unfavourable), Breast cancer:1.11e-5 (unfavourable) Expressed in all Expressed in all prostate: 173.6 TPI1 ENSG00000111669 Triosephosphate isomerase 1 12 6867119-6870948 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA050924, HPA053568 Uncertain Validated Nucleoplasm Liver cancer:1.04e-5 (unfavourable), Renal cancer:6.54e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 942.9 TPM1 C15orf13, CMH3 ENSG00000140416 Tropomyosin 1 (alpha) 15 63042632-63071915 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000261, HPA009066, CAB017698, HPA047089, HPA053624 Supported Approved Actin filaments
Cytosol Urothelial cancer:7.30e-4 (unfavourable) Expressed in all Expressed in all heart muscle: 6465.2 TPM2 AMCD1, DA1, NEM4 ENSG00000198467 Tropomyosin 2 (beta) 9 35681992-35691020 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA047089, HPA053624 Approved Renal cancer:8.51e-10 (unfavourable), Colorectal cancer:2.64e-4 (unfavourable) Expressed in all Tissue enriched 6 skeletal muscle: 13469.0 smooth muscle: 2265.6 TPM3 NEM1, TRK ENSG00000143549 Tropomyosin 3 1 154155304-154194648 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA000261, HPA009066, HPA047089, HPA053624 Approved Approved Actin filaments
Cytosol Liver cancer:6.73e-6 (unfavourable), Ovarian cancer:2.39e-5 (favourable), Renal cancer:3.12e-5 (unfavourable), Pancreatic cancer:3.65e-4 (unfavourable), Lung cancer:4.01e-4 (unfavourable) Expressed in all Tissue enriched 7 skeletal muscle: 2869.9 bone marrow: 429.2 TPM4 ENSG00000167460 Tropomyosin 4 19 16067021-16103005 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004685, HPA047089, HPA053624 Approved Approved Actin filaments
Cytosol Renal cancer:1.26e-10 (unfavourable), Pancreatic cancer:3.07e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 808.6 TPR ENSG00000047410 Translocated promoter region, nuclear basket protein 1 186311652-186375693 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA019661, HPA019663, HPA024336 Supported Validated Nuclear membrane Liver cancer:1.06e-4 (unfavourable), Head and neck cancer:4.71e-4 (favourable) Expressed in all Expressed in all testis: 78.8 TPX2 C20orf1, C20orf2, DIL-2, p100 ENSG00000088325 TPX2, microtubule-associated 20 31739271-31801805 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA005487 Uncertain Supported Nucleoplasm
Mitotic spindle Renal cancer:0.00e+0 (unfavourable), Liver cancer:8.07e-7 (unfavourable), Endometrial cancer:2.43e-6 (unfavourable), Pancreatic cancer:2.68e-5 (unfavourable), Lung cancer:6.46e-4 (unfavourable) Expressed in all Tissue enhanced testis: 55.4 lymph node: 31.8 TRAF1 EBI6 ENSG00000056558 TNF receptor-associated factor 1 9 120902393-120929173 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA001852, CAB009593 Approved Approved Nucleoplasm Pancreatic cancer:2.19e-5 (favourable), Renal cancer:4.42e-5 (unfavourable) Expressed in all Tissue enhanced lymph node: 38.1 appendix: 28.1 TRAF2 TRAP3 ENSG00000127191 TNF receptor-associated factor 2 9 136881912-136926607 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004603, HPA009972, HPA010634 Uncertain Validated Cytosol Renal cancer:2.09e-4 (unfavourable), Liver cancer:3.06e-4 (unfavourable), Colorectal cancer:9.32e-4 (unfavourable) Expressed in all Expressed in all lymph node: 23.1 TRAF3 CAP-1, CD40bp, CRAF1, LAP1 ENSG00000131323 TNF receptor-associated factor 3 14 102777476-102911500 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA002933 Uncertain Liver cancer:1.02e-5 (unfavourable), Pancreatic cancer:2.42e-5 (favourable) Expressed in all Mixed appendix: 26.5 TRAF4 CART1, MLN62, RNF83 ENSG00000076604 TNF receptor-associated factor 4 17 28743984-28750958 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA052377 Supported Expressed in all Mixed duodenum: 48.5 TRAF7 DKFZp586I021, MGC7807, RFWD1, RNF119 ENSG00000131653 TNF receptor-associated factor 7, E3 ubiquitin protein ligase 16 2155698-2178129 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA041229 Approved Supported Vesicles
Plasma membrane Expressed in all Expressed in all duodenum: 41.1 TRIM23 ARD1, ARFD1, RNF46 ENSG00000113595 Tripartite motif containing 23 5 65589680-65625975 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA039605 Approved Expressed in all Expressed in all cerebral cortex: 47.0 TRIM24 hTIF1, RNF82, TIF1, Tif1a ENSG00000122779 Tripartite motif containing 24 7 138460334-138589993 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA043495, HPA061717 Approved Validated Nucleoplasm Lung cancer:6.57e-4 (favourable), Liver cancer:9.94e-4 (unfavourable) Expressed in all Expressed in all testis: 49.5 TRIM25 EFP, RNF147, ZNF147 ENSG00000121060 Tripartite motif containing 25 17 56887909-56914038 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA005909 Approved Approved Nucleoplasm
Nuclear bodies
Cytosol Pancreatic cancer:3.36e-4 (favourable), Stomach cancer:9.35e-4 (favourable), Liver cancer:9.37e-4 (unfavourable) Expressed in all Expressed in all skin: 34.9 TRIM27 RFP, RNF76 ENSG00000204713 Tripartite motif containing 27 6 28903002-28923989 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA048684, HPA053408 Supported Approved Nucleus
Nucleoli Renal cancer:3.50e-6 (unfavourable), Urothelial cancer:2.71e-4 (favourable) Expressed in all Mixed appendix: 5.8 TRIM33 FLJ11429, KIAA1113, PTC7, RFG7, TF1G, TIF1G, TIF1GAMMA, TIFGAMMA ENSG00000197323 Tripartite motif containing 33 1 114392777-114511160 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA004345 Supported Approved Nucleoplasm
Vesicles Colorectal cancer:6.20e-4 (favourable), Head and neck cancer:8.93e-4 (favourable) Expressed in all Expressed in all testis: 46.0 TRIM7 GNIP, RNF90 ENSG00000146054 Tripartite motif containing 7 5 181193924-181205293 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA039213 Approved Approved Nucleoplasm
Vesicles
Cytosol Mixed Group enriched 5 skeletal muscle: 67.7;skin: 22.2 esophagus: 8.7 TRIO ARHGEF23 ENSG00000038382 Trio Rho guanine nucleotide exchange factor 5 14143702-14532128 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA008157, HPA064664 Supported Approved Vesicles
Cytosol Renal cancer:3.11e-5 (unfavourable), Endometrial cancer:1.90e-4 (unfavourable) Expressed in all Expressed in all breast: 30.8 TRIP11 CEV14, GMAP-210, GMAP210, Trip230 ENSG00000100815 Thyroid hormone receptor interactor 11 14 91965991-92040896 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002570, HPA070684 Supported Validated Nucleus
Golgi apparatus Renal cancer:1.78e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 37.7 TRIP4 HsT17391, ZC2HC5 ENSG00000103671 Thyroid hormone receptor interactor 4 15 64387748-64455303 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA016605, HPA050666 Approved Supported Nucleoplasm
Nuclear bodies Renal cancer:6.34e-6 (favourable) Expressed in all Expressed in all thyroid gland: 42.0 TRO KIAA1114, MAGE-D3, MAGED3 ENSG00000067445 Trophinin X 54920462-54931431 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB033947, HPA053358 Uncertain Approved Nucleus
Nucleoli fibrillar center Endometrial cancer:4.41e-5 (unfavourable), Pancreatic cancer:1.93e-4 (favourable) Mixed Mixed cerebral cortex: 30.0 TRRAP PAF400, TR-AP, Tra1 ENSG00000196367 Transformation/transcription domain-associated protein 7 98877933-99013243 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054376 Supported Nucleoplasm
Golgi apparatus Liver cancer:8.77e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 22.2 TSC1 hamartin, KIAA0243, LAM, TSC ENSG00000165699 Tuberous sclerosis 1 9 132891348-132944633 Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB011568, CAB012481, HPA074132 Supported Validated Cytosol Liver cancer:6.03e-6 (unfavourable), Renal cancer:7.91e-4 (favourable), Pancreatic cancer:8.01e-4 (favourable) Expressed in all Expressed in all testis: 34.3 TSC2 LAM, PPP1R160, TSC4, tuberin ENSG00000103197 Tuberous sclerosis 2 16 2047465-2088720 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002225, HPA030409, HPA049679 Approved Validated Cytosol Pancreatic cancer:5.06e-4 (favourable) Expressed in all Expressed in all seminal vesicle: 35.7 TSG101 TSG10, VPS23 ENSG00000074319 Tumor susceptibility 101 11 18468336-18527232 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004283, HPA006161 Approved Supported Nucleoli
Plasma membrane
Cytosol Liver cancer:3.74e-6 (unfavourable), Renal cancer:5.52e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 80.4 TSHR LGR3 ENSG00000165409 Thyroid stimulating hormone receptor 14 80954989-81146302 Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000473 Approved Tissue enriched Tissue enriched 277 thyroid gland: 443.8 lymph node: 1.6 TSPAN8 CO-029, TM4SF3 ENSG00000127324 Tetraspanin 8 12 71125085-71441898 Cancer-related genes, Predicted membrane proteins Evidence at protein level CAB026009, HPA044337 Supported Approved Nucleoplasm Urothelial cancer:7.36e-5 (favourable), Renal cancer:9.66e-5 (unfavourable) Tissue enhanced Tissue enhanced colon: 926.1;duodenum: 931.2;rectum: 922.7;small intestine: 928.3 stomach: 574.1 TSPO BZRP, DBI, IBP, MBR, mDRC, PBR, pk18, PKBS ENSG00000100300 Translocator protein (18kDa) 22 43151514-43163242 Cancer-related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB011232, HPA046260 Uncertain Approved Vesicles
Mitochondria
Cytosol Liver cancer:1.61e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 301.2 TTL MGC46235 ENSG00000114999 Tubulin tyrosine ligase 2 112482154-112541739 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA066819 Approved Nucleoplasm
Vesicles Liver cancer:5.65e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 4.5 TTLL9 C20orf125, dJ310O13.1 ENSG00000131044 Tubulin tyrosine ligase-like family member 9 20 31870702-31944963 Cancer-related genes, Predicted intracellular proteins Evidence at transcript level HPA041772, HPA055676 Uncertain Uncertain Nucleoplasm
Microtubules Tissue enhanced Tissue enhanced fallopian tube: 6.4;testis: 5.8 epididymis: 2.8 TTR CTS, CTS1, HsT2651, PALB ENSG00000118271 Transthyretin 18 31591726-31599021 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB002517, HPA002550, CAB062567, CAB073406 Supported Approved Golgi apparatus Group enriched Tissue enriched 27 liver: 6311.4 pancreas: 235.0 TUBA1A B-ALPHA-1, FLJ25113, TUBA3 ENSG00000167552 Tubulin, alpha 1a 12 49184796-49189324 Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB008686, HPA039247, HPA043684, HPA063394 Supported Validated Microtubules Renal cancer:2.90e-4 (unfavourable) Tissue enriched Expressed in all cerebral cortex: 1377.5 TUSC2 C3orf11, FUS1, PAP, PDAP2 ENSG00000114383 Tumor suppressor candidate 2 3 50320027-50328251 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA030116 Approved Vesicles
Cytosol Renal cancer:8.70e-7 (favourable), Liver cancer:2.84e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 42.2 TWIST1 ACS3, bHLHa38, BPES2, BPES3, CRS, CRS1, H-twist, SCS, TWIST ENSG00000122691 Twist family bHLH transcription factor 1 7 19020991-19117672 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level Mixed Tissue enhanced adipose tissue: 22.7;endometrium: 30.7 placenta: 17.2 TXLNA DKFZp451J0118 ENSG00000084652 Taxilin alpha 1 32179686-32198285 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA045383, HPA072477 Supported Approved Nucleoplasm
Centrosome
Cytosol Renal cancer:7.21e-7 (unfavourable), Liver cancer:1.57e-6 (unfavourable), Pancreatic cancer:8.69e-5 (favourable), Head and neck cancer:5.53e-4 (favourable), Breast cancer:6.24e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 48.0 TXNDC8 bA427L11.2, SPTRX-3, TRX6 ENSG00000204193 Thioredoxin domain containing 8 (spermatozoa) 9 110303521-110337884 Cancer-related genes, Predicted intracellular proteins Evidence at protein level Not detected Tissue enriched 59 testis: 43.8 fallopian tube: 0.7 TXNIP EST01027, HHCPA78, THIF, VDUP1 ENSG00000265972 Thioredoxin interacting protein 1 145992435-145996600 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA031085, HPA053694 Approved Approved Plasma membrane
Cytosol Expressed in all Expressed in all adipose tissue: 1573.3 TXNRD1 GRIM-12, Trxr1, TXNR ENSG00000198431 Thioredoxin reductase 1 12 104215779-104350305 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001395, CAB004607, CAB015834, HPA043871 Approved Supported Nucleus Liver cancer:1.12e-5 (unfavourable), Renal cancer:1.20e-5 (unfavourable) Expressed in all Expressed in all adrenal gland: 109.8 TYMP ECGF1, MNGIE ENSG00000025708 Thymidine phosphorylase 22 50525752-50530056 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA000530, HPA001072, CAB002518 Approved Approved Nuclear bodies
Golgi apparatus Renal cancer:3.50e-8 (unfavourable), Endometrial cancer:4.34e-5 (favourable) Expressed in all Tissue enhanced appendix: 103.2 spleen: 54.0 TYMS HsT422, TMS, TS, Tsase ENSG00000176890 Thymidylate synthetase 18 657604-673578 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002784 Approved Liver cancer:5.10e-6 (unfavourable) Expressed in all Mixed testis: 58.9 TYRO3 Brt, Dtk, Etk-2, Rek, RSE, Sky, Tif ENSG00000092445 TYRO3 protein tyrosine kinase 15 41557675-41583586 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA071245 Approved Expressed in all Tissue enhanced cerebral cortex: 67.6;ovary: 61.4 testis: 36.9 U2AF1 RN, RNU2AF1, U2AF35, U2AFBP ENSG00000160201 U2 small nuclear RNA auxiliary factor 1 21 43092956-43107587 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA044833, HPA052083 Supported Validated Nucleoplasm Not detected Expressed in all thyroid gland: 71.4 UBA1 A1S9T, CFAP124, GXP1, POC20, UBE1, UBE1X ENSG00000130985 Ubiquitin-like modifier activating enzyme 1 X 47190861-47215128 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000289, HPA001506, CAB019435, CAB073410 Approved Validated Nucleoplasm Liver cancer:6.10e-5 (unfavourable), Thyroid cancer:1.78e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 235.0 UBE2C UBCH10 ENSG00000175063 Ubiquitin-conjugating enzyme E2C 20 45812576-45816957 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB011464, HPA034569, CAB035990, HPA054975 Approved Validated Plasma membrane
Cytosol Renal cancer:0.00e+0 (unfavourable), Liver cancer:6.24e-6 (unfavourable), Pancreatic cancer:6.91e-4 (unfavourable) Expressed in all Mixed tonsil: 59.1 UBE2I UBC9 ENSG00000103275 Ubiquitin-conjugating enzyme E2I 16 1308880-1327018 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level HPA003909, CAB009021 Approved Validated Cytosol Thyroid cancer:5.68e-4 (favourable), Liver cancer:7.50e-4 (unfavourable) Expressed in all Expressed in all ovary: 116.8 UBE2N MGC8489, UBC13, UbcH-ben ENSG00000177889 Ubiquitin-conjugating enzyme E2N 12 93405673-93442262 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA044976 Approved Supported Nucleus
Nucleoli fibrillar center Liver cancer:2.41e-4 (unfavourable) Expressed in all Expressed in all testis: 252.8 UBR5 DD5, EDD, EDD1, HYD, KIAA0896 ENSG00000104517 Ubiquitin protein ligase E3 component n-recognin 5 8 102253012-102412841 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA053688 Supported Nucleoplasm
Cytosol Liver cancer:1.26e-4 (unfavourable) Expressed in all Expressed in all testis: 79.7 UGT1A1 GNT1, UGT1, UGT1A ENSG00000241635 UDP glucuronosyltransferase 1 family, polypeptide A1 2 233760248-233773299 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level Tissue enriched Group enriched 33 duodenum: 205.0;liver: 155.7;small intestine: 83.9 kidney: 4.4 UGT1A10 UGT1J ENSG00000242515 UDP glucuronosyltransferase 1 family, polypeptide A10 2 233636454-233773305 Cancer-related genes, Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Pancreatic cancer:4.55e-4 (unfavourable) Tissue enhanced Tissue enhanced colon: 50.4;duodenum: 83.1;small intestine: 60.3 rectum: 40.2 UGT1A3 UGT1C ENSG00000243135 UDP glucuronosyltransferase 1 family, polypeptide A3 2 233729108-233773299 Cancer-related genes, Enzymes, Predicted membrane proteins Evidence at protein level Tissue enriched Tissue enriched 7 liver: 38.1 small intestine: 5.7 UGT1A4 HUG-BR2, UGT1D ENSG00000244474 UDP glucuronosyltransferase 1 family, polypeptide A4 2 233718778-233773299 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level Tissue enriched Tissue enriched 31 liver: 212.1 duodenum: 6.9 UGT1A9 HLUGP4, LUGP4, UGT1AI ENSG00000241119 UDP glucuronosyltransferase 1 family, polypeptide A9 2 233671853-233773300 Cancer-related genes, Enzymes, Predicted membrane proteins Evidence at protein level Renal cancer:5.04e-5 (unfavourable) Group enriched Group enriched 586 kidney: 461.7;liver: 93.2 cerebral cortex,colon: 0.4 UHRF1BP1L KIAA0701 ENSG00000111647 UHRF1 binding protein 1-like 12 100028455-100142848 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA039671, HPA040399 Uncertain Approved Plasma membrane Expressed in all Mixed cerebral cortex: 33.0 USH1C AIE-75, DFNB18, harmonin, NY-CO-37, NY-CO-38, PDZ-73, PDZ73, PDZD7C ENSG00000006611 Usher syndrome 1C 11 17493895-17544416 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB013690, HPA027398, HPA027492, HPA028033 Supported Validated Cytosol Liver cancer:2.20e-4 (unfavourable), Renal cancer:9.41e-4 (favourable) Group enriched Tissue enhanced duodenum: 101.9;small intestine: 109.0 kidney: 55.1 USP6 HRP1, Tre-2, TRE17, Tre2, TRESMCR ENSG00000129204 Ubiquitin specific peptidase 6 17 5116438-5175034 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA046969 Uncertain Uncertain Vesicles Tissue enriched Tissue enhanced testis: 17.8 skeletal muscle: 7.5 VAMP3 CEB ENSG00000049245 Vesicle-associated membrane protein 3 1 7771269-7781432 Cancer-related genes, Predicted membrane proteins Evidence at protein level Renal cancer:2.36e-4 (favourable) Expressed in all Expressed in all lung: 135.4 VCAM1 CD106 ENSG00000162692 Vascular cell adhesion molecule 1 1 100719742-100739045 Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB000154, HPA034796, HPA069867 Supported Approved Cell Junctions Head and neck cancer:7.19e-5 (favourable), Cervical cancer:3.82e-4 (favourable) Tissue enriched Tissue enriched 5 spleen: 557.0 lymph node: 111.2 VEGFA VEGF, VEGF-A, VPF ENSG00000112715 Vascular endothelial growth factor A 6 43770184-43786487 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB005429, CAB039240, HPA069116 Approved Renal cancer:1.76e-5 (unfavourable), Liver cancer:2.34e-5 (unfavourable), Endometrial cancer:2.10e-4 (unfavourable), Urothelial cancer:2.73e-4 (favourable), Cervical cancer:4.50e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 455.6 VEGFB VEGFL, VRF ENSG00000173511 Vascular endothelial growth factor B 11 64234538-64238793 Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level Expressed in all Expressed in all adipose tissue: 194.9 VEGFC VRP ENSG00000150630 Vascular endothelial growth factor C 4 176683538-176792727 Cancer-related genes, Disease related genes, Potential drug targets, Predicted secreted proteins, RAS pathway related proteins, Transporters Evidence at protein level Lung cancer:7.88e-5 (unfavourable), Renal cancer:1.17e-4 (unfavourable) Expressed in all Tissue enhanced thyroid gland: 51.4 placenta: 30.4 VHL VHL1 ENSG00000134086 Von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase 3 10141008-10152220 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB005430, HPA031631, HPA031632 Uncertain Validated Nucleoplasm
Cytosol Liver cancer:1.32e-5 (unfavourable), Breast cancer:9.02e-5 (unfavourable), Stomach cancer:7.84e-4 (favourable) Expressed in all Expressed in all lymph node: 35.2 VIL1 D2S1471, VIL ENSG00000127831 Villin 1 2 218419092-218453295 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002452, HPA006884, HPA006885 Supported Supported Plasma membrane Tissue enhanced Group enriched 7 colon: 175.1;duodenum: 409.9;rectum: 199.9;small intestine: 489.9 gallbladder: 44.9 VIP ENSG00000146469 Vasoactive intestinal peptide 6 152750798-152759765 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA017324, CAB018649, HPA072701 Supported Approved Endoplasmic reticulum Group enriched Group enriched 5 appendix: 215.7;colon: 72.6;rectum: 69.1;small intestine: 53.7;smooth muscle: 57.4 duodenum: 17.3 VTI1A MVti1, Vti1-rp2, Vti1a ENSG00000151532 Vesicle transport through interaction with t-SNAREs 1A 10 112446998-112818744 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054108 Supported Supported Golgi apparatus
Vesicles Liver cancer:6.50e-5 (unfavourable), Renal cancer:7.27e-5 (favourable) Expressed in all Mixed parathyroid gland: 12.1 VTN VN ENSG00000109072 Vitronectin 17 28367276-28373091 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB016695, CAB016765, HPA060933 Supported Supported Endoplasmic reticulum
Vesicles Renal cancer:4.10e-11 (unfavourable), Liver cancer:3.74e-4 (favourable) Tissue enriched Tissue enriched 28 liver: 2540.4 gallbladder: 91.6 VWF F8VWF ENSG00000110799 Von Willebrand factor 12 5948874-6124770 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB001694, HPA001815, HPA002082, CAB072874, CAB072875 Supported Stomach cancer:2.31e-4 (unfavourable) Expressed in all Mixed adipose tissue: 154.4 WAS IMD2, THC, WASP, WASPA ENSG00000015285 Wiskott-Aldrich syndrome X 48676596-48691427 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA002022, CAB004290 Supported Renal cancer:5.58e-6 (unfavourable), Head and neck cancer:3.78e-4 (favourable), Endometrial cancer:4.95e-4 (favourable) Expressed in all Tissue enhanced appendix: 71.0;lymph node: 61.6;spleen: 70.8 bone marrow: 37.6 WASF3 KIAA0900, SCAR3, WAVE3 ENSG00000132970 WAS protein family, member 3 13 26557703-26688948 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB037086 Approved Pancreatic cancer:2.21e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 86.7 thyroid gland: 28.0 WEE1 WEE1A ENSG00000166483 WEE1 G2 checkpoint kinase 11 9573681-9593457 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004619, HPA068845 Approved Approved Nucleoli Renal cancer:5.19e-4 (unfavourable) Expressed in all Expressed in all endometrium: 89.6 WFDC2 dJ461P17.6, EDDM4, HE4, WAP5 ENSG00000101443 WAP four-disulfide core domain 2 20 45469706-45481532 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA042302 Supported Approved Cytosol Renal cancer:4.44e-5 (favourable), Glioma:5.87e-5 (unfavourable) Expressed in all Tissue enriched 6 cervix, uterine: 6507.3 seminal vesicle: 1038.0 WHSC1 MMSET, NSD2 ENSG00000109685 Wolf-Hirschhorn syndrome candidate 1 4 1871424-1982207 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA015801, CAB068246, CAB068247 Supported Supported Nucleus Liver cancer:2.61e-4 (unfavourable), Renal cancer:7.19e-4 (unfavourable) Expressed in all Expressed in all testis: 66.9 WHSC1L1 FLJ20353, NSD3 ENSG00000147548 Wolf-Hirschhorn syndrome candidate 1-like 1 8 38269697-38382272 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA005659, CAB013721, HPA018893 Uncertain Approved Nucleoplasm
Mitochondria Pancreatic cancer:7.48e-4 (unfavourable) Expressed in all Expressed in all placenta: 47.5 WIF1 ENSG00000156076 WNT inhibitory factor 1 12 65050626-65121566 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA039104 Approved Tissue enhanced Tissue enriched 6 lung: 159.7 cerebral cortex: 26.5 WISP1 CCN4 ENSG00000104415 WNT1 inducible signaling pathway protein 1 8 133191039-133230344 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA007121, CAB012205 Uncertain Validated Cytosol Renal cancer:1.91e-5 (unfavourable) Expressed in all Mixed smooth muscle: 21.8 WNT1 INT1 ENSG00000125084 Wingless-type MMTV integration site family, member 1 12 48978453-48981676 Cancer-related genes, Disease related genes, Predicted secreted proteins Evidence at protein level Not detected Mixed cerebral cortex: 1.3 WNT2 INT1L1, IRP ENSG00000105989 Wingless-type MMTV integration site family member 2 7 117276631-117323289 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA020920 Approved Vesicles Mixed Group enriched 6 endometrium: 23.6;placenta: 92.5 lung: 9.2 WRN RECQ3, RECQL2 ENSG00000165392 Werner syndrome, RecQ helicase-like 8 31033801-31173769 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA028661 Approved Supported Nuclear speckles Expressed in all Mixed endometrium: 14.7 WT1 AWT1, GUD, WAGR, WIT-2 ENSG00000184937 Wilms tumor 1 11 32387775-32435630 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000327, HPA035717, HPA053848 Supported Supported Nucleoplasm Tissue enriched Tissue enhanced endometrium: 112.0;fallopian tube: 123.1;smooth muscle: 78.9 testis: 53.8 WWTR1 DKFZp586I1419, TAZ ENSG00000018408 WW domain containing transcription regulator 1 3 149517235-149736714 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA007415, CAB017483, CAB068248 Approved Validated Nucleoplasm
Nuclear bodies
Cytosol Expressed in all Mixed endometrium: 70.7 XBP1 XBP2 ENSG00000100219 X-box binding protein 1 22 28794555-28800597 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level Not detected Expressed in all breast: 907.4 XIAP API3, BIRC4, hILP ENSG00000101966 X-linked inhibitor of apoptosis, E3 ubiquitin protein ligase X 123859724-123913979 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009203, HPA042428 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Breast cancer:9.21e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 35.0 XIRP2 CMYA3 ENSG00000163092 Xin actin binding repeat containing 2 2 166888487-167259753 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA034813 Uncertain Tissue enriched Group enriched 26 heart muscle: 68.8;skeletal muscle: 301.7 prostate: 7.2 XPA XP1, XPAC ENSG00000136936 Xeroderma pigmentosum, complementation group A 9 97674909-97697357 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB000155, HPA056856 Supported Approved Nucleus
Cytokinetic bridge Renal cancer:4.28e-5 (favourable) Expressed in all Expressed in all thyroid gland: 38.9 XPC RAD4, XPCC ENSG00000154767 Xeroderma pigmentosum, complementation group C 3 14145147-14178783 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009932, HPA035707, HPA069673 Supported Validated Nucleus
Plasma membrane Renal cancer:4.14e-7 (favourable), Urothelial cancer:2.46e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 51.3 XPO1 CRM1, emb ENSG00000082898 Exportin 1 2 61477849-61538626 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level CAB010184, HPA042933 Supported Validated Nucleoplasm
Nuclear membrane
Vesicles
Cytosol Liver cancer:1.84e-5 (unfavourable), Renal cancer:3.74e-4 (unfavourable) Expressed in all Expressed in all testis: 138.5 XRCC1 RCC ENSG00000073050 X-ray repair complementing defective repair in Chinese hamster cells 1 19 43543040-43580473 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB005427, HPA006717 Supported Validated Nucleoplasm Liver cancer:7.33e-5 (unfavourable) Expressed in all Expressed in all ovary: 34.6 XRCC2 ENSG00000196584 X-ray repair complementing defective repair in Chinese hamster cells 2 7 152644779-152676165 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA065153 Approved Nucleoplasm
Vesicles Mixed Mixed testis: 3.8 XRCC3 ENSG00000126215 X-ray repair complementing defective repair in Chinese hamster cells 3 14 103697609-103715504 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA062422, HPA068953 Validated Nucleus Expressed in all Expressed in all skin: 46.0 XRCC4 ENSG00000152422 X-ray repair complementing defective repair in Chinese hamster cells 4 5 83077498-83353787 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA006801, HPA051538 Supported Supported Nucleus Breast cancer:1.80e-5 (unfavourable) Expressed in all Mixed testis: 16.0 XRCC5 KARP-1, KU80, Ku86, KUB2 ENSG00000079246 X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining) 2 216107464-216206303 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004468, HPA025813, HPA064685 Supported Validated Nucleoplasm Liver cancer:2.10e-7 (unfavourable) Expressed in all Expressed in all thyroid gland: 212.5 XRCC6 D22S671, D22S731, G22P1, KU70, ML8 ENSG00000196419 X-ray repair complementing defective repair in Chinese hamster cells 6 22 41621119-41664048 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004254, HPA047549, HPA062226 Supported Validated Nucleoplasm Expressed in all Expressed in all testis: 395.0 YBX1 BP-8, CSDA2, CSDB, DBPB, MDR-NF1, NSEP-1, NSEP1, YB-1, YB1 ENSG00000065978 Y box binding protein 1 1 42682427-42702349 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB005875, HPA040304, HPA057159 Supported Validated Vesicles
Cytosol Liver cancer:9.87e-10 (unfavourable), Renal cancer:3.59e-7 (unfavourable) Expressed in all Expressed in all testis: 1538.1 YWHAB YWHAA ENSG00000166913 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta 20 44885676-44908532 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB003759, HPA007925, HPA011212 Supported Supported Cytosol Liver cancer:1.91e-6 (unfavourable), Renal cancer:2.52e-5 (favourable), Endometrial cancer:5.46e-4 (unfavourable), Lung cancer:6.01e-4 (unfavourable), Head and neck cancer:6.14e-4 (unfavourable), Breast cancer:9.18e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 446.4 YWHAE FLJ45465 ENSG00000108953 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon 17 1344272-1400378 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA008445, CAB016200, CAB021109, CAB047350 Approved Uncertain Cytosol Endometrial cancer:6.48e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 452.9 YWHAH YWHA1 ENSG00000128245 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta 22 31944461-31957603 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB025918 Uncertain Liver cancer:1.59e-5 (unfavourable) Expressed in all Tissue enriched 7 cerebral cortex: 899.0 lung: 138.0 ZBTB16 PLZF, ZNF145 ENSG00000109906 Zinc finger and BTB domain containing 16 11 114059593-114250676 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA001499, CAB004540 Uncertain Renal cancer:2.21e-4 (favourable) Tissue enhanced Mixed ovary: 59.6 ZCCHC8 DKFZp434E2220 ENSG00000033030 Zinc finger, CCHC domain containing 8 12 122471600-122501073 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA037483, HPA037484 Supported Validated Nucleoplasm
Nuclear bodies Renal cancer:5.36e-4 (unfavourable), Melanoma:7.40e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 33.1 ZFHX3 ATBF1, ZNF927 ENSG00000140836 Zinc finger homeobox 3 16 72782885-73059698 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA059353 Uncertain Supported Nucleoplasm Renal cancer:1.37e-5 (favourable), Breast cancer:1.55e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 28.7 thyroid gland: 12.5 ZFP36L1 Berg36, BRF1, cMG1, ERF1, RNF162B, TIS11B ENSG00000185650 ZFP36 ring finger protein-like 1 14 68787660-68796253 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001301 Uncertain Expressed in all Expressed in all endometrium: 580.8 ZFP36L2 BRF2, ERF2, RNF162C, TIS11D ENSG00000152518 ZFP36 ring finger protein-like 2 2 43222402-43226609 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA047428 Approved Expressed in all Expressed in all thyroid gland: 273.3 ZMAT3 FLJ12296, MGC10613, PAG608, WIG-1, WIG1 ENSG00000172667 Zinc finger, matrin-type 3 3 179017223-179072279 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA028671, HPA054356 Supported Nucleoplasm Expressed in all Mixed cerebral cortex: 29.1 ZMYM2 FIM, MYM, RAMP, ZNF198 ENSG00000121741 Zinc finger, MYM-type 2 13 19958670-20091829 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA031765 Approved Approved Nucleoplasm
Endoplasmic reticulum Urothelial cancer:6.07e-4 (favourable) Expressed in all Expressed in all testis: 87.6 ZNF132 pHZ-12 ENSG00000131849 Zinc finger protein 132 19 58432814-58440222 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA008726 Uncertain Approved Vesicles
Intermediate filaments Renal cancer:7.26e-13 (favourable), Pancreatic cancer:1.92e-4 (favourable) Mixed Mixed parathyroid gland: 10.6 ZNF180 HHZ168 ENSG00000167384 Zinc finger protein 180 19 44474428-44500524 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA028979, HPA028980 Uncertain Approved Nucleoplasm Expressed in all Mixed parathyroid gland: 11.9 ZNF300 ENSG00000145908 Zinc finger protein 300 5 150894392-150904983 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA028975, HPA051777 Uncertain Supported Nucleoplasm
Nucleoli Renal cancer:3.21e-6 (unfavourable) Expressed in all Mixed ovary: 12.4 ZNF331 RITA, ZNF361, ZNF463 ENSG00000130844 Zinc finger protein 331 19 53520981-53580269 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA063157 Approved Nucleoplasm Stomach cancer:4.79e-4 (unfavourable), Thyroid cancer:7.43e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 210.3 ZNF384 CAGH1A, CIZ, NMP4, NP, TNRC1 ENSG00000126746 Zinc finger protein 384 12 6666477-6689572 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA004051 Supported Supported Nucleoplasm Expressed in all Expressed in all endometrium: 65.7 ZNF471 KIAA1396, Z1971 ENSG00000196263 Zinc finger protein 471 19 56507843-56530221 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA066695 Uncertain Supported Nucleus Renal cancer:2.37e-4 (favourable) Mixed Mixed ovary: 28.0 ZNF483 KIAA1962, ZKSCAN16, ZSCAN48 ENSG00000173258 Zinc finger protein 483 9 111525159-111577844 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA055041 Uncertain Approved Nucleoli Tissue enhanced Mixed cerebral cortex: 13.0 ZNF521 EHZF, Evi3 ENSG00000198795 Zinc finger protein 521 18 25061926-25352190 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA023056, HPA023849 Approved Approved Nucleoplasm Mixed Mixed spleen: 29.4 ZNF620 MGC50836 ENSG00000177842 Zinc finger protein 620 3 40505992-40518736 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA031452 Uncertain Approved Plasma membrane Mixed Mixed thyroid gland: 6.0 ZNF750 FLJ13841, Zfp750 ENSG00000141579 Zinc finger protein 750 17 82829435-82840578 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA021573, HPA023012 Approved Approved Nucleus
Nucleoli
Vesicles Mixed Tissue enhanced esophagus: 60.7;skin: 54.5 salivary gland: 13.0 ZNF814 ENSG00000204514 Zinc finger protein 814 19 57848731-57889074 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA043800, HPA053762, HPA072145 Approved Uncertain Nucleus Mixed Mixed thyroid gland: 18.5 ZNF844 FLJ14959 ENSG00000223547 Zinc finger protein 844 19 12064699-12081565 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA046982 Uncertain Renal cancer:0.00e+0 (favourable) Expressed in all Mixed thyroid gland: 20.2 ZNF91 HPF7, HTF10 ENSG00000167232 Zinc finger protein 91 19 23304991-23395560 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at transcript level Urothelial cancer:3.48e-4 (favourable), Renal cancer:7.58e-4 (favourable) Expressed in all Mixed thyroid gland: 17.5 ZRANB3 DKFZP434B1727 ENSG00000121988 Zinc finger, RAN-binding domain containing 3 2 135136916-135531236 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA035234 Supported Nucleus Mixed Mixed testis: 8.5 ZRSR2 U2AF1-RS2, U2AF1L2, URP, ZC3H22 ENSG00000169249 Zinc finger (CCCH type), RNA-binding motif and serine/arginine rich 2 X 15790472-15823260 Cancer-related genes, Predicted intracellular proteins Evidence at protein level Renal cancer:4.87e-5 (unfavourable), Endometrial cancer:8.50e-5 (favourable), Urothelial cancer:2.97e-4 (favourable), Breast cancer:7.96e-4 (favourable) Expressed in all Expressed in all spleen: 34.8